An Investigation Into the Effect of Myristoylation on the Interactions Between HIV-1 Nef and Cellular Proteins by Boulton, Victoria J
AN INVESTIGATION INTO THE EFFECT OF MYRISTOYLATION ON 
THE INTERACTIONS BETWEEN HIV-1 NEF AND CELLULAR
PROTEINS
VICTORIA J BOULTON
A thesis submitted for the degree of Doctor of Philosophy
Department of Veterinary Pathology 
Faculty of Veterinary Medicine 
University of Glasgow 
May 1998
© Victoria J Boulton
ProQuest Number: 13818617
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13818617
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
GUSGOW  UNIVERSITY 
LIBRARY
n u t  (ro
GLASGOW! 
UNIVEESITT I  
UBRABT 1
2DECLARATION
The studies described in this thesis were carried out in the Department of Veterinary 
Pathology at the University of Glasgow Veterinary School between October 1994 
and March 1998. The author was responsible for all the results except where it is 
stated otherwise. No part of this thesis has been presented to any university
Victoria J Boulton
May 1998
3CONTENTS:
Page number
Abbreviations 13
Symbols for amino acids 15
Acknowledgements 16
Summary 17
CHAPTER 1 INTRODUCTION
1.1 HIV and the Retroviridae 21
1.1.1 Introduction 21
1.1.2 Prototype genes, gag, po\ and env 23
1.1.3 HTV virus structure 26
1.1.4 Auxiliary genes 27
1.1.5 Viral cell tropism 31
1.1.6 Therapeutics 33
1.2 Nef 35
1.2.1 Introduction 35
1.2.2 Gene structure 35
1.2.2.1 Physical features 35
1.2.2.2 Significance of nef in vivo 38
1.2.3 The protein product of the nef gene 40
1.2.3.1 Characteristics 40
1.2.3.2 Myristoylation of Nef 41
1.2.3.3 Nef subcellular localization 44
1.2.4 Nef mediated virion infectivity 45
1.2.5 Nef disruption of cell signalling pathways 48
1.2.5.1 Nef phenotype 48
1.2.5.2 Nef putative interaction partners 49
1.2.6 Nef mediated CD4 down-modulation 51
1.2.7 The role of Nef in HIV immune evasion 54
1.2.8 Miscellaneous 55
1.3 Nef and the Src tyrosine kinases 56
41.3.1 Introduction to the Src tyrosine kinases
1.3.2 Evidence for Nef interactions with Src tyrosine kinases
1.4 Aims of the thesis
CHAPTER 2 MATERIALS AND METHODS
2.0 General chemicals and enzymes
MOLECULAR BIOLOGY TECHNIQUES
2.1 Molecular biology techniques - Materials
2.1.1. Chemical and enzymes
2.1.2. Radiochemicals
2.1.3. Bacterial strain
2.1.4. Cloning vectors
2.1.5. Stock solutions
2.1.6. Media and antibiotics
2.2 Molecular biology techniques- Experimental methods
2.2.1 Agarose gel electrophoresis
2.2.2 Polymerase chain reaction (PCR)
2.2.3 Restriction enzyme digests
2.2.4 DNA purification from agarose gels
2.2.5 Ligation of DNA molecules
2.2.6 Plasmid transformation using competent DH5a E.coli
2.2.7 Small scale alkali purification of Ecoli plasmid DNA
2.2.8 Large scale purification of plasmid DNA from Ecoli
2.2.9 Sequencing of DNA
2.2.9.1 Manual
2.2.9.2 Sequencing gel
2.2.9.3 LI-COR automated
YEAST PROTOCOLS
2.3 Yeast protocols- Materials
56
59
62
67
67
67
67
67
67
69
70
70
70
71
71
71
72
72
72
72
74
74
75
75
77
77
77
77
78
79
79
80
81
81
81
81
82
82
83
84
85
85
86
87
87
88
88
89
90
90
91
91
92
Chemicals and enzymes 
Radiochemicals 
Yeast strain
Yeast interaction trap plasmids
Yeast media and supplements
Complete minimal (CM) dropout powder
Carbon sources
Dropout plates and media
X-Gal plates
lOxBU salts
Nomenclature of media plus supplements
Storage and freezing of yeast
Yeast protocols- Experimental methods
Transformation of yeast by the high efficiency lithium acetate
method
Testing baits for transcription activation 
Constructing the transcriptional activation selection strain 
Transcriptional activation assay 
Repression assay
Selecting interactors from library transformants 
Transformation of the library plasmid and determination 
of colony forming units (CFU)
Isolating interactors on Leu-plates 
(3-Galactosidase filter assay 
Verifying the specificity of the interactions 
RFLP analysis of PCR products 
Primers for RFLP PCR 
Yeast plasmid miniprep 
Yeast cell lysis using glass beads 
Labelling of Yeast with 3H Myristic Acid
6BACULOVIRUS PROTOCOLS
2.5 Baculovirus protocols -  Materials 94
2.5.1 Chemicals and enzymes 94
2.5.2 Radiochemicals 94
2.5.3 Insect cell line 95
2.5.4 Baculovirus strain 95
2.5.5 Expression plasmids 95
2.5.6 Stock solutions 96
2.5.7 Preparation of culture medium 96
2.5.8 Growth and maintenance of insect cell cultures 96
2.5.9 Counting the Sf9 cells 97
2.5.10 Freezing, storage and recovery of Sf9 cells in liquid nitrogen 97
2.5.11 Preparation of glutathione-agarose (GA) -beads 98
2.6 Baculovirus protocols -  Experimental methods 98
2.6.1 Transfection of Spodoptera frugiperda (Sf9) insect cells
to generate recombination baculoviruses 98
2.6.1.1. Preparation of viral DNA 99
2.6.1.2. Transfection of Sf9 insect cells 99
2.6.1.3. Plaque assay to harvest the recombinant virus 100
2.6.2 Verifying expression of the protein of interest by the
recombinant baculovirus 101
2.6.3 Large scale production of viral stocks 101
2.6.4 Plaque assay for virus titre 102
2.6.5 Production of Sf9 cell lysates 102
2.6.5.1 Single baculovirus infections 103
2.6.5.2 Coinfections 103
2.6.6. Purification of affinity reagents 103
2.6.6.1 Large scale virus infections GST-fusion protein purification 103
2.6.6.2 Lysis of infected cells and purification of GST fusion proteins 103
2.6.7 In vitro binding assay 104
2.6.7.1 Binding purified protein to GA-beads 105
2.612  Binding assay 105
72.6.8 In vivo binding assays 105
2.6.9 Metabolic labelling 106
PROTEIN BIOCHEMISTRY
2.7 Protein biochemistry- Materials 107
2.7.1 Chemicals and enzymes 107
2.7.2 Radiochemicals 107
2.7.3 Stock solutions 108
2.8 Protein biochemistry - Experimental methods 108
2.8.1. SDS-PAGE gel analysis 108
2.8.2. Coomassie staining 109
2.8.3. Radioactive gels 109
2.8.4. Western blot 110
2.8.4.1 Transfer to PVDF membrane 110
2.8.4.2 Western blot 110
2.8.4.3 Reprobing the membrane 110
2.8.5 Immunoprecipitation 112
2.8.6 Bradford assay 112
2.8.7 In vitro transcription-translation 112
2.8.8 Autophosphorylation assay 113
2.8.9 Protein kinase assays 113
2.8.10 HTV-1 protease experiments 114
CHAPTER 3 Use of the yeast interaction trap to investigate novel cellular 
interactions with HTV-1 Nef
3.0 General introduction 117
3.1 Results 120
3.2 Modification of the bait plasmid to accept proteins as
N-terminal fusions 125
3.3 Verification of expression and myristoylation of Nef in pVEG 125
3.4 Activation and repression assays 128
83.5 Screening a Jurkat T-cell library with p VEG Nef for
novel protein-protein interactions 132
3.6 Further investigation of groups A1, B1 and C1 -  sequence
data and specificity tests 139
3.6.1 Analysis of the sequence and specificity results obtained
for groups C1 and B1 142
3.6.2 Re-analysis of group A2 146
3.6.3 Analysis of the specificity results obtained for Group A1 149
3.7 Further analysis of the Nef-Al (p9) interaction 152
CHAPTER 4 Investigation of a putative Nef interaction with Lck
4.1 Introduction 156
4.2 Background 159
4.3 Summary of work presented hereafter 160
4.4 Construction of the recombinant baculoviruses 160
4.5 Confirming the authenticity of the proteins 161
4.5.1 Expression and kinase activity 164
4.5.2 Confirming the authentic acylation of Lck 164
4.6 In vitro binding assays 167
4.6.1 Overview of preliminary studies 167
4.6.2 Follow up in vitro binding studies 169
4.6.3 Identifying the cause of the differences between protein stocks 172
4.6.4 How were the protein conformations altering between stocks 175
4.7 Construction of constitutively active and inactive Lck mutants
to assess conformational binding criteria 177
4.8 Confirmation of the expression and kinase activities of the 
mutant Lck recombinant baculoviruses; Lck G2A/K273R/
Y505F (LckGKY) and Lck G2A/Y505F (LckGY) 179
4.9 In vivo binding studies 183
4.9.1 In vivo binding studies for LckGY and LckGKY 183
4.9.2 A comparative study of Lck mutant binding abilities to N-G 186
94.10 Identification of region in Nef important in mediating its
in vivo binding to LckGKY 189
4.10.1 Investigation of Lck binding to different Nef alleles 189
4.10.2 Screening of a panel of Nef deletion mutants for interactions 191 
with LckGKY
CHAPTER 5 Analysis of Hck interactions with NEF
5.1 Introduction 197
5.2 Summary of results presented hereunder 198
5.3 Construction of the SID, SID and SH3-SH2 domain 
fusions to the activation domain of pJG4-5 for expression
and interaction analysis in the YTHS 199
5.4 Analysis of YTHS interaction between the Src homology
regions and myristoylated Nef 202
5.5 Construction of recombinant baculoviruses 210
5.6 Verifying the authenticity of the recombinant baculovirus
expressed mHck, Src and Fyn 210
5.6.1 Determining full length expression and kinase activity 210
5.6.2 Determination of authentic acylation of the proteins 213
5.7 In vitro binding assays 216
5.8 In vivo binding assays 219
5.9 Analysis of the contribution of the N-terminus of Nef to
Hck binding 222
5.10 Analysis of the contribution of the N-Terminus of Hck to
Nefbinding 224
5.11 Screen of a panel of Nef mutants and isolates 228
5.11.1 Results from the Nef mutant screen 228
5.11.2 Results from the Nef isolate screen 232
5.12 Effect of Nef on Hck enzymatic activity 235
10
CHAPTER 6- Discussion
6.1 Screening for novel Nef interactors 239
6.2 Conformational requirements for the Lck interaction with Nef 245
6.3 Interactions of Nef with Hck 255
6.4 Final discussion 263
LIST OF FIGURES:
3.1 Summary of approach taken to modify the bait plasmid to
accept proteins as N-terminal fusions 123
3.2 Results of the [3H] myristic acid labelling of yeast 127
3.3 Activation assay for pVEG-Nef, pVEG-G2A and pEG-Nef 130
3.4 Results of the repression assay for pVEG-Nef, pVEG-G2A and
pVEG-Nef 131
3.5 Classification of potential Nef interactors after the library screen 134
3.6 Results from the rescreening of the library interactors 138
3.7 Western blot analysis of interactor expression 141
3.8 Computational analysis of sequence data for groups Cl and B1 143
3.9 Results of the specificity tests 145
3.10 Computational analysis of sequence data for groups A2
and A1 (clone39) 147
3.11 Results of the specificity screen for group A1, clone 39 151
3.12 Quantitative analysis of amount of GST-39 bound to GA-beads 153
4.1 Analysis of expression and phosphorylation of recombinant
baculoviruses expressing wtLck and AcLck 163
4.2 Establishing the authentic acylation of wtLck 166
4.3 Results from the preliminary studies 168
4.4 In vitro binding assay results of the crosswise comparison of reagents 171
4.5 Effect of serum on Lck binding to N-G 174
4.6 Autophosphorylation assays to compare wtLck, AcLck and oAcLck 176
4.7 Analysis of the expression and kinase activities of LckGKY
and LckGY relative to AcLck, LckG2A and Lck273A 181
11
4 .8 Results of in vivo binding assays for LckGY and LckGKY 185
4.9 Comparison of Lck wildtype and mutants ability to bind N-G 188
4.10 LckGKY in vivo binding assays for 5 different Nef alleles
PCR2,3 and 4 HIV-1 clinical isolates, SIV J5 and Bru 190
4.11 In vivo binding assays for LckGKY plus the panel of Nef
deletion mutants 194
5.1 Verification of SH3, SH2 and SH3-SH2 domain expression
for Hck, Lck, Src and Fyn in yeast 201
5.2 Nef interactions with Hck and Src SH3 domains in the YTHS 207
5.3 Nef interactions with Hck and Src SIC domains in the YTHS 208
5 .4 Interactions between Nef and Src kinase SH3-SH2 domain fusions 209
5 .5 Confirmation of kinase activity and expression of mHck, Src and Fyn 212
5.6 Confirmation of authentic acylation of mHck, Src and Fyn 215
5.7 In vitro binding experiments for mHck and Src 218
5.8 Results of the in vivo binding studies with Nef plus mHck and Src 221
5.9 Effect of HTV-1 protease cleavage on the N-G Hck complex 224
5.10 Results of in vivo binding studies for A78hHck and G2AhHck 227
5.11 Results of mHck binding to the panel of Nef mutants 230
5.12 Comparison of mHck, G2 A- and A78- hHck binding to PAAP Nef 231
5.13 Screening Nef alleles for mHck binding 233
5.14 Comparison of the effect of wildtype and PAAP Nef on mHck activity 236
LIST OF DIAGRAMS:
1.1 Genomic organisation of HTV-1 25
1.2 A schematic representation of virion assembly 27
1.3 HTV-1 genome structure and mRNA expression 31
1.4 Summary of the nef gene structural features 38
1.5 Myristate bound to the N-terminal glycine residue 41
1.6 A schematic representation of the Nef polyproline type II helix 57
1.7 Schematic diagram of Lck 60
3.1 Construction of p VEG2 124
12
3.2 Map of pVEG2, including sequence around the polylinker 126
3.3 Orientation of samples for the rescreening of putative interactors 13 7
3.4 Orientation of plates for specificity screening of the interactors 140
4.1 A model for the activation of Src tyrosine kinases 182
5.1 Orientation of samples for the SID, SID and SH3-SH2
interactor hunt with Nef as bait 203
5.2 Flow diagram of experimental procedure 223
5 .3 Sequence alignment of BH10 Nef with the primary patient
isolates (PCR2-5iso) 234
6.1 Homology of clone 39 to 3 ’,5 ’-cyclic nucleotide phosphodiesterase 243
LIST OF TABLES
2.1 General use chemicals and enzymes, including abbreviations 65
2.2 Further general use chemicals and enzymes, including abbreviations 66
2.3 Chemicals and enzymes for yeast protocols including abbreviations 77
2.4 Table of amino acid quantities required for the complete minimal
dropout powder 80
2.5 Nomenclature of media and dropout plates (in single letter
and triple letter code) 82
2.6 Chemicals and enzymes for baculovirus protocols 94
2.7 Volumes used for different culture dishes/flasks 103
2.8 Chemicals and enzymes for protein protocols 107
2.9 Antibodies used in the studies, suppliers and amounts used 111
4.1 Summary of Nef mutants 193
5.1 Summary of PCR primers for the cloning of the SID. SID
and SH3-SH2 domains into pJG4-5 200
BIBLIOGRAPHY 268
ABBREVIATIONS
AIDS Acquired immunodeficiency syndrome
AP-1 Activator protein
(3-gal (3-galactosidase
CA Capsid
CTL Cytotoxic T Lymphocyte
DB domain DNA binding domain
DNA Deoxy-ribotnucleic acid
EIF3 Eukaryotic initiation factor 3
ER Endoplasmic reticulum
FCS Foetal calf serum
GA-beads Glutathione-agarose beads
G-protein Guanine nucleotide binding protein
GPI Glycosyl-phosphatidylinosital
GST Glutathione S-Transferase
hCMV Human Cytomegalovirus
HIV Human immunodeficiency virus
IL2-R IL2-Receptor
IN Integrase
IT AMs Immune-receptor-tyrosine-based activation motifs
kDa KiloDaltons
Lck Lymphoid cell kinase
LTR Long terminal repeat
MA Matrix protein
MAPK Mitogen activated protein kinase
MHCI Major histocompatibility complex
MIP Macrophage inflammatory
NAK Nef associated kinase
NaOV Sodium orthovanodate
NC Nucleocapsid
NCBI National Center for Biotechnology Information
Nef Negative factor
NES Nuclear export sequence
NMR Nuclear magnetic resonance
ORF Open reading frame
PAGE Polyacrylamide gel electrophoresis
PAK p21 activated kinase
PBMC Peripheral blood mononuclear cell
PCR Polymerase chain reaction
PIC Preintegration complex
PKC Protein kinase C
PR Protease
RACKS Receptors for activated C-kinase
RANTES Regulated upon activiation, normal T expressed and secreted
Rev Regulator of late gene expression
RFLP Restriction fragment length polymorphism
RNA Ribonucleic acid
rpm Revolutions per minute
RRE Rev-response element
RT Reverse transcriptase
SDF-1 Stromal-cell derived
SH2 Src homology 2
SH3 Src homology 3
SIV Simian immunodeficiency virus
TA domain Transcriptional activation domain
TAR Trans-activating response
Tat 7hms-activator protein
TCR T-cell receptor
TNF Tumour necrosis factor
U Unit
UAS Upstream activating sequence
Vif Viral infectivity factor
Vpr Viral protein R
Vpu Viral protein U
Vpx Viral protein X
YTHS Yeast two-hybrid system
SYMBOLS FOR AMINO ACIDS
A Ala Alanine
C Cys Cysteine
D Asp Aspartic acid
E Glu Glutamic acid
F Phe Phenylalanine
G Gly Glycine
H His Histidine
I lie Isoleucine
K Lys Lysine
L Leu Leucine
M Met Methionine
N Asn Asparagine
P Pro Proline
Q Gin Glutamine
R Arg Arginine
S Ser Serine
T Thr Threonine
V Val Valine
w Trp Tryptophan
Y Tyr Tyrosine
16
ACKNOWLEDGEMENTS:
Thanks are due to a number of people, but first and foremost to my supervisor 
Dr.Mark Harris for all his encouragement and support throughout the duration of 
my studies. Prof. Jim Neil for keeping an eye on me in Mark’s absence, not to 
mention the lunchtime tennis matches. Tom McP. for generally looking after both 
me and my laboratory requirements. All in the north office; in particular Nighean 
for all her recent help and for our sanity Sunday afternoon excursions; ex-members 
Lizzie and Karen C and of course Andy the honoury member. All downstairs at 
molecular oncology and gene therapy. Also Graham, Sanya, Duncan, Nick, Flods 
and cuz P. for maintaining my humour, and Craig for maintaining his distance and 
allowing me to finish my studies! In particular I’d like to thank Ma, Pa and 
Grandpa without whose assistance and paternal support I could never have 
contemplated this.
17
SUMMARY:
The nef gene is conserved across the primate lentiviruses. It is an auxiliary gene 
and encodes a myristoylated 27-34kDa protein expressed early in the viral 
replicative cycle. Data from in vivo macaque studies and analysis of long term non- 
progressor cohorts has implicated nef as a critical factor in the progression from 
latent HIV infection to full blown AIDS. However the exact mechanism of action 
of Nef remains controversial. These studies were undertaken to investigate Nef 
interactions with cellular proteins. The yeast-two-hybrid-system (YTHS) was 
modified to express Nef as an N-terminal fusion protein, allowing interactions to 
be evaluated for the authentically myristoylated Nef species. Screening of a Jurkat 
T-cell library identified a novel Nef interaction with an uncharacterised 
polypeptide (clone 39). Specificity screens confirmed the authenticity of the 
interaction and the polypeptide was further demonstrated to bind HIV-1 p55Gag. 
The cDNA sequence had no homologies to known genes but 99% homology to a 
human expression sequence tagged (EST) cDNA and 76% homology to a mouse 
EST-cDNA sequence, however no protein homologies were found to either of 
these sequences. A fragment of the clone 39 peptide sequence was found to have 
significant homology to cAMP phosphodiesterase; thus raising the interesting 
possibility that Nef may be capable of binding native phosphodiesterases causing 
the deregulation of cAMP levels typically associated with HIV infection. As 
cAMP is a key secondary messenger influencing a number of cellular signal 
transduction pathways a Nef interaction with phosphodiesterase might also explain 
the pleiotropic functions ascribed to Nef.
A highly conserved (PXX^P proline motif in Nef had been previously been 
demonstrated to confer Nef binding to isolated Src homology 3 domains (SH3) of 
members of the Src tyrosine kinase family in vitro. The latter half of the studies 
described herein were therefore designed to determine whether Nef-SH3 complex 
formation was maintained in vivo in the context of the full length native proteins. 
Firstly Nef interactions with the T-lymphocyte specific kinase Lck were assessed. 
Nef was found to associate with Lck in a conformation-dependent manner. Nef 
binding was conferred by the open active conformation of Lck, indicative of the 
interaction occurring concomitantly with cell membrane receptor aggregation,
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possibly during viral entry. The Nef interaction with Lck was found to be mediated 
at least in part by the conserved (PXX)3P motif in Nef in conjunction with an 
N-terminal region in Nef. Secondly, Nef interactions with primarily Hck but also 
Src and Fyn were investigated. For this purpose both the YTHS and baculovirus 
expression systems were utilised. Interactions with native Nef and the isolated Src 
homology domains SH3, SH2 and SH3-SH2 were evaluated in the YTHS, the 
results of which demonstrated a conserved SH3 domain-mediated interaction with 
Nef for Hck and Src. No interaction was detected for Fyn. This result was 
corroborated by in vitro binding assays with the baculovirus expressed full length 
native proteins. The interactions between Nef and Hck was found to be conserved 
in vivo, however complex formation was independent of the Nef (PXX^P motif. 
Indeed deletion of a number of regions in Nef did not perturb the interaction, 
although unexpectedly the Bru laboratory isolate of Nef had severely impaired Hck 
binding ability. This suggested Hck binding was Nef isolate dependent and that 
subtle changes in amino acid sequence in targeted areas outside the (PXX)3P motif 
were sufficient to inhibit the association. Results from peptide substrate assays to 
assess the effect of Nef on Hck kinase activity revealed that the (PXX)3P motif was 
however critical for the Nef induced enhancement of Hck enzymatic activity.
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CHAPTER 1 - Introduction:
The nef gene is unique to the primate lentiviruses. It has been unequivocally linked 
with the destructive pathogenesis of HIV in vivo and as such, represents a challenge 
to basic research. Historically the function of Nef has provided much controversy 
and to date its precise role in viral infection is still unknown. In these studies the aim 
was to define the interactions between Nef and cellular proteins. The remit for the 
initial work was to identify novel cellular partners for Nef using the yeast-two- 
hybrid system. Further studies, using the baculovirus expression system and protein 
binding assays, were undertaken to analyse factors important in mediating the 
interaction of Nef with the family of Src tyrosine kinases. Principally the 
interactions of Nef with the T-lymphocyte specific p56Lck and the 
macrophage/monocyte specific Hck proteins were investigated.
In this chapter the basic features of the Retrovirus family are outlined. The 
significance of characteristics unique to the primate lentiviruses and current 
therapeutic strategies will be discussed. Following this, a review of the literature of 
Nef covering potential functions, cellular interactions and in vivo implications. A 
brief introduction to the Src kinases will be provided and then the aims of the 
project will be presented in detail.
1.1. HIV and the Retroviridae:
1.1.1. Introduction:
The human immunodeficiency virus type 1 (HTV-1) is a complex retrovirus. 
Together with HIV-2 and SIV (simian immunodeficiency virus) (Desrosiers et al., 
1989), it is a member of the primate lentivirus subclass of retroviruses. HIV has 
been identified as the causative agent of AIDS (acquired immunodeficiency 
syndrome) in humans. Progression of the disease is characterised by a period of 
latency (average of 8 years) followed by the onset of AIDS. Disease correlates 
include selective CD4 T-lymphocyte depletion, wasting syndromes, neoplasms and 
a susceptibility to opportunistic infections. In contrast, STV can exist 
apathogenically in some primate species, although in unnatural hosts such as
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macaques (e.g. Rhesus) a similar debilitating and fatal disease profile occurs. Thus, 
macaques have provided an invaluable animal model for the study of disease 
pathogenesis, therapeutics and vaccine strategies (Desrosiers et al., 1989; Lewis and 
Johnson, 1995).
It was originally believed that the period of latency between infection with HIV and 
progression to AIDS was due to viral latency per se. However, it has emerged 
during in vivo studies of the kinetics of HTV infection, that the observed steady 
CD4 lymphocyte count during latency is not due to a lack of replication of the 
virus. It is conversely due to, the rapid turnover of the CD4 lymphocyte population 
(average 2 days) in response to high levels of virion production (Perelson et al., 
1996; Ho et al., 1995). This observation has had enormous therapeutic implications 
(see section 1.1.6), since it follows that 98.5% of the circulating plasma viraemia is 
from newly infected cells. Hence, current dogma is that a shift from latency to 
AIDS is caused by the exhaustion of the regenerative capacity of the hosts immune 
system.
Retroviruses have both RNA and DNA components to their life-cycle (Varmus, 
1988). There are 2 (+) sense RNA molecules per virion, each encoding all of the 
viral genes and regulatory apparatus. The defining feature of retroviruses is their 
ability to reverse transcribe their RNA genome to DNA, using the virally encoded 
reverse transcriptase (RT) (Goff, 1990). This reverse transcription event generates 
duplicated 3’ and 5’ ends, termed LTRs (long terminal repeats). The double 
stranded (-/+) DNA viral copy (or provirus) is then randomly integrated into the 
host chromosomal DNA. Once integrated the 5’ LTR is specifically recognised by 
host cell transcription factors and acts as a promoter. The 3’ LTR provides the 
polyadenylation signal for the mRNA transcripts. Most members of the retrovirus 
family are dependent on available transcription factors for their replication. 
Therefore, retroviruses establish chronic infections and as a consequence more 
commonly transform a cell, than destroy it e.g. oncoviruses. This cellular 
transformation occurs either, i) as a direct result of random integration leading to 
the disruption of cellular gene regulation or, ii) due to recombination of the
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retrovirus with the cellular DNA, resulting in the incorporation of an oncogene (v- 
onc) into the retroviral genome. Although viral oncogenes are cellular homologues 
they usually contain point mutations or fusions to gag sequences, which results in 
their transforming ability. Alternatively, retroviruses can exist benignly within the 
host chromosomal DNA. Many vertebrate species harbour endogenous proviral 
sequences in their genome, resulting from the historical integration of retroviruses 
into germ line cells. The biological significance of these endogenous retroviruses, in 
shaping genome plasticity and potentially conferring disease protection, is reviewed 
in (Lower et al., 1996).
Lentiviruses differ from other members of the retrovirus family because in addition 
to the prototypical gag, pol and env genes, they have a number of auxiliary genes. 
The existence of transcriptional regulatory genes among these, allows self 
regulation of viral replication. A further defining feature of the lentiviral infection 
conferred by the auxiliary gene products is an ability to infect quiescent cells 
(Goldfarb, 1995), see section 1.1.4. Normally retroviruses are reliant on the 
breakdown of the nuclear envelope during mitosis to successfully integrate into the 
host genome. This ability to infect quiescent cells and upregulate viral replication is 
consistent with the productive infection seen during lentiviral, and in particular HIV 
infection.
1.1.2. Prototype genes, gag, pol and env:
The genomic size for HIV is about 9.8Kb, with 3 major open reading frames (ORF) 
encoding the conserved retroviral gag, pol and env genes. Expression from the 
proviral LTR promoter results in the transcription of multiply spliced and frill length 
viral mRNAs (Kieny, 1990). The primary transcript for HIV is a full length mRNA 
which is translated into the Gag and Pol polyprotein precursors. The full length 
Gag-Pol polyprotein precursor is only produced at a ratio of approximately 1:20 of 
the p55Gag precursor. Gag-Pol translation requires a (-1) ffame-shift event to read 
through the Gag stop codon. The Gag-Pol polyprotein is subsequently 
proteolytically cleaved to form the Gag, matrix (MA)-pl7, capsid (CA)-p24 and 
nucleocapsid (NC)-p7 and p6, proteins which comprise the internal structural
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proteins of the virus, see section 1.1.3. Pol is cleaved to form the viral protease 
(PR)-plO, reverse transcriptase (RT)-p66/55 and integrase (IN)-p32 enzymes. The 
specific proteolytic cleavage of these proteins is performed by PR, which is 
activated during viral budding. The ffame-shift mechanism allows the high levels of 
expression necessary for Gag structural proteins, in comparison to the relatively low 
levels for the Pol encoded enzymes. This read through ability represents a common 
translational control level among retroviruses e.g. the murine and feline leukaemia 
viruses, control their gag stop codon read through event by utilising RNA 
secondary structures.
The Gag MA protein is myristoylated and targets the p55 Gag precursor to the cell 
surface membrane (Gottlinger et al., 1989; Spearman et al., 1994). A stretch of 
basic amino acids in the N-terminal 31 amino acids have been demonstrated to 
facilitate membrane targeting (Zhou et al., 1994). In the virion MA functions as an 
integral structural protein (see section 1.1.3.), but on virus entry a small percentage 
is tyrosine phosphorylated resulting in its association with the preintegration 
complex (PIC). In this context the MA helps target the PIC to the host nucleus 
(Bukrinskaya et al., 1996; Vonschwedler et al., 1994; Gallay et al., 1995a; Camaur 
et al., 1997). Multiple functions have also been proposed for the CA protein, 
inferred due to phenotypic changes within the viral particles caused by specific CA 
mutations (Dorfman et al., 1994; Zhang et al., 1996; Reicin et al., 1996). The 
N-terminal CA region confers important structural constraints on the viral core 
necessary for virion infectivity, while more C-terminal amino acid sequences are 
involved in virion assembly. MA, CA, NC and p6 are all necessary for virion 
infectivity (Lee and Linial, 1995; Furuta et al., 1997; Zhang and Barklis, 1997; 
Huang et al., 1995).
The HIV RT, encoded by pol, possesses both RNA dependent DNA polymerase 
and RNaseH activities. The molecule comprises a p66/51 heterodimer. The p51 
species arises as a result of limited proteolysis of the C-terminus of p66. 
Crystallography studies (Jones et al., 1993; Stammers et al., 1994), in combination 
with sequence analysis and in vitro mutagenesis experiments, have implicated the
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15KDa C-terminal region of p66 as the location of the RNaseH activity The HIV 
RT lacks 3’ to 5’ exonuclease proof reading activity and as a result is highly error 
prone during DNA synthesis (Bebenek et al., 1989; Preston et al., 1988). This high 
ratio of mutagenesis provides a heterogeneous viral genome, which is thought to 
facilitate the virus in its evasion of the immune system. The viral IN also encoded by 
pol, acts to cleave and ligate the proviral into the host genome during integration.
The third major gene product is Env, which forms the viral envelope. The env 
transcript is singly spliced and is translated to form an apoprotein of 88KDa. This is 
subsequently glycosylated in the endoplasmic reticulum (ER) to form the gpl60 
precursor glycoprotein. The gpl60 precursor is cleaved in the Golgi apparatus by 
cellular proteases, to form gpl20, the envelope (surface) glycoprotein and gp41, the 
transmembrane envelope glycoprotein. These remain associated in an oligomeric 
complex that is transported to the cell surface for incorporation into the virion. 
During HIV virion entry into a target cell, the gpl20 surface glycoprotein binds the 
CD4 cell surface receptor, which serves as the primary receptor for the virus. 
Selective binding of gpl20 to secondary chemokine receptors drives the cellular 
tropism of the virus, for a review of the current literature see section 1.1.5. gp41 
serves as a transmembrane anchor to which gpl20 glycoprotein is noncovalently 
attached (Wyatt et al., 1997), see diagram 1.1 below for a schematic representation 
of the HIV-1 genome.
Diagram 1.1. Genomic organisation o f HIV-1, structural genes and the 5 ’ and 
3* LTRs are shaded, the auxilliary genes are represented by open boxes:
rev
tat
vpu n ef
vpr
3’ LTR5’ LTR
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1.1.3. HIV virus structure:
HIV virion production occurs at the plasma membrane, via a self assembly process.
The p55Gag and pl60Gag-Pol precursors generate virus particles in association 
with gpl20, gp41 and two copies of the viral (+) RNA genome. Particles bud from 
the membrane, incorporating host molecules incidentally (Cantin et al., 1997).
Immature budding particles appear spherical by electron microscopy. 
Morphological changes occur within the particle, concurrent with budding, due to 
the cleavage of the p55Gag precursor by PR (Nakai and Goto, 1996). The viral 
particles are non-infectious prior to this maturation process. The mature virions are 
icosahedral in shape and approximately 110-122nm in diameter (Hockley et al.,
1994; Nermut et al., 1994), see diagram 1.2 below. They are composed of an inner 
core surrounded by an outer lipid bilayer (envelope) formed from the cell 
membrane, in which characteristic spikes of envelope protein (70-80 in total), are 
anchored (Nakai and Goto, 1996). Each spike contains trimers (Weissenhom et al 1997) of 
envelope glycoproteins. The MA Gag protein is a myristoylated protein and as such 
interacts with the hydrophobic phospholipids of the viral envelope. Mutations that 
block this modification completely inhibit viral assembly (Spearman et al., 1994;
Morikawa et al., 1996). The MA protein of Gag is necessary for the incorporation 
of both gpl20 and gp41 into the virion and a direct interaction between MA and 
HIV viral envelope, but not the viral envelope domains of other retroviruses, has 
recently been demonstrated (Lee et al., 1997).
The inner cone shaped, core of the virion is formed by an outer shell of Gag CA 
protein enclosing the dimeric RNA genome, in close association with the Gag NC 
protein and the viral enzymes RT, PR and IN. The NC proteins are very small, and 
rich in proline and basic amino acids, this in combination with two zinc finger 
domains gives them a high affinity for nucleic acid (Berthoux et al., 1997). The high 
concentration of NC in the inner core drives non-specific NC binding to the single 
stranded RNA genomes providing protection from nuclease attack. Further studies 
on NC have implicated a role for the zinc finger motifs in the specific recognition of 
the viral RNA genome in the cellular cytoplasm during encapsidation (Zhang and 
Barklis, 1997; Berkowitz and Goff, 1994; Berkowitz et al., 1995) and an
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involvement of the basic amino acids in activating DNA strand transfers during 
reverse transcription to form the LTRs (Berthoux et al., 1997) reviewed (Darlix et 
al., 1995). Other auxiliary proteins also incorporated into the virion include - Nef, 
Vpr and Vpx although their exact location has not yet been determined.
Diagram 1.2. A schematic representation o f virion assembly:
gp41 (Transmembrane 
glycoprotein)
Protease (p ll 
p24 Gag Capsid
Reverse transcriptase (p66/p51)
gpl20 (Surface glycoprotein)
Lipid bilayer 
Integrase (p32)
p i7 Gag Matrix
p9 Gag Nucleocapsid
1.1.4. Auxiliary genes:
The auxiliary genes can be divided into early and late expressers. The early mRNA 
transcripts include the multiply spliced tat (/raws-activator protein), rev (regulator 
of late gene expression) and nef (negative factor) transcripts. Late mRNA 
transcripts include for HIV-1, vif (viral infectivity factor), vpr (viral protein R), and 
vpu (viral protein U), see diagram 1.3. In HIV-2 and SIV the vpu gene is exchanged 
for vpx (viral protein X), with some exceptions involving variations of the inclusion 
of vpr, vpu and vpx. Tat and Rev have been implicated in the control of proviral 
expression and are both encoded by two separate exons flanking the env gene. 
Neither is incorporated into the virion, although both are essential for virion 
production. Tat is necessary for the elongation of the viral mRNA transcripts. A 
direct interaction of Tat with a distinct RNA *ram-activating response region, 
termed TAR, located 40bp downstream from the transcription initiation site, has 
been widely demonstrated (Gait and Kam, 1993). However, recent studies have
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suggested that Tat association with TAR is not directly responsible for the observed 
increase in RNA processivity. It is has been shown using western blotting and cell- 
free transcription reactions (Keen et al., 1997), that the TAR element plays a role in 
recruiting RNA polymerase and cellular cofactors, but once transcription has been 
initiated, removal of TAR does not affect the Tat mediated elevated RNA synthesis. 
The function of Tat as a transactivator is not limited to viral transcription but also 
includes activation of cellular genes including, tumour necrosis factor (TNF), 
interleukin 6 (EL-6), CD4, IL-2, IL-2Ra, IL-10, transforming growth factor-P 1 
(TGF-pi) and CD95 ligand. Since Tat is known to be released extracellularly and is 
successfully translocated to the nuclei of uninfected T-cells, it has been postulated 
that Tat facilitates the rapid loss of CD4 T-lymphocytes during progression to 
ADDS. A potential mechanism for this is via the sensitisation of uninfected cells to 
CD95 mediated apoptosis.
The second proviral regulatory protein Rev, also recognises a specific RNA 
element, the Rev-response element (RRE) (Gait and Kam, 1993), see diagram 1.3 
below. Rev provides a mechanism whereby large unspliced viral, but not cellular 
mRNA, can be selectively translocated across the nuclear membrane to the 
cytoplasm (Dundr et al., 1996; Fischer et al., 1994; Fischer et al., 1995; Fritz and 
Green, 1996). In the absence of Rev the RRE which is located within the env gene 
mediates retention of transcripts in the nucleus. This results in transcript splicing 
and the production of the early mRNA transcripts including Rev. As Rev 
concentrations increase, hence RNA synthesis shifts to the production of viral late 
transcripts necessary for virion assembly. Investigation of the mechanism of Rev 
mediated nuclear export of RNA has led to the discovery of a nuclear export 
pathway, potentially conserved across all eukaryotic cells. It has emerged that the 
carboxyl terminus of Rev, the effector domain, acts as a nuclear export sequence 
(NES). This specifically targets the protein and the associated mRNA, to a putative 
exporting nuclear pore. It has been proposed that the NES-containing protein 
moves through the pore by sequential interactions with nucleoporins (Fritz et al.,
1995). One hypothesis for the movement of the molecule through the pore, based 
on relative affinities of the NES for various nucleoporins, is that affinity for the
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NES increases through the pore, being strongest on the cytoplasmic side (Fritz and 
Green, 1996).
The third early transcript is nef the characteristics of which will be discussed in 
depth in the following section, 1.2. This leaves the late transcripts, vif vpr, vpu and 
vpx the expression of which is variable across different HIV-1, HTV-2 and SIV 
strains, but all are encoded by single exons. The strain specific and hence, to a large 
degree, species specific expression of vpr, vpx and vpu, argues a role for viral cell 
tropisms or virus-host interactions. Vif (Camaur and Trono, 1996), Vpr 
(Mahalingam et al., 1995) and Vpx (Wu et al., 1996) are all present in the virion. 
Similar to the Nef research effort, there has been much controversy surrounding the 
absolute requirement by the virus for these genes (Gibbs et al., 1995). However in 
vivo, where efficient viral replication, ability to infect quiescent cells and a diversity 
in cellular tropism are important in establishing persistent viraemia, it is likely that 
these auxiliary genes play a crucial role, in their respective hosts.
Vif is a highly basic, predominantly cytoplasmic, 23KDa protein. The primary 
function for Vif is believed to be during early viral infection, where it associates 
with the cellular cytoskeleton potentially aiding in the transport of the preintegration 
complex to the nucleus (Karczewski and Strebel, 1996). Other proposed functions 
for Vif include maintaining the stability of the viral nucleoprotein complex prior to 
integration of the provirus and aiding in viral assembly. In the absence of Vif a 1000 
fold reduction in infectivity has been reported in some cell types.
Vpr is a 15KDa protein and also plays a role in targeting the preintegration complex 
to the nucleus although, like Vif it does not contain a conventional NLS motif. It is 
clear Vpr accumulates in the nucleus, but exactly how it mediates the translocation 
of the preintegration complex across the nuclear membrane is unknown. 
Competitive inhibition of the importin-dependent nuclear import pathway does not 
prevent Vpr nuclear entry, therefore the mechanism is independent from this classic 
NLS entry route (Stevenson, 1996; Silver, 1991). Expression of Vpr has also been 
shown to have a cytostatic affect, due to cell cycle arrest in the G2 phase (Re et al.,
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1995; Emerman, 1996). The observation that cells produce elevated levels of virus 
during G2 , suggests a role for Vpr in maximising virus production, before cells are 
destroyed by the hosts immune system - the half life of an infected T-cell being 
approximately 2 days (Perelson et al., 1996; Ho et al., 1995). Vpr and Vpx are both 
specifically packaged into the virion through association with the p55Gag 
precursor. They remain associated with p6 portion of Gag on viral entry in the 
preintegration complex. Vpx has regions of sequence homology with Vpr, hence it 
has been suggested they may be evolutionary duplicates of one another.
Vpu is a small lOKDa, hydrophobic protein. It associates with internal membranes 
of infected cells via a hydrophobic helix that serves as a membrane anchor. 
Proposed functions include the release of gpl60 from complexes of CD4/gpl60 
that are retained in the ER. Vpu interacts with the cytoplasmic tail of CD4 causing 
its degradation (Willey et al., 1992; Lenburg and Landau, 1993; Chen et al., 1993; 
Willey et al., 1994; Buonocore et al., 1994) and the release of gpl60 (Raja et al., 
1994; Kimura et al., 1994; Fujita et al., 1997). A second recently proposed function 
for Vpu is an ability to form ion channels across the cellular membrane. The 
resultant increase in membrane permeability has been implicated in facilitating viral 
budding. One continuous theme emerging through the study of the auxiliary 
proteins is their pleiotropic nature. The apparent level of functional redundancy 
between proteins may reflect the different virus-host interactions required for 
infection across different cell types.
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Diagram 1.3. HIV-1 genome structure and mRNA expression. Top. genome map. 
Middle: The 9.2kB virion RNA, including the retroviral packaging signal (\|/) which also 
acts as the mRNA for gag-pol. The virion RNA and each of the late mRNAs contain 
the RRE sequence located in the coding sequence o f the env gene, to which the early 
regulatory protein Rev binds preventing further splicing events. Each mRNA contains 
the TAR sequence at the 5’ end and the U3 sequence at the 3 ' end Bottom: Early gene 
expression is composed of small multipley spliced mRNAs encoding the regulatory 
genes.
1.1.5. Viral cell tropism:
Early studies on CD4, the primary receptor for HIV, demonstrated that CD4 alone 
was not sufficient to confer susceptibility upon cells (Ashorn et al., 1990). It was 
shown that murine cells expressing human CD4 were capable of binding the HIV 
viral particles but the virus did not internalise, additional human factors were 
required for this process(Ashorn et al., 1990; Dragic et al., 1992; Dragic and 
Alizon, 1993). Determinants of HIV-1 cell tropism were mapped to a short region 
in the V3 loop of Env outside of the CD4 binding domain. Taken together this
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implicated the existence of a further cellular receptors necessary for HIV cell 
tropism. Subsequently, the inability of murine NIH3T3-hCD4 cells to support HIV 
infection was exploited by the laboratory of Dr. E. Berger (Feng et al., 1996; 
Ashorn et al., 1993; Alkhatib et al., 1996). In these studies they transiently 
transfected NIH3T3-hCD4 cells expressing T7 RNA polymerase and cDNA library 
plasmid pools. The cells were then monitored for their ability to fuse with NIH3T3 
cells, which expressed vaccinia encoded Env and contained the E.coli lacL gene 
linked to the T7 promoter. In situ staining with X-Gal identified cell fusion events. 
This method allowed the identification of a gene which conferred susceptibility to 
HIV infection upon the CD4-hybrid cells (Feng et al., 1996). This gene encoded a 
chemokine receptor, a member of a family G-protein coupled receptors with 7 
transmembrane spanning domains. They respond to chemokines which recruit 
leukocytes and lymphocytes to areas of inflammation. As predicted, the repertoire 
of HIV co-receptors has expanded as different cell types and HIV strains have been 
investigated (Bron et al., 1997; Sol et al., 1997; Alkhatib et al., 1997; Luo and 
Garcia, 1996) reviewed in (Unutmaz and Littman, 1997; Wilkinson, 1996; Broder 
and Collman, 1997; Berger, 1997). However, the two main receptor groups which 
correspond well to the main viral cell tropisms described, are the P-chemokine 
receptor, CC-chemokine receptor 5 (CCR5) (Deng et al., 1996; Alkhatib et al.,
1996) and the a-chemokine receptor CXC-chemokine receptor 4 (CXCR4) (Feng 
et al., 1996). The names reflect their respective chemokine ligands, with the 
arrangement of the cysteines in a conserved motif either CXC or CC defining the 
subfamily groupings.
CCR5 is expressed primarily in peripheral blood mononuclear cells (PBMCs) and 
macrophages and has been identified as fundamental to the transmission of the virus 
(Deng et al., 1996; Alkhatib et al., 1996; Bieniasz et al., 1997). This correlates with 
tissue macrophages and dendritic cells being among those cell types exposed to the 
virus, and is consistent with the predominance of HIV macrophage-tropic strains 
(M-tropic strains) early in infection (Clark, 1996). Conversely, CXCR4 is expressed 
primarily in PBMCs and on some macrophages, but mainly in T-cells and 
immortalised cell lines. Hence it is primarily the co-receptor for T-lymphocyte
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tropic (T-tropic strains) or dual tropic HIV strains (Feng et al., 1996; Bleul et al., 
1997). The transition from predominating M-tropic to T-tropic HIV strains is 
concurrent with progression to AIDS and CXCR4 receptor usage. Previous studies 
had shown that exposure to HIV did not in every case lead to seroconversion. This 
lack of transmission has since been attributed to homozygous deletions in the CCR5 
receptor, rendering it non-susceptible to HIV M-tropic infection (Dean et al.,
1996). Similar resistance has been observed in vitro in the presence of the 
chemokine ligands for CCR5, such as RANTES (regulated-upon-activation, normal 
T expressed and secreted) and the macrophage inflammatory proteins (MIP) -a and 
-p, which are postulated to confer resistance via competitive inhibition of the 
receptor. Stromal-cell-derived factor (SDF-1), a chemokine ligand for CXCR4 
behaves in the same way for T-tropic HIV strains (Bleul et al., 1996; Oberlin et al.,
1996). Despite the undisputed requirement for chemokine receptors in HIV entry, 
relatively little is known as to their role in virus-cell fusion. One hypothesis is that 
binding of Env to CD4 and a chemokine receptor induces a conformational change 
in Env, exposing the N-terminal fusogenic region of gp41 in the process (Chang et 
al., 1997; Hill et al., 1997; Weissenhorn et al., 1996; Chen et al., 1995) promoting 
subsequent viral entry. Evidence for this mechanism is based on analogies to the 
influenza virus entry (Chen et al., 1995), in conjunction with the demonstration of a 
direct interaction between Env, CD4 and various chemokine receptors (Lee et al., 
1997; Bieniasz et al., 1997; Hill et al., 1997).
1.1.6. Therapeutics:
The elucidation of the chemokine receptor family as a vital component in HIV 
infection has had important repercussions for the design of therapeutic agents. To 
date, the treatment of HIV has been limited to extending the lifespan of the patient, 
a complete cure has never been achieved. This destructive pathogenesis has been 
attributed to the plasticity of the viral genome caused by the highly error prone RT 
enzyme, which allows drug resistance strains to emerge rapidly. This has 
necessitated the administration of combination therapies which have been 
demonstrated to be more effective at suppressing HIV replication over longer 
periods of time (Larder, 1995). In addition, the nucleoside and non-nucleoside RT
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inhibitors and the PR inhibitors currently available can have severe side effects on 
healthy bystander cells, resulting in complications such as, renal and hepatic 
dysfunctions. The discovery of the HIV co-receptors has provided a novel 
mechanism to selectively target HIV infected cells. Preliminary in vitro studies by 
two groups, (Mebatsion et al., 1997; Schnell et al., 1997), used engineered HTV 
cellular receptors expressed on the surface of modified viral vectors, as novel 
therapeutic agents. In the studies, both groups replaced the G-envelope protein of 
rhabdoviruses, either Rabies or Vesicular Stomatitis virus, with both CD4 and 
CXCR4 receptors. In order for these modified viral vectors infect cells in the 
absence of their G-envelope protein, both HIV gpl20 and gp41 had to be present 
on the target cells, hence the selective targeting of only HIV infected cells. 
Mebatsion et al used replication incompetent viral vectors and were able to 
demonstrate a substantial reduction in HIV levels in vitro. In contrast, the viral 
vector designed by Schnell et al was capable of self-propagation and reduced HIV 
levels by 1000 fold. The latter vector was reported to remain viable for up to 30 
days and was effective against further bursts of HIV infection that had initially 
escaped detection. Although these modified viral vectors clearly represent a unique 
mechanism by which to destroy HIV infected cells there are safety issues 
surrounding their use that will need to be resolved. An attractive alternative (Nolan,
1997) is that the co-receptors be incorporated into liposomes containing therapeutic 
agents able to chemically destroy HIV infected cells on fusion. The strategy of 
targeting HIV gpl20 and gp41 proteins has the advantage over current therapies in 
that it has the potential to neutralise cell free virus. This is highly significant in the 
light of the rapid turnover of plasma virions identified by Ho et al and Perelson et al. 
In their work they emphasise the need to target HIV replication as opposed to 
stimulating the patients immune system. They cite the onset of AIDS as an indicator 
of the finite regenerative capacity of the immune system and suggest that viral levels 
increase as a direct result of the depletion of the host T4 lymphocyte population.
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1.2. Nef:
1.2.1. Introduction:
The nef gene encodes one of the six HIV auxiliary proteins and is unique to the 
primate lentiviruses. The initial identification of antibodies to the Nef protein in the 
serum of HIV exposed individuals implied a functional role for Nef in vivo (Allan et 
al., 1985). However, early in vitro studies concluded that the nef gene was 
dispensable for viral replication and that its protein product imposed a negative 
regulatory effect on the rate of transcription from the viral LTR, hence the acronym 
nef (Yu and Felsted, 1992; Terwilliger et al., 1986; Ahmad and Venkatesan, 1988; 
Luciw et al., 1987). Subsequent research has attempted to clarify the viral 
requirement for Nef. In vivo data from macaque simian AIDS models established 
the existence of strong selective pressures for the conservation of nef with 
engineered point mutations in the nucleotide sequence of nef rapidly reverting to 
wild type (Kestler et al., 1991; Sawai et al., 1996; Whatmore et al., 1995). The 
model also clearly illustrated, contrary to the described in vitro negative replicative 
effects of Nef, that nef incorporation into the viral genome was necessary for high 
viral loads and progression to simian AIDS. Despite the establishment of a crucial 
role for Nef in viral pathogenesis its mechanism of action still remains unclear, with 
no consensus on protein function yet agreed. Several studies have identified 
pleiotropic functions for the Nef protein, the most consistent of which include its 
ability to downmodulate CD4 expression from the cell surface, enhance viral 
infectivity and disrupt cell signalling pathways (reviewed (Harris, 1996; Trono, 
1995)). However, the significance of these and other more infrequently reported 
multiple Nef phenotypes is still to be discovered. In this section, the current 
literature on Nef molecular biology, biochemistry and cellular interactions will be 
reviewed, with emphasis given to implications for the role of Nef in viral 
pathogenesis.
1.2.2. Gene structure of nef:
1.2.2.1. Physical features:
Alleles of nef are heterogeneous in length with the HIV-1 ORF being approximately 
618bp (206 amino acids), extending to 750bp (250 amino acids) and 795bp (265
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amino acids) for HIV-2 and SIV respectively (Allan et al., 1985; Harris et al., 1992; 
Shugars et al., 1993; Rud et al., 1994). The nef sequence is highly polymorphic 
between strains and even within isolates obtained from the same individual, 
sequence variation has been frequently reported. HIV-1 nef is located at the 3’ end 
of the viral genome with -56% of its C-terminal ORF overlapping the U3 region of 
the 3’ LTR. U3 LTR sequences within the nef ORF include the polypurine tract and 
putative binding sites for the transcription factors chicken ovalbumin upstream 
promoter transcription factor (COUP-TF) (codons 125-140), activator protein 
(AP-1) (codons 133-135 and 138-139), nuclear factor 1 of activated T-cells 
(NFAT-1) (codons 151-163 and 176-180), upstream stimulatory factor (USF) 
(codons 190-195) and T-cell factor 1 alpha (TCF-a) (codons 202-206) (Shugars et 
al., 1993). The Nef protein is encoded by a number of variably spliced ^/-specific 
mRNA transcripts, the significance of which is unknown since the nef ORF is totally 
contained on the 3’ exon, one proposal is that these may constitute transitory 
species that occur during processing. These ^/-specific transcripts form 
approximately 80% of all early transcribed mRNA, the remaining 20% comprising 
tat and rev specific transcripts, therefore inferring a substantial role for nef during 
early events in viral infection (Robert-GurofFet al., 1990).
Sequencing studies have been performed on several primary and laboratory nef 
isolates in order to ascertain conserved nucleotides potentially important for nef 
function (Shugars et al., 1993; Harris et al., 1992), a brief synopsis of which is given 
hereunder (summarised in diagram 1.4). Features identified at the N-terminus of nef 
have included (codon numbering as used Shugars et al 1993); an invariant 
N-terminal myristoylation signal (codons 2-7); a stretch of highly heterogenic 
nucleotides encoding predominantly hydrophobic and basic amino acids (codons 8- 
15); and a conserved ATG codon at position 20 which acts as an internal translation 
initiation site in HTV strains. To date, no second ATG has been found in the SIV 
strains analysed. Several studies have concurred that the highest degree of sequence 
homology between nef isolates is in the central region of the ORF. This region 
contains a putative recognition site for protein kinase C (PKC) phosphorylation 
RPMTYK (codons 77-82), located just upstream of a short run of acidic residues
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(codons 62-65). Also, spanning the whole of the conserved region is a proline 
repeat motif (PXX)3P (codons 69-80), which was thought to be significant because 
similar motifs form the recognition sites for SH3 domain containing proteins (Yu et 
al., 1994; Pawson, 1995), see sections 1.3, 4.1 and 5.1. Located immediately 
downstream from this amino acid motif is the polypurine tract (codons 91-96), 
containing 16 purine rich nucleotides, essential during viral replication for priming 
second strand synthesis during reverse transcription.
Towards the C-terminus of the nef ORF the only consistently conserved nucleotides 
identified, encoded a GPG(I/V) amino acid motif (codons 130-133) potentially 
important for structural constraints as the motif is indicative of a (3-turn (Chou and 
Fasman, 1978; Shugars et al., 1993). In general, regions of least conserved 
sequence homology were located at the N- and C-termini of the ORF, with the 
exception of the myristoylation signal and a number of invariant codons. This was a 
surprising find since the 5 potential binding sites for cellular transcription factors 
together with an inverted repeat, necessary for cleavage and integration of the 
proviral DNA, were located at the C-terminus suggesting the existence of possible 
subtle sequence constraints at the RNA level in this region. The remaining feature 
potentially relevant to protein function was a clustering of premature stop codons in 
both laboratory and primary nef isolates, at codon 124. Functional motifs identified 
during these early characterisation studies of the nef gene have been consistently 
observed in most nef alleles since isolated (Huang et al., 1995; Huang et al., 1995; 
Du et al., 1995; Premkumar et al., 1996; Rousseau et al., 1997; Saksena et al., 
1997; Dwyer et al., 1997).
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Diagram 1.4. Summary o f the ne f gene structural features:
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1.2.22. Significance of nef in vivo.
The importance of nef to viral replication in vivo was highlighted during macaque 
studies by Kestler et al 1991 and has subsequently been validated by a number of 
follow up macaque (Sawai et al., 1996, Whatmore et al., 1995) and SCID-hu mice 
(Aldrovandi and Zack, 1996) studies. Kestler et a! initially demonstrated the rapid 
reversion of a stop codon (first detected at 2 weeks post-infection) at codon 93 in 
S I V m aC 2 3 9  nef to a coding codon, resulting in disease progression comparable to that 
caused by wildtype SIVmaC239- Significantly a 182bp deletion contained solely within 
the nef ORF led to a 100 fold reduction in viral burden in the rhesus macaques, with 
no disease symptoms. In further studies, these animals were found to be protected 
from subsequent challenge with wildtype S I V m a c 2 3 9  (Daniel et al., 1992). The 
protection achieved using the deleted nef (Anef) isolate provided the impetus for the 
use of attenuated HIV strains as potential vaccines (Gallimore et al., 1995; 
Ruprecht et al., 1996, StahlHennig et al., 1996; Beer et al., 1997). However, work 
by Baba et al 1995 using a Anef A vpr SIV strain in neonatal macaques, suggested 
that the protection was saturable with higher viral doses still leading to disease. 
Despite this, a key role for nef in viral pathogenesis has been corroborated with the 
investigation of potentially functionally relevant point mutations (Sawai et al., 1996) 
and short deletions (Whatmore et al., 1995) in the nef ORF resulting in reversions
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to the wild type nef sequence, thus confirming the replicative advantage to the virus 
of an intact nef gene.
Data obtained from human patients has also substantiated the requirement for nef in 
vivo. During the monitoring of the development of AIDS in human patients a small 
percentage (-5%) of HIV infected individuals, referred to as long term non- 
progressors, that had not developed AIDS were identified. These individuals were 
typically characterised as lacking clinical symptoms, immunologically normal with 
stable CD4 T-lymphocyte counts and had been infected for over 10 years. As a 
result of the outcome of the Anef SIV studies the viral genomes of several distinct 
long term non-progressor cohorts were analysed for defects in their nef genes. 
Pertinently, sequence data from the Sydney Bloodbank cohort comprising 7 
unrelated individuals infected from transfusions with the same contaminated blood, 
demonstrated a number of deletions in nef (Deacon et al., 1995). When the 
evolution of the mutations were mapped it emerged that the only deletions common 
to all the nef alleles were in their U3 overlap regions removing 46 codons, including 
a putative splice acceptor site located in this region of nef (splice acceptor 12) 
(Deacon et al., 1995). Other mutations potentially contributing to the attenuated 
viral phenotype included further variable deletions in the sequence unique to nef, 
plus duplication and rearrangement events in the untranslated U3 region. 
Subsequent work by Premkumar et al 1996 suggested that such gross mutations 
were not always required to abrogate nef function. The long term non-progressor in 
their study was found to harbour a point mutation at codon 138, the mutation of 
which had been previously linked to avirulent HIV and SIV strains (Dewhurst et al., 
1992; Huang et al., 1995). Studies of viral infectivity in the human T-cell line, H9, 
demonstrated that a cysteine mutation at codon 138 disrupted viral infectivity. From 
this and results obtained in other long term non-progressor cohorts (Saksena et al., 
1997; Rousseau et al., 1997) it has been proposed that subtle sequence variations in 
the nef gene can have important structural and hence functional implications. 
However, with notable exceptions in the long term progressor cohorts (Huang et 
al., 1995) it is likely the patient immunological subtype may also emphasize subtle 
mutant nef phenotypes.
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1.2.3. The protein product of the n e f  gene:
1.2.3.1. Characteristics:
The size of the Nef protein, either 27kDa or 34kDa for HIV and SIV respectively, 
corresponds to the differences in size of their ORFs. Both are predominantly 
expressed as N-terminally myristoylated proteins, see below, although the existence 
of a minor species of HIV-1 Nef has also been reported (Nebreda et al., 1992; 
Kaminchik et al., 1994). This is produced due to the internal initiation of translation 
from a methionine at codon 20. Recently the presence of Nef as a virion protein was 
established and subsequently several studies demonstrated a further species of Nef 
which is present in the virion and is generated by specific cleavage by the viral PR, 
concomitant with viral packaging (Pandori et al., 1996; Welker et al., 1996; 
Bukovsky et al., 1997; Miller et al., 1997). The putative recognition site for this 
cleavage is between residues Trp57 and Leu58, yielding polypeptide products of 
9kDa and 18kDa (Freund et al., 1994b). Incubation of Nef with PR in vitro has 
suggested that these cleavage products are stable and do not expose further 
protease recognition sites. However to date, only a 18-20kDa processed species of 
Nef has been detected in the virion, comprising approximately 50-95% (Pandori et 
al., 1996; Welker et al., 1996) of the total Nef protein. The whereabouts of the 
smaller N-terminal membrane targeted fragment of Nef is still to be ascertained.
Biochemical analysis to determine whether Nef was capable of oligomerization was 
performed by Hodge et al 1995, who reported that the dimerization and to a lesser 
extent tetramization of an HIV-2 allele of Nef occurred both in vitro and in vivo. 
They demonstrated the formation of oligomers was dependent on conserved leucine 
residues in a predicted a-helical region (residues 109-126) of Nef, in combination 
with putative intermolecular disulphide bond formation. Hodge et al also showed 
that the frequency of oligomerization in vitro was concomitant with increasing Nef 
concentrations, although in in vivo infected H9 T-cells, monomers, dimers and 
tetramers of Nef were all detectable. Interestingly, when the phosphorylation status 
of Nef was analysed it was found the only phosphorylated species of Nef was in the 
homodimers. This was not attributable to poor antibody epitope recognition during
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the course of immunoprecipitation of the oligomers since it was reproducible with a 
variety of antibodies.
1.2 .3 2. Myristovlation of Nef:
As previously stated Nef is a myristoylated protein (Allan et al., 1985). 
Myristoylation is a cotranslational event driven by the presence of a specific 
myristoylation peptide signal at the N-terminus of a polypeptide (reviewed (Johnson 
et al., 1994, Bhatnagar and Gordon, 1998)). Proteins containing the motif are 
modified by the irreversible addition of a 14 carbon saturated fatty acid residue via 
amide bond formation with an N-terminal glycine residue, see diagram 1.5 below. 
The reaction is catalysed by the enzyme N-myristoyl transferase present only in the 
cytoplasm of eukaryotic cells. To date, structural studies on Nef have not taken into 
account the addition of this highly hydrophobic fatty acid residue at the N-terminus 
of Nef, the conformation of which is likely to influence the whole structure of the 
protein. Nuclear magnetic resonance (NMR) structural studies of Nef revealed that 
the N-terminal 39 residues of Nef together with an internal fragment between 
residues 159-173 were highly disordered (Freund et al., 1994a; Hadida et al., 1992). 
Similarly, in crystallography studies with Nef complexed to an R96I SH3 mutant of 
Fyn (Lee et al., 1996), an N-terminal truncation of 54 amino acids of Nef was 
required to obtain crystal diffraction of sufficient resolution for analysis (2.5A). 
Pertinently, both studies used nonmyristoylated Nef for their initial analysis, it has 
hence been suggested (Harris, 1996) that structural order in these regions may be 
mediated by myristoylation.
Diagram 1.5. Myristate bound to the N-terminal glycine residue:
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By analogies to other myristoylated proteins, it is possible that Nef may have a 
dynamic conformation, whereby the myristic acid residue is either sequestered into a 
hydrophobic pocket in the protein, or anchored into membrane phospholipid 
bilayers. In support of the former conformation, structural studies have identified a 
distinct accessible hydrophobic pocket on the surface of Nef, with crystallography 
analysis revealing 2 anti-parallel a-helices formed by residues 81-93 and 104-117 
(Lee et al., 1996; Arold et al., 1997). Lining each helix are highly conserved 
hydrophobic residues which align to create the solvent accessible crevice. Structural 
studies have also located the N-terminus of Nef on the outside of the protein 
structure making it accessible to interactions with both its own surface and 
membrane structures. Similar hydrophobic pockets have been described for other 
myristoylated proteins e.g. Recoverin, a Ca2+ binding protein in photoreceptor cells, 
whose conformation alters by a Ca2+-switch mechanism. Crystallography studies of 
recoverin identified a concave hydrophobic pocket consistent with a putative 
intramolecular interaction with its myristoyl group in the absence of Ca2+ (Flaherty 
et al., 1993; Ames et al., 1996; Ames et al., 1997). Also the resolution of cyclic 
AMP dependent kinase, crystallised with an intact myristoyl group, clearly 
demonstrated the ability of proteins to sequester their fatty acid attachment into a 
hydrophobic niche (Zheng et al., 1993). Available structural data for other 
myristoylated proteins with similar labile conformations including the Src non- 
receptor tyrosine kinase family, MARCKS the myristoylated alanine rich C kinase 
substrate and ARFS the myristoylated regulatory GTP binding proteins involved in 
vesicular transport, demonstrates the conservation of distinct surface hydrophobic 
pockets among these unrelated myristoylated proteins (more structural detail can be 
found at website http://www.sdsc.edu/kinases/pk.home.html).
The dynamic nature of the Nef structure is underscored by the abundant evidence 
for the latter, myristoyl membrane anchor conformation of Nef, in conjunction with 
a variety of emerging mechanisms for myristoylation acting as a key switch between 
different protein isoforms (reviewed (McLaughlin and Aderem, 1995)). Initial 
evidence for Nef membrane association came from cellular fractionation studies 
which revealed a Nef interaction with the membrane fraction that was abolished in
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myristoylation defective Nef mutants (Kaminchik et al., 1994). Later it was 
demonstrated that myristoylation was also required for Nef virion association 
(Bukovsky et al., 1997). In viral genomes encoding a myristoylation defective Nef 
there was a profound reduction in the amount of Nef incorporated into the virion, 
resulting in a substantial attenuation of virion infectivity. Also, a direct interaction 
of Nef with CD4 was only demonstrable in the context of a myristoylated Nef in the 
presence of a membrane (Harris and Neil, 1994). Although these examples clearly 
corroborate a dependence on myristoylation for the membrane association of Nef 
the concept of it acting as a membrane anchor per se has been difficult to 
demonstrate. It is known that the addition of a myristic acid residue alone provides 
insufficient membrane affinity to hold a protein in position and that the membrane 
interactions of local amino acid sequences is crucial (Peitzsch and McLaughlin,
1993). Peptide study data has shown that the Nef N-terminal 26 amino acids 
facilitate the insertion of the myristic acid residue into the lipid bilayer, as the 
addition of a myristic acid residue to a peptide derived from internal Nef sequences 
did not disrupt liposome bilayers (Curtain et al., 1994; Curtain et al., 1997). 
Interestingly, a tyrptophan residue at position 5 was shown to be implemental in 
perturbing the phospholipid bilayer and when the peptide was added to a variety of 
cell cultures it was found to be cytotoxic to the cells (Curtain et al., 1997).
Work with other myristoylated proteins has identified a number of factors that are 
responsible for reversible membrane interactions including; specific protein-protein 
interactions with transmembrane proteins, e.g. p56Lck plus CD4 and CD8 
(Veillette et al., 1988; Shaw et al., 1990); additional hydrophobic interactions 
provided by the palmitoylation of a nearby cysteine residue e.g. Src kinases, 
Guanine nucleotide binding protein (G-protein)-linked receptors and the a-subunits 
of heterotrimeric G-proteins; and electrostatic interactions between a cluster of 
basic amino acid residues within the protein and acidic phospholipids in the 
membrane bilayer e.g. MARCKS (Aderem, 1992; McLaughlin and Aderem, 1995). 
The latter, allows reversible membrane association by a process termed the 
“myristoyl-electrostatic-switch” This process is regulated by the phosphorylation of 
residues proximal to the stretch of basic residues within the protein.
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Phosphorylation results in the repulsion of the protein from the phospholipids of the 
membrane and destabilization of the electrostatic interactions. Due to a 
concentration of basic residues between residues 7-22 of Nef with proximal Ser and 
Thr residues the possibility that Nef membrane association was regulated in this 
manner was examined. Previous work had shown Nef was phosphorylated in vitro 
by PKC and that phosphorylation levels were enhanced in recombinant vaccinia 
virus infected BHK21 cells on phorbol ester stimulation (Guy et al., 1987), this was 
corroborated by studies in our laboratory (Coates and Harris, 1995) and others 
(Bodeus et al., 1995; Luo et al., 1997). The extension of these studies to human 
Hela and Jurkat cells (Coates et al., 1997) revealed Nef phosphorylation of Ser 
residues and to a lesser extent Thr residues was inhibited by PKC specific inhibitors, 
but not inhibitors of mitogen activated protein kinase (MAPK) or cyclic AMP 
dependent kinase. Unexpectedly, after fractionation analysis phosphorylated Nef 
was found to be equally distributed between membrane and cytosolic pools. This 
implied Nef phosphorylation was either occurring at variable sites in the protein 
dependent on its subcellular localization or that other protein-protein interactions 
are responsible for its dynamic membrane association, since Nef is not 
palmitoylated.
1.2.3.3. Nef subcellular localization:
The intracellular distribution of Nef has been examined in numerous studies 
(Franchini et al., 1986; Yu and Felsted, 1992; Niederman et al., 1993; Kaminchik et 
al., 1994; Baur et al., 1994; Coates et al., 1997). The consensus from fractionation 
studies is that native Nef associates with primarily the membrane and cytosolic 
fractions of cells (Franchini et al., 1986; Yu and Felsted, 1992; Niederman et al., 
1993; Kaminchik et al., 1994; Coates et al., 1997). There have been some reports of 
Nef interactions with the detergent insoluble cytoskeletal fractions, although this 
appears to vary among Nef isolates with some researchers seeing no association 
(Niederman et al., 1993; Kaminchik et al., 1994) (Harris personal communication). 
Where cytoskeletal association has been reported it was shown to be dependent on 
the (PXX)3P repeat motif in Nef. In all cases myristoylation negative mutants of Nef 
were found exclusively in the cytosolic fractions. One isolated report using
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immunofluoresence microscopy has also documented an abundance of the 
nonmyristoylated species of Nef present in the nucleus (Yu and Felsted, 1992), 
although others have not found this (Greenway et al., 1995). Limited evidence for 
extracellular Nef, has been provided by its ability to be secreted from stress induced 
yeast (Macreadie et al., 1995)and a study by Fujii et al 1993 which suggested Nef 
may be anchored extra-cellularly to the plasma membrane although there has been 
no conformation of these initial studies. In general, due to the vast number of cell 
types and different Nef isolates used in Nef research it is accepted that while the 
occasional different cell type or Nef isolate may deviate, native Nef is predominantly 
distributed dynamically between the membrane and cytosol.
1.2.4. Nef mediated virion infectivity:
The Nef effect on viral infectivity has been dogged by uncertainty and conflicting 
results. Early studies on Nef utilised CD4 T-cell lines of malignant phenotypes or 
activated PBMC cultures, since the initial characterisation of HIV had shown 
propagation of the virus was dependent upon T-cell activation. It was in this 
background that Nef was originally demonstrated to have a negative affect on viral 
replication (Terwilliger et al., 1986; Luciw et al., 1987). Work with LTR reporter 
constructs concurred with Nef induced negative regulation on the rate of 
transcription (Ahmad and Venkatesan, 1988; Yu and Felsted, 1992). Evidence from 
subsequent reports controversially proposed no Nef effect (Hammes et al., 1989) or 
even a slight enhancement of viral replication by Nef (Kim et al., 1989; de Ronde et 
al., 1992). Further conflicting evidence came from the in vivo macaque data (see 
section 1.2.1.2), where the presence of nef was shown to increase viral load in the 
animals, hence inferring a positive role for Nef in viral replication. This 
contradictory data was rationalised by two studies (Miller et al., 1994; Spina et al., 
1994) in which the in vitro tissue culture setting was adapted to more closely mimic 
that of an in vivo environment. By using quiescent CD4 lymphocyte and primary 
macrophage populations infected with different amounts of viral inoculum and 
activated at different times post-infection, Miller et al 1994 and Spina et al 1994 
were able to show a positive viral replication effect for nef In contrast, in the 
background of a continuous cell culture both groups reported no nef enhancement
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of viral infectivity. Significantly, the nef mediated enhancement of infectivity was 
most prominent at low multiplicities of infection. This prompted speculation that nef 
inclusion was critical during early stages of infection, when maximal viral burst from 
infected quiescent cells is necessary for the virus to achieve a persistent infection. It 
was also proposed that in activated cells, cellular factors may mask the nef function 
possibly due to a redundancy in function between Nef and host proteins in this 
setting.
As well as the primary cell culture assay for the analysis of HIV replication kinetics, 
a single cycle assay in CEM cells was also developed (Chowers et al., 1994). The 
establishment of these reliable in vitro systems, facilitated the evaluation of the 
relative contributions of amino acid motifs in nef to the overall replication kinetics 
of the virus. Mutations that abolished myristoylation were shown to completely 
abrogate Nef induced enhancement of viral replication (Chowers et al., 1994; 
Goldsmith et al., 1995; Pandori et al., 1996). This suggested that myristoylation 
must either confer the protein conformation or subcellular location necessary for the 
Nef disruption of cell signalling cascades and the subsequent increase in virion 
production. Data concurring with the importance of the subcellular location of Nef 
was obtained by Baur et al 1994 in experiments using a CD8-Nef chimera, where 
Nef was substituted for the CD8 cytoplasmic sequences. Their results indicated that 
membrane associated CD8-Nef activated Jurkat T-cells. In contrast, cytoplasmic 
CD8-Nef appeared to inhibit the production of T-cell signalling markers. Further 
functionally critical amino acids identified in Nef for viral infectivity have included, a 
run of acidic residues (60-71) adjacent to the viral PR cleavage site (Iafrate et al.,
1997) and the highly conserved (PXX)3P repeat motif (residues 69-80) (Goldsmith 
et al., 1995; Saksela et al., 1995). As a consequence of the latter, Src homology 3 
(SH3) domain containing proteins have been extensively investigated as potential 
interaction partners for Nef, due to their recognition of proline n  helix motifs and 
their involvement in cellular activation pathways, discussed in more detail in section
1.3.
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A number of studies have been undertaken to identify the mechanics of Nef 
stimulation of HIV replication. From these it is clear that Nef exerts its positive 
influence after viral entry into the target cell. It was demonstrated (Miller et al., 
1995; Aiken and Trono, 1995) that a ANef viral genome could be complemented in 
trans in the viral producer cells, but not in the target cells. This was explained by 
the observation of Nef inclusion in the virion. Furthermore, work by Miller et al 
1997 has shown that by enhancing viral PR cleavage of Nef in the virion, an intact 
C-terminal core domain alone is insufficient to mediate the Nef phenotype. The 
mutations in Nef used to demonstrate this were all upstream of the PR cleavage site 
and hence were contained in the N-terminal fragment of Nef. It is therefore possible 
that either full length Nef is required for virion infectivity or that the N-terminal 
fragment plays a crucial role and the mutations in this region disrupted its function. 
A co-operative role for Nef with either the HIV envelope glycoproteins or cell 
surface CD4 during viral entry seems unlikely, as HIV-1 virions pseudotyped with 
the amphotropic murine leukaemia virus envelope glycoproteins show no disruption 
in their Nef mediated phenotype (Aiken and Trono, 1995). Nef enhancement of 
infectivity prior to viral genome integration was inferred by data from transfection 
studies where no differences in virion production was seen between wild type and 
ANef genomes (Chowers et al., 1994). In addition, quantitative PCR analysis 
demonstrated that despite no detectable changes in both the viral RT activity and 
initial RNA levels in the presence of Nef, the rate of DNA synthesis was 
substantially increased (Aiken and Trono, 1995; Schwartz et al., 1995b). It has 
hence been suggested that Nef may act to stabilise the local environment of the 
preintegration complex, or even recruit cellular factors necessary for successful 
reverse transcription of the genome, such as cations or nucleotides. However, in 
view of the fact that no transcriptionally related cellular interaction partners have 
been described for Nef, the involvement of indirect interactions that could 
potentially stimulate their production seems more probable.
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1.2.5. Nef disruption of cell signalling pathways:
1.2.5.1. Nef phenotype:
Accumulating evidence has suggested that Nef may also perturb cell signal 
transduction pathways, potentially contributing to the depletion of CD4+ 
lymphocytes and enhanced virion productivity during HIV infection. However, the 
reported alterations in intracellular signalling mediated by Nef, have not provided a 
clear indication of exactly how, when and where Nef affects these pathways. From 
in vivo Nef transgenic mice models (Skowronski et al., 1993b) it was evident that 
Nef expression, under the transcriptional control of a promoter derived from the 8 
subunit of the CD3-T-cell receptor (TCR) complex, selectively inhibited the 
production of thymic and peripheral T-cells. The CD4+ T-cell subset was identified 
as the most severely affected, although peripheral CD8+ T-cells in young animals 
were initially suppressed, but recovered as the animals matured. The intracellular 
mechanism for this observation was unknown but interestingly it was revealed that, 
despite decreased amounts of thymocytes, the activation status of these cells was 
elevated after specific stimulation with CD3 antibodies. Conversely, stimulation 
with phorbol ester and calcium ionophore, hence effectively bypassing the 
CD3-TCR complex, resulted in unaltered levels of cellular activation. Therefore, 
Nef was specifically enhancing CD3-TCR complex signalling without the 
subsequent T-cell differentiation and proliferation.
In vitro studies have analysed the levels of T-cell activation markers in T-cell lines 
after CD3-TCR stimulation and identified both decreased IL-2 and IL-2 receptor 
production and down-regulation of NF-kB and API transcription factors (Luria et 
al., 1991; Bandres and Ratner, 1994; Greenway et al., 1994; Greenway et al., 1995; 
Collette et al., 1996a; Collette et al., 1996b); thus implying that, contrary to the in 
vivo results, TCR distal events are inhibited by Nef expression in an in vitro setting. 
Consistent with this, a Nef block of early CD3-TCR complex proximal signalling 
was also evident as determined by the early activation antigen, CD69 (Iafrate et al.,
1997). Early signalling events were unaffected by PMA or calcium ionophore 
stimulation. These two agents stimulate cells downstream from the CD3-TCR 
complex via protein kinase C activation or calcium dependent responses
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respectively, it has therefore been postulated that the in vitro block to CD3-TCR 
signalling must occur either upstream of these pathways or to a putative parallel 
pathway. Explanations for the discrepancies between in vivo and in vitro data have 
been speculative, but are primarily based on the combinatorial effects of Nef. It has 
been postulated that the additional influence of the Nef perturbation of CD4 
signalling pathways in the in vivo model could have a profound effect on the overall 
cellular activation. In addition, it has been demonstrated (Baur et al., 1994) that Nef 
expression targeted to the plasma membrane via a CD8-Nef chimera resulted in 
T-cell activation, in contrast cytoplasmic Nef expression inhibited activation. This 
raises the possibility that the high levels of Nef expressed in the in vitro systems 
meant increased levels of cytoplasmic Nef, concurring with the dominant inhibition 
of signalling pathways seen in these systems.
1.2.5.2. Nef putative interaction partners:
In order to identify how Nef was perturbing intracellular signalling, Nef interaction 
partners were investigated. Early work on Nef characterised it as a GTPase with 
autophosphorylation abilities that was phosphorylated on an N-terminal Thr 15 
residue by protein kinase C (Guy et al., 1987). The catalytic activities initially 
associated with Nef have been refuted as a consequence of incomplete purification 
(Backer et al., 1991), but its phosphorylation albeit on variable Ser and Thr residues 
has been confirmed by a number of studies (Coates and Harris, 1995; Bodeus et al., 
1995; Coates et al., 1997; Luo et al., 1997). In T-lymphocytes membrane bound 
Nef was found to be stably associated with a protein complex containing a cellular 
serine kinase (reviewed (Cullen, 1996)). The Nef complex contained two putative 
substrates of the kinase (621dDa and 72kDa) in T-cells, although in COS-7 and 
NIH3T3 cells only the smaller protein was detectable (Sawai et al., 1994; Sawai et 
al., 1995). Nef itself was not phosphorylated by the kinase. Nef mutations 
abolishing kinase binding included the Gly2 necessary for myristoylation, a double 
Arg motif (residues 137 and 138) and the (PXX^P motif (Wiskerchen and 
ChengMayer, 1996). All of these mutations were also demonstrated to abrogate Nef 
augmentation of viral replication and the first two prevented Nef down-modulation
50
of CD4. This has made it difficult to reconcile phenotypes solely attributable to the 
kinase association.
Data has subsequently shown that the Nef associated serine kinase was related to 
the p21-activated kinase (PAK) family of signal transduction molecules, which 
themselves are putative activators of the mitogen activated protein kinase (MAPK) 
family (Luo and Garcia, 1996; Nunn and Marsh, 1996). Activation factors of PAKs 
are small Ras-like GTP-binding proteins, RacI and Cdc42 normally linked to cell- 
surface receptors and involved in actin polymerization and endocytosis. It was 
demonstrated that dominant-negative mutants of RacI and Cdc42 blocked the 
activation of the PAK isozyme by Nef (Lu et al., 1996). A competitive inhibition 
was unlikely, because constitutively active RacI and Cdc42 mutants enhanced the 
Nef associated serine kinase activity, prompting speculation that Nef association 
with and activation of the serine kinase was via RacI and Cdc42. In vivo macaque 
studies using an SIVmac2 3 9 virus containing the double Arg mutation showed rapid 
reversion to wildtype implying a functional requirement for these residues (Sawai et 
al., 1996), whereas point mutations in the (PXX)3P motif did not revert to wildtype 
(Lang et al., 1997). It has hence been proposed that the association of the PAK-like 
serine kinase is dispensable in vivo and that pleiotropic functions conferred by the 
double Arg mutation are of greater significance. The lack of reversion of the 
(PXX)3P motif also had implications for SH3 mediated interactions, discussed in 
section 1.3 and section 6.3. A role for the Nef PAK-like kinase association has also 
been questioned by Luo et al 1996 and 1997, who have suggested it is Nef isolate 
dependent and is not sufficient for the enhancement of infectivity.
Initial investigations of the Nef associated kinase activity revealed two further 
kinases that specifically associated with the N-terminus of Nef (Baur et al., 1997). 
These have been identified as the non-receptor kinase pS b^  (Lck) (discussed in 
more detail in section 1.3) and a serine kinase, distinct from the PAK-like kinase. 
The latter phosphorylated Nef and Lck in vitro. Deletion of a putative amphopathic 
helix at the N-terminus of NefsF2 (A 16-22) which abrogated binding of the kinases 
in vitro, was shown to reduce Nef mediated enhancement of infectivity in primary
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cell culture assays. However, successful incorporation of the mutant Nef into the 
virion was not demonstrated, therefore the decrease in infectivity may be 
attributable to the absence of Nef in the virion. A possible candidate for the 
N-terminal serine kinase is the theta isoform of protein kinase C (0PKC). Recently a 
direct interaction between Nef and 0PKC has been demonstrated, which occurred 
independently of the substrate binding site (Smith et al., 1996). No data was 
presented regarding the phosphorylation status of Nef in these experiments. 
Notably, Nef expression in Jurkat T-cells was shown to decrease levels of cytosolic 
0PKC without the concomitant increase of 0PKC in the particulate fraction. It was 
speculated that this may be due to a Nef mediated disruption of 0PKC binding to 
endogenous anchoring proteins or receptors for activated C-kinases (RACKs) 
rendering the activated kinase susceptible to proteolytic degradation. A Nef block 
or reduction of 0PKC activity would be consistent with the inhibition of CD3-TCR 
signalling pathways previously reported in vitro. An alternative suggestion is that 
the binding of Nef to cellular kinases is relatively non-specific and occurs purely to 
recruit kinases to the virion (Swingler et al., 1997). It is known that 
phosphorylation of the Gag MA protein on both Ser and Tyr residues is necessary 
during viral infection for nuclear targeting of the PIC (Bukrinskaya et al., 1996; 
Gallay et al., 1995b), therefore one of the functions of Nef may be to ensure 
successful packaging of suitable kinases into the virus particles.
1.2.6. Nef mediated CD4 down-modulation:
To date, cell surface down-modulation of the primary receptor of HIV and SIV, 
CD4 has been the only consistently reproducible function of Nef reported. It has 
been demonstrated to be cell type and Nef isolate independent (Abraham et al., 
1991; Anderson et al., 1993; Garcia et al., 1993; Mariani and Skowronski, 1993; 
Foster et al., 1994), but is dependent on Nef myristoylation (Greenway et al., 
1994). In addition, murine and simian CD4 molecules on the cell surface of murine 
T-cells (Garcia et al., 1993; Rhee and Marsh, 1994a), as well as murine CD4 of 
T-cells from transgenic mice were shown to be down-modulated by HIV-1 Nef 
expression (Brady et al., 1993; Skowronski et al., 1993a). The cytoplasmic domain 
of CD4 (38 amino acids) is sufficient for its down-modulation (Garcia et al., 1993;
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Anderson et al., 1994), with a dileucine motif analogous to the endocytosis and 
lysosomal targeting signals found in CD3 y and 5 chains, identified as a crucial 
determinant (Aiken et al., 1994; Bandres et al., 1995; Grzesiek et al., 1996). 
Residues in Nef important for CD4 down-modulation cluster around the N- and 
C-terminal predicted flexible loops (residues 36-56 and 174-179) (Iafrate et al., 
1997; Hua et al., 1997). Further mutational analysis of Nef has demonstrated that 
the down-modulation of CD4 is also independent of Nef mediated infectivity 
(Goldsmith et al., 1995; Saksela et al., 1995; Iafrate et al., 1997).
The mechanism for Nef accelerated CD4 down-modulation has been the subject of 
intense investigation. CD4 is a transmembrane glycoprotein of 55kDa and is 
normally anchored in the plasma membrane by association of its cytoplasmic tail 
with Lck (Veillette et al., 1988; Campbell, S. et al., 1995). The external domain of 
CD4 binds the non-polymorphic region of major histocompatibility complex class II 
(MHC II) and is recruited to the CD3-TCR receptor complex during TCR-MHCII 
antigen recognition where it acts as an enhancer of TCR signalling. Normally 
binding of CD4 to MHCII triggers PKC activation which phosphorylates serine 
residues in the CD4 cytoplasmic tail causing Lck dissociation and activation. 
Without the Lck membrane anchor CD4 is endocytosed and either directed to the 
lysosomes for degradation or recycled back to the cell surface(Veillette et al., 1989; 
Sleckman et al., 1992; Pelchen-Matthews et al., 1993). It was rapidly established 
that Nef expression did not disrupt the synthesis of CD4 mRNA or its transit 
through the endoplasmic reticulum and Golgi to the cell surface. However, it was 
noted that surface CD4 expression was inversely related to Nef expression 
suggesting Nef was inducing CD4 endocytosis. Mutation of the serine residues in 
the cytoplasmic tail of CD4 crucial for normal PKC mediated down-modulation 
were found to have no effect on Nef induced down-modulation of cell surface CD4, 
thus implying it was occurring via a novel mechanism (Garcia and Miller, 1991). 
Pulse-chase experiments revealed the half life of CD4 in cells expressing Nef was 4 
fold lower than control cells, suggesting that Nef was promoting the degradation of 
CD4 (Rhee and Marsh, 1994b; Aiken et al., 1994). The introduction of 
lysomotropic agents, ammonium chloride and chloroquine inhibited CD4
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degradation, confirming Nef was redirecting CD4 to lysosomes. This finding was 
corroborated by a number of groups (Rhee and Marsh, 1994a; Sanfridson et al.,
1994). In addition, immunoelectron and immunofluorescence microscopy studies 
demonstrated the accumulation of CD4 in vesicles throughout the endosomal and 
lysosomal cellular compartments (Schwartz et al., 1995a; Sanfridson et al., 1997).
A direct interaction between Nef and the CD4 cytoplasmic domain has been 
demonstrated in vitro (Greenway et al., 1995; Grzesiek et al., 1996) and in the 
baculovirus (Harris and Neil, 1994) and yeast-two-hybrid expression systems (Rossi 
et al., 1996). In addition, evidence from overlapping HTV-1, HIV-2 and SIV CD4 
target sites inferred a genetic conservation of CD4 recognition (Foster et al., 1994; 
Hua and Cullen, 1997). However it has been proposed that the association is likely 
to be transient as a stable interaction has not been demonstrated in mammalian cells 
and the KD of a CD4 cytoplasmic pseudopeptide complexed with Nef was ~lmM 
(Grzesiek et al., 1996). Conceivably, association of these two molecules could 
allow Nef to confer an altered mechanism of CD4 endocytosis. Pertinently, an 
elevation of Nef phosphorylation associated with PMA/PHA cellular stimulation has 
been demonstrated to correlate with enhanced CD4 down-modulation, suggesting 
Nef may mimic CD4 endocytosis signals (Luo et al., 1997). Furthermore, a series of 
recent studies have suggested a role for Nef as an adapter molecule between CD4 
and the endocytic machinery (Mangasarian et al., 1997; Greenberg et al., 1997; Foti 
et al., 1997). The expression of Nef as a chimera with the green fluorescent protein 
in CD4 positive Jurkat T-cells was shown to co-localize with that of clathrin and the 
(3-subunit of the AP-2 adapter protein complex at the plasma membrane (Greenberg 
et al., 1997). Clathrin is the primary component of hetero-oligomeric complexes 
which along with AP-2, forms coated pits at membrane invaginations (reviewed 
(Schmid, 1997)). It is involved in coated vesicle formation during endocytosis and 
the selective packaging of cargo and as a consequence the normal endocytosis of 
CD4. The expression of Nef was demonstrated by electron microscopy to 
specifically promote CD4 association with clathrin coated pits, since control 
experiments showed the rate of internalization of the transferrin receptor was 
unaltered (Foti et al., 1997). Nef expression in CD4 positive cells also increased the
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percentage of cell surface area occupied by clathrin-coated structures. These Nef 
effects were shown to be dependent on the dileucine motif in the CD4 cytoplasmic 
tail. Nef in the context of a CD4-Nef chimera was also demonstrated to promote 
clathrin coated pit formation, hence it was suggested that Nef itself was a catalyst 
for pit formation (Foti et al., 1997). This has implications for the Nef mediated 
endocytosis of other cellular responses, however awaits confirmation in the context 
of native Nef. While these results are suggestive of a direct interaction between Nef, 
CD4 and components of the endocytic machinery, to date none has been 
demonstrated and a role for Nef as a connector molecule remains interesting but 
speculative.
1.2.7. The role of Nef in HIV immune evasion:
Recently it has been demonstrated that Nef expression increased the endocytosis 
rate of MHC-I molecules from the cell surface in a range of HIV-1 infected cells 
(Schwartz et al., 1996). Perturbation of MHCI presentation is a common strategy of 
immune evasion employed by many viruses e.g. adenovirus, human and murine 
cytomegaloviruses, herpes simplex viruses and poxviruses, and allows virus infected 
cells to avoid detection and destruction by cytotoxic T-lymphocyte (CTL) 
(reviewed (Oldstone, 1997)). It had been previously shown during vaccination 
studies that high levels of Nef specific CTLs (Gallimore et al., 1995) correlated with 
a reduced viral load in macaques. However, evidence that Nef expression conferred 
CTL resistance concomitantly with reduced cell surface MHCI epitope density was 
shown in cell culture by Collins et al 1998. While ANef viruses were susceptible to 
CTL destruction, further work is necessary to confirm MHC-I down-modulation is 
the mechanism of CTL evasion. Another putative mechanism of CTL escape was 
proposed by Xu et al 1997. In their study they demonstrated CTL protection 
correlated with Nef induced increased FasL receptor expression on the surface of 
infected cells. FasL plays a crucial role in the apoptosis of lymphocytes and its 
expression is normally restricted to activated lymphocytes. FasL intercellular 
recognition of its counter ligand Fas, also a cell surface receptor, triggers apoptosis 
in the latter target cells. Research has revealed that during the pathogenesis of HIV 
there is a progressive loss of uninfected, both CD4+ and CD8+ T-cells. The Nef
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enhancement of FasL expression on infected lymphocytes provides a mechanism by 
which this could occur. Levels of FasL expression are intrinsically linked to T-cell 
activation therefore Nef interaction with signal transducers such as those previously 
described in section 1.2. or the Src tyrosine kinases (section 1.3) could be 
instrumental in mediating enhanced FasL expression.
1.2.8. Miscellaneous:
With research currently being directed towards Nef cellular interaction partners 
there have also been a number of isolated associations identified for Nef. Briefly 
these include putative interactions with; (3-COP a non-clathrin vesicle protein 
having possible relevance to Nef mediated endocytosis (Benichou et al., 1994); 
HsN3 a proteasomal subunit involved in nonlysosomal breakdown of misfolded 
proteins in eukaryotic cells e.g. MHC-I viral peptides (Rossi et al., 1997); p53 the 
anti-oncogene involved in apoptotic signalling pathways (Greenway et al., 1995); 
and a novel acyl Co-A thioesterase, inferring a possible role in the alteration of 
cellular fatty acid regulation (Watanabe et al., 1997). Nef has also been reported to 
bind RNA in cell free systems, having possible implications for the observed 
elevated levels of proviral DNA synthesis in the presence of Nef (Schwartz et al., 
1995b). Despite an array of interaction partners it is clear Nef is having cellular 
affects that may not be mutually exclusive. It is likely that the key to the pleiotropic 
functions of Nef lies in its modulation of cell signalling pathways, conceivably 
simultaneously resulting in the down-regulation of specific cell surface molecules 
and enhancement of virion infectivity. The following section presents evidence for a 
Nef interaction with members of the family of Src tyrosine kinases which are highly 
conserved signal transducers and represent a putative Nef target.
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1.3. Nef and the Src tyrosine kinases:
1.3.1. Introduction to the Src tyrosine kinases:
The Src tyrosine kinases are a highly conserved family that regulate cellular 
responses to extracellular signals via their non-covalent association with 
transmembrane receptors (reviewed (Brown and Cooper, 1996; Mayer, 1997)). 
There have been 9 family members identified to date, including Src, Fyn, Yes, Fgr, 
Lyn, Hck, Lck, Blk and Yrk. At least one family member is expressed in all higher 
animal cell types examined, with the highest number identified in cells of 
haematopoietic origin. Family members are characterised by their unique mechanism 
for regulating their kinase activity and their distinctive domain structuring (see 
diagram 1.6.). Each comprises (from N- to C-terminus): i) A short amino-terminal 
sequence, containing a Gly2 residue necessary for myristoylation and membrane 
association. With the exception of Src and Blk all these proteins are reversibly 
palmitoylated on cysteine residues (normally positions 3 or 6). Palmitoylation has 
been directly implicated in the association of these proteins with 
glycosyl-phosphatidylinosital (GPI) linked proteins and plasma membrane 
microinvaginations called caveolae (see section 4.1) e.g. Lck, Fyn, Fyr, Lyn 
(Shenoyscaria et al., 1994; Stenberg et al., 1997), Hck (Robbins et al., 1995). ii) A 
unique domain, which is the only heterogeneous region between family members, 
varying in sequence and size (from 40 to 50 amino acids in Lyn, Hck, Lck and Blk 
extending to -70 amino acids in Src, Yes, Fyn, Yrk and Fgr). The unique domain is 
responsible for mediating the differing protein interactions, subcellular localisations 
and kinase regulation of each member, iii) A Src homology 3 (SH3) domain (50-60 
residues), which recognises left-handed poly-proline type II helices (see diagram
1.7.), similar domains are also found in cytoskeletal components (Yu et al., 1994; 
Alexandropoulos et al., 1995; Pawson, 1995). iv) A Src homology 2 (SIC) domain 
(-100 residues) which specifically binds phospho-tyrosine containing proteins 
(Songyang, 1993; Songyang and Cantley, 1995; Pawson, 1995). The SID and SIC 
domains are non-catalytic modular domains common amongst cell signalling 
proteins and act as intermolecular adapters regulating enzyme-substrate recognition, 
enzyme activity and subcellular localization (Pawson, 1995). The specificity of the 
domains is conferred by localized amino acid sequence of their respective
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recognition motifs (Songyang and Cantley, 1995). v) A catalytic tyrosine kinase 
domain (-250 residues), capable of trans and auto- phosphorylation, important for 
the transmission of external stimuli, vi) A short carboxy-terminal tail, consisting of 
a site for Csk tyrosine phosphorylation involved in the negative regulation of the 
catalytic domain Intermolecular binding of the phosphorylated tail to the SH2 
domain provides one mechanism of occluding the kinase active site from potential 
substrates (Amrein et al., 1993, Cooper and Howell, 1993).
Diagram 1.6. Schematic diagram o f Lck to show sequence and post- 
tramlational features. Specific Lck posttranslational modificatiom are 
shown above the sequence along with the enzymes respomible. The 
characterisation o f domains common to all Src fam ily members is 
labelled below.
Glv2: Myristoylation site 
Cys3: Palmitoylation site
Ser42: Phosphorylated by PKC 
Ser59: Phosphorylated by MAPK
Tyr505: Csk phosphorylation
Tyr394: autophosphorylation site 
Tyrl92: Phosphorylation site (Syk?)
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Currently, there have been three mechanisms of control proposed for the regulation 
of Src tyrosine kinase activity. The first and most established mechanism is provided 
by the reversible phosphorylation of the C-terminal tail (Cooper and Howell, 1993, 
Brown and Cooper, 1996). A paradigm for this is Lck, whereby negative regulation 
occurs due to Csk phosphorylation of the carboxy-Tyr505, as alluded to above. In 
this model the kinase is reactivated on dephosphorylation of Tyr505 by the 
transmembrane phosphatase CD45, hence disturbing the intramolecular association 
with the SH2 domain. However, mutagenesis and structural studies have revealed 
that dephosphorylation is not sufficient to fully activate the kinase and further
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autophosphorylation of Tyr394 in the activation loop of the active site is necessary 
for high levels of kinase activity (Johnson et al., 1996; Yamaguchi and Hendrickson,
1996). The second model proposed as a result of recent crystallography studies 
(reviewed (Mayer, 1997)) (Brown and Cooper, 1996; Xu et al., 1997), shows the 
same intramolecular SH2 binding being activated not by CD45 but by a ligand to 
the SH3 domain: SH3 was shown to form intramolecular associations with a poly­
proline type II helix formed by the linker region between the SH2 and kinase 
domain (Sicheri et al., 1997). Activation of the kinase has therefore been proposed 
to result from SH3 domain displacement, leading to an overall destabilization of the 
inactive structure and release of constraints on the kinase active site (Moarefi et al.,
1997). This would allow autophosphorylation of the activation loop and subsequent 
upregulation of kinase activity. Interestingly, this study was performed using an 
N-terminally truncated Hck A1-77, effectively removing myristoylation, 
palmitoylation and the unique targeting signals. The significance of this is discussed 
in chapter 5, since the ligand used in the study was Nef. There is also evidence from 
other members of the Src family of SH2 ligand mediated kinase activation e.g. Src 
and Fyn exhibit SH2 phospho-tyrosine dependent binding to pTyr residues in the 
PDGF and CSF1 growth factor receptors which has been reported to elevate the 
Src kinases catalytic activity (reviewed (Brown and Cooper, 1996)). In support of 
this activation mechanism, SIB and SIB domains have a higher affinity for their 
respective cellular ligands than their intramolecular binding motifs. This allows a 
specific ligand to compete for its domain and disrupt intramolecular associations. 
This model relies on the principle that neither the SH3 or SIB domain 
intramolecular interaction alone is sufficient to maintain the inactive kinase 
conformation (reviewed (Mayer, 1997)).
The third putative control mechanism for Src kinase activity implicates structural 
changes that are independent of carboxy-terminal phosphorylation events 
(Nakashima et al., 1994; Pu et al., 1996). Pu et al 1996 demonstrated that low 
concentrations of mercuric ions (Hg2+), which specifically bind sulfhydryl groups in 
proteins, caused a rapid elevation of Src kinase activity. Hg2+ can mimic cellular 
disulfide isomerase and cause the formation of a modified disulfide bond
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(R-S-Hg-S-R) between 2 adjacent sulfhydryl groups (R-S). This activation was 
independent of C-terminal phosphorylation because cyanogen bromide cleavage of 
Src showed no reduction in phosphorylation of this residue, after Hg2+ treatment. 
These results were consistent with the observation of elevated Src tyrosine kinase 
activity in cells under oxidative stress. Oxidative stress can result from cellular 
exposure to agents such as oxidants (H2O2), ultraviolet radiation or heavy metal 
ions and leads to the production of oxygen radicals. These in turn promote disulfide 
bond formation among adjacent sulfhydryl groups catalysed by protein disulfide 
isomerase. Further data corroborating the importance of cysteine residues for Src 
kinase activity was obtained during mutagenesis studies of Lck by Veillette et al 
1993. They demonstrated that mutation of either Cys 464 or 475 completely 
abolished all catalytic activity of Lck.
1.3.2. Evidence for Nef interactions with Src tyrosine kinases:
In order to gain an insight into the conflicting data obtained for the Nef mediated 
disruption of cell signalling cascades many groups investigated potential Nef 
interaction partners. The elucidation of the poly-proline type II helix as the 
consensus binding motif for SIC domains, made Nef a suitable substrate/binding 
partner for SH3 containing proteins. Interactions with the family of cytoplasmic Src 
tyrosine kinases were examined since they are myristoylated, membrane associated 
proteins and importantly are intrinsically involved in the cellular activation pathways 
of haematopoietic cells.
Early work using filter binding assays (Saksela et al., 1995), confirmed the (PXX^P 
motif mediated binding of Nef peptides to Hck and Lyn SH3 domains but not Lck 
and Fyn. However, when GST-Nef expressed in E.coli was bound to the SIC 
domains it was found that only Hck SIC retained its ability to bind Nef. Also in this 
assay, a second less conserved proline motif (residues 147-150) towards the 
C-terminus of Nef was necessary for binding in the context of full length 
nonmyristoylated Nef. Comparison of the growth kinetics of Nef+ viruses 
demonstrated that mutations in the conserved (PXX)3P motif abolished Nef 
enhancement of virus replication. No affect on CD4 down-modulation was detected
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(Saksela et al., 1995). Measurement of the affinities of these Nef-SH3 interactions 
revealed that full length Nef bound to Hck SH3 with a KD of 250nM, the highest 
reported affinity for an SH3 interaction (Lee et al., 1995). However binding of a 
(PXX)3P peptide exhibited a reduced affinity (KD=91p.M) suggesting that other 
protein-protein interactions were important in stabilizing the association. 
Interestingly, in these latter studies using a soluble system, mutations in the 
C-terminal proline motif had no affect on Nef binding. Furthermore, a single R96I 
mutation in the Fyn SH3 domain was able to confer binding to the full length Nef 
with similar affinity to Hck SH3. It was concluded that residues in the “RT loop” of 
SH3 domains were crucial for specificity, and that the Nef association was 
dependent on hydrophobic interactions with the isoleucine residue in the RT loop. 
This high binding affinity of Nef as a ligand for Hck SH3 domains was exploited 
during a study on the mechanisms of activation of Src kinases (see sections 1.3 .1. 
and 1.5.) (Moarefi et al., 1997). See diagram 1.7 below, for the orientation of Nef 
residues from the (PXX)3P motif in the PP-II helix.
Diagram 1.7. A schematic representation o f the N e f polyproline type II  
helix, the circled residues form  the SH3 binding surface, as detailed 
Arold et al 1997 the arrow indicates the direction from  the amino 
to the carboxy terminus:
Nef (PXX)3P motif- PVTPQVPLRP
Hck is exclusively expressed in myeloid cells and although these cells have been 
implicated in maintaining a reservoir of HIV infection during disease pathogenesis
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Hck is exclusively expressed in myeloid cells and although these cells have been 
implicated in maintaining a reservoir of HIV infection during disease pathogenesis 
Nef interactions with Hck did not explain the depletion of CD4+ lymphocytes. As 
Lck is expressed in T-cell lineages and moreover acts as a CD4 anchor it 
represented a putative Nef target in T-cells. Data from the Nef induced CD4 down- 
modulation studies revealed no consensus as to the effect of Nef on Lck. There 
were some reports that Lck dissociation from CD4 was accelerated in the presence 
of Nef (Anderson et al., 1994; Rhee and Marsh, 1994b) and indeed that its 
presence conferred enhanced Nef down-modulation of CD4 (Bandres et al., 1995). 
These results also raised the question as to the effect of the increased cytosolic 
levels of Lck, after Nef mediated CD4 down-modulation (Anderson et al., 1994). A 
number of groups have now demonstrated a direct interaction between Nef and 
Lck. The first of these (Greenway et al., 1995), used GST-Nef as an affinity reagent 
for in vitro binding studies with MT-2 cell and PBMC lysates. They determined that 
the interaction was dependent on the N-terminal region of Nef, since the use of 
GST-Ne£25 (where the ORF started at the internal methionine, position 20) 
significantly reduced Lck binding. Furthermore, during normal cellular activation 
Lck is phosphorylated on serine residues within its unique domain, but in the 
presence of Nef this phosphorylation was inhibited. This inferred Nef was either 
blocking or inhibiting the Ser/Thr kinases PKC and MAPK. Preliminary data has 
suggested that Nef may be capable of direct interactions with both these kinases 
(Greenway et al., 1996; Smith et al., 1996). Subsequent studies using Nef peptides 
demonstrated a requirement for the (PXX)3P motif in Nef for Lck SH3 and MAPK 
bindings. A Nef induced inhibition of both catalytic activities was also evident 
(Greenway et al., 1996). These results were corroborated by Collette et al 1996 
who demonstrated a synergistic mode of action for Lck SH3 and SH2 domains in 
binding Nef and confirmed a Nef inhibition of Lck tram  and auto- phosphorylation 
activities in CD4+ T-cells. Consistent with these reports, the N-terminus of Nef has 
recently been implicated in binding not only Lck, but also an unidentified serine 
kinase (Baur et al., 1997).
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Final evidence in support of Nef interactions with members of the Src tyrosine 
kinase family comes from the investigation of a highly pathogenic strain of SIV, 
SIVpbji4 . This strain causes an acute illness in macaques and death within 10 days 
(Fultz et al., 1989). Unusually it is able to replicate in unstimulated PBMCs, 
apparently due to an inherent ability to activate the cells (Fultz, 1991). Genetic 
analysis revealed a double point mutation of RQ to YE (at positions 17 and 18) in 
the Nef ORF was sufficient to confer the phenotype to SIVmac2 3 9 (Du et al., 1995). 
This mutation resulted in the formation of a consensus sequence between residues 
10-43 in SIV Nef for recognition by SH2 binding domains. Consistent with this 
NefyE was shown to bind Src in cotransfected COS cells, tyrosine phosphorylation 
of both Src and NefyE was also demonstrated. The wildtype SrVmac2 3 9 Nef bound 
Src and was tyrosine phosphorylated but to a lesser degree. It has been speculated 
that as Nef functions to enhance infectivity in vivo, the aggressive pathogenesis 
observed as a result of NefyE incorporation maybe due to an exaggeration of normal 
cell function.
1.4. Aims of the thesis:
The aims of these studies were two fold. Firstly, to identify novel Nef cellular 
interactions in order to aid in the characterisation of its pleiotropic phenotypes 
(chapter 3). Secondly, to further define the Nef interactions with members of the 
Src tyrosine kinase family (chapters 4 and 5).
To analyse novel cellular interactions the yeast-two-hybrid system was utilised 
which allowed library screening of protein-protein interactions. The system was 
modified to accept Nef as an N-terminal fusion, facilitating the screening of 
interactors in the context of a myristoylated Nef. Any potential Nef interaction 
partners isolated were sequenced and evaluated for the specificity of their 
interactions with Nef. The characterisation of Nef interactions with the Src tyrosine 
kinases fell into two categories. Initially Nef interactions with the T-cell specific Src 
kinase, Lck were examined using reagents available within the laboratory. The 
studies mainly addressed protein conformations necessary for the Nef-Lck
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interaction, in vitro and in vivo. For this and subsequent studies using Hck, Src and 
Fyn the baculovirus expression system was used. This system had the advantage of 
allowing authentic posttranslational modifications of the proteins such as 
myristoylation, palmitoylation and phosphorylation potentially crucial to 
intermolecular interactions, whilst expressing the proteins to sufficiently high levels 
for alterations in protein-protein interactions to be detected. The latter was an 
important consideration because toxicity of both Nef and Src kinase proteins had 
been previously reported, therefore it might be anticipated that their coexpression 
would be unviable. Work with Hck was undertaken to confirm an interaction with 
Nef was possible in the context of the full length native proteins. Src and Fyn were 
included primarily as controls to verify the specificity of Nef interactions in this 
system. Determinants for Nef interactions with Hck were further evaluated, 
including the (PXX^P motif, in conjunction with assessments of the Nef affect on 
full length Hck activity. In addition the yeast-two-hybrid-system (YTHS) was 
employed to evaluate myristoylated Nef interactions with the isolated Src homology 
domains, SH3, SH2 and SH3-SH2 for each of Hck, Src and Fyn.
CHAPTER 2
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CHAPTER 2. Materials and methods:
2.0. General chemicals and enzymes:
Chemicals were obtained from the SIGMA chemical company, BDH chemicals, 
Boehringer Mannheim, Pharmacia or Life Technologies except where otherwise 
stated. All chemicals were of Analar quality. Enzymes, unless otherwise stated, 
were supplied by Life Technologies along with appropriate buffers. Chemicals 
common to each section are detailed below with their abbreviations while more 
specialised chemicals are detailed in their relevant section.
Table 2.1. General use chemicals and enzymes in alphabetical order, purchased 
from either BDH or SIGMA, including abbreviations (continued over page):
Purchased from;
BDH, Poole, Dorset, UK SIGMA, Poole, Dorset, UK,
2-mercaptoethanol Ammonium hydroxide
Butanol Ammonium persulphate (APS)
Caesium chloride (CsCl) Ampicillin (Amp)
D (+) Glucose (Glu) Aprotinin
Di-sodium-hydrogen-phosphate Di-methyl-sulphoxide (DMSO)
(NasHPCVTHjO)
Ethanol (EtOH) Dithiothreitol (DTT)
Ethidium bromide (EtBr) Ethylenediaminetetra acetic acid
(EDTA)
Glacial acetic acid Leupeptin
Glycerol Lysozyme
N,N,N’,N’, Tetra-methyl-ethylene-
diamine (TEMED)
Polyethylene glycol MW4000 PepstatinA
(PEG4000)
Potassium acetate (KAc) Magnesium chloride, MgClj-bHjO
(Mgcy
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BDH, Poole, Dorset, UK. SIGMA, Poole, Dorset, UK.
Potassium chloride (KC1) Magnesium sulphate, MgS04-7H20 
(MgS04)
Sodium acetate (NaAc)
Sodium azide
Sodium azide
Sodium chloride (NaCl)
Sodium dodecyl sulphate (SDS)
Sodium hydroxide pellets (NaOH) TRIZMA® Base (Tris)
Sodium-dihydrogen-phosphate
(NaHjPO,*)
Sucrose
TritonX-100
Table 2.2. Further general use chemicals and enzymes in alphabetical order, 
including companies purchased from and abbreviations:
Chemical/enzyme: Company:
4- (2-aminoethyl) benzene- 
sulphonyl-fluoride -HC1 (AEBSF) 
Dimethyl formamide (DMF) 
Electrophoresis grade agarose 
RNase A
5-bromo-4-chloro-3-indolyl- 
(3-galactosidase (X-Gal)
Calbiochem-Novabiochem Corp.
Rathburn Chemicals Ltd, Scotland 
Life Technologies Inc.
Pharmacia
Melford Labs. Ltd, Ipswich, UK
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MOLECULAR BIOLOGY TECHNIQUES:
2.1. Molecular biology techniques- Materials:
2.1.1. Chemicals and enzymes:
All detailed in general use chemicals, section 2.0.
2.1. 2. Radiochemicals:
Redivue™ [a35S] dATP, specific activity, lOOOCi/mmol, used for manual 
sequencing, was purchased from Amersham Life Science, UK.
2.1.3. Bacterial strain:
E.coli DH5a: F~. <J)80d/tfcZAM15, endAX, recAX, hsdRXl, (rK-, mK+), supE44, thi- 
1, deoR, gyrA96, re I AX, (AJacZYA-argF), U169,^-. Purchased as competent cells 
from Life Technologies Inc.
2.1.4. Cloning vectors:
pCR™: lacZ+, ampR+, kariR+, plasmid designed for the specific cloning of PCR 
products, by making use of the non-template dependent addition of a single 
deoxyadenosine to the 3’-ends of duplex DNA molecules catalysed by Taq 
polymerase (Invitrogen).
PBluescript®!! KS+/-: lacZ+, ampR+, T3 and T7 promoters flanking the 
polylinker, used for in vitro transcription-translation assays (Stratagene).
pGEX-4T-l: ampR+, pBR322-derived plasmid which carries part of the 
Schistosoma mansoni glutathione-S-transferase (GST) gene (Smith and Johnson, 
1988) and a tac chemically inducible promoter for high levels of expression in E.coli 
(Pharmacia Biotech).
pAcCL29: ampR+, one of the original baculovirus vectors adapted by (Livingstone 
and Jones, 1989), contains a unique BamHI downstream from the polyhedrin 
promoter, plus an M l3 intergenic region allowing single stranded DNA production
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in bacteria in the presence of an M l3 helper phage. Kindly provided by Dr Ian 
Jones, NERC Institute of Virology and Environmental Microbiology, Oxford, UK.
pAcES: ampR+, this was an inhouse modification of pAcCL29, a linker was 
incorporated into the BamHI site to generate the unique cloning sites EcoRI, Smal 
and BamHI.
pAcGST: ampR+, this was an inhouse modification of pAcCL29 to include the 
coding sequence for Glutathione-S-transferase (GST) downstream of the unique 
BamHI site (Harris and Coates, 1993).
pEG202: A yeast -E.coli shuttle vector containing a yeast expression cassette that 
includes the promoter from the yeast ADH1 gene (pADHl), sequences encoding 
amino acids 1 to 202 of the bacterial repressor protein LexA (DNA binding and 
dimerization domains), a polylinker (containing unique restriction sites: EcoRI, 
BamHI, Sail, Ncol, Noil and Xhol) and the transcription terminator sequences from 
the yeast ADH1 gene (tADHl). It also contains an E.coli origin of replication (pBR 
ori), ampR+ gene, a yeast selectable marker gene (his3+) and a yeast origin of 
replication (2p ori). It confers upon a his3- yeast strain the ability to grow in the 
absence of histidine and directs the constitutive expression of LexA fused to 
approx. 17 amino acids encoded by the polylinker, or a gene of interest inserted into 
the polylinker. Obtained as part of the yeast interaction trap system from Dr Roger 
Brent, Massachusetts General Hospital, Boston, USA.
pVEG’: A modification of pEG202 including all the same elements except that the 
position of the polylinker was modified to allow fusion proteins to be expressed at 
the N-terminus of the LexA protein, see chapter 3 for a more detailed description.
pJG4-5: A y e a s t coli shuttle vector that also contained a yeast expression 
cassette, including the inducible promoter from the yeast gene GAL1 (pGALl) 
followed by 106 amino acids encoding an activation tag, a polylinker and the 
transcription terminator sequences from the yeast ADH1 gene (tADH). The
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activation tag was made up of; the nuclear localisation signal from the SV40 virus 
large T-antigen (PPKKKRKVA), the bacterial B42 transcriptional activation 
domain and the haemagglutinin (HA-1) epitope tag (YPYDVPDYA). The plasmid 
also contained an E.coli origin of replication (pUC ori), ampR+ gene, a yeast 
selectable marker gene (TRP1) and a yeast origin of replication (2p ori). Obtained 
as part of the yeast interaction trap system from Dr Roger Brent.
2.1.5. Stock solutions:
Ampicillin (TOOOx): lOOmg/ml in ddH^O. Filtered through a 0.22pm filter,
aliquoted and stored at -20°C.
Agarose Gel loading buffer (lOx): 50% glycerol, 0.5% bromophenol blue, 0.5% 
xylene cyanol, in lx TBE. Stored at room temperature.
DNA size markers: Phi (<J)) X I74 RF DNA digested with HaeIII. Lambda (A,) DNA 
digested with Hindlll, both from Life Technologies Inc. Both used at lpg/lOpl.
Ethidium bromide: lOmg/ml stock in ddHjO, working concentration 0.5pg/ml. 
Stored in the dark at room temperature.
Oligonucleotides: Oligonucleotides were synthesised on an Applied Biosystems 
3818A Automated DNA Synthesiser (operated by Mr. T..McPherson, Veterinary 
Pathology, Glasgow University). DNA was eluted from the columns in 2ml of 
concentrated ammonium hydroxide and deprotected overnight by heating at 55°C. 
Deprotected oligonucleotides were lyophilised, resuspended in ddK^O at lpg/pl 
and stored at 4°C.
Polyacrylamide solution with urea (Easigel): Purchased from Scotlab, 6% 
polyacrylamide, 7M urea, lx TBE, used for sequencing.
SOC: SOC was prepared by adding filter sterile 20mM glucose (from a 1M stock) 
and lOmM MgCl2, lOmM MgS04 (from 1M stocks) to an autoclaved SOB
70
solution: 2% bacto-tryptone, 0.5% yeast extract, lOmM NaCl, 2.5mM KC1. This 
was then stored at 4°C.
TBE (lOx): 0.9M Tris-HCl, 0.9M Boric acid, 25mM EDTA pH8.3. Stored at room 
temperature.
TE: lOmM Tris, ImM EDTA, pH’d as required. Autoclaved and stored at room 
temperature.
X-Gal (5x): 40mg/ml in dimethyl formamide (DMF). Stored in ahquots protected 
from light at -20°C.
2.1.6. Media and antibiotics:
L-Broth: 1% (w/v) bacto-tryptone (DLFCO), 0.5% (w/v) yeast extract (DIFCO), 
1% (w/v) NaCl in ddH20  autoclaved and stored at room temperature, lx ampicillin 
(100pg/ml) was added as required.
L-agar: as for L-broth, but also contained 1.5% (w/v) agar, lx ampicillin 
(lOOpg/ml) or kanamycin (at 25pg/ml), were added just prior to pouring the plates 
(approx. 50°C).
2.2. Molecular biology techniques- experimental methods:
2.2.1. Agarose gel electrophoresis:
Gels containing 0.5-1.5% agarose (w/v) and 0.5pg/ml ethidium bromide in lx TBE 
were used to separate and analyse DNA molecules. 50-100ml gels were poured in 
perspex tanks and wells were cast using appropriate combs. Gel loading buffer was 
added to samples at a final concentration of lx, samples were then electrophoresed 
in lxTBE at 5V/cm. Known concentrations of DNA size markers were run 
alongside the samples in order to gauge both product size and yield of DNA. 
Subsequent to electrophoresis, DNA fragments were visualised using a short wave 
UV transilluminator and photographed with a Polaroid camera.
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2.2.2. Polymerase chain reaction (PCR):
The polymerase chain reaction allows the rapid amplification of selected regions of 
DNA from small amounts of starting template DNA (Saiki et al., 1985). All the 
necessary reagents were purchased from USB or Cambridge Bioscience and were 
used according to the manufacturers instructions. The Thermits aquaticus (Taq) 
DNA polymerase was used as the enzyme for the reactions since it leaves template 
independent deoxyadenosine overhangs at the 3’ ends of duplex DNA which were 
easily cloned into pCR™ plasmids (Invitrogen). Amplification was initiated from 
primers targeted to specific regions of the template DNA by cyclical high 
temperature denaturation of template DNA, followed by annealing and 
polymerisation steps at lower temperatures. Standard reaction conditions were as 
follows: depending on the template l-100ng of template DNA was added to a 50pl 
reaction mix containing, 5pl lOx reaction buffer (supplied with enzyme), 0.25mM 
of each nucleoside-tri-phosphate and lpg of each primer. The reactions were 
carried out in 0.2ml thin walled micro-centrifuge tubes in a Perkin Elmer heated lid 
thermocycler. A typical cycling reaction was; denaturation at 94°C for 7 minutes 
and then 25 cycles of; denaturation at 94°C for 1 minute, annealing at 50°C for 1 
minute, polymerisation at 72°C for 1 minute; with a 7 minute polymerisation at 
72°C after the cycles. Samples were stored at 4°C overnight, but frozen at -20°C for 
longer storage.
2.2.3. Restriction enzyme digests:
These were carried out in the appropriate buffer supplied with the restriction 
enzyme (Life Technologies Inc.). Typically lunit of enzyme per lpg of DNA was 
sufficient, reactions were incubated at 37°C for 1.5hours.
2.2.4. DNA purification from agarose gels:
The Geneclean II® Kit from BIO 101, supplied by Stratech Scientific Ltd, was used 
to obtain highly purified DNA, as described in the manufacturers instructions. For 
ligation purposes it was assumed that 80% of the DNA was recovered by this 
procedure.
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2.2.5. Ligation of DNA molecules:
Ligations were carried out according to the manufacturers protocols supplied with 
the T4 DNA ligase and 5x reaction buffer (Life Technologies Inc.). Generally, 50ng 
of plasmid DNA and a 3-4 fold molar excess of insert DNA were ligated in a 
volume of 20pl. Ligations were carried out overnight at 14°C.
2.2.6. Plasmid transformation using competent DH5a E.coli.
For each transformation a 20pl aliquot of competent DH5a E.coli, (stored at 
-70°C) was used; the number of aliquots required were thawed on ice. To each, lpl 
of purified sample DNA/ligation mixture (approx. 20ng/ul) was added and mixed by 
pipetting. This was incubated on ice for 30 minutes. The mixture was then heat 
shocked at 42°C for 45 seconds, then returned to ice for a further 2 minutes. 80pl 
of SOC, was then added to each and the tubes were incubated for 1 hour at 37°C. 
Each transformation reaction was plated onto L-agar plates supplemented with the 
appropriate antibiotic. The plates were incubated overnight at 37°C to allow colony 
formation. This method was essentially adapted from the protocol originally 
described by (Hanahan, 1983).
2.2.7. Small scale alkali purification of E.coli plasmid DNA:
This method was originally described in (Maniatis et al., 1982). Colonies from the 
transformation plates were picked using a sterile toothpick and used to seed 2ml 
cultures of LB broth supplemented with ampicillin. These cultures were incubated 
overnight at 37°C with vigorous shaking, (180rpm). lml of culture for each was 
transferred to a micro-centrifuge tube and pelleted using a microfuge (13,000rpm/ 1 
minute). The remainder of the culture was stored at 4°C. The medium was removed 
by aspiration and the pellet was then resuspended in lOOpl glucose solution (50mM 
Tris pH 8.0, 50mM glucose, lOmM EDTA), by vortexing. To this lOOpl of lysis 
buffer (0.2M NaOH, 1% w/v SDS), was added, the micro-centrifuge tubes were 
inverted several times to mix and left at room temperature for 5 minutes.
Next lOOjj.1 of 3M KAc pH5 (made in 20ml aliquots; 12ml 5M KAc, 2.3ml glacial 
acetic acid, 5.7ml water), was added and gently vortexed. The samples were then
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centrifuged for 5 minutes in a microfuge (13,000rpm). The supernatant, approx. 
300|il, was transferred to fresh micro-centrifuge tubes and to this 750|j,l of ethanol 
(EtOH) was added. The samples were incubated at -20°C for at least 15 minutes. 
Following this they were centrifuged for a further 5 minutes (12,000g) and the 
pellets washed in 70% EtOH. The pellets were dried under vacuum for 2 minutes, 
resuspended in 20|il TE containing lOOpg/ml RNaseA and incubated at 37°C for 30 
minutes.
2.2.8. Large scale purification of plasmid DNA from KcoR:
Bulk preparation of plasmid DNA was by the Triton lysis procedure outlined in 
(Maniatis et al., 1982) with final plasmid preparation by centrifugation on a 
CsCl/EtBr gradient.
For each plasmid to be purified an overnight 2ml culture of E.coli in LB broth 
supplemented with ampicillin was used to seed a 200ml culture. This was incubated 
overnight at 37°C shaking, (a 400ml culture was used if a low copy plasmid was to 
be purified). The bacteria were pelleted using either a Beckman JA14 (6 x 250ml) 
or JA10 (6 x 500ml) rotor at 8K for 5 minutes at 4°C. The medium was discarded 
and the pellet resuspended in 2.5ml 25% (w/v) sucrose, 50mM Tris-HCl pH 8.0 and 
transferred to 50ml Oakridge tubes (Beckman). To these 0.5ml of 20mg/ml 
lysozyme in 0.25M Tris pH 8.0 was added. The samples were incubated on ice for 5 
minutes, then 0.5ml 0.5M EDTA was added and the samples were incubated on ice 
for a further 5 minutes. Next 4ml 2% (v/v)Triton X-100, 50mM Tris pH 8.0, 62.5 
mM EDTA was added to each and incubated on ice for 15 minutes.
The samples were centrifuged for 30 minutes in a Beckman JA20 rotor at 20K, 4°C. 
The supernatant was transferred to a universal and lg of CsCl per ml of supernatant 
added plus lOOpl of lOmg/ml EtBr. This was divided between 2 heat sealing tubes 
(Beckman), VTi65, (approx. 5.5ml), the volume being made up to the top of the 
tubes using lg/ml CsCl in TE buffer. The samples were centrifuged overnight for 
approx. 16 hours (Beckman, VTi65 rotor) at 55K, 20°C. To harvest the plasmid 
band the ultracentrifuge tubes were secured in a retort stand. The top of the tubes
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were punctured using a syringe needle to prevent a vacuum forming when the 
plasmid band was drawn off. Then a syringe and needle was used to puncture the 
tube just below the lower closed circular plasmid band and the band was gently 
drawn off When exceptionally pure DNA was required (for yeast transformations 
and baculovirus transfections) the plasmid DNA was transferred to Beckman 
TLV100 tubes (approx. 2ml) and centrifuged for 4 hours at 100K. The same 
method was used to harvest the plasmid band from these tubes. EtBr was removed 
from the samples by Butanol extraction.
Butantol extraction: In 15ml falcon tubes 5ml of saturated butanol was added to 
the samples, they were briefly vortexed and centrifuged to separate out the aqueous 
layer. The top layer was discarded and then 5ml of unsaturated butanol was added, 
the samples were briefly vortexed and centrifuged again and the top layer discarded. 
This process was repeated until all the EtBr had been removed, usually at least 3 
times.
The sample volume was made up to 3 ml with distilled water and 8ml of EtOH was 
added to precipitate the plasmid DNA. The samples were incubated at room 
temperature for 30 minutes, centrifuged at 3500rpm for 15 minutes, then the pellet 
was washed in 70% EtOH. The tubes were inverted on a paper towel to dry the 
pellets before they were resuspended in 450pl TE. This was transferred to micro- 
centrifuge tubes and 50pl 3M NaAc plus 1ml of EtOH was added to each. The 
samples were allowed to precipitate for 20 minutes at room temperature and the 
DNA repelleted in a microcentrifuge, 13K, 5 minutes. Again the pellet was washed 
in 70% EtOH to remove any salt and then the pellet was dried under vacuum and 
resuspended in 200-500pl TE depending upon the amount of DNA (l-2pg/pl).
2.2.9. Sequencing of DNA:
2.2.9.1. Manual:
The ^Sequencing™ Kit from Pharmacia Biotech was used for manual sequencing 
with Redivue a [35S] dATP. The kit utilised the original dideoxy base-specific 
termination of enzyme-catalysed primer extension reactions first described by 
Sanger et al (Sanger et al., 1977), except that T7 DNA polymerase was substituted
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for the Klenow fragment of E.coli DNA polymerasel due to its increased 
polymerization rate. The reactions were undertaken exactly as outlined in the 
manufacturers instructions using miniprep DNA as template.
2.2.9.2 Sequencing gel:
To run the samples a Biorad sequencing apparatus was used. The glass plates were 
cleaned with 70% EtOH and the back plate was siliconised with Repelcote (BDH) 
prior to assembly. A 20ml plug was poured, 20ml polyacrylamide mix (Scotlab), 
90pl 25% (w/v) APS plus 40pl TEMED. Once set the sequencing gel was poured- 
50ml polyacrylamide mix, 180pl APS, 40pl TEMED. Samples were heated to 95°C 
for 2 minutes and loaded immediately. The gel was run at approx. 2000volts, 60 
watts.
2.2.9.3. LI-COR automated:
Automated DNA sequencing was carried out using a LI-COR model 4000 DNA 
sequencer. This had the advantage of being able to sequence 500-900bp DNA, 
however it was only used to confirm pCR™ sequences. This type of sequencing 
utilises infrared dye labelled primers which are incorporated into the DNA during 
the sequencing reactions. Sequencing reactions were performed as detailed in the 
Thermo Sequenase Fluorescent Labelled Primer Sequencing Kit supplied by 
Amersham Life Science. CsCl purified DNA was always used for automated 
sequencing. Mineral oil was layered over the reaction mix since the volume used 
was so small. After the thermocycling sequencing (denaturation 5 minutes at 95°C, 
30 cycles of 95°C for 30 seconds, 55°C for 30 seconds, 70°C for 1 minute), 4pi of 
stop solution was added to each sample and the mineral oil removed as outlined in 
the manufacturers instructions. The samples were stored at -20 °C in the dark and 
remained stable for up to 2 weeks. Prior to loading on the sequencing gel the 
samples were denatured for 2 minutes at 95°C and put on ice. Gels were run 
according to LI-COR instructions.
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The primers used to sequence the pCR™ plasmids were the universal primers 
modified to contain an infra red-label:
M13 (-29) forward primer: 5’- CAC GAC GTT GTA AAA CGA C -3*
Reverse primer: 5 GGA T AA C AA TTT CAC AC A GG -3 ’
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YEAST PROTOCOLS.
2.3. Yeast protocols- Materials:
2.3.1. Chemicals and enzymes:
Chemicals specific to this section are detailed in the table below, including 
abbreviations.
Table 2.3. Chemicals and enzymes for yeast protocols including abbreviations 
and companies purchased from.
Chemical/Enzyme: Company:
Amino acids
Di-methyl-sulphoxide (DMSO)
Lithium acetate, CjH^OjLi^HjO (LiAc) 
Zymolase
SIGMA, Poole, UK
Interaction Trap including host yeast strain, 
plasmids and Jurkat T-cell library.
R. Brent and R. Finley, Massachusetts 
General Hospital, USA
Salmon Sperm DNA Life Technologies Inc.
2.3.2. Radiochemicals:
Metabolic label, 3H myristic acid, in EtOH, specific activity 40-60Ci/mmol, was 
obtained from Amersham Life Sciences, UK. Prior to use, aliquots were dried under 
vacuum and resuspended in DMSO lmCi in 30pi DMSO per 5ml culture 
(0.2mCi/ml culture).
2.3.3. Yeast strain:
EGY48: LexAop-LEU2, his3-, trp\~, ura3-. This contained an integrated copy of 
the LEU2 gene in which the normal upstream regulatory sequences were replaced 
with 3 tandem LexA operators. The presence of both the LexA DNA binding 
domain (pEG202 or pVEG’) plus the B42 bacterial activation domain (see pJG4-5)
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were required for LEU2 expression which was necessary for the strain to grow in 
the absence of leucine. Auxotrophic selection markers were provided by the lack of 
his3, trp\ and ura3 genes allowing the cotransformation of the 3 plasmids used in 
the yeast-two-hybrid system. This yeast strain was supplied as part of the 
interaction trap kit kindly provided by Dr Roger Brent’s laboratory (Massachusetts 
General Hospital, Boston, USA).
2.3.4. Yeast interaction trap plasmids:
All plasmids used for the interactor hunt were yeast-E.coli shuttle vectors and had 
an ampR+ gene and an auxotrophic selectable marker. Those that were used for 
cloning genes of interest are outlined in more detail in section 2.1. Plasmids were 
supplied as part of the interaction kit, except pVEG’ which was a modification of 
pEG202, see chapter 3.
PEG202. pVEG* (his3+): Each encoded the bait protein either as C-terminal or N- 
terminal fusions, respectively, to the LexA DNA binding domain. The region of 
LexA expressed in the plasmid contained the bacterial DNA binding and 
dimerization domains which specifically recognised LexA operators cloned 
upstream of the reporter genes (lacZ in the pSH18 plasmid and the chromosomally 
integrated LexAop-LEU2 gene).
pRFHM-1. pSH17 (his3+). Control bait plasmids used for comparisons in the 
activation assay, pSH17-4 was inherently transactivating while pRFHM-1 behaved 
as a model bait protein in the assay.
pSH18-34 (ura3+): LacZ reporter plasmid used in addition to the LexAop-LEU2 
reporter cloned into the genome. This plasmid contained the GAL1 TATA, 
transcription start and a small part of the GAL1 coding sequence fused to lacZ 
however the GAL1 upstream activating sequences (UAS’s) had been replaced with
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an Xhol site into which various numbers of LexA operators could be cloned, for 
these studies 4 were used, making the reporter highly sensitive.
pJKlOl (ura?)+\. LacZ reporter plasmid used to measure repression by the LexA 
fusions indicating the ability of the fusions to enter the nucleus. It contained most of 
the GAL1 UAS’s with a single LexA operator cloned between the UAS and the 
GAL1 TATA transcription start site. Therefore if a LexA DNA binding domain 
bound to the operator transcription of the lacZ gene was repressed.
pJG4-5 (trpl+): Encoded either individual, known, protein coding sequences (i.e. 
Src tyrosine kinases) or the Jurkat T-cell cDNA library fused to the C-terminus of 
the activation tag under the control of an inducible GAL1 promoter. The activation 
tag included a nuclear localisation signal, the bacterial B42 transcription activation 
domain and the haemagglutinin (HA-1) epitope tag which was useful for western 
blot analysis to confirm expression of the fusion proteins.
2.3.5. Yeast media and supplements:
Yeast was grown in a complete minimal media which contained a yeast nitrogen 
base, without amino acids (YNB) (purchased from DIFCO), a carbon source 
(galactose, raffinose [DIFCO] or D(+) Glucose [BDH]) and a mixture of nutrients 
(all amino acids were from SIGMA) the latter of which were varied depending on 
the auxotrophic selection required. See section 2.3.5.6. for the nomenclature of 
dropout medias and supplements.
2.3.5.1. Complete minimal (CM) dropout powder:
This contained a mixture of nutrients shown in Table 2.3.1 with one or a few 
omitted, hence- dropout powder. A dropout powder was made corresponding to 
each of the dropout medias required in the experiments i.e. for media lacking 
histidine (his-), the dropout powder used would contain all of the nutrients,
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quantities of which are shown in Table 2.2.1, except for histidine. The dropout 
powders were made by grinding all the ingredients in a clean dry pestle and mortar 
until homogenous, this was then stored in the dark at room temperature.
Table 2.4. Table o f amino acid quantities required fo r the complete minimal 
dropout powder:
Nutrient Quantity (g). Final conc. in 
media (ixg/ml)
adenine 2.5 40
L-arginine (HC1) 1.2 20
L-aspartic acid 6.0 100
L-glutamic acid 6.0 100
(monosodium)
L-histidine (his) 1.2 20
L-isoleucine 1.8 30
L-leucine (leu) 3.6 60
L-lysine 1.8 30
L-methionine 1.2 20
L-phenylalanine 3.0 50
L-serine 22.5 375
L-threonine 12.0 200
L-tryptophan (trp) 2.4 40
L-tyrosine 1.8 30
L-valine 9.0 150
uracil (ura) 1.2 20
23.52.  Carbon Sources:
Stocks of the carbon sources were made separately and filter sterilised (20% (w/v) 
galactose, 20% (w/v) glucose, 20% (w/v) raffinose, all dissolved in ddHjO). As
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needed, galactose (Gal) and glucose (Glu) were each added to 2% final 
concentration, raffinose (Raf) was added to 1% final concentration.
2.3.5.3. Dropout plates and media:
For 1 litre of dropout medium 6.7g YNB without amino acids plus 2g dropout 
powder lacking the appropriate amino acid were added to 850ml of deionized 
water. This mix was autoclaved and the carbon source added prior to use from the 
filter sterile stocks. For the production of plates 20g/litre bacto-agar was added 
prior to autoclaving.
2.3.5.4. X-Gal plates:
For 1 litre the standard dropout media mix, was added to 800ml deionized water. 
This was autoclaved, the carbon sources were added and the mix allowed to cool to 
65°C. Then 100ml of lOxBU salts (see below) and 4ml of 20mg/ml X-Gal dissolved 
in DMF (stored at -20°C), were added.
2.3.5.5. lOxBU SALTS:
For 1 litre, 70g Na2HPO4-7H20, 30g Nal^PC^ adjusted pH to 7.0; autoclaved and 
stored at room temperature.
2.3.5.6. Nomenclature of media plus supplements:
The nomenclature for the dropout plates used in these studies is indicated in the 
table below:
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Table 2.5. Nomenclature for media and dropout plates (in single letter and 
triple letter code):
Amino acid “dropped out”: Carbon Source added:
Amino acid Abbreviation Carbon source Abbreviation
histidine H, His- Glucose Glu
leucine L, Leu- Galactose G, Gal
tryptophan T,Trp- Raffinose R, Raf
uracil U, Ura-
G/R UHT or Gal/Raf ura-his-trp- corresponds to plates supplemented with 
galactose and raffinose but lacking, in this example, the amino acids uracil, histidine 
and tryptophan; compared to Glu UHT or Glu ura-his-trp- which would be 
supplemented with glucose instead.
If the plates also contain X-gal an X will be added i.e. Glu UHT-X.
2.3.6. Storage and freezing of yeast:
Yeast were streaked onto the appropriate dropout plates and stored at 4°C for a 
maximum of 5 days. For longer term storage liquid cultures of an OD600= 1.0 
(approx. 3x 107 cells/ml) were mixed with an equal volume of 65% (v/v) glycerol, 
0.1M MgS04, 25mM Tris pH 7.5 and aliquoted into sterile microcentrifuge tubes 
and stored frozen at -70 °C.
2.4. Yeast protocols- Experimental methods:
2.4.1. Transformation of yeast by the high efficiency lithium acetate method:
This method was adapted from a method published by (Gietz et al., 1995). An 
overnight culture, of the appropriate dropout media, was grown at 30°C with
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shaking (-150 rpm) and used to seed a 200ml culture. For high transformation 
efficiencies it was important to start the 200ml culture at OD600= 0.2 or less and 
allow it to grow to OD600= 0.8, so that the cells were in mid-log phase when 
harvested (an OD600 of 1.0 was taken to correspond to about 3 x 107 cells/ml). The 
culture was harvested by centrifuging at 500g for 5 minutes and the supernatant 
poured off. The cells were washed once in 10ml of sterile ddHjO. These centrifuge 
steps and all the following manipulations were carried out at room temperature. The 
cells were resuspended in 5ml of filter sterilised LiAc/TE (lOmM Tris HC1 pH 7.5, 
ImM EDTA, lOOmM LiAc; made from a filter sterile stock of 1M LiAc, pH 7.5), 
pelleted again and the supernatant poured off.
Next the cells were resuspended in 1.0ml LiAc/TE, 50pl of this suspension 
provided enough competent cells to be transformed with lpg of DNA. Generally 
for a single plasmid transformation lOOng was sufficient. The use of more than lpg 
DNA per 50pl of cells resulted in the introduction of multiple plasmids in each yeast 
cell, this was used to advantage to allow multiple plasmids to be transformed 
simultaneously. However when transforming the library plasmid, where it was 
important not to introduce multiple plasmids in each yeast cell, a lower 
concentration of library plasmid DNA was used. This ensured that the selection 
assays were performed on only one library plasmid at a time.
After aliquoting the required amount of the yeast suspension the tubes were 
incubated at 30°C for 15 minutes, DMSO was added to a final concentration 10% 
(v/v), since it has been documented to improve efficiency by 3 to 5 fold. At this 
stage salmon sperm DNA was also added (5pl at lOpg/pl). 300pi of filter sterilised 
40% PEG4000 in LiAc/TE (freshly made from stocks of 1M LiAc pH7.5, filter 
sterilised 50% PEG4000 in water, 1M Tris-HCl pH7.5 and 0.5M EDTA) was 
added. The tubes were gently vortexed to mix and subsequently incubated at 30°C 
for 30 minutes without agitation.
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The transformations were then subjected to a heat shock at 42°C for 20 minutes 
after which they were immediately returned to room temperature. Before plating the 
cells were pelleted and the PEG solution removed. The cells were resuspended in 
sterile water and plated on the appropriate dropout plates.
For library transformations the following alterations to the protocol were included 
to increase efficiency: Aliquots of 150pl of competent yeast in sterile micro­
centrifuge tubes were used. To each aliquot 2pg of library DNA was added and 
200pg of carrier DNA (single stranded salmon sperm, in a total volume of 20pl). 
The volume of 40% PEG4000 in LiAc/TE was increased to 900pl. The number of 
aliquots used depended on the desired number of transformants and the expected 
transformation efficiency. In pilot transformations efficiencies of 105 transformants 
per p.g were achieved, therefore each aliquot was expected to yield 200,000 
transformants, all of which was plated onto a single 24cm x 24cm plate. It was 
found the quality of the salmon sperm DNA, fresh solutions and the density of the 
cells when harvested were crucial in obtaining high transformation efficiencies.
2.4.2. Testing baits for transcription activation:
This assay was one of two assays which determined whether the proposed bait was 
suitable for use in the interactor study. The bait plasmid (either pEG202 or pVEG) 
encoded the protein of interest fused to LexA (a DNA binding domain that 
recognised the specific UASs). These LexA UASs were incorporated upstream of 
two reporter genes, an auxotrophic marker, Lexop-/ew2 encoded in the yeast 
genome, and lacZ encoded by the reporter plasmid (pSH18-34). For the bait to be 
suitable for use in an interactor hunt it had to successfully enter the nucleus and 
bind the LexA operators failing to transactivate either of the reporter genes, i.e. it 
should not possess any innate transactivation activity. This was determined by 
utilising the auxotrophic marker and comparing the growth of yeast cultures on
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dropout plates +/- leucine. Typically both controls and baits grew at similar rates on 
plates containing leucine (Gal/Raf ura-his-), however if yeast growth was 
reproducibly diminished for a given bait, it indicated that its expression was toxic to 
yeast. Baits containing a non-activating LexA fusion did not grow after several days 
on plates lacking leucine (Gal/Raf ura-his-leu-). Any that activated transcription, i.e. 
grew equally on the Gal/Raf ura-his-leu- plates and Gal/Raf ura-his- plates, were 
discarded as unsuitable in this study.
2.4.2.1 Constructing the transcriptional activation selection strain:
To construct the selection strain, the host strain EGY48 was transformed using the 
LiAc method, with a URA3 lacZ reporter plasmid, (pSH 18-34) and transformants 
selected on Glu ura- plates. Plates were incubated at 30°C for 3-4 days. From these, 
three colonies were combined and grown in Glu ura* liquid media and transformed 
with the HIS3 bait plasmid (pEG202 or pVEG-Nef) or control plasmids (pSH17-4 
positive, pRFHMl negative). Transformants were selected on Glu ura'his- plates, 
incubated at 30°C, 3-4 days. Four individual colonies from each transformation 
were picked and each colony was used to inoculate 5ml Glu ura’his* liquid cultures. 
The same four transformants were also streaked to another Glu ura’his* plate for 
storage and later recovery. The plates were incubated at 30°C until colonies formed 
(about 3-4 days) and then stored at 4°C. If all four colonies behaved identically in 
the tests outlined below, any one was chosen to serve as the selection strain into 
which the library was introduced.
2.4.2.2. Transcriptional activation assay:
Liquid cultures were grown at 30°C with shaking to mid-log phase or OD600= 0.5 
(corresponding to about 1.5 xlO7 cells/ml). Dilutions of 10*2 and 10’3 of each 
culture were made in sterile water. These were spotted in a volume of lOpl, 
together with the undiluted culture onto two plates either, Gal/Raf ura-his- or 
Gal/Raf ura-his-leu-. For side by side comparison both the bait plasmid being tested
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and yeast containing the control plasmids were spotted onto the same plates. The 
plates were incubated at 30°C. (Note: galactose is used in the media because the 
actual selection will eventually be performed on galactose plates to induce 
expression of the activation tagged cDNA protein. Raffinose was added to aid yeast 
growth; it provides a better carbon source than galactose alone but does not block 
the ability to induce the GAL1 promoter). The growth of the cultures in the spots 
were monitored every 24hours for a period of several days. The yeast that did not 
grow on leucine minus plates were followed up with the repression assay, below.
2.4.3. Repression assay to show that the bait enters the yeast nucleus and 
binds the operators:
This was the second assay used to determine the suitability of a bait for an 
interactor hunt. It was performed to ensure baits that did not activate the 
auxotrophic LexAop-LEU2 reporter in the transactivation assay were able to enter 
the nucleus and bind the LexA operators.
In this instance the reporter plasmid was pJKlOl, which has a LexA operator 
positioned between the TATA transcription start site and UAS’s. LacZ expression 
was induced by growth on galactose but was still detectable at lower levels in the 
presence of glucose because the negative regulatory elements in GAL1 that 
normally keep it repressed in glucose were not present in this plasmid. If LexA or a 
LexA fusion bound the LexA operator the lacZ gene activation was repressed 
indicating the bait could enter the nucleus. Yeast lacking LexA in the nucleus began 
to turn blue on the Gal/Raf plates after one day and appeared light blue on the 
glucose plates after two or more days, while yeast containing a bait that entered the 
nucleus and bound the operator turned blue more slowly, if at all.
The host strain, EGY48 was transformed with the plasmid pJKlOl and selection for 
transformants was on Glu ura- plates. Three colonies were combined from these
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plates and transformed with the HIS3 bait plasmid, pEG202 or pVEG (or HIS3 
control plasmids, pSHI7-4 positive, pRFHM-1 negative). These transformants were 
selected on Glu ura-his- plates. Four individual colonies from each transformation 
were picked and streaked in a patch onto Glu ura-his- and Gal/Raf ura-his- plates 
containing X-Gal. These were incubated at 30°C. The X-Gal plates were examined 
after 1, 2 and 3 days, those that remained white could be used for the interactor 
hunt, in this instance pVEG-Nef.
2.4.4. Selecting interactors from library transformants:
pVEG-Nef was used as a bait to screen a Jurkat T-cell cDNA library (cloned into 
pJG4-5). This was carried out in stages. Firstly it was confirmed using pJG4-5 alone 
that high efficiency transformation levels could be achieved with the pVEG-Nef, 
pSH18 selection strain. The library was then transformed without induction on Glu 
ura-his-trp- plates to prevent the loss of any potential interactors that might be toxic 
to the yeast. These colonies were harvested, stored and the colony forming units per 
ml (CFU/ml) determined. The colonies could then be screened for interactors using 
both the LEU2 and LacZ reporter constructs. Potential interactors were hence 
isolated for further investigation.
2.4.4.1. Transformation of the library plasmid and determination of colony forming 
units (CFLT):
The Jurkat T-cell library, pJG4.5 (TRP1), was introduced into the selection strain, 
as outlined in the high efficiency lithium acetate method, under conditions designed 
to ensure that each individual transformed cell contained only one library plasmid. 
The transformants were plated onto Glu ura-his-trp- plates to maintain selection for 
the library plasmid (TRP1) and both the bait, pVEG (HIS3) and reporter, pSH18 
(URA3) plasmids already contained within the selection strain. The plates were 
incubated at 30°C for 3 days or until the colonies were approximately 1 to 2mm in 
diameter. To harvest the colonies the agar plates were placed at 4°C for 2-4 hours
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to harden the agar. The colonies were then washed off the plates by pipetting 
several times with 10ml of sterile TE (lOmM Tris pH8, ImM EDTA). The resulting 
cell suspension was transferred to a sterile 50ml Falcon tube and pelleted at 500g, 
4°C, for 5 minutes. The cells were then washed a further 2 times with 2-3 volumes 
of sterile TE. The cells were finally resuspended in 1 pellet volume of glycerol 
solution (65% glycerol vol/vol, 0.1M MgS04, 25mM Tris pH 7.5) by gentle 
vortexing. Aliquots of 1ml were frozen at -70°C.
To determine the plating efficiency of the transformants an aliquot of the library 
transformation was thawed and serial dilutions were made in sterile water. lOOpl of 
each dilution was plated onto 100mm Gal/Raf ura-his-trp- plates. The colonies that 
grew after 3 days at 30°C were counted and from this the plating efficiency in 
colony forming units (CFU) per volume of frozen cells was established.
2.4.4.2. Isolating interactors on leu- plates:
Library transformants which encoded a protein that interacted with the bait 
exhibited galactose-dependent growth on media lacking leucine and galactose 
dependent P-galactosidase activity. This was tested by thawing an appropriate 
number of aliquots to allow a final concentration of 107 cells per 24x24cm plate. 
These cells were diluted 10-fold into Gal ura-his-trp- liquid media. To induce the 
GAL1 promoter and synthesis of the activation-tagged cDNA-encoded proteins 
they were incubated with shaking at 30°C for 4 hours. The cells were pelleted at 
500g at room temperature for 5 minutes and resuspended in sterile water and plated 
onto Gal/Raf ura-his-trp-leu- plates. The selection plates were wrapped in para-film 
to prevent them from drying out and incubated at 30°C for 3-5 days.
2.4.4.3. B-Galactosidase filter assay:
To confirm that the colonies able to grow in the absence of leucine contained 
interacting proteins, the colonies were replica plated onto nitrocellulose filters in
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order to assess expression of the lacZ marker by p-galactosidase assay. 24x24cm 
nitrocellulose filters were gently placed on the ura-his-trp-leu- dropout plates 
containing l-2mm sized colonies. The orientation of the filters was marked for later 
reference and then the filters were immediately removed. The filters were immersed 
in liquid nitrogen for 1 minute to lyse the yeast. 3MM paper was cut to fit in the lid 
of a 24x24cm plate and 18ml per plate of buffer Z (60mM Na2HP04, 40mM 
NaHjPO^ lOmM KC1, ImM MgS02, 50mM P-mercaptoethanol, pH to 7.0, made 
fresh) containing 450pl per plate of X-Gal (40mg/ml in DMSO) was added. The 
nitrocellulose replica was placed colony side up on the 3MM paper being careful to 
avoid bubbles or wrinkles. This was then incubated at 30°C for between 30mins and 
3 hours, until blue colonies were apparent.
2.4.5. Verifying the specificity of the interactions:
Once potential interactors had been identified the colonies were picked and streaked 
(on Glu UHT) plates to single colonies and glycerol stocks taken from one of the 
single colonies. The interaction was then double checked for each single colony by 
patching them onto Glu UHT-X, G/R UHT-X and Glu UHTL, G/R UHTL 100mm 
plates. This established which of the interactions were inducible, not due to 
mutations arising in the genomic DNA and confirmed the correct colonies had been 
picked. To confirm the library plasmids were interacting directly with the bait rather 
than non-specifically with LexA, the promoters, or some part of the transcription 
machinery, the library plasmids had to be rescued from the yeast.
Library plasmids were rescued from the yeast by performing a rapid yeast miniprep, 
see below. Since the library screen, after repatching to the dropout plates to confirm 
the interactions, yielded nearly 100 interactors it was decided before checking each 
individual cDNA for specificity it would be prudent to first check for duplicates. 
This was determined by PCR of the yeast miniprep DNA, followed by restriction 
fragment length polymorphism (RFLP) analysis of the PCR products. Once
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duplicates had been identified the yeast miniprep DNA, containing all 3 plasmids 
used in the interactor hunt, was used to transform E.coli. Transformants were 
plated onto L-agar plates containing X-Gal and white colonies picked, thus 
excluding the lacZ reporter plasmid. Library plasmids were identified by restriction 
digests of miniprep plasmid DNA. Once isolated from E.coli the library plasmids 
were reintroduced to yeast containing LexA alone (pEG202) and unrelated baits 
(p55Gag and ORF94), to which they should not interact.
2.45.1. RFLP analysis of PCR products:
To identify duplicate interactors from the crude yeast miniprep DNA, PCR 
reactions (for a more detailed explanation of PCR see section 2.2) were set up as 
follows. In 0.5ml tubes, 13 pi ddt^O, 2pi lOx Taq polymerase buffer, 2pl dNTP 
mix (all 4 dNTPs at 2.5mM each), lpl of each primer (O.lpg/pl), see below and
0.2pl Taq polymerase was added and to each lpl of yeast miniprep DNA was 
added. The reactions were incubated in a thermocycler for 25 cycles of 92°C for 30 
seconds, 65°C for 2 minutes and 75°C for 30 seconds. Next two tubes were set up 
for each PCR reaction containing lpl of the appropriate restriction enzyme buffer 
and lpl of either Alul or Haelll, these restriction enzymes were chosen because 
they are frequent cutters and work well in the presence of the PCR reagents. To 
each tube 8pl of the PCR mix was added. The restriction digests were incubated at 
37°C for 2 hours after which they were analysed on a 1.5% agarose gel (see section 
2 .2).
2.4.5.2. Primers for RFLP PCR:
5’ primer derived from the library vector fusion moiety sequence:
BCOl 5’- CCA GCC TCT TGC TGA GTG GAG ATG -3’
3’ primer derived from the ADH1 terminator sequence in the library vector:
BC02 5’- GAC AAG CCG ACA ACC TTG ATT GGA G -3’
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2.4.6. Yeast plasmid miniprep:
A 2ml overnight liquid culture of yeast was pelleted and the pellet resuspended in 
lml of TE (the OD600of this suspension was between 2 and 5). The yeast were 
repelleted and resuspended in 0.5ml S buffer (lOmM KP04 pH7.2, lOmM EDTA, 
50mM 2-mercaptoethanol, 50mg/ml zymolase) and incubated at 65°C, 30 minutes. 
To this 166pl of 3M KAc was added and the samples were chilled on ice for 10 
minutes. Subsequently they were centrifuged, 13K, 10 minutes and the supernatant 
poured into a fresh tube. The DNA was precipitated by the addition of 0.8ml of 
cold ethanol, incubated on ice for 10 minutes and centrifuged for a further 10 
minutes. The ethanol was aspirated and the pellet washed with 70% ethanol. The 
pellet was dried under vacuum and resuspended in 40pl sterile ddf^O. lpl of this 
crude preparation was sufficient to transform E.coli.
2.4.7. Yeast cell lysis using glass beads:
This protocol was adapted from Current protocols, 1993, (Ausubel et al., 1993) for 
small scale preparations of yeast lysates. In general a 10ml culture of yeast in the 
exponential growth phase (OD600= 0.8) was harvested, although this was scaled up 
according to requirements. The cells were pelleted by centrifugation at 500g for 5 
minutes at 4°C. The pellet was washed with 10 volumes of ice cold dH^O, 
repelleted and washed with glass bead disruption buffer (20mM Tris-HCl, pH 7.9, 
lOmM MgCl2, ImM EDTA, 5% glycerol, ImM DTT, 1M KC1). The packed cell 
volume was estimated and the cells resuspended in 3 volumes of glass bead 
disruption buffer containing protease inhibitors (see section 2.5, under lysis buffers). 
The suspension was then transferred to a screw-capped micro-centrifuge tube. 4 
volumes of chilled, acid-washed glass beads were added to the tube (glass beads 
were prepared by washing in 1M HC1 for lhour, followed by 3 washes with dH20  
after which they were autoclaved). From this stage onwards all buffers contained 
protease inhibitors.
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The suspension containing glass beads was vortexed for 60 seconds and iced for 2 
minutes. This process was repeated 5 times. The beads were allowed to settle and 
the supernatant decanted. To remove all the supernatant the bottom of the 
eppendorf was pierced with a needle and the tube placed in a second eppendorf. 
The two tubes were centrifuged at a low speed and the supernatant collected in the 
lower tube was pooled with the previously decanted supernatant. Next a further 2 
volumes of the glass bead buffer was added to the beads and carefully mixed and 
collected as previously.
The pooled supernatants were adjusted to 1% Triton X-100 and 0.1% SDS, by 
adding a 1:10 vol. of 10% (v/v) Triton X-100, 1% (v/v) SDS, in glass bead buffer. 
These were incubated on ice for 30 minutes. The tubes were centrifuged at 13K for 
10 minutes at 4°C and the lysate transferred to a fresh tube. If the lysates were to be 
immunoprecipitated (see protein protocols, 2.8) an aliquot was taken at this stage, 
lysates were otherwise stored at -20°C. Before immunoprecipitation the salt 
concentration was reduced to 0.5M KC1 by adding an equal volume of glass bead 
buffer minus KC1, see section 2.8 for immunoprecipitation methods.
2.4.8. Labelling of Yeast with 3H Myristic Acid:
To confirm that proteins were being successfully myristoylated on their N-terminal 
glycine residue in yeast, 3H myristic acid was used to label yeast cultures during 
their exponential growth phase. Myristoyl proteins were then visualised by SDS 
PAGE and fluorography.
For labelling experiments, samples were grown in duplicate, one set were labelled 
with 100|iCi per sample of 3H myristic acid while the second set were analysed by 
western blot (for method see protein protocols, 2.8). 3ml cultures were grown 
overnight and used to seed 5ml cultures at very low levels, when these cultures
reached OD600= 0.15, the 3H myristic acid in DMSO was added (lmCi per sample 
was dried down under vacuum and resuspended in 30pl DMSO). 30pi of DMSO 
alone was also added to each of the yeast cultures to be analysed by Western blot. 
The cultures were then incubated at 30°C with shaking. The cultures were harvested 
when they reached an OD600 of 0.8. The washes and lysis of the yeast was 
essentially the same as outlined in the glass bead method detailed above except that 
the needle step was omitted and the final wash was doubled in volume. The lysates 
recovered were then immunoprecipitated overnight and analysed as outlined in 
section 2.8.
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BACULOVIRUS PROTOCOLS:
2.5. Baculovirus protocols- Materials:
2.5.1. Chemicals and enzymes:
Chemicals and enzymes specific to this section are detailed below any others can be 
found in the general section at the start of this chapter.
Table 2.6. Chemicals and enzymes for baculovirus protocols including 
abbreviations and companies purchased from
Chemical/Enzyme Company
Bsu-361 restriction enzyme New England Biolabs
Lipofectin
Low melting point (LMP) agarose 
Trypan blue stain
Life Technologies
Glutathione-agarose.
Neutral red viable stain
Piperazine- N,N’ -bis (2-ethanesulphonic
acid) (PIPES)
Reduced glutathione
SIGMA, Poole, Dorset, UK
2.5.2. Radiochemicals:
3H myristic acid and 3H palmytic acid, in EtOH, specific activity, 40-60Ci/mmol, 
were purchased from Amersham Life Sciences Ltd, UK. Trans 35S-Label™ (35S 
E.coli hydrolysate labelling reagent containing 70% L-methionine, [35S]), specific 
activity, 1177Ci/mmol (11.88mCi/ml) was obtained from ICN Pharmaceuticals Inc., 
USA.
2.5.3. Insect cell line:
Spodoptera frugiperda (Sf9) insect cell line, was a clonal derivative of the original 
S£21 cell line which itself was derived from the ovarian tissue of the fall army worm.
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Obtained from the American Type Culture Collection, accession number CRL-1711 
(King and Possee, 1992).
2.5.4. Baculovirus strain:
AcMNP V./acZ baculovirus (Autographa californica, multiple nuclear polyhedrosis 
virus) -(PAK6) (Kitts and Possee, 1993) which contains the lacZ gene under the 
control of the late polyhedrin promoter, allowing colour selection of recombinants,. 
Kindly provided by Dr R.D.Possee, NERC Institute of Virology and Environmental 
Microbiology, Oxford, UK.
2.5.5. Expression plasmids:
pAcCL29, pAcES and pAcGST see 2.1.
2.5.6. Stock solutions:
Phosphate buffered saline (PBS): lOOmM NaCl, Na2HPO4-7FI20, 20mM NaHJPO^ 
adjusted to pH7.5. Autoclaved and stored at 4°C.
Neutral red viable stain: 0.1% (W/V) neutral red viable cell stain in PBS containing 
X-GAL at 0.4mg/ml final concentration (from a 40mg/ml X-GAL in DMF stock, 
stored at -20 °C). Filter sterilised and made fresh for each use.
Lysis buffers:
Protease inhibitors were added fresh prior to use, see below.
2x GLB lysis buffer (Glasgow-/ysis-Z>uffer): 2% (v/v) TritonX-100, 240mM KC1, 
20mM PIPES/NaOH pH7.2, 60mM NaCl, lOmM MgCl2, 20% (v/v) glycerol. Filter 
sterilised and stored at 4°C.
lx PBS lysis buffer: Autoclaved PBS with 1% (v/v) TritonX-100 added, stored at 
4°C.
Protease inhibitors: for 1ml of buffer added, lpl lOmM leupeptin (stored at -20°C), 
5pi ImM pepstatin A (stored at *20°C), lpl aprotinin (stored at 4°C), 2pl lOOmM
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AEBSF (stored at 4°C), all supplied by SIGMA except AEBSF which was 
purchased from Calbiochem-Novabiochem Corp., USA.
Protein gel loading buffer (sample buffer): 62.5mM Tris-HCl pH6.8, 20% (v/v) 
glycerol, 2% (w/v) SDS, 5% (v/v) P-mercaptoethanol, 0.05% (w/v) bromophenol 
blue, in ddF^O. Stored at room temperature.
2.5.7. Preparation of Culture Medium:
Bottles (500ml) of TC100 medium (Life Technologies Inc.) were stored at 4°C in 
the dark. Heat-inactivated foetal calf serum (PAA Labs.) and penicillin- 
streptomycin (P/S) (GIBCO), were aliquoted and stored at -20°C. Before use the 
bottles were wiped with 70% alcohol prior to placing in a Class II microbiological 
safety cabinet. Using aseptic techniques 50ml (10% v/v) of the foetal calf serum was 
added to 500ml TCI00. Next 5ml of P/S (5000units/ml) was added. This 
supplemented medium was then referred to as complete TCI00 medium and was 
stored at 4°C, in the dark.
2.5.8. Growth and maintenance of insect cell cultures:
All plastic flasks, petri dishes and pipettes were sterile wrapped and of cell culture 
quality. The insect cells were routinely grown at 28°C, with complete TCI00 
medium. For most purposes the cells were maintained as a monolayer although 
occasionally where larger volumes of cells were required spinner cultures were used 
(see L.A.King and R.D.Possee, 1992, for details of other culture methods). Cell 
culture work and virus infections were always carried out in separate Class II 
microbiological safety cabinets to remove the possibility of contaminating stock 
cells with virus.
For routine passage cell monolayers were seeded at a density of 6x106 cells in a 
volume of 40ml of complete TCI00 medium per T162 flask and inspected under a 
microscope (xlO and x40 magnification) at intervals. The doubling time was 
approximately every 24hours. If the cells were round, healthy and confluent they 
were passaged, if the cells were over confluent and "sausage" shaped they were
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discarded. Since healthy cells firmly adhered to the culture flasks it was possible to 
remove the medium containing any cell debris and replace it with 20ml of fresh 
medium. The cells were then dislodged by gentle scraping with a commercially 
available sterile cell scraper. An aliquot of this cell suspension was removed for 
counting and estimating the viability of the cells.
For the growth of cells in spinner cultures a Techne biological stirrer was used. To 
seed the flasks cells were added with complete TCI00 medium to a give a final 
volume of 50ml at lx l05 cells/ml. The cells were then placed at 28°C and stirred 
slowly at 30-40rpm. The cells were sampled daily for counting and harvested or 
passaged when the cell density reached 2-3x106 cells/ml.
2.5.9: Counting the S19 cells:
0.2ml of cells in suspension were counted using an improved Neubauer counting 
chamber after staining with an equal volume of trypan blue stain. Live cells were 
distinguished from dead cells by their ability to exclude the stain. The number of 
cells was determined by counting cells in the central large gridded area of the 
chamber (1mm2 x 0.1mm depth, divided into 25 squares). Two areas of this size 
were counted and the number of cells averaged, then multiplied by the dilution 
factor (2 in this case). The count was then multiplied by 104 to obtain the number of 
cells/ml:
i.e. count A + count B x2 xlO4 = number cells/ml 
2
Cell viability was generally about 80-90%.
2.5.10. Freezing, storage and recovery of Sf9 cells in liquid nitrogen:
On receipt of the Sf9 cells they were harvested at a low passage number from 
monolayer cultures into a small volume of fresh complete TCI 00 medium. This was 
achieved by pelleting the cells at a slow speed (500-800rpm) for 5 minutes and 
resuspending in fresh TCI00 medium. Cells were only used for freezing if viability 
exceeded 90%. The cell concentration was adjusted to 5xl06 cells/ml with complete
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TCI00, plus 10% DMSO. Cells were then aliquoted to suitable sterile cryogenic 
vials and placed at -70°C overnight. After 24hours the cells were transfered to 
liquid nitrogen storage. In order to confirm successful freezing of the cells after 2 
weeks one of the vials was removed from liquid nitrogen and thawed rapidly by 
hand. The tube was then swabbed with 70% alcohol and the cell suspension 
transferred to a T75 flask in a tissue culture hood and 15ml of complete TCI00 
medium added. The cells were incubated at 28°C for 24 hours and then the medium 
was replaced with fresh complete TCI00. When the cells became confluent they 
were subcultured in the usual manner, see above.
2.5.11. Preparation of glutathione-agarose (GA) - beads:
GA-beads were prepared as follows; 85mg of GA-beads corresponding to 1ml 
packed volume, was weighed into a 15ml conical tube (Falcon) to which 15 ml of 
PBS was added. The tube was incubated on a rotator at 4°C for 30 minutes, after 
which the beads were pelleted (500g, 4°C, 3 minutes) and washed with ice-cold 
PBS. This wash was repeated for a second time and the beads were left with 4ml of 
PBS as a 20% (v/v) slurry. 0.1% (v/v) of sodium azide was added and the beads 
were stored at 4°C. Prior to use the beads were always washed in the buffer to be 
used for the subsequent experiment. A needle (gauge 19) and syringe was found to 
be the best method to remove any traces of wash buffer from the beads.
2.6. Baculovirus protocols- Experimental methods:
2.6.1. Transfection of Spodoptera frugiperda (Sf9) insect cells to generate 
recombinant baculoviruses:
The virus used for the transfection of Spodoptera frugiperda, Sf9, insect cells was 
termed PAK6. This baculovirus contained a lacZ gene under the control of the 
polyhedrin promoter, which allowed blue/white selection of recombinant viruses. 
The gene of interest was cloned into a transfer vector (pAcCL29, pAcES or 
pAcGST) which contained flanking viral sequences. Following cotransfection, 
homologous recombination occurred generating a virus containing the gene of 
interest under the control of the polyhedrin promoter. The polyhedrin promoter is a
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late promoter which allowed the expression of recombinant proteins, such as the 
Src tyrosine kinases, which may have otherwise been toxic to the cells.
Prior to infection, to reduce the contamination of wildtype virus within the final 
recombinants, the baculoviral DNA was linearised at Bsu36I restriction sites within 
the lacZ gene and a downstream essential gene. This ensured that the only 
circularised, and hence infectious, virus genomes were those that had undergone 
recombination with the transfer vector, which replaced the essential gene coding 
sequence (Kitts and Possee, 1993). As detailed below lipofectin was then used to 
transfect these recombinant baculoviruses into Sf9 cells. Following this a plaque 
assay was performed on the supernatant obtained from the infected cells and single 
recombinants expressing the proteins of interest isolated. Protein expression was 
verified by using the plaques picked at this stage to infect Sf9 cells in a 24 well 
plate, these were subsequently harvested, lysed and protein expression determined 
by western blot analysis.
2.6.1.1. Preparation of viral DNA:
For each transfection of Sf9, insect cells, 200ng of wildtype baculoviral DNA 
(PAK6) was used. To linearise the DNA it was digested with an excess of Bsu36I 
(50U/|ig DNA) and incubated at 37°C overnight. A small aliquot of the linearised 
DNA was run on a 0.8% (w/v) agarose gel (see molecular biology section 2.2) to 
confirm the digestion. Linearised DNA entered the gel whereas uncut DNA 
remained in the loading wells of the gel. Bsu-361 was inactivated by heating at 65°C 
for 10 minutes.
2.6.1.2. Transfection of Sf9 insect cells:
35mm culture dishes were seeded with 106 Sf9 cells in 2ml of complete TCI00 
medium. Sufficient dishes for the number of virus samples to be analysed and two 
for controls, mock and AcMNPV infected, were included. To give the cells time to 
adhere to the dishes they were incubated at 28°C overnight. The following day the 
cells were washed twice with 2ml of TCI00 medium only, with no serum or 
antibiotics and left with 1ml of this unsupplemented medium.
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The following step was carried out in a polystyrene container, either a bijou or a 
universal. For each transfection the linearised viral DNA (200ng) and plasmid DNA 
(lpg) were mixed in a total volume of lOpl, to this an equal volume of lipofectin 
pilj-lipofectimHjO) was added. The mixture was incubated at room temperature 
for 20 minutes. This was then added to the cells and incubated at 28°C for 4-5 
hours after which 1ml of complete TCI00 medium was added. The cells were 
incubated at 28°C overnight and the dishes placed in a sealed box to prevent them 
from drying out. The medium was changed to 2ml complete TCI00 the following 
morning, the virus was harvested 2 days later.
2.6.1.3. Plaque assay to harvest the recombinant virus:
To harvest the virus the cells were resuspended by gentle pipetting and the 
suspension transferred to sterile micro-centrifuge tubes. These were then 
centrifuged at 6.5K in a microcentrifuge and the transfection supernatant containing 
the virus was removed and filtered through a 0.22p.m filter (Costar, Spin-ex® 
columns). The supernatant containing the virus was then plaqued as follows to 
isolate the recombinant virus {lacZ-) from any lacZ+ virus still present: 35mm 
culture dishes were set up containing 106 Sf9 cells in 2ml TCI00 medium and 
allowed to adhere overnight. The following day the medium was removed and the 
virus was added to the cells either neat or at a dilution of 10"1 (dilutions were made 
in TCI00 medium), in a volume of lOOpl and rocked at room temperature for 1 
hour. The inoculum was removed and 2ml of a mixture (1:1 ratio) of 3% LMP (low 
melting point) agarose in HjO (warmed to 45°C) and complete TCI00 medium 
(room temperature) was added and allowed to set. Once set the agarose was 
overlaid with 2ml of complete TCI00 medium. The plates were incubated at 28°C 
for 3-4 days.
To visualise the plaques in the Sf9 monolayer the plates were stained with 0.5ml per 
plate of neutral red viable cell stain, containing X-gal. The stain was added to each 
plate for 1 hour at 28°C. The supernatant was poured off and the plates inverted 
and left to stand in the dark, at room temperature, overnight. Any plaques formed
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by recombinant viruses were white since they lacked the lacZ gene. Six white 
plaques per transfection were picked using fresh, sterile, plastic pastettes (Alpha 
Laboratories, Eastleigh, Hampshire, UK) and dispensed into separate bijous 
containing 1ml of complete TCI 00 medium. The bijou's were vortexed to resuspend 
the virus and stored at 4°C.
2.6.2. Verifying expression of the protein of interest by the recombinant 
baculovirus:
A 24 well plate was seeded with 105 Sf9 cells per well. Once the cells had adhered 
to the plate 500pl of each resuspended virus (from the previous plaque picks) was 
added to the cells, the plate was sealed and incubated at 28°C. The cells were 
harvested 5-6 days later and transferred, by gentle pipetting, to screw-topped 
micro-centrifuge tubes. The cells were pelleted in a microcentrifuge, 6.5K, 5 
minutes, the supernatant containing the virus was removed and stored at 4°C. The 
cell pellet was washed in PBS and repelleted as previously. The cells were 
resuspended in 100jj.l lxGLB lysis buffer containing protease inhibitors and 
incubated on ice for 30 minutes. The cell debris was then pelleted in a 
microcentrifuge, 13K, 5 minutes and the lysates transferred to fresh tubes. lOpl of 
each lysate was analysed for protein expression by Western blot (see protein 
protocols, 2.8, for method). The lysates were stored at -20°C. Recombinant viruses 
expressing the proteins of interest were selected for expansion.
2.6.3. Large scale production of viral stocks:
Having obtained a purified recombinant baculovirus expressing the protein of 
interest it was necessary to build up a large working stock of the virus. (This 
method was scaled up when large amounts of virus was required for purification of 
GST-fiision proteins). lOOpl of the stored supernatant from the second round 24- 
well assay was used to infect a T75 flask previously seeded with 5x106 Sf9 cells. 
After 7 days incubation at 28°C the medium was harvested, cell debris pelleted 
(500g for 5 minutes) and the supernatant filtered through a 0.22|im filter. This 
working virus stock generally contained between 107 and 108 plaque forming units 
(pfii) per ml (verified by plaque assay, see below) and was used to bulk up further
102
by infecting larger amounts of cells (e.g. 1.5 x 107 in a T162) at 0.1 pfii/cell. Again 
the virus was harvested after 7 days. At this stage some of the virus was aliquoted 
into 1ml amounts and stored in sterile eppendorfs at 4°C to form the working virus 
stock or frozen overnight at -70°C and then transferred to liquid nitrogen for longer 
term storage.
2.6.4. Plaque assay for virus titre:
Sufficient 35mm culture dishes were seeded with 106 Sf9 cells for the following 
titrations to be carried out in duplicate. Dilutions of the recombinant viruses were 
made (10*4, lfr5 and lffi6) in complete TCI00 medium. The medium was removed 
from the Sf9 cells and lOOpl of each dilution was added to the cells, as detailed 
previously in the plaque assay for harvesting the recombinant virus, 2.6.1.3. After 
3-4 days the plaques were stained with neutral red viable cell stain and counted to 
determine the virus titres in pfu/ml (plaque forming units per ml). Virus titres were 
typically in the order of 107pfu/ml. An example calculation is shown below: 
e.g. If a lOOfil seed at 10'5 dilution gave 20 plaques, 1ml would give 200 or 
2xl02 plaques at the same dilution. Therefore the undiluted virus titre is 105x 
(2x 102)= 2xl07pfii/ml.
2.6.5. Production of Sf9 cell lysates:
Typically monolayers of cells were used for virus infections. Flasks or dishes were 
seeded with the appropriate number of cells to yield subconfluent monolayers. 
These subconfluent cells were infected at a high multiplicity of infection (3-10 
pfii/cell) for optimal protein expression. The medium was removed from the cells 
and the viral inoculum added and rocked for 1 hour at room temperature. For 
protein production the viral inoculum was not removed before the addition of 
complete TCI00 medium. The cells were incubated at 28°C for 3-4 days. Cells were 
harvested to 15ml conical tubes by gentle pipetting, centrifuged (500g, 5 minutes, 
4°C) and washed with 1ml of ice cold lxPBS. The cells were transferred to screw- 
topped micro-centrifuge tubes and repelleted in a microcentrifuge (6.5K, 3 minutes) 
and finally resuspended in the appropriate amount of lxGLB lysis buffer (see table). 
Cells were then incubated on ice for 30 minutes, cell debris was pelleted in a
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microcentrifuge, 13K, 5 minutes and the lysate transferred to fresh screw-topped 
eppendorfs. Lysates were stored at -20°C.
2.6.5.1. Single baculovirus infections: The table below provides a guide to the 
equivalent volumes of virus: cells for the different scales of lysate production.
Table 2.7. Volumes used for different culture dishes/flasks:
Size of Number of cells Inoculum vol. Medium lxGLB vol.
dish/flask o/n min / max vol.
35mm dish 1.0 xlO6 0.1 / 0.5 ml 2ml 50-100(il
25cm2 flask 5.0 xlO6 0.4 / 1.0 ml 5ml 150-500(^1
2.6.5.2. Coinfections: Coinfections were essentially the same as single infections 
and were always carried out within the parameters of the table above. Care was 
taken to keep infection volumes equal within experiments, since different inoculum 
volumes were shown to affect efficiency of infection.
2.6.6. Purification of affinity reagents:
2.6.6.1. Large scale virus infections for GST-fusion protein purification:
In general subconfluent cells were infected at a high multiplicity of infection (3- 
lOpfu/cell) for optimal protein expression. For each protein purified approximately 
5xT162 flasks seeded with 2xl07 Sf9 cells in 30ml of medium were set up several 
hours prior to infection. The medium was removed and the viral inoculum added (3- 
10 pfii/cell, i.e. 6x107 to 2x108 pfu in total) in a final volume of 5ml. After the 
standard 1 hour rocking 30ml of complete TCI00 medium was added to the flasks 
which were then incubated for 3 days at 28°C.
2.6.6.2. Lysis of infected cells and purification of GST fusion proteins:
The cells were harvested by agitating the flasks and gently pipetting several times, 
the cells were pelleted by centrifugation at 500g, 10 minutes, 4°C. The cell pellet 
was washed twice with 10-20ml of PBS by gently resuspending with a 10ml pipette
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and then pelleted again (500g for 10 minutes, 4°C). Since the proteins used in this 
study were all cytoplasmic the cells were lysed in 1 ml/flask of PBS containing 1% 
(v/v) TritonX-100 and protease inhibitors, for 30 minutes on ice. The cell debris 
was pelleted, 9K in sarstedt tubes (Sarstedt, Leicester), 4°C, 20 minutes and the 
supernatant transferred to a fresh 15ml polypropylene tube containing 1ml of 
preswollen GA-beads (see materials 2.5.11.). The lysate was incubated with the 
GA-beads at 4°C for 1 hour with constant mixing on a rotating wheel.
The beads were pelleted (500g for 3 minutes, 4 °C) and washed twice with >10 
volumes of ice cold lysis buffer. The beads were then washed a further 4 times with 
ice cold 50mM Tris-HCl pH 8.0. During each wash the beads were resuspended by 
gentle inversion. After the last wash the beads were resuspended in 10 volumes of 
50mM Tris-HCl pH 8.0 and poured into a 1ml disposable chromatography column 
(Biorad, polyprep). The column was allowed to pack but care was taken not to let it 
dry out. The fusion protein was eluted by adding lOx 250|j,l amounts of 50mM 
Tris-HCl pH8.0 containing 5mM reduced glutathione. Fractions were collected and 
each was assayed for protein content by Bradford assay (see 2.7 protein protocols). 
Fractions containing the protein were pooled and dialysed (visking tubing from 
BDH) overnight against two changes of 50mM Tris-HCl pH8.0. The integrity of the 
protein was verified by SDS-PAGE followed by Coomassie staining (see section 
2.8). The protein was aliquoted and stored at -70°C in lOOpg amounts.
2.6.7. In vitro binding assay:
Purified Nef-GST fusion proteins were used to investigate interactions with cellular 
proteins in a series of in vitro pulldown studies. The Nef-GST fusions were 
immobilised on GA-beads to act as affinity reagents in the experiments. Whole cell 
lysates containing the Src tyrosine kinases and other control proteins were 
precleared with GA-beads alone prior to the pulldowns with the affinity reagents. 
Once the pulldowns had been completed the results were analysed by western blot. 
The presence of both the proteins in the interaction was verified by stripping and 
reprobing the PVDF membrane, (see protein 2.8, protein protocols) with a second 
antibody.
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2.6.7.1. Binding the purified protein to glutathione agarose (GA) beads:
To immobilise the purified GST fusion proteins on GA beads, lOOpg of the protein 
was added to 50pl packed volume of GA-beads (final ratio of 2pg protein per lp.1 
packed beads. The total volume of the protein was made up to lOOpl with 50mM 
Tris pH8.0, to ensure efficient mixing. The mixture was incubated on a rotating 
wheel (Blood mixer) at 4°C for 2 hours. Subsequently the beads were washed twice 
with 1ml 50mM Tris-HCl pH8.0. For immediate use the beads were resuspended 
(1:5, beads:buffer) in lxGLB lysis buffer, however for storage at 4°C the beads 
were resuspended in 50mM Tris-HCl pH8. To confirm that the various proteins had 
bound equally to the GA beads, 5 pi packed volume of beads were heated to 90°C in 
sample buffer and then analysed by SDS-PAGE and Coomassie staining (see 2.8, 
protein protocols).
2.6.7.2. Binding assay:
Unless otherwise stated for each binding assay 5pi of whole cell lysate was used. 
The lysates were precleared with GA-beads alone prior to the pulldowns. Generally 
lOpl of packed volume of GA-beads was used per pulldown and the volume made 
up to lOOpl using lxGLB containing protease inhibitors. If increased stringency 
was required the pulldowns were performed in the presence of 0.5M KC1, 5pl of 
lysate plus lxGLB, 0.5M KC1. An aliquot of precleared lysate was taken and frozen 
at -20°C. The samples were precleared for 30 minutes, rotating, at 4°C. After 
preclearing the samples the beads were pelleted in a microcentrifuge at 6.5K for 30 
seconds. lOOpl of the supernatant was carefully transferred, using fine pipette tips 
to avoid carry over of beads, to lOpl packed volume of each of the affinity reagents. 
These were then incubated on a rotator at 4°C for 3 hours.
To remove any unbound protein the beads were washed several times in lxGLB. If 
0.5M KC1 was used for higher stringency, the beads were washed 3 times in the 
increased salt wash and once in GLB alone (to remove the salt prior to 
electrophoresis), otherwise 4 washes in GLB alone was sufficient. The beads were 
then resuspended in sample buffer and analysed by Western blot.
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2.6.8. In vivo binding assays:
Coinfections of the Src tyrosine kinases plus Nef-GST fusions were carried out as 
detailed above, 2.6.5.2. The in vivo pulldown assay was essentially the same as the 
in vitro pulldown assay, except a preclear step with GA-beads alone was not 
possible. As a result of this high stringency conditions were always used. Typically 
40pl of the coinfection lysate was added together with 1 Ojj.1 of lxGLB adjusted to 
2.5M KC1 and 50pl lxGLB, 0.5M KC1 to give a final salt concentration of 0.5M 
KC1. lOpl of packed volume of GA-beads alone was used as the affinity reagent in 
these pulldown assays. The samples were incubated for 3 hours, with rotating at 
4°C and then washed 3 times with lxGLB, 0.5M KC1, followed by one wash with 
lxGLB to remove the salt. 15pl of lx sample buffer was then added to the beads. 
The samples were then either frozen at -20°C or immediately analysed by western 
blot.
2.6.9. Metabolic labelling:
Radiolabelling was carried out in 35mm dishes, cells were infected as described,
2.6.5. After 24hours the medium was replaced with TC100 medium without 
methionine, containing 1% dialysed foetal calf serum (dialysed against PBS and 
stored at -20°C) and 50|4.Ci/ml 35S or lOOpCi/ml 3H myristic or palmitic acid were 
added, cells were harvested as standard into lxGLB and analysed by SDS-PAGE 
dried down and autoradiographed. In some cases samples were immunoprecipitated 
to enhance specific signals.
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PROTEIN BIOCHEMISTRY:
2.7. Protein biochemistry- Materials:
2.7.1. Chemicals and enzymes:
Chemicals and reagents, including abbreviations, specific to this section can be 
found below. Any general chemicals will be found at the start of this chapter.
Table 2.8. Chemicals and enzymes for protein protocols including 
abbreviations and companies purchased from:
Chemical/Enzyme Company
Secondary antibody conjugates 
Protein A agarose beads (Prot-A) 
Protein G agarose beads (Prot-G) 
Reduced glutathione
SIGMA, Poole, Dorset, UK
(3-mercaptoethanol
Coomassie
Glycine
Methanol
Trichloroacetic acid (TCA)
Tween 20
Anti-foam
BDH, Poole, Dorset, UK
Enhanced chemiluminescence detection 
reagents (ECL)
Amersham Life Science
Marvel (dried skimmed milk) Local supermarket
Polyvinylidene diflouride (PVDF) Millipore
Isopropyl-thio-|3-D Galactopyranoside 
(IPTG)
Melford Labs. Ltd, Ipswich, UK
2.7.2. Radiochemicals:
[y32P] ATP, specific activity, lOCi/mmol (lOmCi/ml), for peptide substrate assays, 
supplied by Amersham Life Sciences.
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2.7.3. Stock solutions:
Bradfords Reagent (5x): lOmg Coomassie, 5ml 95% (v/v) EtOH, 10ml 85% (v/v) 
orthophosphoric acid, made up to 100ml with ddH20. To avoid traces of phosphate 
detergents in glassware, this was made entirely in sterile 50ml polypropylene tubes. 
It was stored at room temperature in the dark. Before use filtered with a 0.22pM 
filter and diluted to lx as required again avoiding all glassware.
Affinity reagents: Beads were stored in PBS containing 0.1% (w/v) sodium azide at 
a 1:5 ratio of beads:buffer. Prior to use the beads were aliquoted to give the 
required packed volume and washed with the buffer to be used in the subsequent 
experiment. A needle (gauge 19) and syringe was used to aspirate the buffer. 
Prot-G was used for rat and mouse antibodies, but Prot-A was used for rabbit 
antibodies.
SDS-PAGE loading buffer (sample buffer) (5x): 125mM Tris-HCl pH6.8, 40% 
(v/v) glycerol, 4% (w/v) SDS, 10% (v/v) P-mercaptoethanol, 0.05% (w/v) 
bromophenol blue, in ddH20. Stored at room temperature.
2.8. Protein biochemistry- Experimental methods:
2.8.1. SDS-PAGE (sodium </odecyl sulphate-poly-acrylamide #el 
electrophoresis) analysis:
The Biorad minigel system (Mini-Protean) was used for protein electrophoresis. 
Stock solutions were made of the following, which were diluted as required:
Ammonium persulphate: 10% (w/v) stock solution, stored at 4°C.
Resolving gel buffer (5x): 1.875M Tris, 0.5% (w/v) SDS, pH8.5 with conc.HCl 
stored at room temperature.
Stacking gel buffer (1 Ox): 1.25M Tris, 1% (w/v) SDS, pH6.5 with conc. HC1, 
stored at room temperature.
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Running buffer (5x): 0.25M Tris, 1.92M glycine, 0.5% (w/v) SDS, stored at room 
temperature.
In general 12.5% acrylamide gels gave sufficient resolution however when smaller 
polypeptides were being analysed a 17.5% gel was used. The acrylamide was 
bought as a 30% acrylamide, 0.8% bis-acrylamide, stock from Scotlab. The glass 
plates were cleaned thoroughly with 70% ethanol before the protein rigs were 
assembled. The resolving gel was then poured (12.5% acrylamide, lx resolving gel 
buffer, plus per 10ml- lOOpl APS, lOpl TEMED) and overlayed with water- 
saturated butanol, to ensure a flat interface. Once the gel had set the butanol was 
poured off and any traces removed with ddHjO, the plates were dried with 3MM 
filter paper. The stacking gel (6% acrylamide, lx stacking gel buffer, plus per 5ml- 
50pl APS, 7.5pi TEMED) was then added and the comb carefully inserted. The 
comb was removed after polymerisation and the wells washed with lx running 
buffer. Sample buffer was added to the protein and then the tubes were heated to 
90°C for 2 minutes prior to loading. Seeblue pre-stained protein standards (Novex, 
USA) were run alongside the samples which as well as providing an indication of 
the size of the proteins also transferred to the PVDF membrane. 14C Rainbow 
markers from Amersham Life Sciences were run for radioactive samples.
2.8.2. Coomassie staining:
Gels were soaked in Coomassie stain (0.2% w/v Coomassie stain, 50% v/v 
methanol, 5% v/v glacial acetic acid) for 30 minutes and then destained in 50% 
(v/v) methanol, 5% (v/v) glacial acetic acid, until the bands became visible.
2.8.3. Radioactive gels:
Gels were soaked in destain, see Coomassie staining, for 5 minutes followed by 5 
minutes soaking in “Enlightening”, from Dupont, NEN, which amplifies the 
radioactive signal. The gels were subsequently dried under vacuum for 15 minutes 
at 80°C and autoradiographed.
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2.8.4. Western blot analysis:
2.84.1. Transfer to PVDF membrane:
As PVDF membrane is hydrophobic it was first wetted in 100% methanol and then 
rinsed in ddHjO, before equilibrating in transfer buffer (25mM Tris, 137mM 
Glycine, 20% v/v methanol). A Biorad Semi-Dry blotting apparatus was used to 
transfer the proteins from the SDS-PAGE gel to the PVDF as outlined in the 
instructions, for 30 minutes at 15volts. The membrane was then either immediately 
western blotted or sealed in a bag and stored at 4°C overnight.
2.8.4.2. Western blot:
The membrane was blocked for 30 minutes, room temperature, shaking, in lx 
TBS-T (20mM Tris pH 7.6, 137mM NaCl, 0.1% v/v Tween) containing 10% (w/v) 
Marvel, followed by one rinse in TBS-T, and 5 minutes wash in TBS-T. The 
primary antibody was added at the appropriate dilution (see table 2.7.1) in TBS-T 
containing 5% Marvel, for 1 hour, with shaking (~40-60rpm). The antibody was 
removed and the membrane rinsed in TBS-T followed by one 5 minute wash and 
one 15 minute wash in TBS-T. The secondary antibody, horse radish peroxidase 
conjugated, was added at a dilution of 1 in 2000, except where otherwise stated, in 
TBS-T containing 5% Marvel. This was incubated for a further 30 minutes, shaking 
after which the membrane was washed thoroughly (4x 5minutes TBS-T) and the 
bound antibody visualised using the ECL detection system, as detailed in the 
manufacturers instructions.
2.8.4.3. Reprobing the membrane:
Antibodies were stripped from the blot by incubating the membrane in strip buffer 
(lOOmM 2-mercapto-ethanol, 2% w/v SDS, 62.5mM Tris pH6.8). This was carried 
out in a hybridization oven (Hybaid) with continuous rotation, at 60°C for 30 
minutes. The membranes were then washed thoroughly in TBS-T (2x 30 minutes) 
before western blotting with an alternative antibody.
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2.8.5. Immunoprecipitation:
Lysates (in GLB) were adjusted to 0.5M KC1 and incubated overnight at 4°C, on a 
rotator with the appropriate antibody. The following morning lysates were 
transferred to fresh tubes containing 1 OjllI packed volume of either Prot-A or Prot-G 
beads, these were incubated for a further 4hours at 4°C. To reduce background a 
preclear step (30 minutes, rotating, 4°C), using the protein A or G beads, was 
utilized prior to incubating with the antibody. After precipitation the beads were 
washed 3 times using lx GLB/0.5M KC1 and lx GLB (see section 2.5 lysis buffers) 
before resuspending in 15pi of sample buffer and analysis by SDS-PAGE.
2.8.6. Bradford Assay:
A standard curve using different amounts of BSA in duplicate (0-5pg) were 
pipetted into a 96 well plate in a volume of lOpl in 50mM Tris-HCl pH8.0. Samples 
to be analysed were also diluted into lOpl of 50mM Tris in duplicate. To each well 
lOOpl of lx Bradford reagent was added. Binding of Coomassie brilliant blue in the 
Bradford reagent to protein present in the samples causes a shift in the absorption 
maximum of the dye from 465 to 595nm (Bradford, 1976). The absorption of each 
of the wells at OD595 can therefore be read and a standard curve plotted for the 
known concentrations of BSA. The standard curve was then used to work out the 
concentration of the sample proteins by using their absorption values to read off the 
amount of protein in mg/ml.
2.8.7. In vitro transcription-translation:
Coupled in vitro transcription-translations were carried out using Trans 35S-Label™ 
and a TnT™ T7 Coupled Rabbit reticulocyte lysate kit supplied by Promega. Genes 
cloned into pSG5 plasmids under the T7 promoter (kindly donated by K.Coates) or 
pCR™ were (see 2.1) used as the template in this assay. Reactions were carried out 
in 50pl volume, 2.5pl Trans 35S-Label™ and lpg plasmid were added per sample. 
The reaction was incubated for 90 minutes at 30°C. Subsequently CaCl2  was added 
to a 2.5mM final concentration, together with O.lmg/ml RNaseA, the reactions 
were incubated for a further 15 minutes at 37°C.
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2.8.8. Autophosphorylation Assay:
lpl of lysate was typically added to 20pl of kinase buffer (20mM PIPES pH7.2, 
3.5mM MgCl2, 3.5mM MnCl2, ImM NaOV) either plus or minus 10pM ATP. This 
was then incubated at 30°C for 30 minutes. The reaction was stopped by the 
addition of sample buffer to a lx concentration. The samples were then analysed by 
Western blot using an anti-phosphotyrosine antibody.
2.8.9. Protein kinase assays:
Kinase activity assays were performed at 30°C in buffer containing 20mM Tris, 
pH7.5, lOmM MgCl2, 800pM peptide substrate (RRLIEDAHYAARG), [y32P] 
specific activity lOCi/mmol (lOmCi/ml) and 500pM ATP. This peptide has been 
reported to be an efficient substrate for Src family kinases, Km=240|jJVT for Src 
(Moarefi et al., 1997; Casnellie, 1991). Generally 3pi of lysate was added to an 
80pl reaction volume. lOpl aliquots were removed from the reaction mix at time 
points required and the reactions terminated by the addition of an equal volume of 
cold 10% (w/v) TCA. These were briefly centrifuged and the supernatants spotted 
onto phosphocellulose paper, (Whatmann-P81), as described (Casnellie, 1991). The 
phosphocellulose pads were washed 5x 5 minutes in 400ml of 150mM phosphoric 
acid, rinsed in ethanol, dried and counted in a scintillation counter to measure the 
incorporation of 32P into the peptide. Reactions were always carried out in 
duplicate. The activity of the kinase enzyme was measured in pmols of phosphate 
transferred to the peptide, which was calculated as follows:
The chemical concentration of the stock was calculated using the formula;
Specific activity (mCi/mmol) = Radioactive concentration (mCi/ml)
Chemical concentration (mmol/ml)
e.g.
Specific activity of the stock = lOCi/mmol = 10,000mCi/mmol 
and the radioactive concentration = lOmCi/ml
therefore, the chemical concentration = 10/10,000 = lxl0 '3mmol/ml = lpmol/ml
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lul [y’2P] was added to each 80pl reaction, therefore the chemical concentration of 
the label was diluted 80 fold = 0.0125(j,mol/ml = 12.5nmol/ml
However, there was also 500|iM of unlabelled ATP per reaction (corresponding to 
500pMol/litre = 0.5|iMol/ml = 500nmol/ml); the amount of labelled ATP 
transferred to the peptide was hence diluted by 500/12.5 = 40. Therefore the final 
scintillation count reading was multiplied by 40 to represent the cpm that would be 
obtained if all the ATP had been labelled.
Next the cpm (counts per minute) of the original stock was calculated to determine 
how much the final cpm reading corresponded to in pmol.
It is known, lmCi = 2.2xl09cpm, (original stock=10Ci/mmol)
therefore, 1 OmCi/pM = 2.2xl010cpm/pmol
= 2. 2x 104cpm/pmol 
Number in pmols of phosphates transferred can be represented by:
40 x scintillation reading = pmols phosphate transferred 
2.2xl04
2.8.10. HIV-1 protease experiments:
Binding assays were carried out as standard (sections 2.6.7 and 2.6.8), after the 
final wash the samples were divided in two and incubated either plus or minus 
purified HIV-1 protease (from the ADDS Directed Programme reagent repository), 
in buffer containing lOmM NaAc, 2-mercaptoethanol, lmM EDTA, 20% (v/v) 
glycerol, 22pg/ml HIV-1 protease, at 30°C for 4 hours. The supernatant was then 
removed for later analysis and the complex bound to beads washed twice in lx GLB 
and sample buffer added.
CHAPTER 3
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CHAPTER 3: Use of the yeast interaction trap to investigate novel cellular
interactions with HIV-1 Nef.
3.0. General introduction:
To date the function of Nef in vivo remains elusive although a variety of in vitro 
roles have been proposed. These include the downmodulation of expression of cell 
surface CD4, enhancement of HIV infection and disruption of cell signalling 
pathways. To understand how Nef can mediate these pleiotropic affects, attention 
has turned to the cellular proteins with which Nef interacts. A variety of interacting 
partners for Nef have been described, including CD4 (Harris and Neil, 1994; Rossi 
et al, 1996; Grzesiek et al, 1996b); the Src kinases- Lck (Collette et al, 1997; 
Collette et al, 1996b), Hck (Lee et al, 1995; Grzesiek et al, 1996a; Moarefi et al, 
1997), Src (Lee et al, 1995) and Fyn (Arold et al, 1997); various serine kinases 
including, NAK (Nef associated kinase) (Sawai et al, 1994; Sawai et al, 1995; Baur 
et al, 1997) MAPK (Greenway et al, 1995; Greenway et al, 1996), 0PKC (Smith et 
al, 1996)and 5PKC (Saksela, 1997); 3-COP (Benichou et al, 1994); HsN3 (Rossi et 
al, 1997); p53 (Greenway et al, 1995); and a novel acyl Co-A thioesterase 
(Watanabe et al, 1997; Liu et al, 1997). Despite the growing repertoire of Nef 
cellular interactors, there is still no consensus as to the functional significance for 
Nef in vivo.
The Nef interaction with [3-COP was identified using the yeast-two-hybrid system 
(Benichou et al, 1994) and has gained recognition due to the Nef mediated 
increased endocytosis of both CD4 (Anderson et al, 1993; Rhee and Marsh, 1994; 
Schwartz et al, 1995) and MHC class 1 (Schwartz et al, 1996). p-COP is a 
ubiquitous protein found on non-clathrin coated vesicles and is involved in 
membrane trafficking of proteins. Exactly how a direct interaction with P-COP a 
non-clathrin endocytic component relates to the recent reports of Nef colocalization 
with clathrin and the AP-2 adaptor complex is unknown (Mangasarian et al, 1997; 
Greenberg et al, 1997; Foti et al, 1997). It is however interesting, that Nef 
mediated endocytosis is specific, leaving other cell surface receptors analysed so far 
unaffected. This suggests that the co-operation of Nef and the endocytic machinery
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results in a targeted mechanism of downmodulation. Proposed mechanisms include, 
either a direct interaction involving P-COP, AP-2, clathrin or an as yet unidentified 
protein of the endocytosis machinery, with Nef acting as an adapter-molecule, or 
via an indirect action, such as perturbation of membrane anchoring caused by a Nef 
association with for example Lck.
Several studies have demonstrated Nef expression perturbs cell signalling pathways 
however these studies have been reliant on the monitoring of fluctuations in the 
expression of activation markers, such as IL-2, CD69, and NFkB which can vary 
depending on the level of Nef expression and its subcellular location (Luria et al, 
1991; Bandres and Ratner, 1994; Baur et al, 1994; Greenway et al, 1995; Collette 
et al, 1996a; Iaffate et al, 1997). The determination of Nef cellular interaction 
partners would therefore aid in the elucidation of its precise effect on cell signalling 
pathways. Putative binding partners identified to date include NAK, MAPK, 0PKC, 
6PKC and the Src tyrosine kinases. The Nef interaction with NAK was first 
demonstrated by the coimmunoprecipitation of Nef with two serine phosphorylated 
proteins, of 62kDa and 72kDa respectively the identity of which remains unknown 
(Sawai et al, 1994; Sawai et al, 1995). Although recent studies have provided 
evidence that NAK is a member of the PAK family of serine kinases (Baur et al, 
1997; Nunn and Marsh, 1995; Geleziunas et al, 1996), data from in vivo macaque 
studies (Lang et al, 1997) and from work with other Nef isolates (Luo and Garcia, 
1996; Luo et al, 1997) has questioned the importance of this kinase association. 
Significantly, a number of other Nef interactions with serine kinases have now been 
identified(Greenway et al, 1996; Smith et al, 1996; Saksela, 1997), one proposal 
being that Nef retains a non-specific ability to recognise a variety of serine kinases 
(Swingler et al, 1997). If the latter hypothesis is accurate the elucidation of a wide 
range of Nef serine kinase interactions might be anticipated. Furthermore, the 
identity of the co-immuno-precipitates and whether these would remain the same 
for alternative serine kinases is unknown.
Currently, no direct interaction of Nef has been identified that exerts an effect on 
both CD4 downmodulation and infectivity, although these remain the most
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conserved Nef phenotypes. Interactions of Nef with the Src tyrosine kinases 
represents an attractive explanation for the pleiotropic functions ascribed to Nef, 
due to their key role in signal transduction pathways and physical association with 
cell surface receptors. In addition high concentrations of the Src kinases have been 
identified in Triton insoluble complexes, indicative of associations with GPI-linked 
proteins, caveolae and the endocytic pathways (see section 4.1). However, the 
downstream affect of Nef interactions with the Src kinases in vivo is unknown. By 
elucidating cellular factors capable of binding Nef an insight into the repercussions 
of the Nef-Src kinase interaction may also be gained.
Evidence that Nef is capable of binding a number of cellular proteins potentially 
forming a complex has been provided by a number of studies (Harris and Coates, 
1993; Cullen, 1996; Baur et al, 1997). By building a profile of these Nef cellular 
binding partners and the factors important for the interactions such as 
myristoylation or full length Nef expression a clearer picture of its role in viral 
pathogenesis will be obtained. To this end, we used the yeast-two-hybrid system to 
help elucidate novel protein interactions with Nef. The yeast-two-hybrid system 
(YTHS) was developed by Fields and Song (Fields and Song, 1989; Fields and 
Stemglanz, 1994). It was based on the observation that the yeast transcriptional 
activation protein, GAL4 was comprised of 2 domains that did not need to be 
covalently attached to cause transcription initiation. The first domain was the DNA 
binding domain (DB domain), which specifically recognised upstream activating 
sequences (UAS), the second a transcriptional activation domain, (TA domain). The 
crucial observation made by Fields and Song was that these 2 domains could be 
fused to independent protein sequences and still function as a transcriptional 
activator if their fusion partners brought them into the same spatial proximity. This 
functional domain separation has since been identified in other transcriptional 
activating proteins including the bacterial LexA protein and has led to the 
development of a variety of yeast-two-hybrid systems, see chapter 2 for details of 
the interaction trap system utilised for these studies.
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The success of the yeast-two-hybrid as a research tool has already been highlighted 
in the HIV field, with the identification of the interaction between Cyclophilin A and 
HIV-1 Gag, latterly identified as necessary for the infectivity of the virion (Thali et 
al, 1994; Franke et al, 1994). With the aid of the yeast-two-hybrid system it was 
established that this Cyclophilin A association is dependent on the multimerization 
of p55 Gag. Further screening of randomly generated Gag deletions identified a 
minimal consensus region within the capsid (CA) domain necessary in conjunction 
with the multimerization signal in the nucleocapsid (NC) domain of Gag for binding 
to Cyclophilin A (Straus and Weiss, 1992; Colgan et al, 1996). The cyclophilins 
were originally identified as the cellular target for the immunosuppressive drug 
Cyclosporin A, therefore the identification of an interaction with Gag was also of 
therapeutic significance (Franke and Luban, 1996). The previous success of the 
yeast-two-hybrid system and its rapid in vivo screening of protein-protein 
interactions hence made it an ideal tool for investigating novel interactions of HTV-1 
Nef.
3.1. Results:
As research continues it is becoming more likely that Nef exists in several distinct 
isoforms within the cell, which may contribute to its pleiotropic effects. It has been 
well documented that a 27kDa and 25kDa species of Nef exist, the smaller resulting 
from the initiation of translation from a downstream methionine. It has recently 
emerged that Nef is incorporated into the virion, where it is specifically cleaved by 
HIV protease to yield 2 fragments of ~9 and ~18kDa (Welker et al, 1996; Pandori 
et al, 1996; Bukovsky et al, 1997). The location of the small N-terminal fragment 
of Nef is yet to be determined. Protease cleavage only occurs in the virion, hence it 
is the full-length myristoylated Nef species that is present in abundance in infected 
cells. The only proteins identified to date that exclusively interact with this species 
of Nef are Lck, CD4 and NAK, the latter of which has been shown to be 
dispensable in vivo. Previous results within the laboratory had demonstrated that 
interactions of a number of Jurkat T-cell proteins were dependent on Nef 
myristoylation in vitro (Harris and Coates, 1993). To further identify these proteins
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a Jurkat T-cell library, kindly provided by Dr R. Brent, was screened for interactions 
with myristoylated Nef using the yeast-two-hybrid system.
Initially the bait plasmid had to be modified to accept Nef as an N-terminal fusion 
protein, to allow myristoylation. The stability and myristoylation of Nef as an 
N-terminal fusion to the DB domain was then confirmed. Subsequently the 
suitability of Nef as a bait in the system had to be determined using the transcription 
activation and repression assays. Following this the screening of the Jurkat T-cell 
library was carried out. Potential cellular interactors with Nef were isolated, 
sequenced and investigated for the specificity of their interactions with Nef.
3.2. Modification of the bait plasmid to accept proteins as N-terminal fusions:
The original yeast interaction trap bait plasmid, pEG202 was constructed by 
E.Golemis in the lab. of Dr R.Brent, is described in detail in section 2.1. The only 
restriction site available upstream of the LexA DB domain, which could be used to 
make N-terminal fusions, was a HindlH site that was not unique. This necessitated 
the use of an intermediate cloning plasmid, into which a cassette containing the 
region of DNA for manipulation could be inserted (see figure 3.1 for this cloning 
process). For this purpose the region of DNA between the two SphI restriction sites 
(1.4Kb) in pEG202 was subcloned into a pBluescript® plasmid (Stratagene, see 
section 2.32.1) that had a modified polylinker containing an SphI site (see figure
3.1, step 1, for linker oligonucleotides used to modify pBluescript®). The LexA 
gene was then removed from the intermediate plasmid using the N-terminal Hindin 
site and a BamHI site in the polylinker (figure 3.1, step 3). Nef was amplified by 
PCR to incorporate a Hindin site and the required junction (~10bp) region between 
the ADH promoter and gene at its N-terminus, and an EcoRI site at its C-terminus. 
This was cloned into a separate pBluescript® plasmid (step 2). Adjoining Nef 
downstream in the pBluescript® plasmid was LexA which had been amplified to 
incorporate EcoRI and BamHI sites at its N- and C-termini respectively (step 2). 
The integrity of the resultant N-terminal Nef-LexA fusion was verified by in vitro 
transcription-translation from the T3 promoter in pBluescript® (figure 3.2). This
whole Nef-LexA cassette was then introduced into the intermediate plasmid using 
the Hindlll and BamHI sites (step3). The SphI cassette was returned, containing 
the Nef-LexA cassette, to pEG202 and the resultant construct called pVEG-Nef 
(see figure 3.1 step 4). Nonmyristoylated Nef (G2ANef) was also cloned using this 
lengthy process, however a further modified pVEG was later constructed to allow a 
one step cloning process.
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Figure 3.1. Summary o f approach taken to modify the bait plasmid to accept 
proteins as N-terminal fusions:
pBluescript® was modified to introduce a unique SphI site with the linkers shown, 
this was then called pBluescript*. The SphI fragment from pEG202 containing the 
LexA gene and the polylinker was then subcloned into pBluescript* (step 1). 
Subsequently Nef was amplified by PCR to incorporate Hindlll (H3) and EcoRI 
(RI) sites at its N- and C-termini respectively, this was cloned into a separate 
pBluescript® plasmid. LexA was amplified by PCR to contain RI and BamHI (BHI) 
and cloned adjacent to Nef (step 2). The Nef-LexA cassette was introduced into the 
pEG202 SphI fragment using the H3 and BHI sites therefore removing the original 
LexA gene (step 3). The SphI pEG202 fragment was then returned to pEG202 
creating the pVEG-Nef plasmid (step 4). This process was repeated to create 
pVEG-G2A. The insert demonstrates the full length expression of Nef-LexA from 
the T3 promoter in the pBluescript® expression plasmid during in vitro 
transcription-translation assays, see section 2.8.7 for method. The products were 
immunoprecipitated with the Nef N-terminal monoclonal antibody and resolved by 
12% SDS-PAGE. The gel was subsequently dried and autoradiographed. Lane 1, 
14C rainbow markers, lane 2 Nef-LexA fusion (~55kDa), lane 3 pBluescript® only 
negative control, pBluescript®-Nef positive control (~27kDa).
Spill
pEG202 LexA
Polylinker
pBluescript*
Modified pBluescript*, the polylinker was 
replaced from Kpnl to SacI with linkers to 
form an SphI site:
5'- .CGCATGCGATATCGAGCT-3 '
3'-CATGGCGTACGCTATAGC....-5' 
SphI
pEG202 was SphI digested 
and both fragments were gel 
purified.
1.
H3 RI BHI
Nef I LexA I
PCR Products
. /
pBluescript* LexA
Nef-LexApBluescript*
4.
Nef-LexA
; pBluescript*
I  pVEG-Nef
o
Nef-LexA
Figure
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V
124
Diagram 3.1. Construction of pVEG2:
SphI fragment 
of pEG202 in ]
RI, BHI, S, Nc, N, XI, S 
Polylinker
Replaced H3 to RI 
with a linker containing 
only the junction region, 
abolishing the H3 site.
❖
RI, BHI, S, Nc, N, XI, S 
Polylinker
LINKER
5 '  AGCTTC AATTCCGGGCGG 3 ‘
3 ' AG TTAAGGCCCGCC TTAA 5'
Reintroduced LexA, BHI/XI
l L
LexA
7 *
RI, BHI 
New Polylinker
\
XI, S
Key: RI-EcoRI, BHI-BamHI, H3-HindIII, Nc-NocI, N-Notl, S-Sall, Xl-Xhol, Sl-SphI
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In order to reconstruct pVEG to allow a single cloning step, it was necessary to 
include unique restriction sites between the junction region and the LexA gene. The 
following steps were carried out in the intermediate modified pBluescript® plasmid 
containing the 1.4Kb SphI fragment from pEG202. A linker was designed to span 
from the Hindlll site, including the junction region to the EcoRI site at the 5’ end of 
the polylinker. The EcoRI site was reconstituted while the Hindlll site was 
abolished, see diagram 3.1. The linker region was sequenced and then the LexA 
gene was reintroduced into the original polylinker, after PCR amplification to 
incorporate BamHI and Xhol sites at its N- and C-termini. Thus maintaining unique 
EcoRI, Smal and BamHI restriction sites N-terminal to the LexA gene. The 
modified SphI cassette was returned to pEG202. When cloning into these unique 
sites the gene of interest needed to contain an ATG and keep the ATG of the LexA 
gene in frame, see diagram 3.2. This plasmid was used to clone genes for the library 
specificity checks and will be referred to as pVEG2.
3.3. Verification of expression and myristoylation of Nef from pVEG:
Previous studies by Macreadie et al (Macreadie et al, 1993) have demonstrated the 
myristoylation of Nef in yeast and the ability of myristoylated Nef to enter the 
nucleus. Studies were performed to confirm that the DNA manipulations had not 
affected the expression capabilities of the pVEG plasmid and that Nef expressed as 
an N-terminal fusion to LexA was myristoylated. 5ml cultures of yeast expressing 
either myristoylated or nonmyristoylated Nef, or pEG202 were grown through the 
exponential phase in the presence of 0.5mCi 3H myristic acid per culture (~6 hours). 
Cultures were harvested in the late exponential phase, as outlined in section 2.4.8. 
The resultant lysates were immunoprecipitated with a Nef specific antibody (2/8 lc) 
(Harris and McKeating manuscript in preparation) and analysed by SDS-PAGE and 
fluorography. A band corresponding to the Nef-LexA fusion protein, was only 
detected in the lane containing the myristoylated Nef, see figure 3.2; thus 
confirming myristoylation of Nef expressed from the pVEG plasmid as an 
N-terminal LexA fusion. Cultures grown simultaneously and analysed by western 
blot confirmed equal levels of Nef expression (data not shown).
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Diagram 3.2. Map ofpVEG2, including sequence around the polylinker:
HIS 3
Amp R
pVEG2 
10,000 bp
■Xba I 2.80
colE1 ori
ADH term.
ADH pro.- ^ 7 - *
SphI 5.00—'
P olylinker - EcoRI BamHI
■Xhol Sal I
The sequence around the modified polylinker is shown below, the gene of interest 
requires an ATG and to fuse in frame with the ATG of the LexA gene.
GAATTCCCGGGGATCCATGAAA 
EcoRI BamHI Start of LexA
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Figure 3.2. Results o f the fH ]  myristic acid labelling o f yeast:
Yeast cultures (5ml) expressing either myristoylated Nef (pVEG-Nef), 
nonmyristoylated Nef (pVEG-G2A) or the bait LexA DB domain only (pVEG2) 
were grown to an OD6oo~10 in the presence of 0.5mCi [3H] myristic acid. The [3H] 
myristic acid was lyophilised prior to use and resuspended in 30pl DMSO per 
culture ad detailed 2.4.8. The cultures were harvested as detailed section 2.4.7. and 
immunoprecipitated with the Nef antibody 2/8 lc. The immunoprecipitates were 
resolved by SDS-PAGE and analysed by fluorography (the example in this figure 
was exposed to film for 1 month). The pVEG2 negative control was loaded in lane 
1, pVEG-G2A in lane 2 and pVEG-Nef in lane 3. A background band was visible in 
every sample, however a myristoylated Nef specific band was clearly detected in 
lane 3 at ~55kDa corresponding to the Nef-LexA fusion protein.
o£
<CN
ai
o
a*
D
zI
a
66kDa
46kDa
Figure 3.2.
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3.4. Activation and repression assays to determine the suitability of 
pVEG-Nef as a bait in an interactor hunt:
To be a suitable bait for an interactor hunt the protein of interest, fused to the LexA 
DB domain, had to bind the UAS’s within the nucleus without transactivating the 
reporter genes. Transcriptional activation activity was determined by monitoring the 
ability of the host yeast strains to grow on leucine. The LEU2 gene was a 
chromosomally integrated auxotrophic marker, utilised as a reporter gene in the 
interaction trap system. If the yeast became prototrophic for leucine it correlated 
with transactivation activity of the bait protein. Figure 3.3 shows a UH dropout 
plate compared to a UHL dropout plate. Yeast were spotted onto the plates at 
increasing dilutions, the UH plate which is permissive for all yeast examined 
confirmed equal culture densities. The UHL plate shows no growth for pVEG-Nef 
or pVEG-G2ANef indicating that Nef, as an N-terminal fusion to LexA, had no 
inherent transactivating capabilities. However pEG-Nef (Nef cloned into the 
original pEG202 plasmid as a C-terminal fusion), did appear to have a low level of 
transactivating ability. The differences in inherent transactivation, between N- and 
C- terminal Nef fusion proteins, was presumably due to the variable proximity of 
acidic stretches of amino acid sequences in Nef to the LexA DB domain. This meant 
that pEG-Nef would not make a suitable bait for an interactor hunt due to the high 
levels of false positives that would be obtained.
Since pVEG-Nef did not transactivate the reporter genes it was necessary to 
confirm it successfully entered the nucleus and bound the UAS. The repression 
assay, explained in more detail in section 2.42.4, was performed to determine the 
ability of the bait to reach the nucleus. A modified constitutively expressing LacZ 
reporter plasmid (pJKlOl) was cotransformed with the pVEG bait plasmid. This 
reporter plasmid contained a UAS between the ATG and TATA box, therefore if 
the bait bound the UAS transcription was blocked. To block the constitutive 
expression of LacZ a bait obviously had to enter the nucleus, this event could be 
determined by the formation of white colonies on plates containing X-Gal. Blue 
colonies would indicate the continued unhindered constitutive expression of the 
lacZ gene. Figure 3.4 shows the prospective baits spotted onto UH G/R plates
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containing X-Gal Both pVEG-Nef and pEG-Nef entered the nucleus and 
successfully blocked transcription of the LacZ gene as indicated by the growth of 
white colonies. A bait that was excluded from the nucleus was included as a control 
for blue colonies. The suitability of pVEG-Nef as a bait for the interactor hunt was 
therefore confirmed. These activation and repression assays were carried out every 
time a new bait was used for the interaction trap system, e.g. p55Gag and ORF94, 
see later.
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Figure 3.3. Activation assay fo r pVEG-Nef pVEG-G2A and pEG-Nef:
The activation assay was carried out as detailed 2.4.2. This example shows the 
pSH18-34 reporter plasmid plus pVEG-Nef, pVEG-G2A, pEG-Nef and the 
pSH17-4 control which possesses inherent transcriptional activation properties. 
Samples were spotted either undiluted (undil.) or at 1/100 or 1/1000 dilutions. The 
same samples were spotted onto the top (G/R UH) and bottom (G/R UHL) plates. 
All the samples grew on the G/R UH plate demonstrating similar culture densities 
for each sample. The lack of growth on the G/R UHL plate for pVEG-Nef and 
pVEG-G2A demonstrated they did not possess transcriptional activation properties. 
Colony growth was detected for pEG-Nef suggesting it would result in a large 
number of false positives if used as a bait in an interactor hunt. As expected the 
control transcriptionally activated the LexA-op-LEU2 gene.
Undil. 1/100 1/1000
pEG-Nef
pVEG-Nef
pVEG-G2A
Control
G/R-UH
Control
Figure 3.3.
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Figure 3.4. Results o f the repression assay fo r pVEG-Nef pVEG-G2A and 
pEG-Nef:
This assay was performed to determine the baits ability to reach the nucleus the 
method is detailed 2.4.3. This example shows the pJKlOl plasmid (detailed section
2.3.4.) transformed with either pVEG-Nef, pVEG-G2A and pEG-Nef or the pSH17 
control (which was constitutively active). The growth of white colonies for 
pVEG-Nef and pVEG-G2A confirmed their ability to enter the nucleus and bind the 
LexA operator which was positioned such that it repressed transcription. A low 
level of transcriptional activation was detected for pEG-Nef consistent with its 
transcriptional activation capabilities.
Undil. 1/100 1/1000
pEG-Nef
pVEG-Nef
pVEG-G2A
Control
G/R-UH
pEG-Nef
pVEG-Nef
pVEG-G2A
Control
G/R-UHL
Figure 3.4.
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3.5. Screening a Jurkat T-cell library with pVEG-Nef for novel protein- 
protein interactions:
The practicalities of obtaining high transformation efficiencies and physically 
screening a library are addressed in section 2.42.4. In the interactor hunt a final 
number of 92 potential Nef interacting colonies were obtained from the Jurkat 
T-cell cDNA library (~2xl06 colonies were screened) . Initially these potential 
interactors were divided into groups according to their RFLP (restriction fragment 
length polymorphisms) patterns, as determined by digestion with the frequent 
cutting restriction enzymes Haelll and Alul. The graph in figure 3.5A shows the 
distribution of the colonies across the groups, with an example of the different 
RFLP patterns, figure 3 .5B (the first 10 lanes are group A2 and the second 10 are 
group Cl). The groups were sorted according to the strength of the interactions, as 
determined by the intensity of blue colouration when streaked on plates containing 
X-Gal (G/R UHT). Strong interactors were referred to as group A (either 1, 2 or 3 
for different RFLP patterns), while group D was the weakest interactor group 
(compare 92 which was classified as group A and 91 which was classified as C in 
figure 3.5C) . The graph distinctly shows, that there was 1 main interactor group, 3 
smaller groups and 6 groups containing only 1 or 2 colonies. The initial 
categorisation of so many smaller groups arose due to ambiguities in RFLP patterns 
and ensured that all potential interactor groups were fully investigated, as will 
become clear. Library plasmids were isolated from the bait and reporter plasmids 
used in the system, then retransformed into Kcoli for sequencing. Manual 
sequencing was carried out using BCOl and BC02 primers, designed within the 
library plasmid to sequence the 5’ and 3’ ends of the cDNA library inserts, see 
section 2.4. In parallel, each library plasmid was also retransformed back into yeast 
together with either pVEG-Nef or pEG202, plus the reporter plasmid (pSH18). 
This established the observed interactions were reproducible and did not result from 
a direct association with the LexA DB domain alone. For the larger groups A2, Cl 
and D2, 3-4 colonies from each were selected to be representative of the group. 
Where differences occurred during sequencing further members were examined.
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After sequencing the distribution of the colonies across the groups altered. The 
majority of colonies sequenced from the weaker interaction groups had homology 
to colonies from larger groupings, with a few unsequenced due to practical 
difficulties. A summary of the reclassification of the interactors after sequencing is 
shown in the graph in figure 3.5D. The total number of different groups was 
reduced to 6.
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Figure 3.5. Classification ofpotential N ef interactors after the library screen:
A  Distribution of potential interactors as classified by RFLP patterns (see B) and 
strength of P-galactosidase activity (see C). The strongest interactors were 
classified as A and the weakest D.
R  An example of the restriction enzyme digests used to classify the interactors. 
Lane 1 contains AHindlll molecular weight markers, lane 2 contains (j)X174 
markers. Lanes 1-5 contain the same samples as 6-10 digested with H aelll and Alul 
respectively, these were classified as A2 on the strength of their interaction. Lanes 
11-20 contain 5 group Cl samples similarly digested.
C  This is an example data set of the library screen. The samples are streaked on 
each plate anti-clockwise, starting left of top clone 83-clone 92. The top left plate is 
Glu UHT-X and demonstrates successful transformation of all plasmids. G/R 
UHT-X (top right) shows different strengths of the interactions (92 was group A2 
and 91 group Cl); Glu UHTL (bottom left) shows no growth and therefore no non­
specific transactivation of the LexA-op-LEU2 reporter. G/R UHTL (bottom right) 
shows colony growth for each confirming the interaction.
D. Redistribution of the interactors after sequencing.
A.
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Figure 3.5
Interactors were selected for more detailed study on the basis of preliminary 
sequence data, in combination with the results obtained from the rescreening of the 
interactions. While groups Al and A2 both maintained a strong interaction with Nef 
and did not activate the negative control, see figure 3.6 (see diagram 3.3 for plate 
orientation), at that time, the only significant nucleotide homology for both was 
with various uncharacterised cDNAs (as determined using FAST A and BLAST 
database searches of Genbank, CDS translations, PDB, Swissprot, Protein 
identification resource (PIR), EMBL, Expressed sequence tagged (EST) division, at 
the National Centre for Biotechnology Information (NCBI)). Amino acid homology 
with the A2 group was found mainly to zinc finger proteins, implicating it as a 
transcriptional activator. Since the in vivo presence of Nef in the nucleus is 
controversial and zinc finger proteins are common false positives found with the 
YTHS (Hengen, 1997), no further studies were performed for A2. However 
sequence available for clone 39, group Al, suggested some amino acid homology to 
a range of proteins involved in oxidative phosphorylation including, NADH 
dehydrogenase, ubiquinol-cytochrome-C reductase and cytochrome B. This clone 
was hence selected for further study. For groups B1 and B2 the interactions were 
shown to be reproducible although low transactivation levels of the LexA DB 
domain alone was seen for the LEU2 auxotrophic marker, see figure 3.6. However 
clone 40, group Bl, had significant nucleotide homology to a 5Kb cDNA that 
contained a 3 .5Kb ORF (open reading frame) previously proposed as a candidate 
gene, EHOC-1 (Epilepsy, HOIoprosencephaly Candidate-1) for progressive 
myoclonus epilepsy (Ac: U19252). EHOC-1 had been identified as encoding a 
putative transmembrane protein the function of which was unknown. Although the 
nucleotide homology for clone 40 was 3’ to the ORF, the previous study had 
analysed cellular transcripts for the 5Kb cDNA using northern blotting. The 
existence of three 8, 7.5, and 5.3Kb mRNA species was determined, which were 
ubiquitously expressed across adult tissues. The prospect of altered splice patterns, 
resulting in the inclusion of the downstream sequences in these transcripts, made 
clone 40 a good candidate for further investigation. In contrast homology for group 
B2 was only found with uncharacterised cDNAs and the amino acid sequence had 
limited sequence homology to laminin, an adhesive glycoprotein found in the
extracellular matrix. Consequently group B2 was not investigated further during 
this study.
The largest interaction group, Cl had nucleotide sequence homology to several 
uncharacterised human cDNAs with amino acid homology to a Saccharomyces 
cerevisiae protein PaclOp (Ac: U29137). PaclOp was identified as one of a group 
of genes necessary in concert with the kinesin-related CIN-8p during mitosis in
S.cerevisiae. The exact function of PaclOp is still to be elucidated therefore it 
provided few clues as to the identity of Cl, except that it may play a role in mitosis. 
Several clones in Cl were rescreened for their specific interaction with Nef, all of 
which showed little or no activation of the LacZ reporter plasmid. However, despite 
a low level of transcriptional activation of LEU2 with the DB domain alone, levels 
of prototrophy for leucine in the presence of Nef were higher than in the absence of 
Nef. This inferred the interaction of Cl with Nef was specific, see figure 3.6. The 
number of clones isolated for Cl suggested an abundance of the transcript in the 
Jurkat T-cell library, it was therefore of interest to establish more conclusively the 
interaction of Nef with this group. No further work with group D1 was performed 
since rescreening the clones resulted in non-specific transcriptional activation of the 
reporter genes, see figure 3.6. Preliminary sequence data confirmed the cDNA had 
strong homology to a variety of zinc finger proteins.
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Diagram 3.3. Orientation of samples for the rescreening ofputative interactors:
A. Position of samples on each agar plate, on each plate 2 different putative 
interactors were analysed, 2 colonies were streaked for each:
1. pVEG-Nef+pJG4-5 library clone A
2. pVEG-Nef+ pJG4-5 library clone A
3. pEG202+pJG4-5 library clone A
4. pEG202+pJG4-5 library clone A;
5. pVEG-Nef+pJG4-5 library clone B
6. pVEG-Nef+pJG4-5 library clone B
7. pEG202+pJG4-5 library clone B
8. pEG202+pJG4-5 library clone B
R. Positioning of plates for each data set:
Glu UHT-X G/R UHT-X
Glu UHTL G/R UHTL
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Figure 3.6. Results from the re screening o f the library inter actors:
The library plasmids were isolated and retransformed with pVEG-Nef or pEG202 
alone to confirm the authenticity of the interactions. In these examples the plates are 
orientated as shown in diagram 3.3.
A. Segments 1-4 are group Al (clone39) and 5-8 are group B1 (clone 40). Only 
one colony picked for 39 retained a strong Nef interaction (segment 4 of each plate) 
as indicated by the growth of blue colonies on the G/R UHT-X plate and growth on 
G/R UHTL plate, the specificity was confirmed by the lack of colony growth on 
G/R UHTL or colour change on G/R UHT-X for 39 plus pEG202 (segments 1 and 
2). Similar results were obtained for clone 40 of group Bl, although a low 
background level of activation was occasionally detected on the Glu UHTL plates 
see segments 5 and 6 of bottom left plate in this example.
B. Segments 5-8 show a retransformed member of group A2 (clone 43). Segments 
7 and 8 clearly show a retained strong interaction with Nef for both the 
P-galactosidase and LEU2 reporters. A slight activation of transcription was 
detected for the LEU2 reporter, segments 5 and 6 G/R UHTL (bottom right).
C  This data set shows two interactors from group Cl (clone 17 and clone 22). The 
reporter construct activation was similar for each, with low activation of both 
P-galactosidase and the LEU2 gene.
D. Results from the rescreen of D1 members demonstrated that all possessed 
inherent transactivating abilities in the absence of Nef, see segments 1 and 2.
UHTL
UHT
UHTL
Figure 3.6.
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3.6. Further investigation of groups A l, B1 and C l- sequence data and 
specificity tests:
The individual clones comprising Al (clone 39) and B1 (clone 40) together with a 
representative clone from Cl (clone 11) were subjected to further sequence 
analysis. To facilitate sequencing the cDNAs were subcloned into the pCR™ 
plasmid using PCR amplification with the BCOl and BC02 primers, see section 
2.42.4. Automated sequencing was carried out with M l3 forward and reverse 
primers, a typical sequence run provided 700bp of nucleotide sequence. A 
consensus nucleotide sequence for each cDNA was determined from several 
different pCR™ clones, allowing the prediction of the expected polypeptide length 
of the TA domain fusion. Figure 3.7 shows a western blot to confirm the actual size 
of the expressed fusion proteins. Western blot analysis was possible due to the 
incorporation of a haemagluttinin epitope tag in the TA domain. The blot revealed 
clone 39 was larger than its predicted size of 5kDa, running at ~24kDa including 
the activation tag corresponding to ~9kDa for clone 39. Clone 11 was significantly 
smaller than its predicted sequence resolving at only ~3kDa suggesting it was 
unstable, while clone 40 was ~4.5kDa in size consistent with the sequencing results. 
Interestingly when this blot was stripped and reprobed to determine the levels of 
Nef expression, elevated levels of Nef were seen in the clone 39 yeast cells, despite 
similar culture densities. This occurred consistently and suggested that expression 
of the clone 39 polypeptide reduced Nef toxicity to the yeast. This is in contrast to 
later studies with full length Lck (see section 5.4) where the co-expression of Nef 
resulted in complete toxicity to the yeast. The sequence data obtained for each 
clone was recently re-analysed by FAST A and BLAST programs to check for any 
homologies to newly submitted sequences. The results are shown in figures 3.8, 
3.10 and 3.12 and will be discussed below in conjunction with the results of the 
specificity tests.
In order to establish whether the observed interactions with Nef were specific, it 
was necessary to cross pair them with further control LexA fusions. For this 
purpose two proteins, HIV-1 p55Gag and ORF94 containing myristoylation signals 
in their coding sequence were cloned into pVEG2. HIV-1 p55Gag is a
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myristoylated protein precursor that is specifically cleaved by HIV-1 protease to 
form the integral structural proteins of the virion, as outlined in section 1.1. Its 
myristoylation in yeast has been previously determined. ORF94 is encoded by the 
human Cytomegalovirus (hCMV) and is produced during latent infection of 
granulocytes. ORF94 has a predicted myristoylation signal, although myristoylation 
of the protein has not been demonstrated. Prior to use as control baits in the 
interaction trap, pVEG2-p55Gag and ORF94 were screened in the activation and 
repression assays to confirm their suitability (data not shown). For the specificity 
tests all plasmids were freshly cotransformed with the library (potential Nef 
interactors) and reporter plasmids, plus one of the following, either: pVEG-Nef, 
pVEG2-Gag, pVEG2-ORF94 or pEG202. For easy comparison, each potential Nef 
interactor was streaked along with each of the baits on an individual plate, see 
figure 3.9, see diagram 3.4 below for orientation of the plates.
Diagram 3.4. Orientation ofplates for specificity screening o f the interactors:
1. pVEG-Nef+pJG4-5-library clone
2. pVEG2-Gag+pJG4-5-library clone
3. pVEG2-ORF94+pJG4-5-library clone
4. pEG202+pJG4-5-library clone
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Figure 3.7. Western blot analysis o f interactor expression:
Yeast cultures (3ml) were grown to an OD6oo~1.0 these were harvested and the 
pellet washed once in lxPBS then resuspended in an equal volume of SDS-PAGE 
sample buffer. The samples were lysed by incubation for 5 minutes on dry ice 
followed by 5 minutes in a boiling water bath. The proteins were resolved by 17.5% 
SDS-PAGE, transferred to membrane and reacted with a-HA-1. Yeast cells alone 
used as the negative control (lane 1) demonstrated there was no yeast cross 
reactivity with the sera, a polypeptide of ~15kDa was detected for the pJG4-5 
plasmid alone consistent with TA domain expression (lane 2) a band of ~18kDa was 
detected for clone 11, group Cl (lane 3) of which ~15kDa comprised the TA domain 
and ~3kDa the cDNA insert; a band of ~24kDa was detected for clone 39, group Al 
(lane 4) of which ~15kDa was the TA domain and 9kDa the cDNA insert; clone 40, 
group B1 (lane 5) resolved at 19kDa corresponding to ~15kDa TA domain and 
~4kDa cDNA insert.!
ct-HA-1
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Figure 3.7.
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3.6.1. Analysis of the sequence and specificity results obtained for groups Cl and 
Bl:
Of all of the groups selected for further investigation, group Cl had the weakest 
observed interaction with Nef in the initial screens. The interaction was only 
detectable above background for the LEU2 auxotrophic marker. However, Cl 
contained the largest number of clones identified as potential Nef interactors, hence 
the decision to investigate the specificity of this Nef interaction further. During the 
specificity screen it was found that the interaction of Cl with Nef was capricious, 
see figure 3.9. The specific interaction with Nef could not be reconstituted despite 
earlier repeats, and it transactivated the reporter constructs in the presence of the 
DB domain (pEG202) alone (bottom right plate figure 3.9A, segment 4). No 
interaction above the transactivation level was seen with either the p55Gag control 
or ORF94 (segments 2 and 3). Preliminary sequence data had shown homology to
S.cerevisiae P ad  Op (section 3.5), but with recent re-analysis it transpired that Cl 
contained a fragment of the VHL (von Hippel Lindau) gene. VHL encodes a 
tumour suppressor protein implicated in the inhibition of transcriptional regulation. 
VHL protein is thought to interact with 2 subunits (B and C) of the elongin 
complex involved in transcriptional regulation; thus preventing their binding to and 
activation of the elongin A subunit. The activation of transcription by VHL in the 
yeast-two-hybrid system, is therefore contrary to its predicted inhibitory function, 
but is probably due to its affinity for the transcriptional apparatus in the context of 
its fusion to the TA domain. This suggests that early interactions seen for Cl with 
Nef, were in fact due to transcriptional activation and that for interactions within 
the yeast-two-hybrid system to be reproducible, both reporter genes must be 
transcribed, with minimal background activity.
Results obtained during the specificity screen for group B l, also concurred with 
those of group Cl, see figure 3.9. In the original screens group Bl exhibited strong 
interactions with Nef. Some background levels of transcriptional activation of the 
LEU2 gene had been seen, but these were significantly lower than that seen in the 
presence of Nef. However, during the specificity screens the levels of 
transcriptional activation of the DB domain alone by group Bl, obscured any 
potential Nef specific interaction (see figure 3 .9B, bottom right plate segment 4). It 
was therefore unlikely that Nef was specifically interacting with group Bl.
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Figure 3.8. Computational analysis o f sequence data for groups Cl and Bl 
(carried out at NCBI using BLAST and FAST A network services):
Group Cl, clone 11:
This was found to have good homology to the tumour suppressor protein VHL. 
FASTA results are not shown as the amino acid homology obtained in BLAST 
searches was so high.
BLAST Results:
Smallest
Sum
High Probability 
Sequences producing High-scoring Segment Pairs: Score P(N) N
U56833 VHL binding protein-1 271 8.6e-33 1
P48363 PA10_YEAST PAC10 PROTEIN. 62 2.6e-07 2
Z81587 T06G6.9 [Caenorhabditis ele. 65 4.9e-06 2
Q10143 YAS7_SCHPO HYPOTHETICAL 19.5 KD PROT. 78 3.1e-05 2
>gi11465751 (U56833) VHL binding protein-1 [Homo sapiens]
Length = 166
Score = 271 (123.5 bits), Expect = 8.6e-33, P = 8.6e-33 
Identities = 53/53 (100%), Positives = 53/53 (100%)
Query: 32 EDVDSFMKQPGNETADTVLKKLDEQYQKYKFMELNLAQKKRRLKGQIPEIKQT 84 
EDVDSFMKQPGNETADTVLKKLDEQYQKYKFMELNLAQKKRRLKGQIPEIKQT 
Sbjct: 1 EDVDSFMKQPGNETADTVLKKLDEQYQKYKFMELNLAQKKRRLKGQIPEIKQT 53
>sp|P48363|PA10_YEAST PAC10 PROTEIN>pir|S59741 PAC10 protein-yeast
(Saccharomyces cerevisiae) > g i 1902026 (U29137) PaclOp 
[Saccharomyces cerevisiae] >gnl|PID|e243428 (Z72863) ORF YGR078c 
Length = 199
Score = 62 (28.3 bits), Expect = 2.6e-07, Sum P(2) = 2.6e-07 
Identities = 12/33 (36%), Positives = 21/33 (63%)
Query: 52 KLDEQYQKYKFMELNLAQKKRRLKGQIPEIKQT 84
K E+ KYKFM+ + ++LK +IP+++ T
Sbjct: 40 KFQERLSKYKFMQESKLATIKQLKTRIPDLENT 72
Score = 55 (25.1 bits), Expect = 2.6e-07, Sum P(2) = 2.6e-07 
Identities = 9/20 (45%), Positives = 15/20 (75%)
Query: 24 GIPEAVFVEDVDSFMKQPGN 43
GIP+A F+E+V+ +K P + 
Sbjct: 14 GIPQAPFIENVNEIIKDPSD 33
144
Figure 3.8. (cont):
Group B l, clone 40:
No statistically significant amino acid homology, but a 94% match to the cDNA 
clone downstream of the ORF encoding the EHOC-1 gene.
FASTA Results:
clone40.txt x ul9252 human putative transmembrane protein
Percent Similarity: 94.083 Percent Identity: 90.533
Sbjct 434 6 CTGATCGGGGTGGATTTGTGTCCCCTAAGGGGTAAAACAGCCGTTTACCG 4395
I I I  I I I I I I I I I I I I I I I II I II 
clone40 1  gaattcggcacgaggcgaaacagccgtttaccg 33
Sbjct 4396 CAGATCCTCTCAT................. ACACCCTTCTAGGGGAGG. C 4427
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
Clone40 34 cagatcctctcattgtgcttttctagaataacacccttctaggggaggcc 83
Sbjct 4428 GGGTGGGGGAGGGAGGGATCATAACCCCTTCTGTGCCTTGGGATGCCGGA 4477
I I I I I I I I I I I I I :::  I I I I I I I I I I I I I I I I I :: I I I I I I I I I : I I I I I 
Clone40 84 gggtgggggagggnnngatcataaccccttctgnnccttgggatnccgga 133
Sbjct 4478 GCTGGGGGACCTGGAGG.CCCATCAGCCGGAGCCACGTGAAAGGTACTGA 452 6
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Clone40 134 gctgggggacctggaggccccatcagccggagccacgtgaaaggtactga 183
Sbjct 4527 AGAAAGCTGAGACCCGGCTGTGAGGAGCGCCTCAGCGGTGAGGTGGTTTA 4576
I I I I I
Cl one 40 184 agaaa................................................  188
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Figure 3.9. Results o f the specificity tests:
The orientation of the plates in this figure is illustrated in diagram 3.4.
A  Results for group Cl, clone 11 show no detectable interaction with Nef 
(segment 1) and non-specific activation of the bait (segment 4, bottom plates).
B. Results for group B l, clone 40 as for group Cl.
UHT
UHTL
Glu I G/R
UHT
UHTL
Figure 3.9.
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3 .6.2. Re-analvsis of group A2:
Since the only reproducible interaction with Nef during the specificity screening was 
with the strongest interactor group Al, see below, it was decided to re-analyse the 
preliminary sequence data obtained for group A2. On re-analysis using FASTA and 
BLAST programs significant homology was found to the human eukaryotic 
initiation factor 3 (eIF3). The amino acid sequence was 96% homologous over the 
N-terminal 26 amino acids, after which there were several ffameshifts, but there was 
a further 100% homology over 8 amino acids at residues 76-82 in eIF3 (see figure 
3.10). The loss of homology at the amino acid level was due to ffameshifts caused 
by discrepancies at the nucleotide level, these need resolving by further sequencing. 
The N-terminal region of eIF3, which was the location of the group A2 homology, 
has been recently implicated in RNA binding, explaining why previous database 
searches showed some homology to zinc finger proteins. It is now conceivable that 
a physiological interaction of Nef with eIF3 in the cellular cytoplasm may occur. 
However, further specificity studies may reveal, as for Cl and Bl, that out of 
context this RNA binding domain is able to bind the LexA UAS’s and activate the 
reporter constructs independently from Nef. Further investigation as to the 
specificity and reproducibility of this intriguing interaction is required. If genuine, 
the interaction of Nef with part of the translation initiation machinery suggests a 
role for Nef in recruiting the host translational apparatus. Therefore, selectively 
translating viral mRNA, providing a mechanism for the observed Nef enhancement 
of viral infection. Consistent with this, it has recently been demonstrated (Echarri et 
al, 1996; Echarri et al, 1997), that Nef has RNA binding capabilities.
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Figure 3.10. Computational analysis o f sequence data for groups A2 and A l 
(clone 39):
Protein homologies identified for group A2:
The recent addition to the database of this translational elongation initiation factor 
provided a statistically significant match to clones from group A2.
FASTA Results:
Percent Similarity: 97.233 Percent Identity: 96.838 
clone 11 x u54559 .gb_jpr2 eIF-p40 [Homo sapeins]
1 gaattcggcacgaggcggcttggaaagatggcgtcccgcaaggaaggtac 50
I I I I I I I I I I I I I I I I I I II I I I I I I I I 
1 ....................... GAAAGATGGCGTCCCGCAAGGAAGGTAC 28
51 cggctctactgccacctcttccagctccaccgccggcncagcagggaaag 100 
I I I I I I I  I I I I I I I  I I I I I  I I  I  I I  I I I  I I I I I  I I I I  I :  I I  I I I I I I I I I I
29 CGGCTCTACTGCCACCTCTTCCAGCTCCACCGCCGGCGCAGCAGGGAAAG 78
101 g..aaaggaaaggcggctcgggagattcagccgtgaagcaagtgcagata 148 
I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
79 GCAAAGGCAAAGGC GGCT C GGGAGAT T CAGC C GT GAAGCAAGT GCAGAT A 128
149 gatggccttgtggtattaaagataatcaaacattatcaagaagaaggaca 198 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
129 GAT GGC C T T GT GGTAT TAAAGATAAT CAAACAT TAT CAAGAAGAAGGACA 178
199 aggaactgaagttgttcaaggagtgcttttgggtctggttgtagaagatc 248 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I 
179 AGGAACTGAAGTTGTTCAAGGAGTGCTTTTGGGTCTGGTTGTAGAAGATC 228
249 .gcttgaaattaccaactgcttctttcc....................... 275
I I I I I I I I I I I I I I I I I I I I I I 
229 GGCTTGAAATTACCAACTGCTTTCCTTTCCCTCAGCACACAGAGGATGAT 278
BLAST Results:
Smallest
Sum
High Probability 
Sequences producing High-scoring Segment Pairs: Score P(N) N
U54559 eIF3-p40 [Homo sapiens] 120 2.6e-13 2
>gi12351380 (U54559) eIF3-p40 [Homo sapiens]
Length = 352
Score = 120 (56.7 bits), Expect = 2.6e-13, Sum P(2) = 2.6e-13 
Identities = 25/26 (96%), Positives = 25/26 (96%)
Query: 10 MASRKEGTGSTATSSSSTAGXAGKGK 35
MAS RKEGTGS TAT S S S S TAG AGKGK 
Sbjct: 1 MASRKEGTGSTATSSSSTAGAAGKGK 26
Score = 45 (21.3 bits), Expect = 5.2, Sum P(2) = 0.99 
Identities = 9/20 (45%), Positives = 15/20 (75%)
Query: 16 GTGS TAT S S S S TAGXAGKGK 35
G+ +T++SS++ A GKGK 
Sbjct: 9 GSTATSSSSTAGAAGKGKGK 28
148
Figure 3.10. (cont):
Score = 39 (18.4 bits), Expect = 2.6e-13, Sum P(2) = 2.6e-13 
Identities = 7/7 (100%), Positives = 7/7 (100%)
Query: 84 LEITNCF 90
LEITNCF 
Sbjct: 76 LEITNCF 82
Analysis of sequence data for group Al, clone 39:
FASTA Results.
The best homology for clone 39 was to an EST tagged cDNA (Ac. N52259) and is 
shown below.
REVERSE-COMPLEMENT of: n52259.gb_est5 check: 2897 from: 1 to: 499 
DEFINITION yz28c06.sl Homo sapiens cDNA clone 284362 3 1|N52259|gll93393
Percent Similarity: 93.304 Percent Identity: 93.304 
n52259.rev x clone 39
251 ATTCCATGCATCTTTGGCAGCTCTTTTCTTCTGCTCAGACCCTTCCCCGT 300 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
4 ttcggcacgaggcgtggcagctcttttcttctgctcagacccttccccgt 53
301 GCTCAGACAGTGCACCGCTGTCCCATCTAAAGAAACCTGTCAGGAATACG 350 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
54 gctcagacagtgcaccgctgtcccatctaaagaaacctgtcaggaatac. 102
351 GAGCTTCTGGGTATGTTTCGTTTCCCATTGCTGTAGCATTTCTTATCCCC 400 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
103 gagcttctgggtatgtttcgtttcccattgctgtagcatttcttatcccc 152
401 T GAGAGC T GAT GAT TAT T GAGGACAGAAGGC T CAGAAACAGT T T GT GACA 450 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
153 tgagagctgatgattattgaggacagaaggctcagaaacagtttgtgaca 202
451 GAAAATGCAGTGTTTCATTTTTCAGGGATAAATGCTAAGATAAAATTGC 499 
I I I I I I I I I I I I I I I I I I I I I I 
203 gaaaatgcagtgtttcattttt............................. 224
BLAST:
Smallest
Siam
High Probability
Sequences producing High-scoring Segment Pairs: Score P(N) N
pir|IS44950 ImbC protein - Streptomyces lincolnens... 66 0.50 1
pir||S25742 Ig lambda chain - human >gi133710 (X57... 49 0.78 2
gi|1117994 (U40786) surface antigen A variant pre... 57 0.81 2
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3.6.3. Analysis of the specificity results obtained for group A l:
Group Al, clone 39 exhibited the strongest isolated interaction with Nef. During 
the specificity screening it became apparent that the Nef interaction with Al was 
also the most reproducible. Al consistently interacted with Nef and showed no 
transactivation capabilities with the DB domain (pEG202) alone. However, 
unexpectedly during the specificity screen, a strong interaction with p55Gag was 
also seen. No interaction was seen with ORF94. To verify whether the interactions 
of Al were as a result of a direct interaction with the myristic acid molecule on 
these proteins, Al was screened with nonmyristoylated Nef. The results of these 
specificity studies are compared in figure 3.11. From the results it was evident that 
the observed Al interactions were not myristoylation dependent, because Al 
consistently bound myristoylated p55Gag and both myristoylated and 
nonmyristoylated Nef The interaction of a cellular protein with both HIV Nef and 
Gag is plausible since it is likely that they accumulate in similar cellular locations.
The cDNA contained in Al was ~1000bp in size. When the fusion protein was 
analysed by western blotting it revealed the protein product to be only ~9kDa (p9), 
see figure 3.7. Sequencing results suggested Al encoded a polypeptide of 43 amino 
acids, which was inconsistent with the expression of a polypeptide of ~9kDa 
inferring that either a posttranslational modification event had occurred or there 
were possible sequence discrepancies. BLAST searches produced no significant 
homologies to the complete Al polypeptide sequence. However, a FASTA search 
revealed a 99% match over 195bp to the reverse complement of an EST tagged 
cDNA (Ac. N52259), which included non-coding sequences after the stop codon. 
The sequences differed by a single guanine nucleotide, causing a ffameshift at amino 
acid 29 in clone 39 relative to the N52259 sequence. The N52259 sequence 
therefore encoded a polypeptide product of -60 amino acids, more consistent with 
the 9kDa product detected in the western blot analysis. To further characterise Al 
and to establish whether it was a fragment of a larger known protein, the UK 
Human Genome Mapping Project database facilities at Cambridge, were searched 
using the EST-BLAST program, for nucleotide sequence. This built up a profile of
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the cDNA sequence surrounding Al, including any recently submitted sequences. 
Along with the previously identified N52259 human cDNA, a series of overlapping 
partial human cDNAs were retrieved. Several highly homologous mouse cDNAs 
were also identified, suggesting the existence of a mouse homologue e.g. 76% 
homology for mouse cDNA Ac. W90938. Two separate human and mouse 
consensus nucleotide sequences were generated for the cDNA in combination with 
the Al query sequence. To avoid frameshifts resulting in spurious homologies, 
netBLAST and GAP-BLAST searches were performed at NCBI using the 
nucleotide sequence. These programs check for homologies in all possible reading 
frames. However, still no significant protein homologies were uncovered. The 60 
amino acid N52259 peptide sequence also produced no statistically significant 
database matches. In addition, the nucleotide sequence was used to check for motifs 
(using Motifs, Profilescan at NCBI and Blocks at the Fred Hutchinson Cancer 
Research Centre (Henikoff and Henikoff, 1994)) although again nothing of 
significance was identified. The lack of homology found on screening the protein 
databases could be as a result of a series of frameshifts along the sequence, but in 
the absence of a longer polypeptide for analysis this could not be investigated 
further. However the existence of highly homologous cDNAs to Al, in both the 
human and mouse genomes implies the presence of Al as an authentic transcript in 
the cell.
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Figure 3.11. Results o f the specificity screen fo r group A l, clone 39:
A  The colonies were streaked as shown in diagram 3.4. The interaction with Nef 
was maintained (segment 1), but it was also found to interact with p55Gag 
(segment 2), no interaction with ORF94 was seen (segment 3) and none with the 
negative control (pEG202) segment 4.
R  Segments 1 and 2 were pEG-Nef cotransformed with clone 39 for which no 
interaction was detected. PVEF-G2A and pJG4-5-39 were streaked in segment 2 
and despite a poor level of colony growth on all plates (in this example) a specific 
interactions between the proteins was clearly evident. pVEG-Nef and pJG4-5-39 
are shown in segment 4.
UHT
UHTL
UHT
UHTL
Figure 3.11.
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3.7. Further analysis of the Nef -Al (p9) interaction:
To further analyse Nef sequences important in the interaction with Al (p9), in vitro 
coprecipitation assays were performed. p9 was cloned using the restriction sites 
EcoRI and Xhol into pGEX4T-l, a bacterial GST fusion expression plasmid; thus 
maintaining it as a C-terminal fusion protein, potentially important for its stability 
and interaction with Nef The GST-p9 fusion was subsequently purified from 
bacteria and immobilized on glutathione agarose (GA)-beads, for use as an affinity 
reagent in in vitro binding assays. Problems were encountered with proteolysis, 
therefore for each sample ~3 times the standard amount of GST-p9 was bound to 
GA-beads as the affinity reagent, see figure 3.12. Protein binding assays were 
performed with 35S-methionine labelled in vitro transcription and translation 
products, to determine protein specificity for GST-p9 in vitro. Proteins analysed 
included Nef, p55Gag, with CD4 and Lck as controls.
In vitro, no binding of GST-p9 to either Nef or p55Gag was seen. The lack of in 
vitro binding was unexpected considering the strength and specificity of the 
interaction of p9 with Nef and p55Gag in vivo. Observed binding differences 
between in vitro and in vivo usually implicates the involvement of cellular factors. 
However in this case, it seems more likely that practical considerations may have 
been affecting the binding potential. As previously observed, the purified GST-p9 
was prone to proteolytic degradation. The lack of in vitro binding suggests that 
despite using increased amounts of GST-p9 as the affinity reagent there was still 
insufficient full length for Nef binding. It is also possible that the p9 protein was 
rendered inaccessible for Nef binding as a GST fusion. In the TA domain fusion, p9 
was separated from the TA domain by the HA-1 epitope, such a linker region was 
absent in the GST fusion. It is conceivable that the linker region allowed the 
polypeptide to form secondary structures necessary for the interactions. Follow up 
studies will be required to circumvent these problems and further characterise the 
observed specific interaction of this short polypeptide with both Nef and p55Gag.
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Figure 3.12. Quantitative analysis o f  amount o f GST-39 bound to GA-beads:
E.coli expressed and purified GST-39 was bound to GA-beads along with GST 
alone as a control (150pg GST-39 was bound to 50pl packed volume of beads and 
50pg GST was bound to the same volume of beads, as detailed 2.6.7.). 5pi of 
packed beads for each sample were analysed by 12% SDS-PAGE and Coomassie 
stained. The results shown in this figure demonstrate GST-39 was substantially 
proteolytically degraded, lane 1; GST alone is shown in lane 2.
Coomassie stained
— _________________
26kDa
17kDa
Figure 3.12
CHAPTER 4
155
CHAPTER 4 - 
Investigation of a putative Nef interaction with Lck
Page number
4.1 Introduction 156
4.2 Background 159
4.3 Summary of work presented hereunder 160
4 .4 Construction of the recombinant baculoviruses 160
4.5 Confirming the authenticity of the proteins 161
4.6 In vitro binding assays 167
4.7 Construction of constitutively active and inactive Lck mutants
to assess conformational binding criteria 177
4.8 Confirmation of the expression and kinase activities of the
mutant Lck recombinant baculoviruses 179
4.9 In vivo binding studies 183
4 .10 Identification of regions in Nef important in mediating its in vivo
binding to LckGKY 189
156
Chapter 4: Investigation of a putative Nef interaction with Lck.
4.1 Introduction:
Similar to Src (reviewed (Brown and Cooper, 1996)), the lck gene (for /ymphoid 
cell Ainase) was first identified as a transforming agent. It was isolated during a 
study of a Moloney murine leukaemia virus-transformed lymphoblastoid cell line, 
where the integration site of the retroviral promoter caused a substantial elevation 
of tyrosine kinase activity in accordance with increased Lck expression (Marth et al, 
1985; Voronova and Sefton, 1986). Its expression has since been predominantly 
detected in T-lineage cells (Marth et al, 1986; Abraham et al, 1991) and some 
B-cells (Perlmutter et al, 1988) and its dysfunction has been associated with 
lymphoid malignancies (Perlmutter et al, 1988; Adler et al, 1988; Marth et al, 
1988). Lck expression is governed by 2 distinct promoters, the first of which is 
adjacent to the lck ORF and utilised in immature thymocytes, while the second is 
~34kb 5’ and active in mature thymocytes and peripheral T-cells (reviewed by 
(Anderson et al, 1994; Perlmutter et al, 1988)). The cellular requirement for 2 
independent promoters is thought to be at the regulatory level as initiation from 
either produces the same transcript. The transcript encodes a 509 amino acid 
polypeptide that is cotranslationally myristoylated and subsequently palmitoylated. 
The polypeptide represents a typical Src non-receptor tyrosine kinase family 
member with the characteristic domain structure, outlined in section 1.3.1.
Lck, in conjunction with the variably spliced Src kinase, Fyn, has been implicated in 
amplifying cellular activation signals during antigenic stimulation of the TCR-CD3 
receptor complex (Abraham et al, 1991; Glaichenhaus et al, 1991). The putative 
model for this outlined below, involves the “accessory” transmembrane receptors 
CD4 and CD8, to which Lck specifically associates via its unique N-terminal 
domain (Veillette et al, 1988; Shaw et al, 1989). Binding of Lck to the cytoplasmic 
tails of these receptors is mediated by common cysteine motifs potentially 
facilitating the co-ordination of a metal ion (Turner et al, 1990). During TCR-CD3 
antigen recognition of either MHCI or MHCII the accessory receptors, CD8 or 
CD4 respectively are recruited to the TCR-CD3 complex. Cross-linking of CD4 has 
been demonstrated to cause the activation and dissociation of Lck which
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subsequently phosphorylates the conserved tyrosine residues in the immune- 
receptor-tyrosine-based activation motifs (ITAMs) of CD3 (Straus and Weiss, 
1992; Biffen et al, 1994). This phosphorylation event is thought to initiate the 
activation cascade by forming putative SH2 binding sites for molecules involved in 
signal amplification such as the Syk family of kinases (Latour et al, 1997). A critical 
role for Lck in TCR-CD3 signalling pathways has also been corroborated by in vivo 
mouse knockout studies. Consistent with its high levels of expression in immature 
lymphocytes, lck knockout mice exhibited pronounced thymic atrophy with severe 
depletion in their double-positive CD4+CD8+ thymocyte population (Molina et al, 
1992). Intriguingly, in the Nef transgenic mice model a similar disruption of T-cell 
development was observed (Skowronski et al, 1993).
Lck has been reported to associate with a number of other cellular proteins 
(reviewed (Anderson et al, 1994)), for example the IL2-receptor (IL2-R), CD45 
tyrosine phosphatase and glycosyl-phosphatidylinositol (GPI) anchored proteins e.g. 
the decay accelerating factor and CD59 (Shenoy-Scaria et al, 1993; Shenoyscaria et 
al, 1994; Parolini et al, 1996). Antibody cross-linking of the IL2-R results in Lck 
activation, however a crucial role for Lck in IL2-R signalling has been disputed as 
IL2-R positive cell types exist that do not express Lck (Anderson et al, 1994). One 
of the mechanisms proposed to activate the Lck kinase activity is dephosphorylation 
of its C-terminal Tyr505 residue by the transmembrane phosphatase CD45, see 
section 1.3.1. Significantly it was discovered in a study by (Gervais and Veillette, 
1995) that the unique region of Lck was necessary for its activation by CD45 and 
membrane association per se was not sufficient. This inferred that specific protein- 
protein interactions are necessary for its activation, and that these interactions may 
be prevented by the binding of other molecules such as CD4 and CD8.
Antibody cross-linking experiments with GPI anchored proteins determined their 
ability to transduce intracellular signals via tyrosine kinase activation (Robinson, 
1991). Subsequently it was demonstrated that both Lck and Fyn but not Src 
co-isolated with the GPI-anchored proteins, decay accelerating factor and CD59 in 
triton insoluble complexes (Shenoy-Scaria et al, 1993; Shenoyscaria et al, 1994;
158
Parolini et al, 1996). This association was dependent on authentic myristoylation 
and palmitoylation of the proteins, explaining the exclusion of Src from the 
complexes due to its lack of palmitoylation. It has been speculated that Lck and Fyn 
may mediate the intracellular signalling of GPI-anchored proteins. However, direct 
contact between the proteins is unlikely since they are each anchored into different 
leaflets of the lipid bilayer, Lck and Fyn are cytoplasmic whereas GPI-anchored 
proteins are extracellular. Current studies are hence addressing the possible 
involvement of a third transmembrane protein or possible inter-connecting lipids. 
GPI-anchored proteins have in the past been reported to associate with plasma 
membrane micro-invaginations termed caveolae, the primary constituent of which is 
caveolin (Parton, 1996). More recent studies using cationic collodial silica particles 
have suggested these represent discrete areas on the cell surface with only a small 
percentage of GPI-anchored proteins associating with caveolae (Schnitzer et al, 
1995; Hoessli and Robinson, 1998). Instead the GPI-anchored proteins have been 
detected in clusters in sphingolipid-cholesterol enriched rafts (Simons and Ikonen, 
1997). The functional significance of this is unknown at present, but both structures 
have been implicated in initiating cellular activation cascades and both represent 
alternative endocytic pathways with which Lck may also be involved (Li et al, 1996; 
Deckert et al, 1996; Parton, 1996).
The studies described here were initiated in response to a number of observations 
that implicated Lck as a target for Nef in vivo. Nef mediated down-modulation of 
CD4 was one of the few consistently reproducible properties ascribed to Nef. In 
addition, evidence was accumulating to suggest that Nef possessed an inherent 
ability to disrupt cell signalling pathways. As previously outlined, in cells of 
lymphoid lineage Lck is putatively involved in a variety of cell surface signal 
transduction pathways, most notably in TCR-CD3 signal amplification. Lck is also 
known to function as a cell surface anchor preventing the interaction of CD4 with 
clathrin coated pits which constitutively endocytose associated macromolecules. 
Significantly it is the depletion of CD4+ T-lymphocytes that provides a marker for 
disease progression. T-cells have also been demonstrated to harbour a rapid, 
aggressive HIV-1 infection with associated high levels of virion production (Ho et
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al, 1995; Perelson et al, 1996). It was therefore of interest to establish whether an 
interaction between Nef and Lck might play a role in the T-cell cytopathology of 
AIDS. As data had inferred a novel mechanism for Nef mediated CD4 down- 
modulation a direct interaction between Nef and Lck in the context of the full length 
native proteins was investigated. Criteria governing the binding was also 
investigated, to provide a clearer indication of exactly when the interaction occurs 
in vivo, allowing the possible consequences of the interaction to be evaluated.
4.2. Background:
Preliminary studies performed within the laboratory had indicated that a direct 
interaction between Nef-GST and a murine Lck was detectable in vitro. (Harris, 
1995). Furthermore it was demonstrated that the interaction was dependent upon 
Nef myristoylation as it was not seen during binding studies using a 
nonmyristoylated Nef. The early results also suggested that an interaction between 
Nef and Lck was dependent on a specific Lck conformation, since the addition of 
the tyrosine phosphatase inhibitor sodium orthovanadate (NaOV) during cell lysis 
inhibited Lck binding to Nef. It was speculated that NaOV as a tyrosine 
phosphatase inhibitor may be acting on a baculovirus specific or insect cell 
phosphatase that was a functional homologue of the CD45 tyrosine phosphatase. 
This would prevent the dephosphorylation of Lck Tyr505, the C-terminal regulatory 
tyrosine residue, and maintain the kinase in its inactive configuration stabilized by 
the intramolecular association of the SH2 domain with phosphorylated Tyr505 
(pTyr505). The corollary being that Nef interacted only with the kinase active 
conformation of Lck. These present studies were hence undertaken to further 
establish the Lck conformation required for Nef binding.
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4.3. Summary of work presented hereafter:
Recombinant baculoviruses were constructed for each of the Lck proteins under 
investigation. Subsequently, the authenticity of the recombinant baculovirus 
expressed proteins were evaluated. Parameters examined included, expression of 
full length proteins, acylation (myristoylation and palmitoylation) and tyrosine 
kinase auto- and trans phosphorylation activities. Protein binding assays were 
performed to analyse the affinity of the recombinant Lck proteins for purified Nef 
during in vitro binding assays. These studies yielded unexpected results which 
resulted in a reappraisal of the experimental approach and the construction of 
additional Lck mutants. These mutants were used for further in vitro and in vivo 
binding studies to directly evaluate the importance of the active and inactive 
conformations of Lck in Nef interactions. In addition, a panel of Nef mutants were 
screened for their Lck binding ability to identify amino acids important in mediating 
the interaction, in particular the (PXX)3P motif previously cited as an SH3 binding 
sequence.
4.4. Construction of the recombinant baculoviruses:
A murine Lck cDNA was subcloned from pSM.Lck (a gift from Dr. Mark Marsh, 
University College, London) into the baculovirus transfer vector pAcCL29. As no 
compatible sites were present both were blunt ended using Klenow and 
subsequently ligated. A recombinant baculovirus (AcLck) expressing Lck was 
generated by standard procedures as previously outlined (Harris, 1995). Subcloning 
maintained cDNA flanking sequences around the Lck ORF. In addition PCR 
amplification was necessary for the construction of mutant Lck clones required for 
the present studies, therefore a second wildtype recombinant baculovirus was 
generated using PCR primers (wtLck). This was cloned into the pAcES baculovirus 
transfer vector. The primers were designed to incorporate an EcoRI site for cloning 
and to reduce the amount of flanking non-coding cDNA sequence in the clone. A 
second 5’ primer was also made to encode a nonmyristoylated Lck (LckG2A). In 
later studies a further 3’ primer was made to mutate the C-terminal tyrosine 505 to 
a phenylalanine (LckY505F) to generate a constitutively active Lck. The K273A
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Lck mutants were also amplified by PCR utilising the same primers for the 
respective mutants, however the template for PCR was pSM.LckK273A kindly 
donated by Dr. Mark Marsh. The primers used for PCR amplification are shown 
below:
Coding primers:
wtLck: 5’- NNNGAATTCAGGGATCATGGGCTGTGTCTGCAGC -3’
LckG2A: 5’- NNNGAATTCAGGGATCATGGCCTGTGTCTGCAGC -3’ 
Non-coding primers:
wtLck: 5 ’- NNNGAATTCAAGGCTGGGGCTGGTACTGG -3 ’
LckY505F: 5’- GAATTCAAGGCTGGGGCTGGAACTGGCCCTC -3’
4.5. Confirming the authenticity of the proteins:
4.5.1. Expression and kinase activity:
Expression of the full length recombinant baculovirus Lck proteins was determined 
concomitantly with their autophosphorylation activity. In vitro autophosphorylation 
assays (+/- ATP) as detailed section 2.8.8, were performed on recombinant 
baculovirus infected Sf9 lysates. These were analysed for Lck expression and 
phosphotyrosine levels by western blotting. The anti-phosphotyrosine blot shown in 
the top gel of figure 4.1 A compares the two independently derived wildtype Lck 
clones AcLck and wtLck to the LckG2A nonmyristoylated mutant and the kinase 
inactive mutant, LckK273A. Since the Lck proteins are significantly over expressed 
by comparison to any endogenous Sf9 cellular proteins the bands detected by the 
anti-phosphotyrosine antibody were solely attributable to Lck tyrosine 
phosphorylation. In all cases, with the exception of the Lck K273A kinase inactive 
mutant, in the presence of ATP the level of phosphotyrosine was elevated. The 
inhibition of tyrosine phosphorylation observed for the K273A mutant demonstrated 
by the lack of bands detected in the a-pTyr western blot, was consistent with the 
essential role for a lysine at this position in the phosphate transfer to Tyr394 during 
autophosphorylation. This inferred that the observed augmentation of tyrosine 
phosphorylation for the wildtype and nonmyristoylated Lck proteins was as a direct 
result of the autophosphorylation of Tyr394. If endogenous kinases were active on
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Tyr394 we would have expected to see an increase in phosphotyrosine levels for 
K273A. Similar protein expression levels in the -/+ ATP lanes were confirmed by 
stripping and reprobing the PVDF membrane (see section 2.8.4) with an anti-Lck 
antibody. Lck expression levels are shown in the bottom gel in figure 4.1 A.
In order to establish the kinases were also active on an exogenous substrate, a 
peptide substrate assay was utilised, described in more detail in 2.8.9. In brief, the 
Lck kinase activity was measured by the number of phosphates transferred in 30 
minutes to a peptide substrate documented to form an optimum substrate for Src 
tyrosine kinases (Casnellie, 1991; Moarefi et al, 1997). [y32P] was included in the 
reaction and the number of phosphates transferred calculated from scintillation 
counter readings. The results are presented in the bar graph in figure 4. IB. The 
number of pmols of phosphates transferred for wtLck was 6 fold higher than that 
observed for LckK273A, indicating that it maintained its kinase activity on an 
exogenous substrate. The Hck 30 minute reading was ~4 fold higher than that 
obtained for Lck. However, the amount of protein used for each assay was 
equilibrated by western blot analysis and therefore used protein specific antibodies. 
Hence, differing protein activities observed for Hck and Lck were most likely 
attributed to varying concentrations of each protein in the assay.
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Figure 4.1. Analysis o f expression and phosphorylation o f recombinant 
baculoviruses expressing wtLck and AcLck:
.A Lysates from Sf9 recombinant baculovirus infected cells were made as detailed 
section 2.6.5 and autophosphorylation assays performed either -/+ ATP, as detailed 
section 2.8.8. The samples were resolved on a 12% SDS-PAGE gel and analysed 
by western blot. The top gel is an anti-phosphotyrosine (a-pTyr) blot and the 
bottom is an anti-Lck (a-Lck) blot. Lanes 1- 2 show AcLck -/+ ATP and lanes 3- 4 
wtLck, both had elevated levels of tyrosine phosphorylation in the presence of ATP, 
corresponding to the ability to autophosphorylate Tyr394. Lanes 3 -4  contain 
LckG2A, which behaved similarly to the wildtype Lck clones. Lanes 4- 5 show the 
control kinase defective LckK273A mutant, for which no tyrosine phosphorylation 
was detectable.
Bi The results from the peptide substrate assays (as detailed 2.8.9), summarised on 
a bar graph, clearly demonstrating that wtLck was active on an exogenous substrate, 
in contrast to LckK273 which was inactive. Hck was used as the positive control in 
these experiments and (3-Gal was used as the negative control. The experiment was 
not quantitative.
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4.5.2. Confirming the authentic acvlation of Lck:
Acylation is a eukaryotic post-translational modification event which results in the 
addition of fatty acid side chains to specific protein motifs. Myristoylation occurs 
cotranslationally and results in the covalent attachment of a 14 carbon saturated 
fatty acid to an adjacent N-terminal glycine residue. The reaction is catalysed by the 
N-myristoyl transferase enzyme and is irreversible. In contrast, palmitoylation is a 
reversible event that occurs post-translationally at the cell membrane. Palmitoylation 
is typically dependent on myristoylation to target proteins to the membrane, where 
the addition of palmitate stabilizes the membrane association. Palmitoylation is 
catalysed by palmitoyl transferase which catalyses the addition of a 16 carbon 
saturated fatty acid to a cysteine residue via a thioester bond (reviewed (Mumby, 
1997)). The baculovirus expression system was selected for use in these studies 
because it is eukaryotic and allows authentically acylated proteins to be expressed 
to high levels.
To ensure the proteins utilised in the interaction assays were authentically acylated, 
Sf9 cells were metabolically labelled with [3H] myristic and [3H] palmitic acid and 
subject to fluorography as detailed section, 2.6.9. In the experiments presented in 
this section the newly constructed wtLck was assessed for acylation, as previous 
work (Harris, 1995) had established authentic acylation of AcLck. The LckG2A 
and LckK273A recombinants were also analysed. The results can be seen in figure
4.2. Gel A shows cells labelled with [3H]] myristic acid. In lane 3 a band 
corresponding to wtLck at ~56kDa is clearly visible, confirming myristoylation of 
the protein. As expected the G2A Lck mutant (lane 4) which encodes an alanine at 
position 2 preventing myristate attachment, was not myristoylated. The kinase 
inactive mutant LckK273A was also authentically myristoylated as anticipated since 
the K273A point mutation was distal to the myristoylation signal (lane 5). Similar 
results were seen for labelling with [3H] palmitic acid, figure 4.2 gel B. However, 
the addition of palmitate by transesterification is a reversible process plus palmitate 
is upstream of myristate in the metabolic pathways. It was therefore possible that 
some of the palmitic acid label had been metabolised to myristate and the signal 
detected by fluorography in gel B was mainly due to myristoylation. To confirm that
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the signal was caused by the incorporation of [3H] palmitic acid the gels were 
treated with 1M hydroxylamine pH7.0. This treatment removes residues attached by 
thioester bonds, but has no effect on myristoylation. Figure 4.2 gels C and D show 
the results after 1M hydroxylamine treatment. Gel C containing the [3H] myristic 
acid labelled proteins remained unchanged (compare to gel A), with the same bands 
detected in each lane. Conversely, gel D shows the loss of signal for wtLck and 
K273A confirming the label originally incorporated into these proteins was 3H 
palmitic acid (compare to gel B); thus the authentic acylation of both wtLck and 
K273A Lck was confirmed.
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Figure 4.2. Establishing the authentic acylation o f wtLck:
St9 cells were metabolically labelled with either [3H] myristic or [3H] palmitic acid 
and labelled proteins were detected by fluorography as described 2.8.1 and 2.6.9.
A: Results of fluorography of the [3H] myristic acid labelled samples. Lane 1; 
contained a P-Gal negative control; lane 2 shows the authentically myristoylated 
wtLck at ~56kD; lane 3 contained an Sf9 lysate negative control; lane 4 contained 
LckG2A a nonmyristoylated mutant of Lck; lane 5 contained LckK273A, the kinase 
defective mutant which was authentically myristoylated.
B: .The same samples were labelled with [3H] palmitic acid. A signal corresponding 
to ~56kDa was detected for both wtLck (lane 2) and LckK273A (lane 5).
C and D: Determination of authentic palmitoylation. The same samples shown in A 
and B were reanalysed, but prior to fluorography the gels were fixed in destain for 
10 minutes and subsequently incubated in 1M hydroxylamine pH7.0 for 30 minutes, 
to remove thioester bound palmitate. Gel C shows the [3H] myristic acid labelled 
samples were unaffected by the treatment whereas all detectable signal was lost in 
gel D for the [3H] palmitic acid labelled samples, indicating the label incorporated 
into the proteins in B was due to authentic palmitoylation.
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4.6. In vitro binding assays:
For the in vitro assays throughout these studies, unless otherwise stated, the affinity 
reagents were baculovirus expressed affinity purified N-terminal GST fusions, 
bound to glutathione-agarose beads (GA-beads), as detailed in section 2.6. The Nef 
allele used for these studies , except where stated was BH10. The authenticity and 
functionality of the Nef isolates and mutants had been determined in previous 
studies with CD4, so will not be shown here (Harris and Neil, 1994; Cooke et al, 
1997). The remit for these studies was to confirm the in vitro binding of Lck to Nef 
seen in preliminary experiments and to investigate an apparent loss of binding in the 
presence of NaOV, a tyrosine phosphatase inhibitor.
4.6.1. Overview of preliminary studies:
During preliminary studies within the laboratory in vitro binding assays were 
performed for AcLck with both Nef-GST (N-G) and nonmyristoylated Nef-GST 
(G2A-G) as affinity reagents. Data obtained from these studies, shown in figure 
4.3 A, demonstrated a direct interaction between full length acylated AcLck and Nef 
was dependent on Nef myristoylation in vitro (compare lanes 3 and 4 to lanes 5 and 
6, gel A). Lck bound to the N-G affinity reagent was further analysed for 
autophosphorylation activity in the presence or absence of ATP (see section 2.8.8. 
for method). The anti-Lck western blot shown in figure 4.3A confirmed the 
N-G/Lck complex was aliquoted equally prior to the autophosphorylation assay 
with similar levels of Lck in both -/+ ATP samples (lanes 3 and 4). As expected the 
levels of phosphotyrosine detected during the anti-phosphotyrosine western blot for 
the Lck lysate alone were elevated in the presence of ATP, consistent with 
autophosphorylation (compare lanes 1 and 2, C). In contrast, there was no 
detectable phosphotyrosine in Lck bound to Nef either minus or plus ATP, even at 
higher ECL exposure times (lanes 3 and 4, C). This preliminary data, since 
corroborated by our collaborators (Collette et al, 1996), suggested that Lck 
autophosphorylation activity was inhibited by Nef binding. In addition in vitro 
binding assays were performed on Lck lysates prepared in the presence of NaOV, a 
tyrosine phosphatase inhibitor. Under these conditions Lck binding was impaired 
(see figure 4.3B lanes 3 and 4). Taken together this data suggested that Nef bound 
the active conformation of Lck and in so doing rendered the kinase active site 
inaccessible to autophosphorylation.
168
Figure 4.3. Results from the preliminary studies:
In vitro binding assays were performed for AcLck plus either N-G or G2A-G. The 
complex immobilized on beads was aliquoted and subject to an autophosphorylation 
assay either -/+ATP. The results were analysed by western blot.
A^  Depicts an anti-Lck blot of the binding assay. Lanes 1 and 2 are the AcLck 
lysate only control; lane 3 and 4 show a band corresponding to AcLck bound to the 
N-G affinity reagent. The absence of bands in lanes 5 and 6 demonstrate that AcLck 
was incapable of binding the G2A-G nonmyristoylated Nef affinity reagent.
B; A replica in vitro binding and autophosphorylation assay as shown in A and C 
except that the Lck lysates used as bait in these assays were prepared in the 
presence of NaOV. This anti-Lck blot shows that treatment of Lck with NaOV 
clearly impaired binding to N-G.
C  This shows the PVDF membrane in A stripped and reprobed with an anti-pTyr 
antibody. The AcLck lysate alone in lanes 1 and 2 provided a control for the 
autophosphorylation assay. The absence of detectable tyrosine phosphorylation in 
lanes 3 and 4 for AcLck bound to Nef suggested a Nef block to Lck 
autophosphorylation activity.
TX B stripped and reprobed with a-pTyr demonstrating no tyrsosine 
phosphorylation was detectable after protein complex formation.
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4.6.2. Follow up in vitro binding studies:
In the current studies standard binding assays were performed for the newly derived 
wtLck recombinant baculovirus using N-G, G2A-G and m-G as affinity reagents. 
Unexpectedly no interaction between Nef and wtLck was detectable (data no 
shown). The assay was repeated with freshly made lysates of the earlier constructed 
recombinant baculovirus AcLck substituted for wtLck and again the interaction 
could not be reconstituted. To reconcile the differences between the experiments 
and to ascertain whether the tissue culture media itself could be contributing by 
causing altered protein conformations, crosswise comparisons of all the reagents 
were carried out. This was facilitated by the availability of the original AcLck 
lysates (oAcLck) and GST affinity reagents (oN-G, oG2A-G and om-G) used in the 
preliminary studies.
The table in figure 4.4A summarises the 6 separate binding assays performed to 
identify compatible Nef-Lck binding partners (the numbers correspond to the 
sample sets shown in 4.4.B). Samples loaded onto the left-hand-side of each gel 
figure 4.4B (lanes 3,4 and 5) had the newly purified GST fusion proteins as their 
affinity reagents, while those on the right-hand-side had the original affinity reagents 
(lanes 7,8 and 9). The top gel in figure 4.4B shows the results for wtLck. If lane 3 is 
compared to lane 7 it is evident that as previously found there was no detectable 
binding of wtLck to N-G (lane 3). In contrast, oN-G bound low levels of wtLck 
(lane 7). In both assays no binding of wtLck to G2A-G or oG2A-G was seen (lanes 
4 and 8). Almost identical results were obtained for AcLck, shown in the middle gel 
of figure 4.4B. However, when the original oAcLck lysate was analysed for binding 
to the affinity reagents (bottom gel), it was found low levels of oAcLck associated 
with the newly purified N-G (lane 3), at a level comparable to that seen for oN-G 
plus either wtLck or AcLck (lane 7, top and middle gels respectively). Significantly, 
when both sets of the original reagents were utilised (bottom gel, lane7) the 
interaction was reconstituted. In lanes 2 and 6 of every gel each Lck lysate 
precleared with GA-beads was loaded, the amount corresponded to one fifth of the 
total input Lck lysate. Therefore oN-G bound -10% of the total oAcLck. The 
preclear samples also illustrated that in every binding assay equivalent levels of Lck
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protein were present. Similar to the preliminary in vitro binding studies Lck binding 
to Nef was found to be dependent on myristoylation (lane 8), although low levels of 
oAcLck binding to G2A-G was evident at higher exposures (lane 4). Figure 4.4C 
(second sheet) shows the loading of the affinity reagents on the GA-beads. This 
revealed the amount of the original reagents was ~2 fold greater than the newly 
purified stock which may have contributed to differences seen between the reagents.
These crosswise comparisons clearly indicated a fundamental difference between 
the original and newly produced stocks for both the affinity reagents and Lck 
lysates. In general, the original oN-G stocks had a higher overall affinity for all the 
Lck recombinant subclones (compare lane 7 of each gel to lane 3), which may or 
may not be attributable to varying concentrations since they were present in excess.. 
Also, oAcLck bound Nef at significantly higher levels than the newly made AcLck 
lysate (compare middle and bottom gels). To identify factors governing the Lck and 
Nef association two questions were addressed. Firstly, what was the cause of the 
differences between stocks and secondly, how were the differences allowing the 
proteins to adopt more favourable binding conformations.
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Figure 4.4. In vitro binding assay results o f the crosswise comparison o f reagents.
Table A: Summarises the reagents used in each assay (total of 6 individual assays).
B; Standard in vitro binding assays were performed to analyse discrepancies 
between different lysate and different affinity reagent stocks. A detailed account of 
the results are provided in the text. The top gel shows binding assays for wtLck, the 
middle for AcLck and the bottom for oAcLck. Lane 1 of each gel was loaded with 
the same Lck positive control to facilitate comparison of ECL exposures. Lanes 2 
and 6 were loaded with precleared samples of each Lck lysate used for the 
respective assays. Lanes 3,4 and 5 for each gel had the newly purified affinity 
reagents (N-G, G2A-G and m-G respectively) while lanes 7, 8 and 9 had the 
original affinity reagents (oN-G, oG2A-G and om-G).
Ci Coomassie stained gel to quantitatively compare the amount of purified protein 
bound to GA-beads. Samples were resuspended in sample buffer and heated at 90°C 
for 2 minutes prior to loading, 5 pi packed volume of GA-beads was loaded in each 
lane. Samples were loaded in the order, N-G, G2A-G, m-G, followed by oN-G, 
oG2A-G and om-G. The results show that there was an increased amount of protein 
bound to beads in the original samples.
A.
Binding
assay No.
Lck Lysate Affinity Reagent
wtLck AcLck oAcLck N-G G2A-G m-G oN-G oG2A- om-G
G
1 ✓ ✓ ✓ ✓
2 ✓ ✓ / ✓
3 ✓ ✓ y ✓
4 ✓ / ✓ /
5 ✓ y y ✓
6 ✓ ✓ / /
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4.6.3. Identifying the cause of the differences between protein stocks:
As the results presented above demonstrated, variations in Lck-Nef binding 
occurred even when the same viral stocks were utilised, it was therefore concluded 
that either tissue culture or cell lysis conditions must be responsible. The most 
variable parameter among which was batch differences in the foetal calf serum used 
to supplement the TCI00 medium. Serum comprises a complex mixture of 
biomolecules including, growth factors, cytokines, hormones, attachment and 
spreading factors, binding proteins, lipids, minerals and anti-proteases. It is hence 
difficult to control for differences between batches (Maurer, 1992). Slight 
alterations in, for example various inorganic minerals and trace elements such as Cu, 
Zn, Co, Mn and Se can abrogate cellular enzyme functions due to their critical role 
as enzyme cofactors, i.e. Selenite has been demonstrated to activate the enzyme 
glutathione peroxidase which is necessary for detoxifying otherwise cytotoxic 
oxygen radicals; therefore a selenite depletion in a batch of serum could potentially 
expose the cells to oxidative stress (Hewlett, 1991). Also concentration variations 
in other components such as growth factors (e.g. epidermal growth factor, 
fibroblast growth factor and platelet derived growth factor) and cytokines (e.g. 
IL-2, tumor necrosis factor (TNF), interferon y, IL-12) normally involved in 
promoting cell proliferation and differentiation, could result in the alteration of an 
abundance of cell signal transduction cascades (Maurer, 1992).
To assess the impact of the serum on Lck association with Nef, Sf9 cells were 
grown for 1 passage in complete TCI00 medium supplemented with 9 different 
serum batches. Once equilibrated the cells were infected with the AcLck 
recombinant baculovirus. In vitro binding assays were performed and the binding 
affinities of the Lck lysates (infected in different sera) for the same N-G affinity 
reagent ascertained. Figure 4.5A shows an anti-Lck western blot of the binding 
assays with N-G, while figure 4.5B shows an anti-Lck western blot of the 
precleared Lck lysates confirming levels of Lck were equal across the samples prior 
to immunoprecipitation. Lanes 1-7 were AcLck lysates produced from Sf9 cells 
grown in randomly selected commercially available serums, lane 8 was the same 
serum utilised for the preliminary studies (GDBCO) and lane 9 was the serum used
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for the more recent experiments (PAA Laboratories). Overall the results of the 
binding studies (gel A) demonstrated that serum batches could significantly 
influence the ability of Lck to bind an invariant N-G affinity reagent (compare lanes 
7 and 8). Due to the high exposure of the autoradiograph binding of AcLck to N-G 
in lane 9 was evident, however after 1 passage in the original sera there was a 
significant increase in the binding efficiency of AcLck to N-G in lane 8. Although 
| the level of binding observed in lane 8 was not returned to that seen in previous 
J  experiments, (figure 4.3 and 4.4) this was probably attributable to the short amount
i
| of time the cells were passaged in the media for this experiment. These results 
j therefore concurred with the prediction that the serum did have an effect on thei
ability of Lck to associate with Nef.
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Figure 4.5. Affect o f serum on Lck binding to N-G:
AcLck lysates were prepared from 9 individual batches of Sf9 cells each grown in 
different sera for 1 passage. The resultant AcLck proteins were analysed for their 
ability to bind N-G. Lanes 1-7 contain samples grown in random selected 
commercially available serum; lane 8 was the original serum; lane 9 was the current 
serum.
A  Results of in vitro binding assays; showing highly variable band intensity for 
AcLck demonstrating the different sera had a profound affect on the ability of Lck 
to bind Nef.
B; AcLck preclear samples, loaded the same as A confirming equivalent amount of 
AcLck was included in each assay.
A .
anti-Lck — 66kDa 
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B.
anti-Lck — 66kDa 
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Figure 4.5.
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4.6.4. How were the protein conformations altering between stocks:
It was conceivable that binding differences detected between Lck and Nef from 
different stocks may be as a result of the presence or absence of an intermediate 
factor. However, even if this was the case, the evidence from the NaOV 
experiments in the preliminary studies suggested it was Lck conformation 
dependent. The obvious affect of serum on the ability of Lck to associate with Nef 
and the intrinsic between serum factors and cell signal transduction pathways led us 
to compare the phosphotyrosine levels of oAcLck with those of AcLck and wtLck. 
Autophosphorylation assays were performed (as detailed 2.8.8) on the same Lck 
lysates utilised for the crosswise comparisons in section 4.6.2. Equivalent levels of 
Lck expression were confirmed by western blot analysis, figure 4.6B. The results of 
the autophosphorylation assay, see figure 4.6A indicated in accordance with earlier 
results (figure 4.1 A) that both wtLck and AcLck had low background levels of 
phosphotyrosine (lanes 2 and 5) which elevated after incubation with ATP (lanes 3 
| and 6). In contrast, it was evident that by comparison oAcLck had elevated
| background levels of phosphotyrosine (lane 8) which did not substantially increasei
I in the presence of ATP (lane 9).
j
| During the autophosphorylation assay presented in section 4.5.1. it was
j demonstrated the incubation of Lck with ATP correlated with an increase in
tyrosine phosphorylation on Tyr394. The most plausible explanation for the high 
levels of pTyr in the oAcLck stock, irrespective of ATP, was that inferred 
phosphorylation of Tyr394 was saturated prior to the addition of ATP i.e. the 
oAcLck stocks were predominantly in the active kinase conformation. Conversely, 
the increase in phosphotyrosine levels on incubation with ATP for wtLck and 
AcLck suggested that these stocks were in the inactive conformation during the 
binding assays. However it was also possible that the elevated levels of 
phosphotyrosine were a result of saturated Tyr505 phosphorylation and that the 
kinase was predominantly inactive. The differential phosphorylation between stocks 
was were consistent with the original hypothesis and confirmed a distinct Lck 
conformation conferred its ability to bind Nef. To address this specific mutants were 
generated see below.
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Figure 4.6. Autophosphorylation assays to compare wtLck, AcLck and oAcLck:
A: Depicts the results of the autophosphorylation assays analysed by western blot 
with an anti-pTyr antibody. Lanes 1-3 show wtLck, 4-6 AcLck and 7-9 oAcLck. 
The first lane for each is untreated lysate and the second two are the results of 
autophosphorylation assays either -/+ ATP. The autophosphorylation activities for 
wtLck and AcLck were similar, with low levels of tyrosine phosphorylation -ATP 
but high levels +ATP. In contrast, oAcLck (lanes 8 and 9) had equal 
phosphotyrosine levels either -/+ ATP, inferring it was constitutively active.
IT Gel A stripped and reprobed with anti-Lck to confirm equivalent levels of Lck in 
each lane.
A:
ATP
anti-pTyr
B:
anti-Lck
66kDa
46kDa
66kDa
46kDa
Figure 4.6.
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It was clear from the crosswise comparison experiment that Lck conformation alone 
was not sufficient to reconstitute the Nef-Lck interaction, a distinction between the 
original and newly purified affinity reagents was also apparent. This could be as a 
result of the varying amounts of protein bound to the GA-beads, but as the affinity 
reagents were added in excess subtle differences would not normally be expected to 
greatly influence the amount of binding. The affect of the serum on Nef at this stage 
can therefore only be speculated. Nef phosphorylation on serine and threonine 
residues has been reported by our laboratory (Coates and Harris, 1995; Coates et 
al’ 1997) and other groups (Guy et al, 1987; Bandres et al, 1994; Bodeus et al, 
1995; Luo et al, 1997). In addition, our collaborators have identified tyrosine 
phosphorylation of Nef (Collette et al, 1996). However the significance of Nef 
phosphorylation is unknown, but may play a crucial role in enhancing Nef 
interactions with cellular proteins. Tyrosine phosphorylation of Nef could 
potentially transform it into an SH2 binding substrate, this in conjunction with the 
SH3 recognition motif, (PXX)3P could provide the additional binding energy 
necessary for its interaction with Lck. As tyrosine phosphorylation is involved in the 
majority of cellular activation pathways, it is plausible that variations in sera may 
have induced variations in Nef tyrosine phosphorylation. Attempts to determine 
whether serum induced phosphorylation of Nef may influence its interaction with 
Lck were unsuccessful. This was due to insufficient sensitivity of the western blot 
analysis utilising anti-phospho serine/threonine and anti-phosphotyrosine antibodies.
4.7 Construction of constitutively active and inactive Lck mutants to assess 
conformational binding criteria:
To confirm whether Lck binding to Nef was dependent on Tyr394 phosphorylation 
per se or if the “open” active conformation was sufficient, two constitutively open 
Lck mutants were constructed. A single point mutation in the C-terminal regulatory 
tyrosine residue, Tyr505 of Lck has been demonstrated to confer cellular neoplastic 
transformation (Marth et al, 1988) analogous to that seen for p60°'Src Tyr527 
mutations (Courtneidge, 1985; Stover et al, 1994; Brown and Cooper, 1996). This 
Lck mediated neoplastic transformation occurs as a result of an inability of the
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enzyme to regulate its kinase activity due to the disruption of the intra-molecular 
association of pTyr505 with the SH2 domain, hence maintaining Lck in the open 
conformation. As a consequence the Tyr505 mutation is accompanied by significant 
increases in Lck Tyr394 phosphorylation and enzyme activity. The first baculovirus 
transfer vector was hence modified to contain the Y505F Lck point mutation, as 
detailed in section 4.4. In addition, a second kinase inactive mutant K273A in 
combination with the Y505F mutant was constructed to provide an “open” inactive 
Lck conformation for comparison. A point mutation of lysine to arginine at position 
273 in Lck has been reported to inhibit the transfer of a phosphate from ATP to 
Tyr394 (Carrera et al, 1993). As phosphorylation of Tyr394 is required for the 
kinase activity of the enzyme, the K273A mutation renders Lck inactive. However, 
when we attempted to introduce these two constructs into recombinant 
baculoviruses the expression of constitutively open conformations of Lck proved 
toxic to the Sf9 cells. As a result recombinant baculoviruses expressing Lck Y505F 
or Lck Y505F/K273A could not be generated. This suggested that the 
constitutively open myristoylated conformation of Lck was causing cytotoxic signal 
transduction via its SH3 and SH2 domains. To combat this nonmyristoylated 
derivatives of these mutants were constructed; thus removing Lck from cellular 
membranes where potential SH3, SH2 and kinase substrates are concentrated. This 
approach was prompted by a previous study by (Abraham and Veillette, 1990) in 
which expression of a nonmyristoylated Y505FLck mutant was reported to reduce 
the overall cellular tyrosine phosphorylation levels and oncogenic potential by 
comparison to a myristoylated Y505FLck mutant.
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4.8 Confirmation of the expression and kinase activities of the mutant Lck 
recombinant baculoviruses; Lck G2A/K273A/Y505F (LckGKY) and Lck 
G2A/Y505F (LckGY):
Prior to evaluating the ability of the constitutively open Lck mutants to bind Nef it 
was necessary to confirm their authentic enzymatic modifications. The results of 
autophosphorylation assays for the newly constructed recombinant Lck 
baculoviruses compared to those obtained for the wildtype AcLck and controls 
(LckG2A and LckK273A) are shown in figure 4.7A. In this instance to compare 
levels of autophosphorylation between samples it is necessary to take into account 
their respective expression levels shown in figure 4.7B. Perhaps unsurprisingly it 
was found both of the open conformation Lck mutants were expressed at low levels 
relative to the Lck wildtype and controls. Intriguingly, the constitutively open active 
nonmyristoylated Lck mutant, LckGY shown in lanes 9 and 10 of figure 4.7 had no 
detectable background phosphotyrosine in the absence of ATP, even at higher 
exposures (gel A). LckGY was however capable of autophosphorylation in the 
presence of ATP, as evidenced by the increase of phosphotyrosine levels (lane 10). 
The triple mutant LckGKY as anticipated was not phosphorylated on tyrosine 
residues either minus or plus ATP concurrent with its open conformation and kinase 
defective mutations (lanes 7 and 8, gel A). This also confirmed the earlier 
hypothesis that phosphotyrosine reactivity was entirely due to Lck activity and not a 
cellular kinase.
By comparison to the open conformation mutants the kinase defective single mutant 
K273A was expressed to substantially higher levels (lanes 5 and 6, gel B). This was 
possibly as a result of Tyr505 phosphorylation occluding its SH3 and SH2 substrate 
binding sites together with an inability to phosphorylate Tyr394. The anti- 
phosphotyrosine blot for LckK273A revealed background levels of phosphotyrosine 
both minus or plus ATP, consistent with a low level of Tyr505 phosphorylation. 
The phosphotyrosine levels detected for LckG2A minus ATP (lane 3) were 
analogous to those detected in the original oAcLck sample. Significantly, the 
background levels were higher than those seen for K273A (lane 5), suggestive of 
substantial Tyr394 phosphorylation. The difference was not attributable to varying
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protein concentrations as both G2A and K273A were expressed to equal levels 
(compare lanes 3 and 4 to lanes 5 and 6, gel B). The results for LckG2A incubated 
plus ATP showed a further increase in phosphorylation (lane 4), implying only a 
proportion of G2A was activated minus ATP. The AcLck wildtype 
autophosphorylation activity was similar to that seen in previous assays with 
elevated phosphotyrosine levels in the presence of ATP and negligible amounts 
minus ATP. AcLck was expressed at intermediate levels relative to the Lck 
mutants.
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Figure 4.7: Analysis o f the expression and kinase activities o f LckGKY and LckGY 
relative to AcLck, LckG2A andLckK273A:
A: Autophosphorylation assay, analysed by western blot with an a-pTyr antibody. 
Elevated levels of tyrosine phosphorylation were detected for LckG2A -ATP (lane 
2) suggestive of Tyr394 phosphorylation; lane 3 contains LckG2A +ATP. Lanes 5 
and 6 contain the LckK273A kinase defective mutant which had negligible tyrosine 
phosphorylation. Lanes 7 and 8 were LckGKY, which had no detectable tyrosine 
phosphorylation due to the C-terminal Y505 mutation and a mutation in its kinase 
active site. Lanes 9 and 10 were LckGY which unexpectedly had no background 
tyrosine phosphorylation (despite mutations to constitutively activate it), however it 
was capable of autophosphorylation as evidenced by the increase in 
phosphotyrosine levels in the presence of ATP.
R: Gel A stripped and reprobed with an a-Lck anitbody to show the variable 
expression levels observed for each of the Lck samples.
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One interpretation of this data, is that the removal of the nonmyristoylated Lck from 
cellular membranes allowed a level of kinase activity that could not be tolerated in 
the myristoylated wild type Lck. Whereas the inference from the results obtained for 
LckGY was that the Tyr505 residue or a conformation conferred by it was required 
for optimal autophosphorylation activity in the absence of high concentrations of 
ATP. It was speculated by Moarefi et al during their Hck activation studies 
(Moarefi et al, 1997) that variable partially active kinase conformations exist for Src 
kinases between the completely inactive and active conformations. In addition, 
external stimuli such as ATP have the potential to override any of these 
conformations converting an enzyme activity from a slow low background level, to 
a rapid high level of kinase activity. The results presented above concur with this 
hypothesis, with the autophosphorylation activities for LckG2A and LckGY being 
equivalent in the presence of ATP (if expression levels are taken into account), but 
variable at low ATP concentrations.
Diagram 4.1. A model fo r the activation o f Src tyrosine kinases (adapted from  
Moarefi et al 1997):
i.) Phosphatase
KINASE INACTIVE
iii.) SH3 Ligand
li.) +ATP
FULLY ACTIVATED
To confirm the recombinant baculovirus Lck mutants maintained their enzymatic 
modifications on an exogenous substrate, peptide substrate assays were also 
performed (as detailed 2.8.9 ). In the assay shown in figure 4.7C LckGKY and 
LckGY were compared to LckK273A with Hck as a positive control. As for the
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wildtype Lck assays (section 4.5.1) an endpoint of 30 minutes was imposed and the 
total pmols of phosphates transferred over this period calculated. The Hck positive 
control used in this assay was not the same as presented in section 4.5.1., therefore 
the results are not directly comparable. However these results confirmed both the 
K273A, and K273A in combination with G2A and Y505F were kinase defective, 
while the double G2A, Y505F Lck mutant was highly active on an exogenous 
substrate.
4.9. In vivo binding studies:
If the previous in vitro binding results with the wildtype Lck proteins held true, one 
would predict that only the Lck species with elevated background levels of 
phosphotyrosine would bind Nef. In the panel of Lck mutants described above only 
the LckG2A mutant would therefore be expected to bind Nef, as the constitutively 
open active mutant LckGY had no detectable Tyr394 phosphorylation in the 
absence of ATP i.e. the conditions under which the binding assay is performed. For 
the assays outlined below the protein interactions were investigated in vivo after 
coinfection of Sf9 cells by the respective recombinant baculoviruses (see sections
2.6.5 and 2.6.8. for methods).
4.9.1. In vivo binding studies for LckGY and LckGKY:
Coinfections for LckGY and LckGKY with either N-G, G2A-G or m-G were 
assessed for protein interactions using the standard binding assay without the 
GA-bead preclear step (see section 2.6.8.). Unexpectedly it was discovered that the 
triple LckGKY mutant bound both N-G and G2A-G (lanes 6 and 7, figure 4.8A), 
but the active mutant LckGY did not associate with Nef (lanes 2 and 3). No 
association with the m-G negative controls were seen (lanes 4 and 8) confirming the 
specificity of the observed interactions. Higher exposures did reveal a faint band in 
lane 2 corresponding to LckGY binding to N-G, but this was not consistently 
reproducible. In fact, as apparent in the anti-GST western blot shown in figure 4.8B 
the co-expression of N-G or G2A-G with LckGY resulted in toxicity to the cells 
and invariably expression of one of the proteins was significantly reduced or lost all
together (lane 3, G2A-G expression was lost in this example). However, when 
co-expression was achieved as shown in lane 2, gel A there was only very minimal 
binding of LckGY to Nef. In contrast, co-expression of N-G with LckGKY 
appeared to increase LckGKY expression apparently reducing its cytotoxicity to the 
cells (data not shown). The lack of binding observed for LckGY corroborated the 
importance of elevated background phosphotyrosine levels for Nef association, but 
binding of LckGKY to Nef in the absence of LckGY binding represented an 
anomaly which will be addressed below.
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Figure 4.8. Results o f in vivo binding assays fo r LckGY and LckGKY:
Coinfections of Sf9 cells were carried out for LckGY and LckGKY plus either 
N-G, G2A-G or m-G and in vivo binding assays performed as described sections 
2.6.5. and 2.6.8.
A: In vivo binding assay, a-Lck western blot. Lane 1 is an AcLck positive control; 
lanes 5 and 9 contain LckGY and LckGKY lysates; lanes 2, 3 and 4 show there was 
no detectable binding of LckGY to either N-G, G2A-G or m-G respectively. 
Conversely the bands corresponding to Lck GKY in lanes 6 and 7 demonstrate its 
ability to bind both N-G and G2 A-G. The lack of binding in lane 8 of LckGKY to 
m-G confirmed the specificity of the LckGKY interactions.
B; Gel A reprobed with an a-GST antibody.
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This also indicated that the coinfection of LckGKY with N-G in this example was 
not successful possibly due to a low multiplicity of infection ie. The amount of 
baculovirus per Sf9 cell, which for coinfections should be between 5-10 virions per 
cell. I
186
4.9.2. A comparative study of Lck mutant binding abilities to N-G:
To directly compare the Nef affinity for the various Lck conformations, coinfections 
were set up simultaneously for each of LckGKY, LckGY, LckK273A, LckG2A, 
AcLck and (3-Gal plus N-G. Western blot analysis of the results are shown in figure
4.9. Gel A shows an anti-Lck western blot of the various Lck mutants bound to 
Nef As previously demonstrated the LckGKY mutant had a strong affinity for Nef 
(lane 2). Interestingly the Lck K273A bound Nef to equivalent levels as LckGKY 
(lane 4). The implication of this result being that the K273A mutation alone is 
sufficient to confer Nef binding, and the G2A and Y505F mutations are redundant. 
However, consistent with its observed elevated phosphotyrosine background the 
LckG2A mutant also bound N-G (lane 5), but with a reduced affinity by comparison 
to the K273A mutants. As in previous experiments no N-G binding was detected 
for LckGY (lane 3) with a very low level detectable for AcLck (lane 6). These 
results suggested that the G2A and K273A mutations may both contribute to the 
maintenance of an Lck conformation capable of Nef binding. The levels of N-G 
expression for each coinfection is shown in gel B. Reduced levels of N-G 
expression were shown for LckGKY, although this did not affect the amount of 
LckGKY bound suggesting the concentration of N-G in these assays is far in excess 
of the threshold level for binding. The amount of Lck expression in each coinfection 
was quanititated by a separate western blot of the lysates prior to 
immunoprecipitation and found to be equivalent (see figure 4.9C).
These results therefore imply that both the LckG2A and LckK273A mutations 
cause the Lck protein to adopt similar conformations. As previously demonstrated 
the LckG2A mutant protein is predominantly in the “open” active conformation, so 
by analogy the K273A Lck mutant must be in the same configuration. The results 
from the autophosphorylation assays showing low levels of tyrosine 
phosphorylation for LckK273A consistent with a lack of Tyr505 phosphorylation 
support this hypothesis. Evidence for a possible open conformation of this mutant 
was provided in a recent study (Gonfloni et al, 1997). During an investigation of the 
role ofthe SH3-catalytic domain linker on the effect of enzymatic activity it was 
discovered mutations around the K273A site rendered the kinase constitutively
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active. It is therefore possible that the K273A mutation causes the protein 
conformation to open but prevents kinase acitivity due to inhibition of the 
phosphate transfer reaction caused by the lack of the lysine residue at position 273.
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Figure 4.9. Comparison o f Lck wildtype and mutants ability to bind N-G:
Coinfections were performed as standard, each individual Lck recombinant 
baculovirus was coinfected with the same amount of the N-G recombinant virus. 
Lysates were made and in vivo binding studies performed.
A: Results of the in vivo binding assay, western blot probed with a-Lck. Lane 1 
was the [3-Gal negative control which did not bind N-G. In lane 2 a band was 
detected at ~56kDa corresponding to LckGKY bound to N-G. Lane 3 shows 
LckGY did not bind N-G; but in lane 4 LckK273A bound to N-G at equivalent 
levels to that of LckGKY in lane 2. Lane 5 shows LckG2A had an intermediate 
binding level for N-G as evidenced by the reduced intensity of the band detected for 
LckG2 A. A faint band in lane 6 was consistent with a very low level of binding of 
Lck to N-G.
B; Gel A stripped and reprobed with a-GST. Similar levels of expression for the 
affinity reagents were seen for (3-Gal (lane 1), LckK273A (lane 4), LckG2A (lane 5) 
and AcLck (lane 6). Levels of N-G were reduced for LckGKY (lane 2) in this 
example, but did not impair the amount of LckGKY binding to N-G. No N-G 
expression was detected in the coinfection with LckGY (lane 3), consistent with 
cytotoxicity upon co-expression of the two proteins.
C; Quantitating the amount of Lck expression in the coinfection lysates. Each 
coinfection lysate was analysed by a-Lck western blot, prior to the binding assay to 
confirm equal Lck expression. The loading of the gel is the same as the above 
examples and the amount of Lck detected for each sample was equivalent.
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4.10. Identification of region in Nef important in mediating its in vivo binding 
to LckGKY:
4.10.1. Investigation of LckGKY binding to different Nef alleles:
To assess whether the binding of LckGKY to BHIONef was conserved between 
different Nef alleles a series of Nef alleles were assessed for their ability to bind 
LckGKY. These included; HIV-1 Bru Nef (from a laboratory adapted HIV strain 
similar to BH10); PCR2iso, PCR3iso and PCR4iso which are primary clinical Nef 
isolates (Harris et al, 1992) and a J5 SIV Nef allele (Rud et al, 1994), all of which 
were expressed from recombinant baculovirses as GST fusions. The results of the in 
vivo binding studies are shown in figure 4.10A. The anti-Lck blot clearly 
demonstrates equal binding to N-G for each of the alleles from left to right, 
PCR4iso, PCR3iso, PCR2iso, followed by SIV J5 and Bru. Equivalent levels of 
expression for the N-G affinity reagent was determined by reprobing the PVDF 
membrane with an anti-GST antibody. It was noticeable at this stage that the level 
of N-G was slightly increased for the PCR4 primary isolate (figure 4.1 OB). 
However when the expression levels of LckGKY prior to the immunoprecipitation 
were analysed they were found to be the same (figure 4.10C). Taken together with 
the lack of variation seen in the binding study (gel A) this suggested that either 
subtle variations in the concentration of the affinity reagent had little effect on the 
amount of bound LckGKY, or that the PCR4iso isolate was not binding as 
efficiently as the other isolates. In an alignment of all the Nef alleles, PCR4iso 
differs in 24 amino acids from the BH10 consensus sequence, however as many as 
30 amino acid changes were seen for PCR3iso (see diagram 5.3) . In addition the 
SIV Nef isolate is only 40% homologous in comparison to HTV-1 Nef. Further 
mutagenesis studies were carried out to analyse the specific amino acid 
requirements in Nef necessary for its interaction with LckGKY.
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Figure 4,10. LckGKY in vivo binding assays fo r 5 different N ef alleles; PCR2, 3 
and 4 HIV-1 clinical isolates, SIV J5 and Bru:
Coinfections and in vivo binding assays were carried out as standard. The results 
were analysed by a-Lck western blot. Levels of expression for the different Nef 
allele affinity reagents were determined by stripping and reprobing the PVDF 
membrane (As detailed 2.6.8 and 2.8.4). The coinfection lysates were also analysed 
for Lck expression prior to the in vivo binding assays, by a-Lck western blotting.
A: Results of the in vivo binding assay. The samples were loaded PCR2 (lane 3), 
PCR3 (lane 2), PCR4 (lane 1), SIV J5 (lane 4) and Bru (lane 5). Levels of LckGKY 
detected in each lane bound to each of the affinity reagents was similar.
B; Gel A stripped and reprobed with an a-GST antibody. Levels of Nef expression 
were equivalent for all except PCR4 (lane 3) which was slightly increased.
Ci Quantitation of the levels of LckGKY prior to jwu— wprecipitation. The 
samples were loaded in the same sequence as the above examples and clearly show 
equivalent levels of LckGKY expression.
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4.10.2. Screening of a panel of Nef deletion mutants for interactions with 
LckGKY:
To determine the regions of Nef important for its association with LckGKY a panel 
of Nef mutants expressed as GST fusions (available within the laboratory) were 
screened for their ability to bind LckGKY during in vivo binding assays (see table
4.1 for a summary of the mutants). From these studies it was found deletions in 
multiple regions of Nef diminished its affinity for LckGKY (figure 4.11 A). The two 
most severely impaired mutants were the PAAP mutant, containing two proline 
mutations in its (PXX)3P motif (lane 3) and the A36-65 mutation (lane 5). Binding 
for both the A7-22 (lane 4) and A74-98 (lane 6) mutants was also reduced by 
comparison to wildtype N-G (lane 1) and All 1-143 (lane 7) samples. Equal levels 
of LckGKY expression in the coinfected lysates are shown in figure 4.11C. To 
confirm equivalent affinity reagent expression, the PVDF membrane shown in figure 
4.11A was reprobed with an anti-Nef polyclonal antibody. Elevated levels of Nef 
wildtype protein (lane 1) were probably attributable to increased antibody 
recognition since each of the deletion mutants had equivalent levels of expression 
and each had a reduced number of antibody epitope sites. The panel of Nef mutants 
was also screened for binding to LckGY, but as with the wildtype Nef no binding 
was detected.
These results were consistent with the predicted involvement of the (PXX)3P motif 
of Nef mediating its interaction with the Lck SID domain. The secondary structure 
of the putative polyproline type II helix was essential to the interaction, as the 
mutation of the 2 central prolines in the PAAP mutant severely impaired Nef 
interaction with LckGKY. The intermediate binding seen for A74-98 suggested that 
the first PXXP maintained affinity for the SH3 domain. The A36-65 deletion 
removed a highly conserved short acidic region of Nef between 62-65, which 
notably has been demonstrated to be critical for Nef enhanced virion infectivity 
(Iafrate et al, 1997). In addition, amino acids 36-38 have been implicated in 
disrupting Nef mediated CD4 down-modulation (Iafrate et al, 1997). It would be 
tempting to speculate that an interaction in this region of Nef with Lck may provide
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a mechanism through which it can simultaneously down-modulate CD4 and enhance 
virion infectivity.
The A7-22 mutation abrogates Nef interactions with cellular membranes possibly 
because it is enriched in hydrophobic and basic residues (Harris unpublished 
observations). The reduction in LckGKY binding with this mutant may result from 
the increased proximity of the Nef myristoyl group to the critical 36-65 amino acid 
region. Alternatively this region of Nef contains 2 consecutive serine residues at 
positions 8 and 9, which could potentially be phosphorylated in native Nef. Analysis 
of the purified N-G by mass spectrometry is currently in progress to determine the 
extent of Nef phosphorylation. Mass spectrometry of the deletion mutants will also 
determine the location of the phosphorylated residues. As the A ll 1-143 Nef 
deletion which is enriched in tyrosine residues showed no reduced binding for Nef, 
we would predict that the tyrosine phosphorylation of Nef is not crucial for its 
interaction with Lck.
Table 4.1. Summary of Nef mutants:
Nef mutants- 
BH10 
[except
Description of mutation Refs.
where stated!
A7-22 Concentration of hydrophobic and basic amino 
acids, potentially important for membrane 
interactions.
Harris unpublished 
observations
OMA7-22 As A7-22 except the Nef myristoylation signal 
was replaced by an optimum myristoylation 
signal.
A36-65 A putative flexible linker region between the 
membrane anchoring region and the compactly 
folded core domain which starts at residue66. 
Also contains the conserved acidic residues at 
position 62-65 linked to Nef mediated disruption 
of cell signalling pathways.
(Freund et al, 1994; 
Iafrate etal, 1997; 
Kawano et al, 1997)
A74-98 The proline motif PxxP (69-78) has been 
demonstrated to be important in mediating Nef 
interactions with Src family SH3 domains, this 
deletion removed the second half of the proline 
motif.
(Saksela ef a/, 1995; 
Lee etal, 1995; Lee et 
al, 1996; Arold et al, 
1997)
PAAP Point mutation of the two middle prolines to 
alanines from the PXXPXXPXXP motif (69- 
78). This mutation has been shown to abolish 
Hck SH3 domain binding to Nef.
(Saksela ef a/, 1995; 
Moarefi ef al, 1997; 
Briggs etal, 1997)
A ll 1-143 It has been suggested that the phosphorylation 
status of Nef may be important in mediating 
interactions. Since Src SH2 domains interact 
with phosphotyrosine residues this tyrosine rich 
region of Nef was deleted.
Collette et al Virology 
in press.
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Figure 4.11. In vivo binding assays for LckGKY plus the panel o f N ef deletion 
mutants:
The assays were performed as standard and analysed by a-Lck western blot. Nef 
expression levels were confirmed by stripping and reprobing the blots with a-Nef 
(1378 polyclonal). The level of Lck expression in the coinfection lysates was 
determine prior to the binding assays by a separate a-Lck western blot of the total 
lysate.
A; In vivo binding assays of the Nef point mutations and deletion mutants with 
LckGKY.
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Chapter 5: Analysis of Hck interactions with Nef.
5.1. Introduction:
The hck gene (for haematopoietic cell kinase) was isolated as a result of the cross­
hybridization of its transcript with an lck cDNA probe (Quintrell et al, 1987). Its 
expression has been detected primarily in myeloid cells, particularly in monocytes 
and granulocytes and cells of B-lymphoid lineage (Quintrell et al, 1987; Zeigler et 
al, 1987; Perlmutter et al, 1988). The presence of high levels of Hck is reported to 
correlate with the differentiation of cells from precursors to mature leukocytes. Two 
Hck protein products have been identified in murine cells as a result of differential 
translational initiations from a single mRNA species, with a larger polypeptide 
generated from a CTG codon 63 bases 5’ of the ATG (Lock et al, 1991). 
Subcellular fractionation of the isoforms revealed differing segregation patterns, the 
smaller p56Hck associated with membrane fractions while the larger p59Hck was 
present in both the cytosol and membrane fractions. This has subsequently also been 
observed for human Hck which encodes proteins of 59kD and 61kD. Further 
analysis has revealed that the differing subcellular locations are a result of the 
palmitoylation of the smaller Hck product (Robbins et al, 1995). In addition, 
palmitoylation has been demonstrated to direct Hck to Triton insoluble complexes, 
indicative of association with membrane sphingolipid cholesterol enriched rafts or 
caveolae. Evidence for Hck involvement in signal transduction pathways is limited, 
but by analogy to other Src family members an ability to transduce signals from 
transmembrane receptors seems highly likely. The recent crystallisation of Hck in its 
inactive form (Sicheri et al, 1997) published together with biochemical studies on 
its ligand mediated activation (Moarefi et al, 1997) provided an insight into the 
regulation of the Src family kinase activities, see section 1.3.1 and below.
Despite the fact that the function of Hck is one of the least well characterised of the 
Src tyrosine kinase family, its ability to bind Nef has been well documented. A 
strong interaction has been demonstrated between the SIB domain of Hck and the 
(PXX)3P motif of Nef. The affinity of this interaction was the highest ever reported 
for an SH3-PxxP interaction (KD=250nM) (Saksela et al, 1995; Lee et al, 1995).
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Data obtained during these studies suggested that the Hck SH3 interaction with Nef 
was not exclusively dependent on the conserved (PXX)3P motif and other amino 
acid interactions were necessary to maintain the high affinity binding. The strength 
of the interaction implied that Nef would be capable of displacing endogenous Hck 
binding partners. This proved to be the case for Hck intramolecular interactions, 
where the SH3 domain stabilizes the inactive conformation by binding a left handed 
polyproline type II helix generated by the linker region between the SH2 and kinase 
domains (Sicheri et al, 1997). It was demonstrated that Nef was capable of 
preferentially binding the SH3 domain of inactive Hck causing its displacement and 
the subsequent activation of the enzyme (Moarefi et al, 1997). Pertinently, these 
studies utilised an N-terminally truncated Hck lacking the unique domain, and 
myristoylation/palmitoylation sites, encoding solely the sequences from the SID 
domain onwards. A nonmyristoylated Nef was used as a ligand during this and all of 
the afore-mentioned experiments. Studies of other Src family members have 
elucidated key roles for their unique N-terminal domains in mediating protein- 
protein interactions e.g. the unique region of p59Fyn is crucial for its association 
with cytoplasmic sequences present in the CD3 zeta (Q, gamma (y), epsilon (e) and 
eta (rj) a murine form of chains (Timson Gauen et al, 1992) which form part of 
the TCR complex; while the unique domain of Lck is necessary for its association 
with CD4 and CD8 (Shaw et al, 1989; Veillette et al, 1988), and activation by the 
tyrosine phosphatase CD45 (Gervais and Veillette, 1995). The studies outlined 
herein were hence undertaken to confirm whether the interaction of Nef with the 
Hck SH3 domain occurred in the context of the full-length native proteins. 
Mutagenesis studies were performed to evaluate the requirement for specific Nef 
motifs and the contribution of acylation plus the unique domain of Hck to the 
interaction was assessed. Finally, the effect of authentic acylation on the activation 
status of Hck in the presence of Nef as a putative SH3 ligand was also investigated.
5.2. Summary of results presented hereunder:
To evaluate the ability of myristoylated Nef to interact with the Hck SID domain, 
the yeast-two-hybrid system was utilised. Nef interactions with Hck SID and an 
SH3-SH2 domain fusion were also investigated. Src, Fyn and Lck were used as
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controls for these experiments. Subsequently, the baculovirus expression system was 
employed to investigate the Hck-Nef interaction in the context of the full length 
native proteins. Recombinant baculoviruses were generated containing murine Hck 
plus chicken Src and human Fyn as specificity controls. Native protein expression 
was verified by western blot analysis, including phosphotyrosine detection to 
confirm autophosphorylation. Enzymatic activity on an exogenous substrate and 
authentic acylation of the proteins was also established. In vitro and in vivo binding 
assays were performed to assess the affect of Nef myristoylation on its interaction 
with native Hck. Following on from this, the ability of HTV protease to specifically 
cleave Nef between residues 57 and 58 was exploited to determine the role of the 
N-terminal region of Nef in the Hck interaction. Additional recombinant 
baculoviruses were generated to analyse the function of the Hck N-terminal 
acylation signals and unique region in the interaction. For these studies a human Hck 
clone was utilised to corroborate the observed murine Hck interactions. A panel of 
Nef mutants were screened for their ability to bind Hck, to analyse the contribution 
of specific residues to the overall efficiency of the interaction in the context of the 
native proteins. A Nef (PXX)3P motif mutation was also included in the screen. 
Lastly, the affect of native Nef in comparison to the (PXX)3P motif mutant of Nef 
on Hck kinase activity was investigated.
5.3. Construction of the SH3, SH2 and SH3-SH2 domain fusions to the 
activation domain of pJG4-5 for expression and interaction analysis in the 
yeast-two-hybrid expression system:
The Src homology domains, either SH3, SH2 or SH3-SH2, were amplified by PCR 
from cDNA clones of Hck, Src, Fyn and Lck. The primers for amplification are 
shown in the table below (table 5.1). Each was subcloned into the pCR™ plasmid 
before transfer into the activation plasmid of the yeast-two-hybrid-system (YTHS), 
pJG4-5. The restriction sites for cloning are indicated in the table, each non-coding 
primer also incorporated a stop codon. These constructs were transformed into 
yeast as detailed in section 2.4.1. and expression of the polypeptides was confirmed 
by western blotting. This was facilitated by the inclusion of an HA-1 epitope tag in
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the activation domain fusion (see 2.1.4 ). The results of the a-HA-1 western blots 
are shown in figure 5.1. The pJG4-5 plasmid has an inducible GAL1 promoter 
therefore extracts were made from both galactose induced and glucose repressed 
yeast cells. Due to the small size of the SH3 domains (—60 amino acids) they were 
resolved on 17.5% SDS-PAGE gels, however, the SH2 and SH2-SH3 domains 
were resolved on 12% SDS-PAGE. For each sample the same number of cells were 
lysed, however it was evident that the domains were expressed at variable levels. 
Polypeptides corresponding to the SH3 domains fused to the pJG4-5 activation 
domain (-160 amino acids in total) were detected at ~24kDa (gel A). For each no 
expression was detected without induction but by comparison to Fyn SF13 (lane 8 ), 
the expression levels for Lck SH3 (lane 2) and Src SF13 (lane 6 ) were significantly 
reduced. Hck SH3 expression was intermediate. Gel B confirms the expression of 
the SH2-activation domain fusions for each protein at ~30kDa, expression levels 
were more consistent for Lck (lane 2), Src (lane 6 ) and Fyn (lane 8 ) but slightly 
raised for Hck SH2 (lane 4). In gel C it is evident that both Src SH3-SH2 and Fyn 
SH3-SH2 fusions were expressed to elevated levels ( - 1 0  fold difference between 
expression levels for Lck and Fyn SH3-SH2).
Table 5.1. Summary o f PCR primers fo r the cloning o f the SH3, SH2 and SH3- 
SH2 domains into pJG4-5:
Prot SH3 PCR Primers R. SH2 PCR primers R
Hck, c: 
nc;
nCsH3/2 •
5 ’ -GAA 7TCTCTGAGGATACC ATTGTG
5 ’ -CTCGAGCT AAGAGTT AAC ACGAGCC AC
ATAGTTGCT
RI/  
XI
5 ’ -GAA TTCTGGTTCTT C AAGGGG AT C 
5 ’ -CTCGAGCT AAC AGGGC ACTGAC AGCTT
5 ’ -GAA 7TCCTAAC AGGGC ACTGAC AGCTT
RI/
XI
RI
Src, c: 
nc:
5 ’ -GAA 7TCGGCGGCGTC ACC ACTTTC 
5 ’ -CTCGA GCT AGGAGTCTG AGGGCGCG AC
RI/
XI
5 ’ -G AATTCT ACTTTGGG AAG ATC ACT 
5 ’ -CTCGAGCTAGC AGACGTTGGTC AGGCG
RI/
XI
Fyn, c: 
nc:
5 ’ -GAA 7TCAC AGGAGTGAC ACTGTTT 
5 ’ -CTCGAGCT AGGAGTCAACTGGAGCC AC
RI/
XI
5 ’ -GAA 7TCTGGT ACTTTGG AAAACTT 
5 ’-CrCG/JGGTAACAGGGAACTACTAGGCG
RI/
XI
Lck, c: 
nc:
5 ’ -GAA 7TCCTGC AAG AC AACCTGGTT 
5 ’ -CrCG4GCTAGCTGTTTGCTTTCGCCAC
RI/
XI
5 * -GAA 77CTGGTTCTTC AAGAATCTG 
5 ’ -CTCGAGCT AGC AAGG ACGGCTC AACTT
RI/
XI
c-coding primer: nc-noncoding primer; R.-restriction sites; RI-EcoRI; Xl-Xhol.
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Figure 5.1. Verification o f SH3, SH2 and SH3-SH2 domain expression fo r  Hck, 
Lck, Src and Fyn in yeast:
Yeast were grown at 30°C to an OD6oo~0.5, when they were pelleted and washed in 
PBS and subsequently grown for a further 4 hours either + galactose and raffinose 
or + glucose. Cells were harvested and lysed by incubation in an equal volume of 
protein sample buffer on dry ice for 5 minutes followed by 5 minutes in a boiling 
water bath (all materials and methods can be found in sections 2.3, 2.4 and 2.7). 
The samples were analysed by western blot (17.5% SDS-PAGE for SH3 and 12% 
for SH2 and SH3-SH2 fusions) with an a-HA-1 antibody. HA-1 was incorporated 
as an epitope tag in the B42 transcription activation domain of pJG4-5.
A  Western blot of the SH3 domains -/+ galactose induction for Lck (lanes 1 and 
2), Hck (lanes 3 and 4), Src (lanes 5 and 6 ) and Fyn (lanes 7 and 8 ). For each no 
expression was detected minus galactose induction. All of the SH3 domains 
resolved at ~24kDa corresponding to -60 amino acids plus the -100 amino acids 
encoding the activation tag (see 2.1.4).
B: The SH2 domains were loaded in the same order as A. The SH2 polypeptides 
were only detected in the presence of induction, resolving at ~30kDa corresponding 
to the -200 amino acids in total for each SH2 domain plus the activation tag.
C  As for A and B, the SH3-SH2 domains resolved at ~40kDa.
A.
o o
ffi 2C/9
c
Galctose
a-HA-1
r? a
-24kD a
B.
— 30kDaa-HA-1
C.
a-HA-1
_  40kDa
Figure 5.1.
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5.4. Analysis of YTHS interactions between the Src homology regions and 
myristoylated Nef:
The authentic expression and acylation of Nef had been previously confirmed, 
together with its suitability as a bait for an interactor hunt, see chapter 3. For each 
interaction under evaluation transformations with either pSH18 and pVEG-Nef or 
pSH18 and pEG202 (as a negative control) were performed. Two clones for each 
transformation were selected and streaked to single colonies. Colonies from these 
plates were then picked and utilised in the interactor hunt. As standard (see sections
2.4.4. and 2.4.5) a single colony was streaked across Glu UHT-X, G/R UHT-X, Glu 
UHTL and G/R UHTL plates and monitored for growth and the development of 
blue colonies over 6 days. For all the examples used in this section the agar plates 
were divided into 5 sections and streaked as shown in the diagram below (diagram 
5.1), with 2 separate clones of the Src domains plus Nef in segments 1 and 2, 2 
clones of the Src domains plus a negative control in segments 3 and 4 (pEG202 bait 
plasmid alone) and a positive control in segment 5 (clone 39, group A1 from the 
studies presented in chapter 3).
Studies on the SH3 domain interactions revealed that co-expression with Nef 
resulted in cytotoxicity to the yeast. Figure 5.2 shows two example sets of data. A is 
the data set for Hck SH3 and B is Src SH3. Both clearly show that in the presence 
of galactose induction on the UHT plate (top right plate of each set) which should 
support colony growth independent of induction, when Nef and the SH3 domains 
were co-expressed there was no colony formation. In the absence of SH3 expression 
on the Glu UHT plates (top left plate of each set) colonies grew as normal indicating 
that all 3 plasmids required for the system to work had been successfully 
transformed. We were hence unable to assess the ability of myristoylated Nef to 
interact with the Hck SH3 domain in the YTHS. Cytotoxicity was also evident for 
the SH2 domains. However, there was sufficient colony formation to determine 
none of the SH2 domains interacted with Nef in this system, as evidenced by the 
presence of white colonies for all of the proteins under investigation (top right plate 
of each set). Examples of these studies are shown in figure 5.3; A is the Hck data set 
and B is Src SH2. Despite only a low level of blue colour development for the
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positive control in these examples, from previous experience this was sufficient to 
detect any protein-protein interactions (compare to results shown in figure 5.4). In 
addition no colony growth was seen on the G/R UHTL plate (bottom right of each 
set), indicating there was no transcription of the second LexAop-LEU2 reporter 
construct.
Diagram 5.1. Orientation of samples for the SH3, SH2 and SH3-SH2 interactor 
hunt with Nef as bait:
A. Position of samples on each agar plate:
1. pVEG-Nef+pJG4-5 SH3/SH2
2. pVEG-Nef + pJG4-5 SH3/SH2
3. pEG202 + pJG4-5 SH3/SH2
4. pEG202 + pJG4-5 SH3-SH2
5. pVEG-Nef + pJG4-5 clone 39 (+ve)
R  Positioning of plates for each interactor data set:
Glu UHT-X G/R UHT-X
Glu UHTL G/R UHTL
In contrast, to the results obtained for the isolated SH3 and SH2 domains the Hck 
SH3-SH2 domain fusion showed a strong interaction with Nef (segments 1 and 2), 
particularly when measured by the (3-Gal reporter construct, see figure 5.4A, 
compare Nef+Hck SH3-SH2 to the positive (segment 5) and negative+SH3-SH2, 
controls (segments 3 and 4) top right plate of the set. As in the previous studies
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co-expression of Nef+Hck SH3-SH2 did result in some toxicity but even at a 
severely compromised level of colony growth the interaction between the 2 proteins 
was still visible, see figure 5.4B. This co-expression induced toxicity limited the 
effectiveness of the LEU2 auxotrophic marker as a reporter in these studies. In a 
typical experiment the growth obtained for two proteins (X and Y) under 
investigation on G/R UHTL (bottom right plate of each set in these examples) 
would be compared to that obtained for the negative control (pEG202 DNA binding 
domain only) and the pJG4-5 “protein Y” construct. If colony growth for the 
proteins X and Y together was substantially more than the negative control and Y 
the proteins can normally be determined interactors. However, in these present 
studies where the co-expression of proteins X and Y resulted in toxicity, comparison 
of colony growth was an unreliable marker for protein interactions. This is 
exemplified by the lack of colony growth for Nef+Hck SH3-SH2 on G/R UHTL 
plates and the presence of growth for the negative+Hck SH3-SH2. Growth on the 
negative+Hck SH3-SH2 segment might suggest that the Hck SH3-SH2 fusion was 
bypassing the Nef bait protein and binding directly to the DNA binding domain 
triggering transcription. However, as described above, a low level of colony 
formation can result from some negative controls especially since in these 
experiments the plates were incubated for 6 days. Consistent with this the colony 
growth seen for the negative control in these experiments was irregular and 
developed between 4-6 days of incubation (see figure 5.4 A and B, bottom right 
plates). In contrast, colony growth for the positive control developed within 2 days 
and showed a regular colony growth. This inferred that the colony growth seen for 
the negative control on the G/R UHTL plates did not result from the Hck SH3-SH2 
domain binding directly to the LexA DNA binding domain. It was therefore 
concluded that the interaction observed for Hck SH2-SH3 and Nef in the presence 
of the (3-Gal reporter reflected a genuine interaction between the two proteins.
A similarly strong interaction was also detected for Nef and the Src SH3-SH2 
domain fusion, figure 5.4C top right plate. To our knowledge this is the only report 
of a wildtype Nef interaction with Src. A previous study demonstrated an increase in 
tyrosine phosphorylation of a modified SrVmaC2 3 9 Nef allele when co-expressed with
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Src (Du et al, 1995). This allele had been mutated to determine the minimum 
sequence requirement necessary to confer the highly pathogenic phenotype 
associated with the pbjn Nef allele. Point mutations RQ to YE at positions 17 and 
18 were sufficient to cause an acute SIV infection in macaques and the ability to 
transform in vitro cell lines similar to the pbju phenotype. It was proposed that this 
was due to the observed increase in tyrosine phosphorylation of Nef and creation of 
an optimal SH2 consensus binding sequence in the N-terminus of Nef. It would be 
tempting to speculate from our results that wildtype Nef binds Src in vivo, but with 
a reduced affinity to the pbjn allele and as a consequence causes a chronic disease 
pathogenesis as opposed to the acute infection seen for SIV pbju. Notably the 
BH10 allele of Nef has no tyrosine residues within the designated SH2 consensus 
sequence. However, it has emerged recently that SH2 binding sequences exist that 
are not tyrosine phosphorylation dependent e.g. Rafl serine/threonine kinase 
interaction with Fyn and Src SH2 domains was found to be dependent on serine 
phosphorylation of Rafl (Cleghon and Morrison, 1994); similarly a cyclin-dependent 
kinase homologue, pl30PITSLRE was also found to bind SH2 domains via an 
N-terminal serine and glutamic acid rich sequence (Malek and Desiderio, 1994). 
Lastly, no interaction was detected between Nef and Fyn SH3-SH2 as determined 
by the formation of white colonies in the presence of X-Gal, see figure 5.4D. 
Co-expression of Nef and Lck SH3-SH2 once again was toxic to the yeast and no 
colonies grew, see figure 5.4E, right hand plate. Growth on the Glu UHT plate 
confirmed the presence of all 3 plasmids required for the system (left hand plate).
Although interactions between myristoylated Nef and the Hck SID domain could 
not be directly evaluated due to cytotoxicity, the lack of interaction between Nef 
and Hck SID suggested that the interaction observed for the SH3-SH2 domain was 
predominantly mediated by the SH3 domain. These results were consistent with 
those previously reported and inferred that the Nef interaction with the Hck SID 
domain could be maintained in the presence of Nef myristoylation. The data also 
implicated a similar mode of interaction between Nef and Src SH2-SH3. This is the 
first report to our knowledge of a Src interaction with a wildtype Nef allele. These 
results in combination with a recent report of a Nef-Fyn SID interaction (Arold et
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al, 1997) as well as the previously documented interactions with Lck SH3 and SH2 
(Hill et al, 1997), Hck SH3 (Saksela et al, 1995; Lee et al, 1995), Lyn SH3 
(Saksela et al, 1995) and a Fyn SH3 R96I mutant (Lee et al, 1995; Lee et al,
1996) infer a conserved ability of Nef to interact with members of the Src tyrosine 
kinase family. It also suggests that as more members of the family are investigated 
further Nef-Src kinase interactions may be discovered. To investigate whether these 
interactions were conserved in the context of the full length native proteins the 
baculovirus expression system was utilised, the results of which are presented in the 
following sections.
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Figure 5.2. N ef interactions with Hck and Src SH3 domains in the YTHS:
pVEG-Nef was used as a bait in these studies, pEG202 was the DNA binding 
domain negative control and the prospective interactors were expressed on G/R 
induction as activation domain fusions. The positive control was clone 39, group 
Al from the library screen in chapter 3. The interactors were streaked across 4 agar 
plates, Glu UHT-X, G/R UHT-X, Glu UHTL and G/R UHTL (see diagram 5.1), a 
detailed description of the reporter constructs for this YTHS can be found in 
section 2.4.
A  Interaction between Hck SHI and Nef. This shows co-expression of Nef and 
Hck SH3 (segments 1 and 2) on the induced G/R UHT-X (top right) and G/R 
UHTL (bottom right) plates was toxic to the yeast. Successful transformation of all 
3 plasmids was confirmed by growth on the Glu UHT-X plate (top left).
B: Interaction between Src SH3 and Nef. As for A co-expression of the two 
proteins resulted in no colony formation.
UHT-X
UHTL
B.
Figure 5.2.
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Figure 5.3. N ef interactions with Hck and Src SH2 domains in the YTHS:
These studies were performed as standard see figure 5.2, for orientation of the 
plates see diagram 5.1.
A: Nef + Hck SH2 showed a similar yeast growth profile to Src SH2 + Nef. In this 
picture the G/R UHTL plate (bottom right) has been rotated anti-clockwise by one 
segment, so the colonies growing in segment 1 (see diagram 5.1) are in fact the 
positive control and those in segment 2 and 3 are Nef + HckSH2 etc.
Bi No interaction was seen for Src SH2 and Nef (segments 1 and 2), as determined 
by the lack of colour change for yeast grown on the G/R UHT plates in the 
presence of X-Gal (top right plate).
UHT-X
UHTL
B.
Figure 5.3.
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Figure 5.4. Interactions between N ef and the Src kinase SH3-SH2 domain 
fusions:
A: Hck SH3-SH2 and Nef. The formation of small dark blue colonies on
co-expression of Hck SH3-SH2 and Nef (segments 1 and 2) on the G/R UHT-X 
plate (top right) indicated a strong interaction between the proteins. See text for a 
full explanation.
Bi Hck SH3-SH2 and Nef. Another example of the Hck SH3-SH2 interaction with 
Nef showing that even when very small colonies were obtained a colour change was 
still apparent on the G/R UHT-X plate.
G Src SH3-SH2 and Nef. A strong interaction was visible as for Hck SH3-SH2 in 
A, on the G/R UHT-X plate (top right).
D: Lck SH3-SH2 and Nef. Only the Glu and G/R UHT-X plates are shown in this 
picture. Colony growth on the Glu UHT-X plate on the left-handside confirmed all 
3 plasmids had been transformed, however the lack of colony growth for Lck 
SH3-SH2 and Nef (segments 1 and 2) on the G/R UHT-X plate showed 
co-expression of the 2 proteins was toxic.
Ei Fyn SH3-SH2 and Nef. The plates shown are as for D. Although only limited 
colony growth for Fyn SH3-SH2 and Nef was visible (segments 1 and 2), they were 
white colonies indicating there was no interaction between Fyn SH3-SH2 and Nef 
in this assay system.
UHTL
E.
Figure 5.4.
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5.5. Construction of recombinant baculoviruses:
The murine Hck (mHck), chicken Src and human Fyn cDNA clones were kindly 
provided by Dr. Mark Marsh (University College, London). Recombinant 
baculoviruses were generated from the pAcES transfer vector containing each 
cDNA subcloned as either EcoRI fragments (mHck and Fyn) or an EcoRI/XhoI 
fragment (Src). The human Hck (hHck) cDNA clone was donated by Prof. Kalle 
Saksela (University of Tampere, Finland). This was amplified by PCR to allow the 
production of a nonmyristoylated species of the protein (G2AhHck) and removal of 
the unique region (A78hHck), EcoRI restriction sites were also incorporated (see 
below for primers). Unfortunately attempts to subclone the wildtype Hck cDNA to 
the pAcES transfer vector were unsuccessful.
Coding primer for G2AhHck:
5 '-GAA TTCC AGATTGATGGCGTGC ATGAAGTCC-3 ’
Coding primer for A78hHck:
5 '-GAA TTCC AGATTGATGGC AGGCTCTGAGGAC ATC-3 ’
Noncoding primer for hHck:
5 '-GAA TTCTC ATGGCTGCTGTTGGT AGTC-3 ’
5.6. Verifying the authenticity of the recombinant baculovirus expressed 
mHck, Src and Fyn:
5.6.1. Determining full length expression and kinase activity:
Lysates of Sf9 cells were infected with recombinant baculoviruses containing either 
the mHck, Src or Fyn cDNAs, were prepared as detailed section 2.6.5. The lysates 
were subjected to autophosphorylation assays and protein expression was 
determined concomitantly with autophosphorylation activity. Western blot analysis 
with the standard anti-phosphotyrosine antibody (PY69 from Santa-Cruz see table 
2.9) detected an increase in tyrosine phosphorylation for Src (lane 4) and Fyn (lane 
6) in the presence of ATP, consistent with the Lck experiments in chapter 4. This 
confirmed both proteins had retained their abilities to autophosphorylate their active 
site tyrosine residues (Tyr416 and Tyr417 respectively). Notably, in the presence of
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ATP a second faster migrating species of Fyn was detected suggesting either 
phosphorylation of the protein exposed it to proteolytic degradation or that the 
overall charge of the protein was altered affecting its electrophoretic mobility. Only 
background levels of phosphotyrosine were detected for both proteins in the 
absence of ATP suggesting the kinases were in the inactive conformation. 
Equivalent levels of protein -/+ ATP were confirmed by reprobing the membranes 
with their respective protein specific antibodies, see figure 5.5.B, lanes 3 and 4 show 
an a-Src blot, while 5 and 6 show an a-Fyn blot.
In contrast, when the Santa Cruz a-pTyr antibody was used as a probe for tyrosine 
phosphorylation in mHck, no bands were detected. However, when the proteins 
were assessed for kinase activity on an exogenous substrate (see below) mHck was 
found to be highly active. As exogenous enzymatic activity requires phosphorylation 
of the active site residue Tyr411, this inferred mHck was capable of 
autophosphorylation. Western blot analysis was repeated with an alternative a-pTyr 
antibody, 4G10 (from Upstate Biotechnology Incorporation) which successfully 
detected mHck phosphotyrosine. The results are shown in figure 5.5A demonstrated 
that similar to Src and Fyn, background phosphotyrosine levels were low with a 
substantial increase in the presence of ATP as a result of autophosphorylation. The 
inability of the a-pTyr Santa-Cruz antibody to detect phosphorylation of the Hck 
active site Tyr411 residue suggested that pTyr411 was presented in a different 
conformation compared to the autophosphorylation sites of Lck, Src and Fyn. This 
variation in configuration of the active sites for these enzymes was probably a 
reflection of their differing substrate specificities.
To confirm the proteins were active on an exogenous substrate, peptide substrate 
assays were performed as detailed in section 2.8.9. The results shown in figure 5.5C 
confirmed all the proteins were enzymatically active. As the levels of protein 
expression had been determined by western blot equivalent amounts of protein for 
each of mHck, Src and Fyn could not be guaranteed, hence the apparent variations 
in activity.
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Figure 5.5. Confirmation o f kinase activity and expression o f mHck, Src and Fyn:
Standard autophosphorylation and peptide substrate assays were performed to 
determine the kinase activity of the enzymes as sections 2.8.8. and 2.8.9.
A  Autophosphorylation assays analysed by a-pTyr western blotting; the standard 
a-pTyr antibody was used for Src (lanes 3 and 4) and Fyn (lanes 5 and 6) and 4G10 
from Upstate Biotechnology Incorporation for mHck (lanes 1 and 2), see text. All 
samples were incubated -/+ATP and all showed increased tyrosine phosphorylation 
levels in the presence of ATP, indicative of ATP induced autophosphorylation.
B: Confirmation of equivalent expression levels in the -/ATP samples; the
membranes shown in A were stripped and reprobed with the protein specific 
antibodies i.e. a-mHck, a-Src and a-Fyn.
Ci Bar graph representation of the results of the exogenous phosphotransferase
activity of the enzymes. Activity of the enzymes is shown in pmols of phosphate
transferred to the peptide substrate at either time 0 or after 30 minutes (time 30).
The reduced activity seen for Src and Fyn probably corresponds to reduced levels
of expression in the lysates used for this experiment by comparison to mHck.
The negative control in this experiment was 0-Gal. j
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5.6.2. Determination of authentic acvlation of the proteins:
To confirm that the proteins for use in the binding studies were authentically 
acylated metabolic labelling experiments were performed with tritiated palmitic or 
myristic acid as outlined in section 2.6.9. The results of the fluorography detection 
are shown in figure 5.6. As expected mHck, Src and Fyn were myristoylated with 
bands corresponding to ~60kDa detected for each, lanes 1, 2 and 3 respectively in 
figure 5.6A. However, the results from [3H] palmitic acid metabolic labelling 
showed bands for Src and Fyn but not mHck. This was an apparent anomaly as both 
wildtype mHck and Fyn contain cysteine residues at position 3 (also in position 6 for 
Fyn), the putative location for palmitoylation, however wildtype Src does not 
contain a cysteine residue until residue 193 and is not normally palmitoylated. These 
results suggested that either Src contained a cryptic palmitoylation site recognised 
by the Sf9 cells or that a point mutation had been introduced into Src during 
cloning. As alternative palmitoylation sites generally occur proximal to 
transmembrane regions or other fatty acid residues such as prenylation (for a recent 
review see (Mumby, 1997)) palmitoylation of wildtype Src in Sf9 cells seemed 
unlikely. Unfortunately technical difficulties have made the latter proposal difficult 
to prove, but it represents the most likely cause for the detection of [3H] palmitic 
acid in Src. The possibility of the signal being a result of metabolism of palmitic acid 
to myristic acid was ruled out by treatment of the gel with hydroxylamine which 
removed all detectable fluorography signal consistent with the removal of palmitate 
(data not shown), see 4.5.2 for method.
The intensity of the bands detected for each of the proteins in the [3H] myristic acid 
labelling experiment suggested that mHck was expressed at reduced levels by 
comparison to Src and Fyn. To determine if mHck was palmitoylated but expressed 
at insufficient levels to be detected, a lysate of [3H] palmitic acid labelled cells 
infected with the recombinant baculovirus expressing mHck was 
immunoprecipitated with an mHck specific antibody. Metabolically labelled (3-Gal 
was used as a negative control for the immunoprecipitation studies. The [3H] 
myristic acid labelled mHck served as a positive control. The results are shown in 
figure 5.6.6. The [3H] myristic acid samples were loaded on the left-handside of the
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gel. Lane 1 contains (3-Gal which confirmed the specificity of the a-mHck 
immunoprecipitation antibody and in lane 2 an ~60kDa protein was specifically 
immunoprecipitated corresponding to myristoylated Hck. In lane 3 again no bands 
were detected for the p-Gal palmitic acid negative control, however an mHck 
specific band was detected in lane 4 confirming its authentic palmitoylation. Again 
hydroxylamine treatment removed any detectable signal confirming authentic 
acylation of mHck (data not shown).
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Figure 5.6. Confirmation o f authentic acylation o f mHck, Src and Fyn:
Recombinant baculovirus infected Sf9 cells were metabolically labelled with either 
[3H] palmitic acid or [3H] myristic acid for 24 hours as detailed 2.6.9. Cells were 
harvested and then lysed in lxGLB. Proteins were resolved by 12% SDS-PAGE 
and subsequently detected by fluorography. The examples shown in A and B were 
exposed to film overnight, C was exposed for 20 days.
A  Determination of myristoylation, the samples were loaded Hck, Src, Fyn, lanes 
1, 2 and 3 respectively. Bands were detected in each lane at ~60kDa, confirming the 
proteins authentic myristoylation. The relative intensities of the bands also reflected 
their relative abilities to be palmitoylated (B).
B; Determination of palmitoylation. Bands corresponding to Src (lane 2) and Fyn 
(lane 3) were detected for palmitate metabolic labelling but none for Hck (lanel).
C  Immunoprecipitation of metabolically labelled Hck samples; lane 1 contained a 
(3-Gal negative control for myristoylation, lane 2 was a [3H] myristic acid labelled 
Hck sample included as a positive control; lane 3 contained a [3H] palmitic acid 
(3-Gal negative control and lane 4 shows the authentically palmitoylated Hck protein 
detected after immunoprecipitation.
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5.7. In vitro binding assays:
In vitro binding assays were performed to evaluate whether the Hck SH3 mediated 
binding to Nef was conserved in the context of the native proteins. Binding of Nef 
to native Src and Fyn was also investigated in this assay. In addition the contribution 
of Nef myristoylation was assessed. The affinity reagents used for these in vitro 
binding studies were BH10 Nef (N-G), nonmyristoylated Nef (G2A-G) and 
myristoylated GST (m-G) which served as a specificity control for binding. Binding 
assays were performed as standard (detailed in sections 2.6.5; 2.6.6; 2.6.7) for each 
of Hck, Src and Fyn. In the example shown in figure 5 .7 the binding assays were 
carried out in duplicate for each sample.
The results of the in vitro binding assays demonstrated specific binding of mHck to 
N-G, with binding to G2A-G detectable at reduced efficiency. Gel A lanes 1 and 2 
show a band corresponding to the correct molecular weight ~56kDa for p56 mHck 
bound to the N-G affinity reagent. A similar fainter band was detected in lanes 3 and 
4 consistent with G2A-G binding. The specificity of the interactions were confirmed 
by the lack of corresponding bands in the m-G lanes (5 and 6). These results 
demonstrated that Nef and Hck retained the ability to interact in the context of the 
full length acylated proteins. Furthermore, the intensity of the bands in lanes 1 and 2, 
compared to 3 and 4 suggested that myristoylation enhanced the interaction in vitro. 
The results from in vitro binding assays with Src are shown in figure 5.7B. It was 
found Src also bound N-G (lanes 1 and 2) more efficiently than G2A-G (lanes 3 and 
4), albeit binding was at a reduced overall level compared to that seen for Hck. This 
corroborated our earlier results of a Nef-Src SH3-SH2 interaction identified in the 
YTHS and confirmed as with Hck that the interaction occurred in the context of the 
full length acylated proteins. In contrast, no association of Nef with Fyn was 
detectable in this assay (data not shown). Since these experiments an interaction has 
been reported between nonmyristoylated Nef and the SID domain of Fyn in vitro, 
indeed the complex crystallised (Arold et al, 1997). However our data suggests that 
this interaction was not sufficient to mediate binding between the native proteins. 
Notably, the results from the autophosphorylation assays suggested Fyn was in the 
inactive conformation. It would be interesting in future studies to determine whether
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the Nef interaction with Fyn SH3 was sufficient to confer Nef binding to the ‘open’ 
active Fyn conformation analogous to the Nef-Lck binding demonstrated in chapter
4. As both Fyn and Lck are involved in TCR-CD3 signal transduction a Nef 
interaction with both proteins could have a drastic affect on T-cell receptor 
activation of cells. The amount of affinity reagent bound to the GA-beads used 
through-out all of these experiments was determined by SDS-PAGE and Coomassie 
blue staining and is shown in figure 5.7C.
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Figure 5.7. In vitro binding experiments fo r mHck and Src:
GST fusion proteins were expressed and purified from Sf9 cells as described 2.6.6. 
and bound to GA-beads to generate the affinity reagent for the in vitro binding 
studies. Affinity reagents included N-G, G2A-G plus m-G which was included as a 
control for specificity. The method for the binding assays is outlined in detail in 
section 2.6.7, briefly mHck, Src and Fyn lysates were precleared with GA-beads 
and then incubated with the affinity reagents at 4°C for 3 hours with rotation. The 
complex bound to the GA-beads was subsequently resolved by 12% SDS-PAGE 
and bound proteins detected by western blot with either a-Hck, a-Src or a-Fyn 
antibodies. Only the results for the mHck and Src binding assays are shown in this 
figure, samples were loaded in duplicate.
A: Results of the in vitro mHck binding assay; lanes 1 and 2 show proteins
associated with the N-G affinity complex, the ~56kDa a-Hck specific bands, 
confirmed mHck interaction with N-G. Lanes 3 and 4 show mHck did bind G2A-G 
but with reduced efficiency. The absence of bands in lanes 5 and 6 confirmed the 
specificity of the interactions.
B: Results of in vitro Src binding assays. The detection of Src specific bands in lane 
1 and 2 plus 3 and 4 confirmed its ability to bind both N-G and G2A-G in the 
context of the full length acylated proteins. Lanes 5 and 6 contain the m-G negative 
control.
C  Coomassie stained gel of the affinity reagents (N-G, G2A-G and m-G) bound to 
5pil (packed volume) GA-beads. Lane 1 contained N-G, lane 2 G2A-G and lane 3 
m-G. These results show the amount of G2A-G bound to the beads was slightly less 
than N-G.
A .
a-Hck
<N <N
- 66kDa
- 46kDa
B.
a-Src
- 66kDa
- 46kDa
c.
Coomassie
stained
(N
66kDa
. 46kDa
Figure 5. 7.
0
219
5.8. In vivo binding assays:
To establish whether the same specificity of Nef binding to the Src kinases was 
maintained in vivo, coinfections of recombinant baculoviruses expressing either 
N-G, G2A-G or m-G plus Hck, Src or Fyn were performed. Whole cell lysates 
expressing both proteins were analysed in in vivo binding assays as detailed 2.6.8. In 
these assays a preclear step with GA-beads was not possible therefore higher 
stringency washes (0.5M salt) were employed. Figure 5.8 shows the western blot 
results for each of the precipitations.
The results of the mHck binding assay are shown in figure 5.8A and demonstrated 
as for the in vitro assays that mHck maintained its ability to interact with N-G in the 
context of the native proteins in vivo (lane 2). However in these in vivo studies 
equivalent binding of mHck to G2A-G was also apparent (lane 3). Low levels of 
binding were seen for mHck and m-G (lane 4), but this was probably due to the 
removal of the preclear step. In contrast, for the in vivo Src studies a high 
background level of Src binding was detected using all 3 affinity reagents, inferring a 
non-specific interaction with the GA-beads (Gel B). It was therefore impossible 
under these assay conditions to investigate the Src-Nef protein interactions in vivo. 
Future experiments will need to address this problem. The same problem was also 
encountered with Fyn (data not shown). To confirm equivalent levels of GST fusion 
expression the blots were stripped and reprobed with a-GST, shown in C and D 
respectively. Levels of mHck expression prior to the precipitation were also shown 
to be equivalent for each affinity reagent in a separate western blot (data not 
shown).
To confirm that the Hck-Nef interaction was not an artifact of the GA-bead 
pulldown assay, lysates of coinfected cells were immunoprecipitated with a-Hck and 
anlaysed by western blot with the a-Nef polyclonal 1378 antibody. The results of 
the a-Nef blot are shown in figure 5.8E and demonstrated that both myristoylated 
and nonmyristoylated Nef were specifically co-immunoprecipitated with the Hck 
specific immune complex (lanes 1 and 2 respectively). This polyclonal Nef antibody 
was raised to Nef-GST and is cross reactive with GST therefore the lack of GST
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precipitation, as determined by the absence of bands in lane 3, provides good 
evidence for the specificity of the Hck-Nef interaction. A recent study (Briggs et al,
1997) has since corroborated these results and demonstrated the ability of Nef to 
form a stable complex with Hck in Rat-2 fibroblasts. In addition they confirmed the 
previous reported in vitro activation of Hck by Nef was maintained in vivo and 
ultimately resulted in the formation of transformed foci of cells.
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Figure 5.8. Results o f the in vivo binding studies with N ef plus mHck and Src:
Sf9 cells were coinfected with N-G, G2A-G and m-G plus either mHck, Src or Fyn. 
The resultant lysates were immunoprecipitated with GA-beads (as detailed section 
2.6.8) and the results analysed by western blot.
A Results of the in vivo mHck binding to Nef (a-Hck western blot) demonstrated 
both N-G (lane 2) and G2A-G (lane 3) were capable of forming stable complexes 
with Hck. In each lane bands at ~56kDa were visible corresponding to mHck. The 
lack of mHck binding to m-G (lane 4) confirmed the specificity of the interactions. 
An mHck lysate alone was loaded in lane 1 as a control for the blot.
B. Results of the in vivo Src binding assay. Binding of Src to N-G, G2A and m-G 
was visible in lanes 2, 3, and 4 corresponding to non-specific binding of Src to the 
GA-beads. A Src lysate positive control was loaded in lane 1.
C and D. These are the same membranes shown in A and B stripped and reprobed 
with and a-GST antibody, therefore sample loading is the same as A and B. The 
results show that the affinity reagents were expressed to similar levels.
H Results of the immunoprecipitation of Hck (with an a-Hck antibody) from 
coinfected lysates demonstrates that the association of Nef and Hck is stable and 
independent of the immunoprecipitation reagent. The gel was probed with a-Nef 
(polyclonal 1378); lane 1 shows a band corresponding to Nef-GST at ~52kDa, lane 
2 is G2A-G. No binding for m-G was detected in lane 3.
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5.9. Analysis of the contribution of the N-terminus of Nef to Hck binding.
As binding of Nef to mHck was unaffected by Nef myristoylation it was decided to 
investigate whether the N-terminal truncated species of Nef was sufficient to confer 
the in vivo interaction. This species of Nef is normally found associated with the 
virion and results from the specific cleavage of Nef by HIV protease (Pandori et al, 
1996; Welker et al, 1996; Bukovsky et al, 1997; Miller et al, 1997). This was 
assessed by treating Nef immunoprecipitated complexes with HIV-1 protease and 
monitoring for the release of mHck. The results shown in figure 5.9 (a flow diagram 
of the method is shown below in diagram 5.2) demonstrate binding of mHck to both 
N-G and G2A-G was unaffected by the protease cleavage of Nef. The 
immunoprecipitate bound to beads after protease cleavage is shown in A. If lanes 1 
and 2 (minus protease) are compared to lanes 5 and 6 (plus protease) it is clear 
similar levels of mHck remain bound to both N-G and G2A-G in the presence of 
protease. This was confirmed by analysing the protein released into the supernatant 
after protease cleavage. An a-Hck western blot of the supernatants is shown in B, 
the mHck lysate positive control in lane 9 is the same as gel A to facilitate 
quantitative comparison of the blots. The lack of Hck detectable in C after protease 
cleavage demonstrated that the Nef-Hck complex remained stably associated. Both 
of these blots were subsequently stripped and reprobed with a-GST to establish 
successful HTV protease cleavage of Nef.
N-G lysate alone was included as a control for protease cleavage and is shown either 
-/+ protease in lanes 4 and 8 respectively. Incubation with protease resulted in the 
production of 2 smaller Nef species. As the putative protease cleavage site was 
between residues 57 and 58 we would have expected a polypeptide of 57 amino 
acids to be released, corresponding to ~7.5kb. This accounted for the N-G 
polypeptide detected at ~45kDa (N-G was ~52kDa), but not the smaller N-G 
species suggesting that an alternative protease cleavage site may also exist in this 
BH10 nef allele. Also, protease cleavage of the N-G lysate utilised in these studies 
did not result in 100% cleavage of Nef. Further studies of protease cleavage with 
purified N-G (data not shown) gave similar results suggesting it was a Nef 
conformational effect not an Sf9 lysate artifact. Notably the Nef cleavage pattern
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was the same for both G2A-G (lane 6, gel B) and N-G (lane 5, gel B) complexed 
with mHck suggesting the same cleavage site(s) remained accessible during mHck 
binding. The a-GST blot of the proteins released into the supernatant (gel D) 
revealed similar background levels of GA-bead dissociation for all samples, 
suggesting this was a result of long incubation periods required for the experiment 
(~4hours). From these results it can be concluded that the affinity of mHck for the 
N-terminal truncated virion produced Nef is equal to its affinity for the full length
native Nef. However, it should be noted that the lack of release of Hck could be due
to the residual full length Nef remaining bound to the GA-beads. 
Diagram 5.2. Flow-diagram o f experimental procedure:
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Figure 5.9. Effect o f HIV-1 protease cleavage on the N-G Hck complex.
A summary of the protocol used for these experiments is shown in the flow-diagram 
in diagram 5.2. Standard in vivo binding assays were performed on coinfected 
lysates. The complexes bound to GA-beads were subsequently divided in 2 and 
incubated either -/+ protease at 30°C on a rotator for 4 hours. The supernatant was 
retained and analysed in parallel to the complex bound to beads by western blot.
A  Results of protease treatment of the Hck-Nef complex bound to beads. This 
shows an a-Hck western blot of immunoprecipitations with either N-G (lane 1), 
G2A-G (lane 2), m-G (lane 3) minus protease or plus protease lanes 5, 6 and 7 
respectively. Lanes 4 and 8 contain an N-G lysate alone. The results show that Hck 
was detected in lanes 1, 2, 5 and 6 and that binding was independent of protease 
treatment. An Hck lysate positive control is in lane 9.
R  Protein released into the supernatant after protease treatment. This shows an 
a-Hck blot, loaded as for gel A. Lane 9 is loaded with the same Hck lysate as gel B, 
demonstrating that the exposure is comparable to gel B. Faint bands were detected 
for Hck both -/+ protease.
C  Gel B stripped and reprobed with a-GST to confirm protease cleavage of N-G. 
N-G was cleaved from ~52kDa to 2 smaller species ~45kDa and -43kD in lanes 5,6 
and 8 consistent with incubation with HIV-1 protease. In the absence of protease
1,2 and 4 N-G remained full length at ~52kDa.
D. Gel C stripped and reprobed with a-GST. This confirmed that any Hck detected 
in the supernatant in gel C was as a result of affinity reagent dissociation from the 
GA-beads and not due to N-terminal Nef fragment release. Faint bands were 
detected consistently across both -/+ protease treated sample sets.
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5.10. Analysis of the contribution of the N-terminus of Hck to Nef binding:
To assess the impact of the unique N-terminal domain of Hck on Nef binding in vivo 
it was necessary to make an N-terminally truncated Hck. In vitro studies reported at 
the time by Moarefi et al 1997, had demonstrated that a bacterial expressed Nef 
was capable of activating an N-terminal truncated human Hck clone. In order to 
make a direct comparison to these studies a recombinant baculovirus was generated 
expressing a similarly truncated human Hck, A78hHck see section 5.5. A 
nonmyristoylated G2AhHck mutant was also constructed, but unfortunately cloning 
difficulties were encountered for the wildtype hHck cDNA. The hHck clone was 
kindly donated by Prof. Kalle Saksela (University of Tampere, Finland) and was the 
same allele of Hck used in the experiments by Moarefi et al. These constructs not 
only allowed us to investigate the importance of the Hck unique region in Nef 
binding in vivo but also corroborate our previous results with the murine Hck. 
Authentic kinase activity of the enzymes is shown in figure 5.14.
In vivo binding assays performed for A78hHck and G2AhHck demonstrated that 
they retained their ability to bind both native Nef and nonmyristoylated Nef in vivo. 
As the A78hHck protein lacked its unique domain an alternative a-Hck antibody for 
western blot detection was utilised, purchased from Affiniti, Exeter, UK (see table 
2.9), termed a-A78hHck herein. The results of the assays are shown in figure 5.10. 
The level of binding detected for A78hHck was not directly comparable to that for 
G2AhHck as the a-A78hHck antibody gave high levels of background for 
G2AhHck. The standard a-Hck antibody (Santa Cruz, see table 2.9) was therefore 
used as a probe for G2AhHck. Figure 5.10A shows an a-Hck western blot of the 
results for the binding assay with G2AhHck. Lanes 1 and 2 show significant levels 
of binding of G2AhHck to both N-G and G2A-G with none detectable for m-G 
(lane 3) confirming the specificity of the interaction. The apparent increase in 
binding of G2AhHck to N-G in this example was explained when the membrane was 
stripped and reprobed with a-GST. The a-GST western blot analysis revealed levels 
of N-G were substantially elevated by comparison to G2A-G and m-G. In contrast, 
results from the A78hHck in vivo binding assays suggested A78hHck bound with a 
reduced affinity to nonmyristoylated Nef by comparison to N-G. Figure 5.1 OB
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shows an a-A78hHck western blot of the results. The amount of A78hHck bound to 
N-G in lane 1 is ~7 fold more than that bound to the G2A-G affinity reagent (lane 
2). This was a genuine manifestation of different binding efficiencies as equivalent 
levels of the affinity reagents were confirmed by stripping and reprobing the blot 
with an a-GST antibody shown in D. In addition, for each of the experiments 
equivalent levels of Hck in the coinfected lysates prior to immunoprecipitation were 
confirmed on separate blots (data not shown).
From these results it can be concluded that nonmyristoylated hHck binds to both 
myristoylated and nonmyristoylated Nef with equal efficiency similar to the binding 
observed for the wildtype mHck isolate. However, the latter results for A78hHck 
suggest that myristoylation does enhance the stability of the Nef-Hck complex 
because in the absence of Nef myristoylation binding of the A78hHck was reduced. 
As differences between N-G and G2A-G Hck binding were only seen for A78hHck 
the results implied both myristoylation and the unique domain of Hck serve to 
enhance the interaction and that the removal of each individually is not sufficient to 
perturb the interaction. This raises the possibility that the Hck-Nef complex is 
formed by an accumulative number of weak interactions acting in concert and 
modifications such as myristoylation maybe necessary to stabilize the interaction 
under physiological conditions. To determine regions in Nef essential for the 
interaction and to confirm the observed in vivo interaction was Nef isolate 
independent a panel of Nef mutants and isolates were screened for their ability to 
interact with Hck.
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Figure 5.10. Results o f in vivo binding studies for A78hHck and GlAhHck:
In vivo binding assays were performed as detailed previously. A78hHck binding to 
the affinity reagent was determined by a-A78hHck (Affiniti) western blot, while 
G2AhHck was detected by the standard a-Hck (Santa Cruz). Subsequently both 
membranes were stripped and reprobed with a-GST antibody to determine levels of 
affinity reagent expression.
A. Results of in vivo binding assay for G2AhHck. These demonstrated that 
G2AhHck bound to N-G (lane 1) and G2A-G (lane 2) specifically with no binding 
to m-G (lane 3). N-G was expressed to higher levels see C consistent with increased 
G2AhHck binding in this example.
H  Results of in vivo binding assay for A78hHck, western blot (a-A78hHck). Lane 
1 shows increased binding of A78hHck to N-G by comparison to binding levels in 
lane 2. No binding to the m-G negative control in lane 3 was observed.
C  A, stripped and reprobed with a-GST showing increase levels of N-G in lane 1 
by comparison to G2A-G (lane 2) and m-G (lane 3).
D. B, stripped and reprobed with a-GST confirming equivalent levels of expression 
of the affinity reagents.
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Figure 5.10.
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5.11. Screen of a panel of Nef mutants and isolates to identify regions 
important for Hck binding and verify the in vivo binding was not Nef isolate 
dependent:
5.11.1. Results from the Nef mutant screen:
Nef mutants were screened for interactions with murine Hck in vivo. Results 
obtained for G2A- and A78- hHck will also be presented. Coinfections and in vivo 
binding assays were performed as previously outlined and the relative binding 
affinities of Hck for the various Nef mutants and alleles determined. The Nef 
mutants screened, including a description of the salient points for each are shown, 
table 4.1.
The results of the coinfection binding assays for the murine Hck are shown in figure
5.11. A, shows the uniform binding of Hck to each of N-G, G2A-G, A36-65, A74- 
98, A ll 1-143, PAAP, A7-22, OMA7-22 (lanes 1, 2, 4, 5, 6, 7, 9 and 10 
respectively). The apparent reduction in Hck binding to the 3 deletion mutants 
(lanes 4-6) was explained by the reduced levels of expression observed for these 
mutants (see B). These results therefore implied that Hck bound to each of the Nef 
mutants with equal efficiency as the wildtype N-G. To ensure the results had not 
been affected by variable Hck levels a separate a-Hck western blot of the coinfected 
lysates was performed. This confirmed equivalent levels of expression of Hck in 
each of the coinfected lysates (see C). The binding of mHck to PAAP was 
unexpected as previous studies had demonstrated an intact (PXX)3P motif in Nef 
was critical for the association (Saksela et al, 1995; Moarefi et al, 1997; Briggs et 
al, 1997). To establish binding to the PAAP Nef mutant observed in our current 
studies was not an anomaly of the mHck isolate the experiments were repeated for 
G2AhHck and A78hHck. The results shown in figure 5.12 clearly demonstrated 
binding of G2A- and A78- hHck to the BH10 PAAP-G mutant (lanes 1 and 4, A) 
consistent with the mHck results. To confirm these results were not an in vivo 
phenomenon the assay was repeated in vitro for mHck plus PAAP compared to 
N-G, G2A-G and m-G (see C and D) and again mHck bound PAAP with an equal 
efficiency as N-G and G2A-G. This suggested that either the conformation adopted
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by the proteins expressed in Sf9 cells differed from the previous studies or that the 
loss of binding was Nef isolate dependent.
The screening of the remainder of the Nef mutants for G2A- and A78- hHck binding 
gave similar results to those seen for mHck. The conserved Hck ability to bind to 
the panel of Nef mutants, suggested either; i) a critical motif had been maintained 
throughout the mutants; or ii) multiple Hck binding sites exist in Nef and the 
elimination of one is not sufficient to destabilize the Hck association.
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Figure 5.11. Results o f mHck binding to the panel o f N ef mutants:
In vivo binding assays were performed as standard (see sections 2.6.5. and 2.6.8.) 
and the results analysed by western blot.
Results of the in vivo binding assay for mHck with the Nef mutants as the 
affinity reagents. This a-Hck western blot shows equal mHck binding in all lanes 
except lane 3 which was the m-G negative control. Samples were loaded N-G (lane
1), G2A-G (lane 2), A36-65 (lane 4), A74-98 (lane 5), A ll 1-143 (lane 6), PAAP 
(lane 7), mHck lysate positive control (lane 8), A7-22 (lane 9), OMA7-22 (lane 10). 
R  The same blot as shown in A, stripped and reprobed with a-GST, demonstrating 
the affinity reagents were expressed to similar levels.
C  A separate a-Hck western blot of the coinfected lysates prior to 
immunoprecipitation, confirming equivalent levels of mHck expression in all 
samples.
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Figure 5.12. Comparison o f mHck, G2A- and A78- hHck binding to PAAP Nef:
In vivo binding assays were carried out for G2A- and A78- hHck plus either PAAP 
Nef, N-G or m-G (see sections 2.6.5. and 2.6.8. for methods). In addition an in 
vitro binding assay was performed for mHck plus the same affinity reagents 
including G2A-G.
A. In vivo binding assays for G2A- A78- hHck. Equal binding to the PAAP Nef 
mutant was apparent for both Hck derivatives (lanes 1 and 4) by comparison to the 
BH10 N-G wild type (lanes 3 and 6). Specificity was confirmed by lack of binding 
to m-G for each (lanes 2 and 5). The G2AhHck blot was probed with a-Hck and 
the A78hHck with the a-A78hHck antibody.
R  The same membranes as shown in A both stripped and reprobed with a-GST 
confirming equivalent levels of affinity reagents were present.
C  In vitro binding assay of mHck with PAAP-G (lane 1), N-G (lane 2), G2A-G 
(lane 3) and m-G (lane 4), the method is detailed 2.6.7. Equivalent binding of mHck 
to all except the m-G specificity was detected.
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5 .11.2. Results from the Nef isolate screen:
To determine whether the Hck binding affinity for Nef isolates was inherently 
variable in vivo binding assays were performed for BH10, Bru (a laboratory HIV 
strain derived Nef similar to BH10); PCR2iso, PCR3iso, PCR4iso, PCR5iso (Harris 
et al, 1992)(all primary patient Nef isolates); and SIV J5 (Rud et al, 1992). It was 
found mHck was capable of consistently binding all of the PCR patient isolates at 
equivalent levels to BH10 Nef (A, lanes 1-4). Similar results were also obtained for 
the SIV J5 Nef isolate (lane 8) although this consistently expressed to lower levels 
mHck binding was proportional to expression levels. However unexpectedly the Bru 
Nef isolate was consistently impaired in mHck binding (lane 7). In the example 
shown in figure 5.13 mHck binding levels to Bru in A are equal to those observed 
for SIV J5, but if the levels of the affinity reagents are compared in B, Bru is 
expressed at -14 fold higher levels that SIV J5. In addition, Bru-GST (lane 7) is 
expressed at equal levels relative to N-G (lane 6, B) but the amount of mHck 
associated with Bru in the binding assay was -10 fold less that that detected for 
BH10 Nef. The Bru amino acid sequence only differs from BH10 by 7 amino acids 
(see diagram 5 .3) and none of these changes are in the conserved Nef motifs. There 
are 2 point mutations to threonine residues, A16T and N52T, which could 
potentially result in the generation of serine/threonine kinase substrate sites, but the 
remaining changes are all highly conservative. Mass spectrometry studies are 
currently in progress to analyse whether the introduction of 2 additional threonine 
residues in Bru resulted in its phosphorylation in Sf9 cells.
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Figure 5.13. Screening N ef alleles for mHck binding:
In vivo binding assays were performed for mHck with the laboratory Nef alleles 
BH10, Bru, the primary isolates PCR2iso, PCR3iso, PCR4iso, PCR5iso and SIV J5 
(see section 2.6.5. and 2.6.8.) as affinity reagents. The complex bound to GA-beads 
was analysed by western blot, a-Hck was used as a probe for mHck binding, the 
membrane was subsequently stripped and reprobed with a-GST.
A  Binding of mHck to the different Nef alleles. This demonstrated that mHck 
bound the primary Nef isolates at equivalent levels PCR5iso (lane 1), PCR4iso (lane
2), PCR3iso (lane 3), PCR2iso (lane 4). The specificity of the interaction was 
confirmed by m-G in lane 5. Binding to BH10 (N-G) is shown in lane 6. In this blot 
it appeared levels of mHck binding to Bru and J5 were similar (lanes 7 and 8), 
however if the expression levels of the affinity taken into account (see B) it is 
evident Bru was a poor affinity reagent for mHck.
R  Expression levels of the affinity reagents, A reprobed with a-GST therefore 
loading is the same as in A. PCR2iso-PCR5iso were expressed at the same levels 
(lane 1-4), as were N-G (lane 6) and Bru (lane 7). SIV J5 was expressed at a 
substantially reduced level (lane 8) consistent with the reduction in mHck binding.
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5.12. Effect of Nef on Hck enzymatic activity:
To determine if the PAAP BH10 mutant bound Hck in the same manner as wild type 
Hck the effect on enzyme activity was investigated. The Nef (PXX)3P mediated 
binding to Hck via its SH3 domain had been demonstrated to activate the kinase 
activity. We therefore hypothesised that as the PAAP BH10 mutant was clearly 
binding independently of the (PXX)3P motif, the effect on Hck activity may also be 
perturbed. Peptide substrate assays were carried out as described section 2.8.9. In 
this experiment increasing concentrations of N-G, Nef-6His (described elsewhere 
(Harris and Coates, 1993)), PAAP-G or m-G were added to each Hck sample and 
the number of phosphates transferred to a peptide substrate in 30 minutes 
determined. The results are presented in the bar graph in figure 5.14. Increasing 
concentrations of Nef-6His resulted in enhanced Hck kinase activity. However, it 
was found increasing m-G levels did slightly enhance Hck enzyme activity. The 
recent reports of reducing conditions causing the formation of sulfhydryl bonds and 
subsequent enzyme activity (see section 1.3) are consistent with this m-G observed 
activation of mHck. However, a clear difference between N-G and PAAP-G was 
still evident. Increased concentrations of N-G resulted in the elevation of enzyme 
activity, while PAAP had no detectable effect on enzyme activity in this assay. This 
confirmed the hypothesis that binding of Nef to Hck involves an additional 
interaction, independent of the (PXX)3P-SH3 domain binding. Furthermore it 
suggested that Nef is capable of binding Hck without the accompanying increase in 
enzyme activity. However significantly, native Nef retained its Hck activation ability 
corroborating the results of Moarefi et al 1997, who proposed that SH3 domain 
recruitment by the (PXX)3P motif in Nef leads to enhanced enzyme activation.
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Figure 5.14. Comparison o f the effect o f wildtype and PAAP N ef on mHck 
activity:
Peptide substrate assays were performed for equal amounts of mHck in the 
presence of varying concentrations of either N-G, PAAP-G, m-G, Nef-6His or BSA 
(0, 2 or 5 pg). These were carried out in duplicate and the results averaged. The 
results of the number of phosphates transferred to a peptide substrate after 30 
minutes are shown in the bar graph. It was clear increasing concentrations of 
Nef-6His resulted in elevated mHck enzymatic activity with a significant increase in 
the number of phosphates transferred detectable. BSA had no effect on kinase 
activity and although m-G did enhance enzyme activity slightly (see text) the levels 
of activity in the presence of N-G were almost doubled. Significantly increasing 
concentrations of PAAP did not effect mHck enzyme activity.
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CHAPTER 6- DISCUSSION:
6.1. Screening for novel Nef interactors:
Studies on Nef have revealed a wide variety of functions each with a corresponding 
hypothesis as to the implications for HIV pathogenesis. In an attempt to understand 
the pleiotropic nature of Nef an increasing number of groups have been 
investigating potential endogenous cellular binding partners for Nef. As the nef 
transcript comprises 70% of the early viral mRNA it might be predicted that any 
potential cellular interaction partner would be similarly abundantly expressed. 
Moreover, at this stage in the viral life-cycle Nef is expressed predominantly in its 
full length myristoylated form. The cotranslational addition of myristate to the 
N-terminus of Nef could have important consequences for both its subcellular 
location and by analogy to other myristoylated proteins its overall structural 
configuration; thus exerting a strong influence on its intracellular binding partners. 
To investigate Nef protein-protein interactions it was therefore necessary to utilise a 
system that would express Nef in its native conformation and simultaneously allow 
the rapid screening of protein-protein interactions. The YTHS represented an ideal 
tool for these purposes.
At this time available YTHS were not sufficiently developed to allow expression of 
the bait protein as an N-terminal fusion. The pEG202 bait plasmid supplied with the 
interaction trap system was therefore modified by a complex cloning procedure to 
accept bait-cDNA N-terminally to the DB domain (see section 3.2). This left the 
N-terminus of the bait protein under investigation accessible for posttranslational 
modifications, such as myristoylation required during these experiments. The 
generation of pVEG2 as an alternative bait plasmid will provide a valuable basic 
research tool for protein interactions dependent on free N-termini or an N-terminal 
modification. In addition, if the results obtained in the activation assay for the 
pVEG-Nef and pEG-Nef (the N- and C- terminal fusions respectively) constructs 
set a precedent, it is possible that by expressing some proteins as N-terminal fusions 
inherent transactivating properties will be circumvented, allowing the proteins to be
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used as a bait in the system. This is in contrast to the drastic steps of deleting 
regions of acidic amino acid sequences normally recommended for transactivating 
baits. The experiments performed in these studies confirmed that the full length 
expression of myristoylated and nonmyristoylated Nef, p55Gag and ORF94 as DB 
domain fusions in pVEG and pVEG2 was stable and non-toxic to yeast. The 
suitability of the protein fusions as baits in the YTHS was assessed by the activation 
and repression assays. These showed that pVEG(2)-Nef, -p55Gag and -ORF94 
were capable of entering the nucleus and binding the UAS but did not possess 
intrinsic transcriptional activation properties. The studies also confirmed the 
authentic myristoylation of Nef in this system. Previous work by Macreadie et al 
1993 has demonstrated the ability of a myristoylated Nef to enter the nucleus 
(Macreadie et al, 1993).
The human haploid genome is 2.8xl06kb; given that we were screening a Jurkat 
T-cell cDNA library for Nef interaction partners and that mRNA populations reflect 
the relative abundance of protein expression in a cell to ensure a reasonably 
complete library screen it was necessary to screen 106-107 clones (Old and 
Primrose, 1989). In these studies ~2xl06 colonies were screened, consistent with 
our hypothesis that Nef interactors would exist among the enriched mRNA 
population. A total number of 92 potential interactors were identified which on 
RFLP and sequencing analysis partitioned into 6 groups. On the basis of; 
preliminary sequence data; strength of the detected interactions as determined by 
J3-galactosidase activity; and the number of interactors within each group; groups 
Al, B1 and Cl were selected for further investigation. A representative from each 
group was isolated and retransformed back into yeast where they were reassessed 
for their ability to interact with the Nef-DB domain fusion, a negative control 
(pEG202 encoding the DB domain only) and the 2 specificity controls p55Gag and 
ORF94. From these results it was determined that only one clone was genuinely 
interacting specifically with Nef, clone 39, from group Al.
The largest group of false positives was in fact the largest group of identical clones 
isolated, group Cl. Cl was found to have homology to the recently cloned VHL
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(von Hippel Lindau) gene encoding a tumour suppressor protein involved in 
transcriptional regulation. Although false positives are a common problem with the 
YTHS (Hengen, 1997) the isolation of this protein probably also reflected the 
Jurkat T-cell line used as the cDNA source for these studies, as the expression of 
oncogenic proteins is likely to be enhanced in continuous cell lines. Other false 
positives isolated included 2 different groups of polypeptides with significant zinc 
finger protein homology. The isolation of zinc finger containing DNA binding 
proteins represents an ongoing problem with the YTHS and arises as a result of 
their expression in the context of an activation domain fusion. In addition Nef 
exhibited a spurious interaction with a polypeptide derived from cDNA encoding 
the EHOC-1 (Epilepsy, HOIoprosencephaly Candidatie-1) gene. A database of 
YTHS false positives is currently being compiled by E.A.Golemis from the 
laboratory of Dr.RBrent. From the data made available to date it is evident that a 
number of proteins are consistently isolated during interactor hunts and due to 
either specificity problems or physiological reasons, are classified as false positives. 
As with EHOC-1 there is often no apparent reason why these proteins are isolated 
except perhaps their relatively high level of expression. Frequently isolated cDNAs 
include for example, heat shock proteins, ribosomal proteins, cytochrome oxidase, 
ferritin and proteasome subunits. Interestingly, the HsN3 proteasomal subunit has 
recently been reported by Rossi et al 1997 to specifically interact with Nef. These 
studies were predominantly performed in the YTHS and in view of the results 
compiled by E.A.Golemis it appears proteasome subunits may be inherently ‘sticky’ 
proteins in the YTHS. Future studies in alternative expression systems will therefore 
be required to confirm this Nef interaction.
The specificity of the clone 39 interaction in the YTHS with both Nef and p55Gag 
was intriguing, especially given the strength of the interaction as determined by 
p-galactosidase activity. The lack of interaction observed in vitro was therefore 
unexpected and as detailed in section 3.7 was probably a result of practical 
considerations. The cDNA insert in clone 39 was ~1000bp, however it was found to 
encode a polypeptide of only 43 amino acids as determined by sequencing, although 
western blot analysis suggested the transcript encoded a polypeptide of ~9kDa.
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FAST A DNA analysis revealed statistically significant homology to a human cDNA 
(Ac: N55259) in that the Poisson P value was <0.01 (the Poisson P value is 
calculated by the FASTA program and is the probability of the match occurring by 
chance given the number of residues in the query sequence and the database). The 
homology of N55259 to clone 39 was found to extend through to the untranslated 
region, up to 195bp. The N55259 cDNA sequence included a frame shift caused by 
an additional guanine at codon 29 relative to clone 39 (clone 39 numbering). It 
therefore encoded a 60 amino acid polypeptide more consistent with the 9kDa 
product detected by western blot analysis. The N55259 cDNA sequence was hence 
utilised to screen the HGMP EST tagged cDNA databases in an attempt to identify 
further flanking DNA sequences with possible known protein homologies. These 
searches revealed the existence of a mouse homologue, but no flanking cDNA 
sequence data. Partial cDNA sequences identified during the database searches 
were used to compile consensus DNA sequences for both human and mouse cDNA 
sequences. BLAST searches of these consensus sequences revealed no statistically 
significant protein sequence similarities.
In view of the problems encountered during the sequencing clone 39 due to 
stretches of high concentrations of guanine and cytosine nucleotides it was also 
possible that the N52259 sequence contained inaccuracies. This was supported by 
the calculation of the number of amino acids theoretically required to form a 9kDa 
polypeptide which is nearer 80 amino acids. Recent reanalysis of the clone 39 
peptide sequence alone in the absence of the N52259 frame shift revealed 75% 
homology over a 12 amino acid stretch to 3’,5’-cyclic-nucleotide- 
phosphodiesterase. This homology reduces to only -21% if taken over the whole 
peptide sequence and is lost completely if the N52259 frame shift is included. As 
3’,5’-cyclic-nucleotide phosphodiesterase is a specific regulator of 3’,5’-cyclic- 
adenosine monophosphate (cyclic-AMP) a Nef interaction with this protein could 
be highly significant. Phosphodiesterases hydrolyse cAMP to AMP, this is an 
essential process as cAMP acts as a second messenger for many hormones, 
including epinephrine, glucagon, luteinizing hormone, melanocyte stimulating 
hormone and thyroid stimulating hormone. Significantly cAMP is involved in
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physiological processes such as the degradation of storage fuels, acid secretion by 
the gastric mucosa and the dispersion of melanin pigment granules, each of which is 
severely affected during ADDS. Consistent with this elevations in cellular cAMP 
levels have been detected in HIV infected cells (Nokta and Pollard, 1991; Hofmann 
et al, 1993). In addition a number of lines of evidence make it a plausible Nef 
target. It has been proposed that elevated levels of cAMP cause an early block in 
T-cell signalling events (Tamir and Isakov, 1991; Tamir and Isakov, 1994; Tamir et 
al, 1996) resulting in transcription inhibition of IL-2, IL-2R and c-Jun expression. 
Furthermore, increased cAMP levels have been found to block the shift in 
electrophoretic mobility indicative of Ser59 phosphorylation which was also 
reported to be inhibited by Nef expression (Greenway et al, 1995a) see section 6.2. 
This cAMP block of Lck serine phosphorylation has been proposed to result from 
an inhibition of PKC and MAPK activities (Tamir et al, 1996) again consistent with 
reports of Nef effects (Greenway et al, 1996; Smith et al, 1996). Intriguingly it has 
recently been demonstrated that elevated levels of cAMP in myeloid cell lines 
results in the selective inhibition of CD4 endocytosis, suggesting in the presence of 
high concentrations of cAMP Nef expression may be required to target CD4 to 
clathrin coated pits (Foti et al, 1997). It would therefore be of interest to determine 
whether clone 39 represents a novel phosphodiesterase. Future studies will also be 
required to determine whether Nef is capable of binding other phosphodiesterase 
family members and to establish the effect of this interaction on cellular cAMP 
levels. In addition the interaction of p55Gag with clone 39 raises the possibility that 
phosphodiesterases may be recruited to the virion. Further work will also be 
required to address which Gag polypeptide mediates the interaction, it is even 
possible phosphodiesterase interactions may influence the micro-environment of the 
PIC.
Figure 6.1. Homology o f clone 39 to 3 \  5’-cyclic-nucleotide phosphodiesterase:
pir|IA36317 3',51-cyclic-nucleotide phosphodiesterase C 
cAMP-specific - human 
Length = 686
Score = 40 (19.8 bits), Expect = 0.18, Sum P(2) = 0.17 
Identities = 7/12 (58%), Positives = 9/12 (75%)
Query: 20 CTAVPSKETCQE 31
C A  S+ETCQ+
Sbjct: . 18 CKATLSEETCQQ 29
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The results obtained during the specificity study for clone 39 demonstrated that its 
interaction with Nef was myristoylation independent. This was contrary to the 
prediction that myristoylation would influence protein-protein interactions, but does 
not preclude the existence of such myristoylation dependent interactions. The 
development of false positive databases, plus automated sequencing techniques will 
make future YTHS library screenings more efficient. This should also facilitate 
comparative library screenings where both myristoylated and nonmyristoylated Nef 
could be used as baits to screen the same library. Ideally library sources should be 
primary cell lineages to ensure the mRNA population is not qualitatively distorted. 
A comparative study of different cell lineages would also be beneficial to distinguish 
between Nef binding partners in T-cell lineages and those of myeloid origin. The 
p-galactosidase reporter construct would allow the relative affinities of the 
interactions in each cell type to be determined. In addition, multiple library 
screenings would identify ubiquitously expressed Nef cellular targets, potentially 
alluding to those that are of functional significance in all cell types maximising the 
potential targets for therapeutic drug design.
In summary of the data obtained during this study; the modification of the bait 
plasmid to accept cDNA inserts as N-terminal fusions to the DB domain was 
successful increasing the repertoire of proteins that can be used as baits in the 
system; myristoylation was not found to mediate the clone 39 interaction detected 
for Nef, but as only one putative interaction was identified it is likely that further 
screening would reveal further interactors; clone 39 showed a strong specific 
interaction for myristoylated and nonmyristoylated Nef and p55Gag in the YTHS 
but it was not reproducible in vitro under the conditions used in these experiments; 
clone 39 showed strong homology to both human and mouse cDNA EST tagged 
sequences, but only limited protein sequence homology to 3’,5’-cyclic-nucleotide 
phosphodiesterase, further studies will be necessary to establish whether this limited 
homology reflects a Nef ability to interact with 3 ’,5 ’-cyclic-nucleotide- 
phosphodiesterase.
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6.2. Conformational requirements for the Lck interaction with Nef:
The results presented in these studies clearly demonstrated Lck conformational 
dependent Nef binding. Furthermore multiple regions in Nef were found to 
contribute to Lck binding including the highly conserved (PXX)3P motif and a 
region between residues 36-65 previously implicated for Nef mediated virion 
infectivity. A summary of the results obtained followed by a discussion of the 
functional implications of an Lck conformational dependent interaction with Nef 
will be detailed below.
A detailed investigation of the Lck conformation compatible with Nef binding was 
prompted by two observations. Firstly, Lck binding to native Nef was severely 
impaired after a change in foetal calf serum (FCS) used to supplement the complete 
TCI00 media for Sf9 cell culture, and secondly a similar loss of binding had been 
noted in previous experiments when the Lck lysates were prepared in the presence 
of NaOV. A further comparison of Nef binding affinities for Lck expressed in 
lysates from Sf9 cells grown in media supplemented with different FCS batches 
revealed a marked variability in the level of Lck bound to Nef for each sera. As FCS 
is comprised of variable concentrations of innumerable biomolecules all providing a 
subtle balance between cell proliferation, differentiation and apoptosis and all 
intrinsically linked with cell signal transduction pathways, it was hypothesised that 
Lck conformation was being altered by the varying sera. If this hypothesis was 
correct it followed that Lck enzymatic activity would also be effected. In 
accordance with this, a-pTyr (PY69, Santa Cruz) western blot analysis of the 
different Lck stocks demonstrated an increase in overall tyrosine phosphorylation in 
stocks compatible with Nef binding. To address whether this increase in tyrosine 
phosphorylation was due to a saturation of the active site Tyr394 phosphorylation 
indicative of the active “open” kinase conformation, or conversely the inactive 
Tyr505 phosphorylated Lck form, recombinant baculovirus Lck mutants were 
constructed.
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A constitutively “open” active Lck was constructed by mutating the C-terminal 
Tyr505 to Phe. This mutant had a two fold effect, as well as constitutively 
activating Lck by disrupting the intramolecular association of pTyr505 with the 
SH3 domain, it also removed the alternative Tyr505 phosphorylation site. Detection 
of tyrosine phosphorylation for this mutant would therefore be solely attributable to 
Tyr394 phosphorylation. However it was found expression of the Y505F mutation 
both separately or in combination with a kinase inactivating K273A mutation in the 
phospho-transfer site of the active site of the enzyme, was toxic to Sf9 cells. This 
resulted in the inability to generate recombinant baculoviruses expressing the 
Y505F mutation in this background. A further G2A mutation was necessary to 
facilitate the production of recombinant baculoviruses expressing this Y505F 
mutant protein. The reduced toxicity of LckY505F in this context was probably due 
to the removal of the protein from cell membranes. It is well documented that Lck 
signalling at the cell membrane is necessary for T-cell activation and removal from 
the membrane impairs signalling (Abraham and Veillette, 1990). Consistent with 
this the oncogenic potential of a nonmyristoylated Y505F Lck mutant was much 
reduced compared to myristoylated LckY505F (Abraham and Veillette, 1990). This 
is a conserved family characteristic as myristoylation is also required for the 
transforming capacity of v-Src in fibroblasts (Cross et al, 1984; Kamps et al, 1985; 
Catling et al, 1993).
Kinase assays for LckGY demonstrated its trans and auto-phosphorylation activity, 
but unexpectedly despite its open conformation LckGY did not have an elevated 
background level of Tyr394 phosphorylation. The reasons for this are unclear but 
may be related to its cytotoxicity. That LckGY expression was barely tolerated by 
the cells was evident when it was co-expressed with Nef, resulting in a dramatic 
reduction in the levels of expression for each protein. This was consistent with its 
recruitment to the membrane by myristoylated Nef. The kinase assays for LckGKY 
revealed that it was kinase defective consistent with the K273A substitution in the 
active site, no phosphotyrosine was detected by western blot analysis either 
-/+ATP. This also confirmed that levels of phosphotyrosine detected in previous 
autophosphorylation assays were due to Lck autophosphorylation activity and not
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endogenous cellular kinases phosphorylating Tyr394 in the active site. 
Autophosphorylation assays were also performed for LckG2A and LckK273A. The 
results from these revealed LckG2A was predominantly in the active conformation 
with elevated levels of Tyr394 phosphorylation in the absence of high 
concentrations of ATP. A low level of tyrosine phosphorylation was detected for 
LckK273A which confirmed that the increases in tyrosine phosphorylation detected 
for the previous Lck species occurred on Tyr394. Furthermore the low level of 
tyrosine phosphorylation detected for LckK273A implied that the PY69 Santa 
Cruz, antibody did not detect Tyr505 phosphorylation or that the K273A mutant 
was not tyrosine phosphorylated and was in the open conformation.
From the results obtained for Lck expressed in the presence of different sera it was 
predicted that Nef binding should correlate with elevated Lck tyrosine 
phosphorylation. However screening of these multiple Lck mutants also allowed us 
to assess whether Nef complexed with the “open” or “closed” conformation of Lck 
and whether Tyr394 or Tyr505 phosphorylation was required. A lack of Nef 
binding for LckGY observed in the in vivo binding assays inferred either Tyr394 
phosphorylation was necessary for the Nef interaction with the open conformation 
or that it complexed with the closed conformation of Lck. However it is difficult to 
interpret the results of this experiment due to the cytotoxicity exhibited following 
co-expression of Nef and LckGY. Significantly, Nef binding was detected at high 
levels for LckGKY and LckK273A and to an intermediate level for LckG2A, of 
which only LckG2A maintained elevated phosphotyrosine levels and enzyme 
activity.
The efficiency of Nef binding to LckGKY suggested that the open Lck 
conformation was required for Nef binding and furthermore that Tyr394 
phosphorylation was not necessary for the interaction. The requirement of an open 
conformation was further corroborated by LckG2A-Nef binding. The intermediate 
binding of LckG2A to Nef seen during the binding assays was consistent with only a 
percentage of the Lck expressed in the lysate complexing with Nef. Evidence for a 
variable LckG2A conformation in the lysates was provided by the results of the
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autophosphorylation assays: These demonstrated that, despite elevated background 
levels of tyrosine phosphorylation for LckG2A, an increase in the presence of ATP 
was still observed. This confirmed that background Tyr394 phosphorylation levels 
were not saturated. It therefore followed that only a percentage of LckG2A present 
in the lysate was in the active conformation and compatible with Nef binding, 
consistent with the intermediate amount of LckG2A detected complexed to Nef in 
the in vivo binding assays. The LckK273A mutant was included as a control for the 
inactive conformation of Lck in these experiments, therefore its high affinity binding 
to Nef was unexpected. However data from a recent study (Gonfloni et al, 1997) 
demonstrated that mutations in this region of Lck render the kinase constitutively 
active inferring this mutant was in fact in the open conformation. In this study the 
role of the linker region between the SH2 and N-terminal lobe of the catalytic 
domain of the Src kinases in activating the enzyme was analysed. Mutations of 
P274E and Q269E introduced into the (33 loop of Lck, proximal to the a-C helix 
were found to abrogate the kinase regulatory ability of the C-terminal tail, rendering 
the kinase constitutively active. These results argue that the conformation of the 
p3/a-C loop plays a dominant role in determining Lck kinase activity. If this 
observation is extended to the results obtained in our current study, a conformation 
for the K273A mutant Lck may be envisaged where the a-C helix is in the active 
orientation. This would cause the overall protein structure to open and occupy the 
active configuration, but remain kinase defective due to the absence of the crucial 
lysine 273 residue necessary for phosphate transfer. On the basis of these results we 
propose that that Nef selectively binds the open conformation of Lck and that 
complex formation can occur independently from both Tyr394 phosphorylation and 
Gly2 myristoylation.
The most complete crystallography studies performed to date, have resolved the 
structures of human Hck (Sicheri et al, 1997), human Src (Xu et al, 1997) and 
chicken Src (Williams et al, 1997) in their inactive C-terminally regulated 
conformations;, all lacking their acylation signals and unique N-terminal domains. 
The structures revealed the catalytic domain comprises two lobes. The smaller 
N-terminal lobe is comprised of a 5 stranded anti-parallel P-sheet with a single helix
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(a-C). The a-C helix contains a highly conserved glutamate residue (Glu 310 in 
Src) the position of which is crucial for the activity of the enzyme and is indirectly 
involved in the positioning of the a  and p phosphates of ATP. It is the position of 
this a-C helix that mutations in the 03 loop are thought to affect (Gonfloni et al, 
1997). The larger C-terminal lobe is predominantly a-helical and contains the active 
site tyrosine residue (Tyr 416 in Src) which localised to a disordered flexible loop in 
the crystal structure (activation segment), plus residues involved in substrate 
binding. The lobes are stabilized in the inactive conformation by associations with 
the SH3 and SH2 domains, which dock on the back of the catalytic domain and are 
thought to restrict the access of ATP to the active site, as illustrated below, diagram 
6.1 The SH2 domain binds the C-terminal pTyr505 tail, while the SH3 domain 
forms a tripartite interaction between the SH3 ligand binding surface, a polyproline 
type II helix formed by the SH2-catalytic domain linker and the back of the small 
lobe of the catalytic domain. The inactive kinases exhibited a closed configuration 
of their N- and C- terminal lobes, with a solvent exposed positioning for the a-C 
helix. It has been proposed that phosphorylation of the active site Tyr416 would 
result in a widening of the cleft, reorientation of the a-C helix and activation of the 
enzyme (Xu et al, 1997). However the precise order of events is unknown at 
present. Evidence for a dramatic conformational change for the activation segment 
has been provided by the crystallisation of the Lck catalytic domain in its active 
configuration (Yamaguchi and Hendrickson, 1996). However it has also been 
demonstrated that Tyr394 phosphorylation and partial activation of Lck can occur 
in the presence of Tyr505 phosphorylation (D'Oro et al, 1996), a similar phenomena 
has been reported for Src (Boemer, 1996). These conformations are consistent with 
the proposal put forward by Moarefi et al 1997 that various degrees of activity exist 
for Src kinases. The results from our current study however suggest that the local 
configuration of the catalytic domain is not sufficient to confer Nef-Lck complex 
formation. Moreover the results indicated that a completely open Lck conformation 
was essential for Nef binding. This suggested that motifs occluded in the closed 
protein structure mediate the Nef interaction.
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The concept of an open conformation of Lck conferring Lck-Nef binding ties in 
well with the recent reports of this association (Collette et al, 1996; Greenway et al, 
1995b; Greenway et al, 1996; Baur et al, 1997). Studies on the CD45 phosphatase 
regulation of Lck have revealed that in cell lines lacking CD45 such as fibroblasts, 
Lck resides in its pTyr505 inactive state, conversely in CD45 positive cell lines such 
as PBMCs, Jurkat T-cells and MT-2 cells Lck is predominantly in its open 
conformation (Gervais and Veillette, 1995). Significantly the recent reports of 
Lck-Nef complex formation used these T-cell lines (Collette et al, 1996; Greenway 
et al, 1995b; Greenway et al, 1996; Baur et al, 1997). In addition similar in vitro 
co-precipitation assays were performed in two of the studies (Collette et al, 1996; 
Greenway et al, 1996) using the SH3 and SH2 isolated domains expressed as GST 
fusions as affinity reagents. The results from the studies concurred that the SH3 
domain alone was able to precipitate Nef and that the efficiency of the interaction 
was greatly enhanced in the GST-SH3/SH2 domain fusions. In vitro peptide binding 
assays delineated the (PXX)3P motif in Nef as critical for the SH3 domain 
interaction. The studies presented here corroborate and extend these earlier results 
and demonstrated that in the context of the native proteins the Nef (PXX)3P motif 
remains critical for the interaction. The results demonstrated that the mutation of 
the 2 central prolines severely impaired Lck binding. However deletion of the 
second half of the motif (A74-98 Nef) did not have such a drastic effect on complex 
formation suggesting two adjacent prolines are sufficient to maintain the PP-II helix 
structure. Significantly there are only two prolines in a PxxP motif in the SIV and 
HIV-2 Nef isolates (Rud et al, 1994; Lang et al, 1997)
A second region of Nef implicated in our current studies as important for Lck 
binding was the residues spanning positions 36-65. As the Lck SH2 domain has 
been identified to significantly enhance Lck-Nef interactions it would be tempting to 
speculate that amino acids 36-65 might be involved in this interaction. It had been 
previously proposed (Collette et al, 1996) that tyrosine phosphorylation of Nef may 
contribute to the SH2 domain association. However follow up studies in which all 
the tyrosine residues in Nef were systematically mutated revealed that Nef tyrosine 
phosphorylation was not required for the interaction (Collette et al, Virology in
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press). In this context, a number of reports have detailed phosphotyrosine 
independent substrate binding to various SH2 domains including; a cyclin dependent 
kinase homologue pl30prrsLRE (Malek and Desiderio, 1994), Raf as a substrate for 
Fyn and Src SH2 domains (Cleghon and Morrison, 1994), Bcr binding to Abl SH2 
domain (Pendergast et al, 1991; Muller et al, 1992), each of which is dependent on 
either serine or threonine phosphorylation instead. Notably Nef contains 2 adjacent 
serine residues at positions 45 and 46 which were deleted in the A36-65 Nef 
mutant. These serines are also conserved in SIV-J5 where they are located at 
positions 51 and 52. Furthermore, serine phosphorylation of Nef has been 
demonstrated in a number of studies although the serine residues targeted have not 
been elucidated (Coates and Harris, 1995; Bodeus et al, 1995; Luo et al, 1997; 
Coates et al, 1997). For future studies it would therefore be interesting to determine 
whether mutation of these residues produced the same reduction in Lck binding as 
the A36-65 Nef mutant and whether this correlates with a reduction in Nef serine 
phosphorylation. In addition data from Baur et al 1997 demonstrated that the 
N-terminal 22 amino acids of SF-2 Nef were sufficient to confer a low level of 
binding to Lck with any increase after 35 amino acids conferring the same level of 
binding as the N-terminal 94 amino acids. There are at least 2 serine residues in the 
N-terminal 22 amino acids of most Nef alleles making this another region worth 
investigating for SH2 binding in future studies. The requirement for this region of 
Nef would be consistent with the reduction in Lck binding observed for the A7-22 
Nef isolate in these current experiments. Further mutagenesis studies will be 
required to address the importance of these various N-terminal serine residues in 
conferring Lck SIC binding.
Taken together the results presented here and from others (Collette et al, 1996; 
Greenway et al, 1995a; Greenway et al, 1996) suggests that the Nef mediated Lck 
binding occurs via interactions with the SH3 and SIC domains. However it is clear 
from our results that either the affinity of the interaction is not sufficient to perturb 
the inactive conformation or that the regions in Lck necessary for the interaction are 
occluded in the inactive conformation of the enzyme. Interestingly, it has recently 
been reported that c-Src in its C-terminal phosphorylated down regulated
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conformation is monomeric (Weijland et al, 1997). In contrast structural studies of 
the Lck SH3-SH2 isolated fragment co-crystallised with a phosphotyrosine peptide 
or unliganded suggested an ability of this fragment to dimerize. Considering the 
highly conserved nature of this family of proteins if these results are extrapolated it 
is possible that in the active conformation where the SH3 and SH2 domains are 
unrestricted the proteins are capable of dimerisation. This could potentially facilitate 
intermolecular activation of Lck enzymatic activity analogous to that reported for 
Src (Barker, 1994; Cooper and MacAuley, 1988) and Hck (Moarefi et al, 1997). 
This would be consistent with Lck activation by for example the aggregation of 
T-cell receptors. This also raises the possibility that dimerisation of Lck is necessary 
for Nef recognition or alternatively Nef may prevent Lck dimerisation. The latter 
proposal would be more consistent with the reduction in Lck activity on Nef 
binding reported in other studies (Collette et al, 1996; Greenway et al, 1996). A 
further potentially relevant factor is the possibility of Nef oligomerisation. While 
Nef oligomerisation has been demonstrated for HIV-2nihz Nef (Hodge et al, 1995) 
it has yet to be established whether this characteristic is conserved in HIV-1 and 
SIV and indeed whether it has any functional significance. Future studies will be 
required to address the oligomeric status of both Nef and Lck during the interaction 
and to further evaluate the mechanism of Lck enzymatic inhibition mediated by Nef.
It would be tempting to speculate that as Nef specifically binds the open active 
conformation of Lck and that Lck activation occurs as a result of CD4 antigen 
recognition the Lck-Nef interaction may occur immediately on viral entry. 
Significantly, the avidity of the interaction would be enhanced at this time due to 
CD4 Aggregation. A Nef disruption of Lck signalling could have a drastic impact on 
cellular responses. Evidence from in vivo transgenic lck null mice models 
demonstrated that in the absence of a functional Lck, T-cell development was 
arrested with a substantial reduction in the double positive (CD4+,CD8+) 
thymocyte population (Molina et al, 1992). Intriguingly Nef transgenic mice have a 
similar T-cell profile with a severe depletion in their peripheral CD4+ T-cell 
population (Skowronski et al, 1993). Moreover the reduction in Lck enzyme 
activity in the presence of Nef (Collette et al, 1996; Greenway et al, 1996) would
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effect the Lck phosphorylation of IT AM motifs in the TCR-CD3 receptor complex, 
thereby preventing ZAP70 recruitment causing an early block in T-cell receptor 
signalling (Zenner et al, 1995).
The requirement of the SH3 and SH2 domains of Lck for Nef binding also suggests 
that the endogenous cellular interactions of these domains at this stage would be 
perturbed. Pertinently this would encompass interactions with for example; the 
phosphatidylinositol 3-kinases (PI3K) (Amrein et al, 1993; Vogel and Fujita, 1993; 
Prasad et al, 1993). The identity of the exact PI3K that binds Lck is unknown at 
present, but all family members phosphorylate hydroxyl groups at position 3 on the 
inositol ring of the phosphoinositides: phosphatidylinositol (Ptdlns), Ptdlns (4)P and 
Ptdlns (4,5)P2. The PI3Ks have been linked to a number of cellular pathways 
(reviewed (Vanhaesebroeck et al, 1997; Sheperd et al, 1996)) including for 
example; the regulation of membrane vesicle trafficking of the prelysosomal system. 
It is possible that a Nef mediated deregulation of trafficking in this cellular 
compartment could result in the redirection of CD4 to the lysosomes (Rhee and 
Marsh, 1994; Aiken et al, 1994; Schwartz et al, 1995; Sanfridson et al, 1997). The 
PI3K lipid substrates and products are also involved in activating various PKC 
isozymes which have been implicated in both Nef phosphorylation and the 
N-terminal Nef complex formations (Coates and Harris, 1995; Bodeus et al, 1995; 
Baur et al, 1997). In addition the PI3K contain adaptor molecule binding motifs 
implicating a role for them in the Nef mediated recruitment of CD4 to clathrin 
coated pits (Vanhaesebroeck et al, 1997; Sheperd et al, 1996; Mangasarian et al, 
1997). Interestingly, it has also been reported that HTV gpl20 crosslinking of CD4 
results in ~5 fold increase in PI3K activity (Prasad et al, 1993). Further studies will 
be required to determine whether Nef acts to elevate these levels or conversely 
functions to block the PI3K activity during gpl20 mediated receptor crosslinking. 
Data from a number of SID and SID domain deletion studies has further 
highlighted the requirement for these domains in T-cell signalling. Their absence has 
been demonstrated to result in profound reductions in spontaneous IL-2 production 
when the deletions are combined with the C-terminal Y505F mutation (Luo and 
Sefton, 1992; Caron et al, 1992) and a reversal of the oncogenic transforming
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capabilities of the Y505F mutant (Veillette et al, 1992). However the most 
compelling evidence for the intrinsic involvement of the SH3 and SH2 domains in 
intracellular signalling pathways came from a study which demonstrated increased 
T-cell activation levels, relative to wildtype, when the Lck SH3-SH2 domains were 
expressed in the absence of the catalytic domain (Xu and Littman, 1993).
Studies are currently in progress to corroborate that Lck conformational 
dependence is maintained in mammalian cells. In order to do this, the lack of CD45 
expression in 3T3 fibroblast cells is being exploited. This should result in a 
constitutively phosphorylated Lck and as a consequence the C-terminal pTyr505 
should form intramolecular interactions with its SH2 domain, leading to an inactive 
conformation of the protein. According to the hypothesis proposed herein this 
should be incompatible with Nef binding. Conversely, Lck expressed in Jurkat 
T-cells which express CD45 should be maintained in its open Tyr505 
dephosphorylated active conformation, and be compatible with Nef binding. In 
addition cyanogen bromide cleavage studies would confirm the tyrosine residues 
phosphorylated in the respective cell lines. Given that a second N-terminal site in 
Nef was apparently necessary for the Lck binding, mutagenesis studies of the serine 
residues in this region would enable us to determine whether serine phosphorylation 
contributes to Lck SIC domain interactions. Following on from this it would be 
interesting to evaluate the effect of Nef-Lck complex formation on downstream 
effectors such as PI3K.
In summary of the results presented in this section: It was successfully 
demonstrated that the Lck-Nef association was dependent on the Lck open and 
active conformation and that the interaction occurred independently of Nef 
myristoylation. The conformational dependency of the interaction was conserved 
for the laboratory isolate-Bru, the primary Nef isolates and the J5 SIV Nef. The 
(PXX)3P motif was found to be necessary for efficient complex formation and 
N-terminal regions in Nef between residues 7-22 and 36-65 were also found to 
contribute to the association.
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6.3. Interactions of Nef with Hck.
In these studies we demonstrated that the reported interactions of an E.coli 
expressed Nef with the Hck SH3 domain in vitro was conserved in vivo in the 
YTHS with a myristoylated Nef and in the context of both full length native 
proteins expressed in the baculovirus expression system. In addition studies with the 
BH10 Nef (PXX)3P motif mutant (PAAP) both in vivo and in vitro raised questions 
as to the absolute requirement of this motif for Nef binding to Hck. The possibility 
of an additional binding site was corroborated by peptide substrate kinase assays 
which demonstrated that the PAAP Nef mutant had lost its ability to activate Hck.
Firstly, the YTHS was employed to address whether myristoylated Nef was capable 
of interacting with the Hck SH3 domain. For these studies the SH2 domain and 
SH3-SH2 domain fusions were also evaluated for Nef binding. These results 
demonstrated that the co-expression of Nef plus the Hck SH3 domain was toxic to 
the yeast. This was not Hck specific as similar results were obtained for Lck, Src 
and Fyn SH3 domains. No binding of Nef to the Hck SH2 domain was detected, 
however Nef was found to specifically interact with the Hck SH3-SH2 domain 
fusion. The lack of SH2 binding suggested that the observed Nef-Hck SH3-SH2 
binding was mediated by the Hck SH3 domain. These results were consistent with 
the previous in vitro substrate affinity studies and confirmed that native, 
myristoylated Nef retained its Hck SID binding ability in the context of an 
SH3-SH2 fusion in vivo. During the studies Src SH3, SH2 and SH3-SH2 domains 
were also assessed for Nef binding. It was found the results obtained for each Src 
domain mimicked those seen for the Hck isolated domains i.e. co-expression of Src 
SID with Nef was toxic to the yeast, the Src SID domain gave no detectable 
interaction with Nef and the Src SH3-SH2 domain fusion exhibited a high affinity 
for Nef in this system. The relative specificity of these interactions was 
corroborated by the lack of Nef binding to the isolated Fyn domains. Co-expression 
of Nef with each of the Lck isolated domains resulted in toxicity therefore potential 
interactions between Nef and Lck could not be evaluated.
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From structural studies on the specificity and selectivity of the Nef interaction with 
the Hck SH3 domain it was proposed that a single amino acid in the Hck SH3 
domain could confer high affinity Nef binding to SH3 domains (Lee et al, 1995). 
This amino acid was located on a variable loop termed the RT loop which projects 
from the main p-barrel structure of the SH3 domain (Lee et al, 1996). Point 
mutation of the corresponding residue in the Fyn SH3 domain, R96I resulted in a 
comparable level of Nef binding to that detected for Hck SH3. It was hence 
proposed that hydrophobic interactions mediated by this isoleucine residue were 
critical to Nef (PXX)3P binding. In sequence alignments of a panel of SH3 domains 
it was noted that Lyn SH3 also contained a similar lie residue consistent with its 
binding to Nef during the filter binding studies. This lie residue was absent in all of 
the remaining Src family members, therefore no further family members were 
investigated for Nef binding in subsequent studies. The results obtained in our 
current study for Src suggest that the presence of an isoleucine residue at position 
96 in the RT loop is not a prerequisite for Nef binding and that the criteria 
governing Nef-SH3 interactions are likely to be more complex.
This conclusion has been recently corroborated in studies by Arold et al 1997, who 
resolved the crystal structures for the liganded and unliganded Nef core domain. 
These structures revealed that the unbound polyproline type II (PP-II) helix in Nef 
was partially disordered inferring an intrinsic flexibility. They proposed that SH3 
domain interactions restrain the flexibility and stabilize the PP-II helix conformation. 
The Nef ligand used in the experiments by Arold et al was wildtype Fyn SH3. 
Analysis of the complex formation revealed a differential binding of Arg 77 in the 
PP-II helix of Nef to Asp 100 in the RT loop of Fyn SH3 to that previously reported 
(Lee et al, 1996) which resulted in altered hydrogen bond formation. This allowed 
the wild type R96 residue to be sequestered into the hydrophobic pocket of Nef and 
the overall reconfiguration of the RT loop to complement Nef binding. PP-II helices 
can bind SH3 domains in either “plus” or “minus” orientations, but in the Nef-SH3 
complexes binding is restricted to the minus configuration (Lee et al, 1996). The 
orientation of the binding is determined by the residues between the prolines 
including Arg71, Val74 and Arg77 in Nef. However due to its differential binding
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capacity it has been proposed that Arg77 is critical for both the orientation of the 
interaction and the ligand induced flexibility of the RT loop. As both Asp 100 of Fyn 
and Arg77 of Nef are highly conserved residues it is possible that their association 
could form the basis of a conserved mechanism of interaction between Nef and all 
members of the Src kinase family. The observed binding of Nef to Src demonstrated 
in these current studies is therefore consistent with the proposed more flexible PP-II 
helix. However the lack of Nef binding seen for Fyn in our study suggests that whil e 
a basic affinity between the proteins may exist additional factors may be required to 
facilitate initial binding prior to the induced RT loop conformational change.
To ascertain whether the Nef interaction with the Hck SH3-SH2 domain fusion was 
conserved for native Hck recombinant baculoviruses were generated. The 
authenticity of the recombinant baculovirus expressed proteins was demonstrated. 
Parameters examined included full length protein expression, authentic acylation 
and enzyme activity as assayed by both auto- and trans phosphorylation. The 
authenticity of the Nef proteins had been previously demonstrated (Harris and Neil, 
1994). These results confirmed the expression of the native full length proteins in 
the baculovirus expression system. The proteins were subsequently analysed by in 
vitro binding assays for Nef binding ability. The results from these studies 
demonstrated that Nef retained its ability to bind mHck in the context of the full 
length proteins. Notably, the efficiency of binding was reduced for the 
nonmyristoylated Nef in vitro. Consistent with results from the YTHS, binding o f 
Nef to Src was also observed, but none was detected for Fyn. A reduction in 
nonmyristoylated Nef binding to Src was also detected.
Following on from these in vitro studies, in vivo binding assays were performed on 
recombinant baculovirus coinfected Sf9 lysates. The data from these studies 
revealed the interaction observed between Nef and Hck was specific and stable in an 
in vivo environment. This was consistent with a recent report by Briggs et al 1997 
who demonstrated the co-immunoprecipitation of Nef and Hck from recombinant 
retrovirally coinfected Rat-2 cells. In contrast, Src exhibited non-specific binding to 
the GA-beads, precluding the analysis of Nef binding during these in vivo binding
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studies. In future studies alternative affinity reagents such as Nef-6His will be 
required to confirm the interaction. During the in vivo binding assays the Nef-mHck 
interaction was found to be Nef myristoylation independent with equivalent levels of 
mHck binding detected for each Nef affinity reagent. This was contrary to the in 
vitro binding results, where nonmyristoylated Nef was found to have a reduced 
affinity for mHck. Furthermore results from in vivo binding studies with A78hHck 
concurred with myristoylation enhanced binding, but no difference was seen for 
G2AhHck. The reduced binding observed for nonmyristoylated Nef and A78hHck 
implicated both Nef myristoylation and the unique region of Hck contribute to 
complex formation although removal of only one was not sufficient to perturb the 
interactions. The inference being that a number of weak interactions may be 
necessary to stablise the Nef-Hck interaction in the context of the native proteins. 
The discrepancy between the in vitro and in vivo data suggested that the binding 
was less efficient in vitro and required both an intact myristoylation signal and the 
Hck unique domain. Overall the data from these studies demonstrated both Nef 
myristoylation and the Hck unique domain contribute in enhancing the association 
of the two proteins, probably serving to promote the Nef-Hck interaction in vivo. 
However the loss of either individually is not sufficient to perturb the interaction.
The results from the protease cleavage experiments provided evidence to suggest 
that both the virion associated N-terminally cleaved species of Nef and the full 
length myristoylated Nef have equal affinity for native mHck. The results also 
demonstrated the accessibility of the protease cleavage site in the presence of Hck 
binding, suggesting this region of Nef is not involved in Hck binding. The 
implication from these results is that at all times in the viral life cycle Nef retains its 
ability to interact with Hck. This is indicative of a continued requirement for the 
interaction throughout the viral life cycle and raises the possibility of Hck inclusion 
in the virion. From the results of the myristoylation experiments it is likely that the 
full length myristoylated Nef would have a higher affinity for Hck in solution than 
the protease cleaved Nef species, therefore intuitively one would predict that an 
interaction between the cleaved Nef and Hck is most likely to occur in the virion. 
This could occur either as a result of random Hck incorporation in the virion, or
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more likely as a result of specific Hck recruitment to the virion by viral proteins 
such as Nef. Tyrosine phosphorylation of the Gag MA protein has been 
demonstrated to be critical for the nuclear import of the preintegration complex 
(PIC) (Gallay et al, 1995) and is a prerequisite of HIV-1 infection of terminally 
differentiated macrophages (Vonschwedler et al, 1994). The ability to infect 
quiescent cells is unique to the lentiviruses playing a critical role in HTV 
pathogenesis and is in marked contrast to the oncoretroviruses which require 
nuclear envelope breakdown at mitosis. It would therefore be tempting to speculate 
that Nef binds Hck and recruits it to the virion where it is able to phosphorylate Gag 
MA thereby facilitating HIV infection of non-dividing cells. Protease cleavage of 
Nef would be required to remove the N-terminal membrane targeting domain of Nef 
allowing its incorporation into the PIC along with bound proteins such as Hck. This 
would be consistent with the loss of Nef enhanced viral infectivity in continuous cell 
lines and its enhancement of viral infectivity in quiescent T cells and PBMCs (Kim 
et al, 1989; de Ronde et al, 1992; Miller et al, 1994; Spina et al, 1994).
An unexpected result obtained during these studies was the ability of the PAAP 
mutant of Nef to bind Hck with wildtype affinity. In this mutant the 2 central 
prolines of the conserved (PXX^P motif were substituted for alanines, as these 
mutations had been previously demonstrated to abrogate the Nef-Hck SH3 
interaction in vitro (Saksela et al, 1995; Moarefi et al, 1997) (reviewed (Saksela, 
1997)). The PAAP Nef binding in our studies was conserved for mHck, G2AhHck 
and A78hHck. The ability of the PAAP mutant to bind Hck suggested that the 
BH10 Nef isolate could interact with Hck at an alternative site, or that the mutation 
of the 2 central proline residues had not disrupted the structure of the PP-II helix. 
The original filter binding assays by Saksela et al 1995, demonstrated a loss of Nef 
binding after the mutation of a C-terminal proline motif at residues 147 and 150. 
The panel of Nef mutants screened in these current studies did not include a 
deletion in this region of Nef, possibly providing an explanation for the uniform 
binding of Hck detected for each of the mutants. Significantly Saksela et al utilised 
a nonmyristoylated PAAP mutant Nef together with an N-terminally truncated Hck 
lacking the unique domain. From the results of our G2A-G and A78hHck binding
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studies it is possible that the addition of the proline mutant may have been sufficient 
to completely perturb the interaction. From the data presented here it can be 
concluded that the (PXX)3P motif is not necessary for binding to Hck. This 
observation implies the existence of additional binding sites.
Clues as to the Nef requirement for Hck binding came from the inability of Bru Nef 
to interact with Hck. Amino acid sequence alignments revealed only 7 differences 
between BH10 and Bru, see diagram 5.3. Interestingly 2 of the changes were 
E l5ID and LI53V proximal to the putative C-terminal proline motif. A dramatic 
effect for such conserved amino acid substitutions is not unprecedented for SH3 
domain interactions, Lee et al 1995 demonstrated a single R96I change in the Fyn 
SH3 RT loop was sufficient to alter a weak interaction with Nef to a binding affinity 
equal to that obtained for Hck SH3 domains. Other contributing factors to the loss 
of Nef Bru binding may have been the additional A15T and N52T changes in Bru 
which introduce further putative phosphorylation sites into the N-terminal region. 
This could conceivably result in N-terminal structural changes and the loss of the 
N-terminal PP-II helix recognition. Mass spectrometry studies are currently in 
progress to determine whether Bru is phosphorylated on these threonine residues. 
Further mutational analysis will also be required to resolve this apparent loss of 
binding affinity. Since the completion of these studies it has been demonstrated that 
the interaction between SF2 Nef and Hck during in vivo Rat-2 coinfection 
experiments was, in contrast to our results, dependent on the (PXX)3P motif in Nef 
(Briggs et al, 1997). However these studies used RIPA buffer which contains an 
ionic detergent in contrast to the non-ionic TritonX-100 based detergent used in our 
studies, it is therefore possible that the increased stringent conditions perturbed 
interactions with the (PXX)3P motif mutant. Also notably, they used a different Nef 
allele to the BH10 Nef allele used here emphasising the variability of Nef isolate 
interactions with Hck. For future studies it would be interesting to compare T-cell 
tropic and macrophage tropic Nef derivatives for Hck binding and to determine 
whether Nef-Hck binding correlates with macrophage tropic HTV strains.
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From the results of the study by Moarefi et al 1997 it was proposed that SH3 
domain ligands cause the rapid activation of Hck. They demonstrated that the 
presence of Nef dramatically increased the rate of phospho-transfer to a peptide 
substrate by Hck and that a Nef (PXX)3P mutant was incapable of similarly 
activating Hck. Pertinently the conditions employed in this study were comparable 
to those used by Saksela et al 1995 who demonstrated a loss of Hck binding for this 
Nef mutation. However, the results obtained during the in vivo binding assays 
performed in our current studies suggested that Hck retained the ability to bind the 
PAAP Nef mutant in the context of the native proteins and that another binding site 
with equal affinity for Hck existed in the BH10 allele. To attempt to resolve this 
potential conflict, peptide substrate assays were performed to establish whether the 
PAAP Nef mutant used here retained the ability to enhance Hck activity. Consistent 
with the results of Moarefi et al the level of Hck activation was enhanced in the 
presence of Nef. However, the results for the PAAP Nef assays revealed it had no 
effect on Hck activity. This inferred that PAAP Nef binding to Hck did not involve 
SH3 recruitment with concomitant enzyme activation. Furthermore the ability of 
BH10 Nef to activate Hck in contrast to the PAAP mutant confirmed the previous 
proposal of a critical role for the PXXP motif in activating Hck. Taken together 
these results suggest that two Hck binding sites exist within Nef only one of which 
is capable of activating Hck enzymatic activity. Alternatively, it is possibly that 
PAAP still binds the SH3 domain but with insufficient binding affinity to displace it. 
From the results of the crystallography studies it was apparent that a number of 
interactions stablise the interface between Nef and Fyn SH3. One possibility is that 
the RT loop of Hck bound to PAAP in our study had not undergone the 
conformational change necessary for the high affinity interaction, if this is the case 
washes with an ionic detergent such as RIPA buffer should dissociate the 
PAAP-Hck complex.
Notably despite alternative Hck binding sites, the dominant effect of the wild type 
BH10 Nef allele was activation of Hck kinase activity. However the significance of 
this in vivo has been questioned in recent macaque studies by Lang et al 1997. 
These studies demonstrated a lack of reversion of an AxxA Nef allele in macaques
262
infected with SIVmaC23 9 containing this mutation. Furthermore, contrary to 
expectations the disease pathogenesis was accelerated in these monkeys. These 
results suggested that PxxP binding alone was not sufficient to perturb the Nef in 
vivo phenotype and that this mutation had enhanced other protein interactions 
causing accelerated pathogenesis. This is consistent with the results presented 
herein and infers that the (PXX)3P mediated Hck activation may not be relevant in 
vivo and other possible (PXX)3P independent effects on Hck SH3/SH2 signalling 
events should be investigated. It should be noted that SIV Nef isolates contain only 
a single PxxP motif at the putative SH3 recognition site, compared to the (PXX)3P 
motif in HIV-1 alleles. However if this was critical to viral infectivity it would be 
anticipated an even greater selection pressure to revert to wild type would be 
imposed.
Additional studies will be required to further analyse residues important in 
mediating the Hck interactions with Nef. In future studies it would be interesting to 
establish which Nef isolates rely on their (PXX)3P motifs for Hck binding and the 
functional relevance of the alternative Hck binding site. If sufficient isolates are 
screened it should be possible to delineate key amino acid residues necessary for 
this dual binding. Alternatively a recently developed derivative of the YTHS the 
“reverse” YTHS would allow the rapid screening of randomly generated protein 
mutants. This system works by detecting the dissociation of known protein binding 
partners and would allow the rapid screening of the interactions in a eukaryotic 
system in vivo (White, 1996).
In summary the data presented in these studies confirmed that the interaction 
between native Nef and Hck was conserved in vivo. The stability of the association 
during protease cleavage was also demonstrated raising the possibility of Hck 
recruitment to the virion by Nef. In addition the PAAP in vivo binding assays and 
peptide substrate data implicated two mechanisms of Nef-Hck binding. The first of 
which is likely to be PxxP SIC domain mediated and result in Hck activation. 
However the second occurs independently from the PxxP motif and given the in 
vivo macaque data may represent a more physiologically relevant Hck binding site.
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6.4. Final Discussion:
The remit for these studies was to identify novel interactions between Nef and 
cellular proteins and to further characterise the Nef associations with the Src 
tyrosine kinase family. The results from the former study revealed a strong novel 
interaction between Nef and an uncharacterised polypeptide (clone 39), which had 
high homology to both human and mouse cDNAs. The strength and specificity of 
the interaction in the in vivo eukaryotic background of S.cerevisiae implied the 
interaction may have a physiological relevance. Intriguingly the polypeptide also 
exhibited a high affinity binding to p55Gag. As both Nef and p55Gag are 
myristoylated, membrane associated, virion incorporated proteins it is plausible that 
they might share common binding partners. Indeed the possibility of Nef 
complexing with p55Gag or one of its cleavage products would be worth 
investigating for future studies. Due to the GC rich regions in the cDNA of clone 39 
it was difficult to unequivocally determine the polypeptide sequence. However, a 
short stretch of amino acids were found to have homology to 3’,55 cyclic-nucleotide 
phosphodiesterase. Observations of elevated cAMP levels in infected cells suggest 
that a Nef interaction with phosphodiesterases might be physiologically relevant, 
making this an interesting potential Nef binding partner worth evaluating in future 
binding studies.
While the YTHS is a powerful analytical tool by comparison to traditional methods 
such as co-immunoprecipitation, crosslinking and copurification through gradients 
or chromatographic columns none of which result in cDNA isolation, it is limited by 
the fact that the protein-protein interactions occur in the nucleus. This has recently 
been overcome by an adaptation of the system. The alternative Sos recruitment 
system (SRS) relies on the ability of hSos and a Ras guanyl nucleotide exchange 
factor to activate Ras only when localized to the plasma membrane (Aronheim, 
1997). In the system Ras activity is required for cdc25-2 gene expression and yeast 
growth at 36°C. Similar to the YTHS, baits and potential interactors are fused to 
either Sos or Ras guanyl nucleotide exchange factors and interactions between the
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two confers growth at 36°C. The system has the advantage that it allows screening 
of protein-protein interactions to occur in the cytosol. In addition the membrane 
localisation of the interactions should facilitate the analysis of interactions between 
myristoylated proteins in their native membrane anchored conformations. This 
system may therefore represent a better background in which to investigate 
potential interactors with myristoylated Nef for future studies. One possible 
drawback of the system for use with the Src tyrosine kinases would be the possible 
toxicity effects of the localisation of the SH3 and SH2 domains at the membrane, 
see section 4.7.
The results obtained in the latter part of these studies demonstrated Nef binding to 
Lck, Hck and Src, but none for Fyn. Data from the YTHS suggested that the Nef 
interaction was mediated by the SH3 domains of Hck and Src. Although Lck 
cytotoxicity in the YTHS prohibited its inclusion in these studies, results from the in 
vivo binding assays with the native proteins confirmed the requirement for the Nef 
(PXX)3P motif suggesting that the Lck interaction was also SID dependent. These 
results were contrary to the proposed requirement for an lie residue in the RT loop 
of the SH3 domains for Nef binding (Lee et al, 1995). Instead they infer a 
conserved ability for the association of Nef and the Src tyrosine kinase domains, 
consistent with the hypothesis of Arold et al 1997.
The results from the Hck in vivo binding studies, however suggested mutations in 
the (PXX)3P motif were not sufficient to perturb Nef complex formation. This 
result went against an SH3 mediated domain binding to Nef suggesting the 
existence of additional interactions. Significantly, when the panel of Nef deletion 
mutants were screened for Hck binding all were found to have equivalent affinities 
for Hck. Notably these deletions did not remove a C-terminal single PxxP motif, 
which in the absence of the (PXX)3P motif could potentially mediate the SH3 
domain interaction. Further studies with the Nef Bru isolate should determine the 
extent of the interaction with this C-terminal PxxP motif. The Hck results were in 
direct contrast to those obtained in the Lck binding assays. Notably Lck binding 
efficiency was impaired for the A7-22, A36-65 and the PAAP Nef mutants.
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Moreover no loss of binding was detected for the Nef Bru isolate to Lck. This 
suggests that the mechanism of Nef binding to each of the Src tyrosine kinases is 
very different and that while the SH3 domains of each might be influential in 
mediating the binding other additional interactions are important in the context of 
the full length native proteins.
As the criteria governing the Nef interactions with the Src tyrosine kinase members 
are established the effect of Nef binding will need to be addressed. To date, it has 
already been demonstrated that Lck activity is inhibited (Greenway et al, 1996; 
Collette et al, 1996), while Hck is activated (Moarefi et al, 1997). Moreover the 
relevance of the effect on kinase activity in vivo has been called into question by the 
macaque data (Lang et al, 1997). A recently developed cDNA microarray or DNA- 
chip technology method capable of differentially screening the expression of 
thousands of mRNA transcripts will make broad scale assessment of these in vivo 
effects possible (reviewed (Ramsay, 1998)). This system not only allows the 
detailed analysis of mRNA expression but also detects changes in mRNA expression 
in response to external stimuli. The system utilises a cDNA array (microarray) as a 
template for hybridization to cDNA probes prepared from RNA samples of cells or 
tissues. Two sets of cDNA probes are utilised labelled with different fluorescent 
dyes such that hybridization of either probe individually or simultaneously is 
distinguishable. This therefore provides both a comparative and quantitative analysis 
of the tissues under investigation. It would hence be possible to evaluate the effect 
of mutations on perturbing interactions or more importantly the downstream 
detrimental effects of such interactions. Similarly, the efficacy of potential 
therapeutic agents in returning the mRNA profile to normal could also be 
monitored. This would provide a valuable analytical tool in elucidating the 
pleiotropic phenotype of Nef during HTV infection and aid in establishing the effect 
of the Nef interactions with the Src tyrosine kinase interactions on cell signal 
transduction pathways.
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The data presented in this thesis illustrates the enigmatic nature of Nef and 
emphasises the importance of analysing protein-protein interactions in the context 
of the native proteins. It further demonstrated combinatorial associations between 
Nef and cellular proteins can have a profound effect on their binding affinities and 
that the affinity may vary depending on the strain of HIV.
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